[{"an_dt":"14-Oct-2026 08:31:28","attFileSize":"413.19 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14102026082951_SEIntimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"14102026083128","exchdisstime":"14-Oct-2026 08:31:29","fileSize":"413.19 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106816663","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-10-14 08:31:28","symbol":"BIOCON"},{"an_dt":"12-Oct-2026 20:16:40","attFileSize":"656.56 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12102026201522_SE.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:01","dt":"12102026201640","exchdisstime":"12-Oct-2026 20:16:41","fileSize":"656.56 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106815029","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-10-12 20:16:40","symbol":"BIOCON"},{"an_dt":"10-Oct-2026 15:09:16","attFileSize":"380.98 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10102026150858_SEIntimation-TaxOrder.pdf","attchmntText":"Biocon Limited has informed the Exchange about Disclosure pursuant to Regulation 30 of the SEBI Listing Regulations","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:00","dt":"10102026150916","exchdisstime":"10-Oct-2026 15:09:16","fileSize":"380.98 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106813530","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-10-10 15:09:16","symbol":"BIOCON"},{"an_dt":"01-Oct-2026 21:32:13","attFileSize":"359.79 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01102026213141_SE_Intimation_Grants.pdf","attchmntText":"Biocon Limited has informed the Exchange about Grant of Employee Stock Options under Biocon Unity Long Term Incentive Plan 2026 read with the Notified Plans thereunder","bflag":null,"csvName":null,"desc":"Options to purchase securities","difference":"00:00:01","dt":"01102026213213","exchdisstime":"01-Oct-2026 21:32:14","fileSize":"359.79 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106805678","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-10-01 21:32:13","symbol":"BIOCON"},{"an_dt":"30-Sep-2026 19:42:07","attFileSize":"322.65 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30092026194151_IntimationTradingWindow.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:00","dt":"30092026194207","exchdisstime":"30-Sep-2026 19:42:07","fileSize":"322.65 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106803643","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-09-30 19:42:07","symbol":"BIOCON"},{"an_dt":"25-Sep-2026 08:35:40","attFileSize":"432.86 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25092026083515_CoStatement25092026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"25092026083540","exchdisstime":"25-Sep-2026 08:35:41","fileSize":"432.86 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106792585","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-09-25 08:35:40","symbol":"BIOCON"},{"an_dt":"21-Sep-2026 08:26:47","attFileSize":"408.81 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21092026082614_Pressrelease21092026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 21, 2026, titled \"Biocon s Pertuzumab Becomes First Biosimilar to Secure EMA CHMP Approval Recommendation Under New Tailored Clinical Approach\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"21092026082647","exchdisstime":"21-Sep-2026 08:26:48","fileSize":"408.81 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106785637","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-09-21 08:26:47","symbol":"BIOCON"},{"an_dt":"09-Sep-2026 13:58:54","attFileSize":"399.32 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09092026135825_SE_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about  Communication regarding remittance of final dividend for the FY 2025-26","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"09092026135854","exchdisstime":"09-Sep-2026 13:58:55","fileSize":"399.32 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106776279","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-09-09 13:58:54","symbol":"BIOCON"},{"an_dt":"08-Sep-2026 15:57:16","attFileSize":"319.61 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08092026155308_Investor_Roadshow_11_Sep_2026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"08092026155716","exchdisstime":"08-Sep-2026 15:57:17","fileSize":"319.61 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106774699","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-09-08 15:57:16","symbol":"BIOCON"},{"an_dt":"08-Sep-2026 08:31:17","attFileSize":"391.98 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08092026083042_Pressrelease08092026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 08, 2026, titled \"Biocon Secures 10-Year Supply Contract for Pertuzumab in Brazil\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"08092026083117","exchdisstime":"08-Sep-2026 08:31:18","fileSize":"391.98 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106774001","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-09-08 08:31:17","symbol":"BIOCON"},{"an_dt":"31-Aug-2026 18:04:29","attFileSize":"241.45 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31082026180408_Nuvama_Credit_Conference_04_Sep_2026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:02","dt":"31082026180429","exchdisstime":"31-Aug-2026 18:04:31","fileSize":"241.45 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106762730","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-31 18:04:29","symbol":"BIOCON"},{"an_dt":"28-Aug-2026 20:59:42","attFileSize":"292.78 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28082026205918_SE_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about \"Communication regarding remittance of final dividend for the FY 2025-26\"","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:02","dt":"28082026205942","exchdisstime":"28-Aug-2026 20:59:44","fileSize":"292.78 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106760845","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-28 20:59:42","symbol":"BIOCON"},{"an_dt":"25-Aug-2026 08:28:30","attFileSize":"314.19 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25082026082811_SE25082026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:02","dt":"25082026082830","exchdisstime":"25-Aug-2026 08:28:32","fileSize":"314.19 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106755125","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-25 08:28:30","symbol":"BIOCON"},{"an_dt":"18-Aug-2026 08:40:08","attFileSize":"408.61 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18082026083950_CoStatement18062026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:00","dt":"18082026084008","exchdisstime":"18-Aug-2026 08:40:08","fileSize":"408.61 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106747757","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-18 08:40:08","symbol":"BIOCON"},{"an_dt":"11-Aug-2026 20:06:25","attFileSize":"239.92 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11082026200613_Motilal_Oswal_Conference_17_August_2026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"11082026200625","exchdisstime":"11-Aug-2026 20:06:26","fileSize":"239.92 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106737738","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-11 20:06:25","symbol":"BIOCON"},{"an_dt":"11-Aug-2026 20:03:23","attFileSize":"942.35 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11082026200302_Cover_Letter_Transcript_Earnings_Call.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"11082026200323","exchdisstime":"11-Aug-2026 20:03:24","fileSize":"942.35 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106737730","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-11 20:03:23","symbol":"BIOCON"},{"an_dt":"08-Aug-2026 21:54:07","attFileSize":"958.77 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08082026215336_Voting_Results_and_Scrutinizer_Report.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Annual General Meeting held on August 06, 2026. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"08082026215407","exchdisstime":"08-Aug-2026 21:54:08","fileSize":"958.77 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106733550","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-08 21:54:07","symbol":"BIOCON"},{"an_dt":"07-Aug-2026 20:46:54","attFileSize":"239.35 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07082026204633_Emkay_Conference_12_August_2026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:02","dt":"07082026204654","exchdisstime":"07-Aug-2026 20:46:56","fileSize":"239.35 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106732420","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-07 20:46:54","symbol":"BIOCON"},{"an_dt":"07-Aug-2026 20:44:24","attFileSize":"239.35 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07082026204337_Emkay_Conference_12_August_2026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"07082026204424","exchdisstime":"07-Aug-2026 20:44:25","fileSize":"239.35 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106732417","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-07 20:44:24","symbol":"BIOCON"},{"an_dt":"07-Aug-2026 20:24:36","attFileSize":"379.70 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07082026202418_NewspaperAd_Financials.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"07082026202436","exchdisstime":"07-Aug-2026 20:24:37","fileSize":"379.70 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106732390","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-07 20:24:36","symbol":"BIOCON"},{"an_dt":"06-Aug-2026 23:26:43","attFileSize":"314.55 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06082026232143_SE_Intimation-Resignation_of_statutory_auditors_of_Subsidiaries.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding resignation of Ms BSR Co & LLP Statutory Auditors of the material subsidiary  of the Company w.e.f. August 06, 2026.","bflag":null,"csvName":null,"desc":"Resignation","difference":"00:00:00","dt":"06082026232643","exchdisstime":"06-Aug-2026 23:26:43","fileSize":"314.55 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106730103","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-06 23:26:43","symbol":"BIOCON"},{"an_dt":"06-Aug-2026 21:08:19","attFileSize":"326.26 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06082026210732_SEs_Intimation_Director.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"00:00:00","dt":"06082026210819","exchdisstime":"06-Aug-2026 21:08:19","fileSize":"326.26 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106729881","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-06 21:08:19","symbol":"BIOCON"},{"an_dt":"06-Aug-2026 21:04:09","attFileSize":"326.26 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06082026210357_SEs_Intimation_Director.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Auditors of the company.","bflag":null,"csvName":null,"desc":"Change in Auditors","difference":"00:00:02","dt":"06082026210409","exchdisstime":"06-Aug-2026 21:04:11","fileSize":"326.26 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106729871","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-06 21:04:09","symbol":"BIOCON"},{"an_dt":"06-Aug-2026 20:59:15","attFileSize":"326.26 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06082026205827_SEs_Intimation_Director.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Re-appointment of Mr Erick Mazumdar as Non- Executive Director of the company w.e.f. August 06, 2026.","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:01","dt":"06082026205915","exchdisstime":"06-Aug-2026 20:59:16","fileSize":"326.26 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106729864","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-06 20:59:15","symbol":"BIOCON"},{"an_dt":"06-Aug-2026 20:42:56","attFileSize":"1.52 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06082026204223_Biocon_AGM_Proceedings_and_Chairperson_Speech.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 06, 2026","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"06082026204256","exchdisstime":"06-Aug-2026 20:42:57","fileSize":"1.52 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106729842","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-06 20:42:56","symbol":"BIOCON"},{"an_dt":"06-Aug-2026 18:43:20","attFileSize":"264.27 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06082026183935_Earning_Calls_outcome05082026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Link of Recording","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"06082026184320","exchdisstime":"06-Aug-2026 18:43:21","fileSize":"264.27 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106729429","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-06 18:43:20","symbol":"BIOCON"},{"an_dt":"06-Aug-2026 07:21:19","attFileSize":"2.36 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06082026072054_IR_PPT_Cover_Letter.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:01","dt":"06082026072119","exchdisstime":"06-Aug-2026 07:21:20","fileSize":"2.36 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106727815","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-06 07:21:19","symbol":"BIOCON"},{"an_dt":"05-Aug-2026 17:08:50","attFileSize":"4.18 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05082026170816_SE_Intimation_-_Monitoring_Agency.pdf","attchmntText":"Monitoring Agency Report for the quarter ended on June 30, 2026","bflag":null,"csvName":null,"desc":"Monitoring Agency Report","difference":"00:00:01","dt":"05082026170850","exchdisstime":"05-Aug-2026 17:08:51","fileSize":"4.18 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106726696","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-05 17:08:50","symbol":"BIOCON"},{"an_dt":"05-Aug-2026 17:02:41","attFileSize":"1.02 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05082026170201_PressRelease05082026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 05, 2026, titled \"Biocon Q1FY27 Total Income at Rs 4,391 Cr, Up 9%; EBITDA at Rs 902 Cr; Net Profit at Rs 141 Cr; Biopharma Revenue Up 17%\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:02","dt":"05082026170241","exchdisstime":"05-Aug-2026 17:02:43","fileSize":"1.02 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106726665","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-05 17:02:41","symbol":"BIOCON"},{"an_dt":"05-Aug-2026 16:51:10","attFileSize":"6.74 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05082026164940_Outcome_of_BM05082026.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"05082026165110","exchdisstime":"05-Aug-2026 16:51:11","fileSize":"6.74 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106726611","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-05 16:51:10","symbol":"BIOCON"},{"an_dt":"03-Aug-2026 08:28:25","attFileSize":"426.26 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03082026082804_SEs_Intimation_v3.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 03, 2026, titled \"Biocon Announces U.S. Commercial Launch of Yesafili , a Biosimilar to Regeneron s Eylea® 2 mg\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"03082026082825","exchdisstime":"03-Aug-2026 08:28:26","fileSize":"426.26 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106721306","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-03 08:28:25","symbol":"BIOCON"},{"an_dt":"03-Aug-2026 08:26:45","attFileSize":"426.26 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03082026082630_SEs_Intimation_v3.pdf","attchmntText":"Biocon Limited has informed the Exchange about Commercial Launch of Product","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"03082026082645","exchdisstime":"03-Aug-2026 08:26:46","fileSize":"426.26 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106721305","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-08-03 08:26:45","symbol":"BIOCON"},{"an_dt":"29-Jul-2026 08:31:09","attFileSize":"310.58 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29072026083047_CompanyStatement29072026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"29072026083109","exchdisstime":"29-Jul-2026 08:31:10","fileSize":"310.58 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106714636","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-07-29 08:31:09","symbol":"BIOCON"},{"an_dt":"28-Jul-2026 20:09:30","attFileSize":"571.76 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28072026200903_BM_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"28072026200930","exchdisstime":"28-Jul-2026 20:09:31","fileSize":"571.76 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106714299","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-07-28 20:09:30","symbol":"BIOCON"},{"an_dt":"28-Jul-2026 12:31:55","attFileSize":"185.79 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/team_sandeshc_15072026114514_Disc1.pdf","attchmntText":"Mylan Inc. has Submitted to the Exchange a copy of Disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"00:00:01","dt":"28072026123155","exchdisstime":"28-Jul-2026 12:31:56","fileSize":"185.79 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106698269","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-07-28 12:31:55","symbol":"BIOCON"},{"an_dt":"22-Jul-2026 19:50:52","attFileSize":"341.53 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22072026194943_SE_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"00:00:01","dt":"22072026195052","exchdisstime":"22-Jul-2026 19:50:53","fileSize":"341.53 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106707103","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-07-22 19:50:52","symbol":"BIOCON"},{"an_dt":"16-Jul-2026 17:30:50","attFileSize":"3.04 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16072026172930_Intimation_NewspaperAd.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"16072026173050","exchdisstime":"16-Jul-2026 17:30:51","fileSize":"3.04 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106700353","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-07-16 17:30:50","symbol":"BIOCON"},{"an_dt":"16-Jul-2026 08:43:39","attFileSize":"302.92 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16072026084200_SECompanyStatement.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"16072026084339","exchdisstime":"16-Jul-2026 08:43:40","fileSize":"302.92 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106699587","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-07-16 08:43:39","symbol":"BIOCON"},{"an_dt":"15-Jul-2026 15:11:13","attFileSize":"25.48 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15072026151000_Biocon_AGM_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 06, 2026","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:00","dt":"15072026151113","exchdisstime":"15-Jul-2026 15:11:13","fileSize":"25.48 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106698568","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-07-15 15:11:13","symbol":"BIOCON"},{"an_dt":"13-Jul-2026 20:42:17","attFileSize":"652.13 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13072026204142_Coveringletter.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:00","dt":"13072026204217","exchdisstime":"13-Jul-2026 20:42:17","fileSize":"652.13 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106696172","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-07-13 20:42:17","symbol":"BIOCON"},{"an_dt":"09-Jul-2026 08:45:13","attFileSize":"409.52 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09072026084447_Pressrelease09072026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 09, 2026, titled \" Biocon Announces Publication of Pivotal Clinical Data Supporting Effectiveness of Yesafili , a Biosimilar to Eylea® (Aflibercept) \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"09072026084513","exchdisstime":"09-Jul-2026 08:45:14","fileSize":"409.52 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106691363","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-07-09 08:45:13","symbol":"BIOCON"},{"an_dt":"07-Jul-2026 19:21:16","attFileSize":"3.32 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07072026192051_Intimation_PriorAGM_-_final.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:02","dt":"07072026192116","exchdisstime":"07-Jul-2026 19:21:18","fileSize":"3.32 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106689605","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-07-07 19:21:16","symbol":"BIOCON"},{"an_dt":"29-Jun-2026 23:22:04","attFileSize":"342.59 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_29062026232036_SEIntimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding allotment of 8786362 securities pursuant to Preferential Issue at its meeting held on Jun 29, 2026","bflag":null,"csvName":null,"desc":"Allotment of Securities","difference":"00:00:00","dt":"29062026232204","exchdisstime":"29-Jun-2026 23:22:04","fileSize":"342.59 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106680352","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-06-29 23:22:04","symbol":"BIOCON"},{"an_dt":"29-Jun-2026 22:51:40","attFileSize":"342.59 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29062026225131_SE_Intimation_-_Allotment__Preferential_Issue_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Acquisition","bflag":null,"csvName":null,"desc":"Acquisition","difference":"00:00:01","dt":"29062026225140","exchdisstime":"29-Jun-2026 22:51:41","fileSize":"342.59 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106680329","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-06-29 22:51:40","symbol":"BIOCON"},{"an_dt":"27-Jun-2026 19:39:27","attFileSize":"235.81 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27062026193903_IntimationTradingWindow.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:01","dt":"27062026193927","exchdisstime":"27-Jun-2026 19:39:28","fileSize":"235.81 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106678641","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-06-27 19:39:27","symbol":"BIOCON"},{"an_dt":"24-Jun-2026 08:33:42","attFileSize":"350.84 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24062026083309_Pressrelease24062026-signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 24, 2026, titled \"Biocon Reinforces Commitment to Diabetes Care in Malaysia as Partner Duopharma Biotech Secures Insulin Tenders\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"24062026083342","exchdisstime":"24-Jun-2026 08:33:43","fileSize":"350.84 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106671802","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-06-24 08:33:42","symbol":"BIOCON"},{"an_dt":"22-Jun-2026 19:37:50","attFileSize":"469.43 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22062026193647_SE_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Communication to the shareholders w.r.t. TDS on Final Dividend","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"22062026193750","exchdisstime":"22-Jun-2026 19:37:51","fileSize":"469.43 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106669956","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-06-22 19:37:50","symbol":"BIOCON"},{"an_dt":"15-Jun-2026 19:12:20","attFileSize":"49.51 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/team_bbodade_23042026184742_BIOCON.pdf","attchmntText":" Kiran Mazumdar-Shaw has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"00:00:01","dt":"15062026191220","exchdisstime":"15-Jun-2026 19:12:21","fileSize":"49.51 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106598459","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-06-15 19:12:20","symbol":"BIOCON"},{"an_dt":"10-Jun-2026 19:50:24","attFileSize":"248.13 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10062026194907_Acquisition_AMPIN.pdf","attchmntText":"Biocon Limited has informed the Exchange about Acquisition","bflag":null,"csvName":null,"desc":"Acquisition","difference":"00:00:01","dt":"10062026195024","exchdisstime":"10-Jun-2026 19:50:25","fileSize":"248.13 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106660212","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-06-10 19:50:24","symbol":"BIOCON"},{"an_dt":"08-Jun-2026 20:41:55","attFileSize":"3.62 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08062026204120_Intimation_to_SE_Postal_Ballot_outcome-SD.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Postal Ballot. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:02","dt":"08062026204155","exchdisstime":"08-Jun-2026 20:41:57","fileSize":"3.62 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106657881","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-06-08 20:41:55","symbol":"BIOCON"},{"an_dt":"08-Jun-2026 19:58:55","attFileSize":"292.03 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08062026195735_Intimation_11June2026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"08062026195855","exchdisstime":"08-Jun-2026 19:58:56","fileSize":"292.03 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106657854","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-06-08 19:58:55","symbol":"BIOCON"},{"an_dt":"01-Jun-2026 08:31:54","attFileSize":"5.40 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01062026083128_IR_Presentation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:02","dt":"01062026083154","exchdisstime":"01-Jun-2026 08:31:56","fileSize":"5.40 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106650444","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-06-01 08:31:54","symbol":"BIOCON"},{"an_dt":"30-May-2026 17:58:20","attFileSize":"6.57 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30052026175808_Intimation_Newspaper_Ad.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"30052026175820","exchdisstime":"30-May-2026 17:58:21","fileSize":"6.57 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106649611","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-30 17:58:20","symbol":"BIOCON"},{"an_dt":"29-May-2026 21:18:26","attFileSize":"3.68 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29052026211740_Intimation_to_SE_Corrigendum_to_Postal_Ballot_Notice.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding \"Corrigendum to the Postal Ballot Notice dated May 07, 2026\"","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"29052026211826","exchdisstime":"29-May-2026 21:18:27","fileSize":"3.68 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106648319","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-29 21:18:26","symbol":"BIOCON"},{"an_dt":"27-May-2026 16:32:41","attFileSize":"3.22 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27052026163200_Investor_meet_June_2026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"27052026163241","exchdisstime":"27-May-2026 16:32:42","fileSize":"3.22 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106643545","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-27 16:32:41","symbol":"BIOCON"},{"an_dt":"22-May-2026 18:32:45","attFileSize":"5.82 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22052026183236_Intimation_IEPF.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"22052026183245","exchdisstime":"22-May-2026 18:32:46","fileSize":"5.82 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106636715","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-22 18:32:45","symbol":"BIOCON"},{"an_dt":"21-May-2026 19:00:11","attFileSize":"3.81 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21052026185839_SEIntimation_IEPF.pdf","attchmntText":"Biocon Limited has informed the Exchange about Reminder Letter to shareholders to claim unclaimed dividends","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"21052026190011","exchdisstime":"21-May-2026 19:00:12","fileSize":"3.81 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106634461","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-21 19:00:11","symbol":"BIOCON"},{"an_dt":"21-May-2026 15:58:04","attFileSize":"3.22 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21052026155735_Investor_Meeting_June_2026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"21052026155804","exchdisstime":"21-May-2026 15:58:05","fileSize":"3.22 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106633722","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-21 15:58:04","symbol":"BIOCON"},{"an_dt":"14-May-2026 16:29:51","attFileSize":"889.19 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14052026162935_Cover_Letter_Transcript_Earnings_Call.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:02","dt":"14052026162951","exchdisstime":"14-May-2026 16:29:53","fileSize":"889.19 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106622585","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-14 16:29:51","symbol":"BIOCON"},{"an_dt":"11-May-2026 08:33:04","attFileSize":"592.85 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11052026083251_CompanyStatement11052026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:02","dt":"11052026083304","exchdisstime":"11-May-2026 08:33:06","fileSize":"592.85 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106616232","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-11 08:33:04","symbol":"BIOCON"},{"an_dt":"09-May-2026 16:20:21","attFileSize":"3.10 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09052026162013_Intimation_Newspaper_Ad.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication on Postal Ballot Notice","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:02","dt":"09052026162021","exchdisstime":"09-May-2026 16:20:23","fileSize":"3.10 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106615895","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-09 16:20:21","symbol":"BIOCON"},{"an_dt":"09-May-2026 16:18:51","attFileSize":"3.10 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09052026161830_NewspaperAd_Financials.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication for Financial Results","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:02","dt":"09052026161851","exchdisstime":"09-May-2026 16:18:53","fileSize":"3.10 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106615894","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-09 16:18:51","symbol":"BIOCON"},{"an_dt":"09-May-2026 01:20:29","attFileSize":"1.32 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09052026011847_Intimation_to_SE_Postal_Ballot_Notice.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Postal Ballot","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:00","dt":"09052026012029","exchdisstime":"09-May-2026 01:20:29","fileSize":"1.32 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106615675","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-09 01:20:29","symbol":"BIOCON"},{"an_dt":"08-May-2026 21:38:43","attFileSize":"340.09 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08052026213821_Earning_Calls_outcome08052026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Link of Recording","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"08052026213843","exchdisstime":"08-May-2026 21:38:44","fileSize":"340.09 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106615409","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-08 21:38:43","symbol":"BIOCON"},{"an_dt":"08-May-2026 08:18:26","attFileSize":"2.02 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08052026081737_IR_PPT_Cover_Letter.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:01","dt":"08052026081826","exchdisstime":"08-May-2026 08:18:27","fileSize":"2.02 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106613938","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-08 08:18:26","symbol":"BIOCON"},{"an_dt":"08-May-2026 00:06:10","attFileSize":"7.66 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08052026000517_MRReport.pdf","attchmntText":"Monitoring Agency Report","bflag":null,"csvName":null,"desc":"Monitoring Agency Report","difference":"00:00:01","dt":"08052026000610","exchdisstime":"08-May-2026 00:06:11","fileSize":"7.66 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106613914","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-08 00:06:10","symbol":"BIOCON"},{"an_dt":"07-May-2026 23:38:58","attFileSize":"1.95 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07052026233830_Outcome_of_BM-Final.pdf","attchmntText":"Biocon Limited has informed the Exchange that Record date for the purpose of Dividend  is 03-Jul-2026.","bflag":null,"csvName":null,"desc":"Record Date","difference":"00:00:00","dt":"07052026233858","exchdisstime":"07-May-2026 23:38:58","fileSize":"1.95 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106613907","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-07 23:38:58","symbol":"BIOCON"},{"an_dt":"07-May-2026 23:37:02","attFileSize":"908.49 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07052026233651_Covering_Letter_Press_Release.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 07, 2026, titled \"Biocon Q4FY26 Total Income at Rs 4,569 Cr EBITDA at Rs 1,073 Cr; Net Profit (before exceptional items) at Rs 179 Cr FY26 Total Income at Rs 17,270 Cr; EBITDA at  Rs 3,798 Cr; Net Profit (before exceptional items) at Rs 436 Cr\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"07052026233702","exchdisstime":"07-May-2026 23:37:03","fileSize":"908.49 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106613906","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-07 23:37:02","symbol":"BIOCON"},{"an_dt":"07-May-2026 23:35:17","attFileSize":"1.95 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07052026233507_Outcome_of_BM-Final.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on May 07, 2026.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"07052026233517","exchdisstime":"07-May-2026 23:35:18","fileSize":"1.95 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106613876","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-07 23:35:17","symbol":"BIOCON"},{"an_dt":"07-May-2026 23:34:25","attFileSize":"1.95 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07052026233418_Outcome_of_BM-Final.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on May 07, 2026-Acquisition","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"07052026233425","exchdisstime":"07-May-2026 23:34:26","fileSize":"1.95 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106613875","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-07 23:34:25","symbol":"BIOCON"},{"an_dt":"07-May-2026 23:33:27","attFileSize":"1.95 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07052026233320_Outcome_of_BM-Final.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on May 07, 2026.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"07052026233327","exchdisstime":"07-May-2026 23:33:28","fileSize":"1.95 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106613844","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-07 23:33:27","symbol":"BIOCON"},{"an_dt":"07-May-2026 23:32:34","attFileSize":"1.95 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07052026233227_Outcome_of_BM-Final.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Auditors of the company.","bflag":null,"csvName":null,"desc":"Change in Auditors","difference":"00:00:01","dt":"07052026233234","exchdisstime":"07-May-2026 23:32:35","fileSize":"1.95 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106613843","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-07 23:32:34","symbol":"BIOCON"},{"an_dt":"07-May-2026 23:31:35","attFileSize":"1.95 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07052026233126_Outcome_of_BM-Final.pdf","attchmntText":"Biocon Limited has informed the Exchange that Board of Directors at its meeting held on May 07, 2026, recommended Final Dividend of Rs. 0.5 per equity share.","bflag":null,"csvName":null,"desc":"Dividend","difference":"00:00:00","dt":"07052026233135","exchdisstime":"07-May-2026 23:31:35","fileSize":"1.95 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106613840","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-07 23:31:35","symbol":"BIOCON"},{"an_dt":"07-May-2026 23:30:24","attFileSize":"1.95 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07052026232841_Outcome_of_BM-Final.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"07052026233024","exchdisstime":"07-May-2026 23:30:25","fileSize":"1.95 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106613839","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-07 23:30:24","symbol":"BIOCON"},{"an_dt":"06-May-2026 21:38:06","attFileSize":"338.70 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06052026213647_Clarification_Letter.pdf","attchmntText":"The Exchange has sought clarification from Biocon Limited with respect to recent news item captioned Biocon s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: Report.  The response from the Company is attached.","bflag":null,"csvName":null,"desc":"News Verification","difference":"00:00:01","dt":"06052026213806","exchdisstime":"06-May-2026 21:38:07","fileSize":"338.70 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106611903","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-06 21:38:06","symbol":"BIOCON"},{"an_dt":"06-May-2026 21:33:51","attFileSize":"338.70 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06052026213325_Clarification_Letter.pdf","attchmntText":"Biocon Limited has informed the Exchange about Rumour Verification - Regulation 30(11)","bflag":null,"csvName":null,"desc":"Rumour Verification - Regulation 30(11)","difference":"00:00:01","dt":"06052026213351","exchdisstime":"06-May-2026 21:33:52","fileSize":"338.70 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106611900","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-06 21:33:51","symbol":"BIOCON"},{"an_dt":"06-May-2026 12:53:44","attFileSize":"0 Bytes","attchmntFile":"-","attchmntText":"The Exchange has sought clarification from Biocon Limited with respect to recent news item captioned Biocon s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: Report.  The response from the Company is awaited.","bflag":null,"csvName":null,"desc":"News Verification","difference":"00:00:01","dt":"06052026125344","exchdisstime":"06-May-2026 12:53:45","fileSize":"0 Bytes","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106610927","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-05-06 12:53:44","symbol":"BIOCON"},{"an_dt":"30-Apr-2026 08:27:47","attFileSize":"368.13 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30042026082653_SEIntimation30042026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"30042026082747","exchdisstime":"30-Apr-2026 08:27:48","fileSize":"368.13 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106604943","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-04-30 08:27:47","symbol":"BIOCON"},{"an_dt":"28-Apr-2026 18:34:56","attFileSize":"1.17 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042026183435_SE_Intimation_Newspaper_Ad28042026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"28042026183456","exchdisstime":"28-Apr-2026 18:34:57","fileSize":"1.17 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106603051","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-04-28 18:34:56","symbol":"BIOCON"},{"an_dt":"23-Apr-2026 20:09:46","attFileSize":"580.98 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23042026200850_BM_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"23042026200946","exchdisstime":"23-Apr-2026 20:09:47","fileSize":"580.98 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106598611","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-04-23 20:09:46","symbol":"BIOCON"},{"an_dt":"21-Apr-2026 08:48:59","attFileSize":"546.45 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21042026084828_Pressrelease21042026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 21, 2026, titled \"Biocon Receives Health Canada Approval of Bosaya  (Denosumab) and Vevzuo  (Denosumab), Biosimilars to Prolia® and Xgeva®\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"21042026084859","exchdisstime":"21-Apr-2026 08:49:00","fileSize":"546.45 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106595004","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-04-21 08:48:59","symbol":"BIOCON"},{"an_dt":"20-Apr-2026 20:31:57","attFileSize":"421.55 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20042026203134_SEIntimation_KYC_Updation.pdf","attchmntText":"Biocon Limited has informed the Exchange about \"Reminder Letter to shareholders holding shares in physical form for furnishing of KYC details\"","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"20042026203157","exchdisstime":"20-Apr-2026 20:31:58","fileSize":"421.55 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106594707","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-04-20 20:31:57","symbol":"BIOCON"},{"an_dt":"08-Apr-2026 08:40:17","attFileSize":"438.84 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08042026083910_SEIntimation08042026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"08042026084017","exchdisstime":"08-Apr-2026 08:40:18","fileSize":"438.84 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106582882","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-04-08 08:40:17","symbol":"BIOCON"},{"an_dt":"07-Apr-2026 20:58:43","attFileSize":"321.89 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07042026205824_Investor_Meeting_07042026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"07042026205843","exchdisstime":"07-Apr-2026 20:58:44","fileSize":"321.89 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106582658","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-04-07 20:58:43","symbol":"BIOCON"},{"an_dt":"07-Apr-2026 20:44:40","attFileSize":"529.59 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07042026204426_Reg745Biocon31032026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:01","dt":"07042026204440","exchdisstime":"07-Apr-2026 20:44:41","fileSize":"529.59 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106582653","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-04-07 20:44:40","symbol":"BIOCON"},{"an_dt":"07-Apr-2026 16:07:06","attFileSize":"357.40 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07042026160635_Pressrelease07042026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 07, 2026, titled \"Biocon Announces U.S. Commercial Launch of Bosaya  and Aukelso , Denosumab Biosimilars\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:00","dt":"07042026160706","exchdisstime":"07-Apr-2026 16:07:06","fileSize":"357.40 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106582142","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-04-07 16:07:06","symbol":"BIOCON"},{"an_dt":"30-Mar-2026 13:11:16","attFileSize":"183.93 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30032026131039_Intimation_Name_change_of_subsidiaries.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Intimation of change in name of step-down subsidiary of the Company'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"30032026131116","exchdisstime":"30-Mar-2026 13:11:17","fileSize":"183.93 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106573940","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-03-30 13:11:16","symbol":"BIOCON"},{"an_dt":"27-Mar-2026 12:17:42","attFileSize":"673.71 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27032026121636_SE_Intimation_on_amendment_in_Trust_Deed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Amendment in Trust Deed'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"27032026121742","exchdisstime":"27-Mar-2026 12:17:43","fileSize":"673.71 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106570930","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-03-27 12:17:42","symbol":"BIOCON"},{"an_dt":"27-Mar-2026 12:07:31","attFileSize":"302.21 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27032026120707_Press_Release.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 27, 2026, titled \"Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:00","dt":"27032026120731","exchdisstime":"27-Mar-2026 12:07:31","fileSize":"302.21 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106570909","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-03-27 12:07:31","symbol":"BIOCON"},{"an_dt":"27-Mar-2026 12:05:19","attFileSize":"1.79 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27032026120510_OutcomeofBM27032026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Key Managerial Personnels who are authorized to determine materiality of an event or information and make necessary disclosures to the Stock Exchange(s) pursuant to Regulation 30 of SEBI Listing Regulations","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"27032026120519","exchdisstime":"27-Mar-2026 12:05:20","fileSize":"1.79 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106570904","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-03-27 12:05:19","symbol":"BIOCON"},{"an_dt":"27-Mar-2026 12:03:00","attFileSize":"1.79 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27032026120203_OutcomeofBM27032026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Change in KMP and SMP","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"27032026120300","exchdisstime":"27-Mar-2026 12:03:01","fileSize":"1.79 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106570901","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-03-27 12:03:00","symbol":"BIOCON"},{"an_dt":"27-Mar-2026 11:58:17","attFileSize":"1.79 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27032026115733_OutcomeofBM27032026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Appointment of CFO and Resignation of Interim FO","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"27032026115817","exchdisstime":"27-Mar-2026 11:58:18","fileSize":"1.79 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106570892","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-03-27 11:58:17","symbol":"BIOCON"},{"an_dt":"27-Mar-2026 11:54:39","attFileSize":"1.79 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27032026115323_Outcome_of_BM27032026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Appointment of CEO and MD, and resignation of CEO and MD.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"27032026115439","exchdisstime":"27-Mar-2026 11:54:40","fileSize":"1.79 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106570883","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-03-27 11:54:39","symbol":"BIOCON"},{"an_dt":"26-Mar-2026 18:08:26","attFileSize":"313.26 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26032026180807_TWC.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:01","dt":"26032026180826","exchdisstime":"26-Mar-2026 18:08:27","fileSize":"313.26 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106570086","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-03-26 18:08:26","symbol":"BIOCON"},{"an_dt":"12-Mar-2026 21:20:30","attFileSize":"255.32 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12032026211918_Intimation_to_SE_US_FDA_approval_gVictoza.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:02","dt":"12032026212030","exchdisstime":"12-Mar-2026 21:20:32","fileSize":"255.32 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106556200","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-03-12 21:20:30","symbol":"BIOCON"},{"an_dt":"05-Mar-2026 15:50:18","attFileSize":"321.38 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05032026154933_Investor_Meeting_05032026-Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"05032026155018","exchdisstime":"05-Mar-2026 15:50:19","fileSize":"321.38 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106550400","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-03-05 15:50:18","symbol":"BIOCON"},{"an_dt":"03-Mar-2026 23:09:33","attFileSize":"3.17 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_03032026230815_SE_Intimation_-_Acquisition_BPL_BBSL_v3_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Acquisition","bflag":null,"csvName":null,"desc":"Acquisition","difference":"00:00:01","dt":"03032026230933","exchdisstime":"03-Mar-2026 23:09:34","fileSize":"3.17 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106549157","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-03-03 23:09:33","symbol":"BIOCON"},{"an_dt":"02-Mar-2026 16:59:59","attFileSize":"3.23 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02032026165738_InvestorMeeting02032026_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"02032026165959","exchdisstime":"02-Mar-2026 17:00:00","fileSize":"3.23 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106548319","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-03-02 16:59:59","symbol":"BIOCON"},{"an_dt":"25-Feb-2026 06:42:02","attFileSize":"2.36 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25022026064140_IR_PPT.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:00","dt":"25022026064202","exchdisstime":"25-Feb-2026 06:42:02","fileSize":"2.36 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106544097","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-02-25 06:42:02","symbol":"BIOCON"},{"an_dt":"24-Feb-2026 21:04:05","attFileSize":"924.16 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24022026210330_Pressrelease24022026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 24, 2026, titled \"Biocon obtains approval for weight management drug,Liraglutide, in the United States\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:00","dt":"24022026210405","exchdisstime":"24-Feb-2026 21:04:05","fileSize":"924.16 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106543835","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-02-24 21:04:05","symbol":"BIOCON"},{"an_dt":"17-Feb-2026 17:20:00","attFileSize":"3.66 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17022026171942_Cover_Letter_Transcript_Earnings_Call_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:02","dt":"17022026172000","exchdisstime":"17-Feb-2026 17:20:02","fileSize":"3.66 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106538140","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-02-17 17:20:00","symbol":"BIOCON"},{"an_dt":"17-Feb-2026 16:50:39","attFileSize":"3.14 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17022026165022_InvestorMeeting17022026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"17022026165039","exchdisstime":"17-Feb-2026 16:50:40","fileSize":"3.14 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106538110","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-02-17 16:50:39","symbol":"BIOCON"},{"an_dt":"14-Feb-2026 15:15:29","attFileSize":"2.44 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14022026151510_AD.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"14022026151529","exchdisstime":"14-Feb-2026 15:15:30","fileSize":"2.44 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106535593","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-02-14 15:15:29","symbol":"BIOCON"},{"an_dt":"13-Feb-2026 15:36:47","attFileSize":"548.20 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13022026153608_Earning_Calls_outcome13022026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Link of Recording","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"13022026153647","exchdisstime":"13-Feb-2026 15:36:48","fileSize":"548.20 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106533842","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-02-13 15:36:47","symbol":"BIOCON"},{"an_dt":"13-Feb-2026 08:23:48","attFileSize":"1.90 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13022026082327_Presentataion13022026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:01","dt":"13022026082348","exchdisstime":"13-Feb-2026 08:23:49","fileSize":"1.90 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106533089","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-02-13 08:23:48","symbol":"BIOCON"},{"an_dt":"12-Feb-2026 19:47:07","attFileSize":"2.31 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12022026194647_SE_Intimation_-_Monitoring_Agency.pdf","attchmntText":"Monitoring Agency Report for the quarter ended on December 31, 2025","bflag":null,"csvName":null,"desc":"Monitoring Agency Report","difference":"00:00:02","dt":"12022026194707","exchdisstime":"12-Feb-2026 19:47:09","fileSize":"2.31 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106532624","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-02-12 19:47:07","symbol":"BIOCON"},{"an_dt":"12-Feb-2026 19:42:23","attFileSize":"998.64 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12022026194149_Press_Release12022026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 12, 2026, titled \"Biocon Q3FY26 Operating Revenue at Rs 4,173 Cr Q3FY26 EBITDA at Rs 951 Cr Q3FY26 Net Profit at Rs 144 Cr \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"12022026194223","exchdisstime":"12-Feb-2026 19:42:24","fileSize":"998.64 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106532608","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-02-12 19:42:23","symbol":"BIOCON"},{"an_dt":"12-Feb-2026 19:28:26","attFileSize":"10.10 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12022026192802_Outcome_of_BM12022026.pdf","attchmntText":"Outcome of Board Meeting - In-principle approval of Acquisition","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"12022026192826","exchdisstime":"12-Feb-2026 19:28:27","fileSize":"10.10 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106532571","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-02-12 19:28:26","symbol":"BIOCON"},{"an_dt":"12-Feb-2026 19:13:34","attFileSize":"10.10 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12022026191251_Outcome_of_BM12022026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on February 12, 2026.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"12022026191334","exchdisstime":"12-Feb-2026 19:13:35","fileSize":"10.10 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106532533","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-02-12 19:13:34","symbol":"BIOCON"},{"an_dt":"12-Feb-2026 19:10:16","attFileSize":"10.10 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12022026190829_Outcome_of_BM12022026.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:00","dt":"12022026191016","exchdisstime":"12-Feb-2026 19:10:16","fileSize":"10.10 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106532524","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-02-12 19:10:16","symbol":"BIOCON"},{"an_dt":"07-Feb-2026 13:03:05","attFileSize":"3.17 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07022026130236_PressRelease0702026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 07, 2026, titled \"Fitch Ratings Upgrades Biocon Biologics Outlook from  Stable  to  Positive \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:00","dt":"07022026130305","exchdisstime":"07-Feb-2026 13:03:05","fileSize":"3.17 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106524880","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-02-07 13:03:05","symbol":"BIOCON"},{"an_dt":"28-Jan-2026 19:05:22","attFileSize":"185.58 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28012026190506_SERecorddate_29012026_200_Cr.pdf","attchmntText":"Biocon Limited has informed the Exchange about Intimation of Record Date for Buy Back of Listed Commercial Paper Issued by the Company","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:02","dt":"28012026190522","exchdisstime":"28-Jan-2026 19:05:24","fileSize":"185.58 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106510159","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-28 19:05:22","symbol":"BIOCON"},{"an_dt":"28-Jan-2026 18:52:17","attFileSize":"230.02 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28012026185155_SERecorddate_29012026_1800_Cr.pdf","attchmntText":"Biocon Limited has informed the Exchange about Intimation of record date for buy back of listed Commercial Paper issued by the Company","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"28012026185217","exchdisstime":"28-Jan-2026 18:52:18","fileSize":"230.02 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106510121","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-28 18:52:17","symbol":"BIOCON"},{"an_dt":"28-Jan-2026 18:20:16","attFileSize":"245.08 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28012026181959_IntimationSE28012026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"28012026182016","exchdisstime":"28-Jan-2026 18:20:17","fileSize":"245.08 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106510010","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-28 18:20:16","symbol":"BIOCON"},{"an_dt":"28-Jan-2026 08:46:01","attFileSize":"454.38 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28012026084529_Pressrelease28012026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 28, 2026, titled \"S&P Global Upgrades Biocon Biologics Credit Rating To  BB+ Revises Outlook to  Stable \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"28012026084601","exchdisstime":"28-Jan-2026 08:46:02","fileSize":"454.38 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106509027","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-28 08:46:01","symbol":"BIOCON"},{"an_dt":"21-Jan-2026 20:12:48","attFileSize":"593.95 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21012026201229_CFOCertificate.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Certificate pursuant to SEBI Master Circular no. SEBI/HO/DDHS/DDHSPoD/P/CIR/2025/0000000137 dated October 15, 2025'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:02","dt":"21012026201248","exchdisstime":"21-Jan-2026 20:12:50","fileSize":"593.95 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106503980","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-21 20:12:48","symbol":"BIOCON"},{"an_dt":"21-Jan-2026 19:59:51","attFileSize":"186.96 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21012026195928_SE_Disclosure_-_BBL_share_acquisition.pdf","attchmntText":"Biocon Limited has informed the Exchange about Update on Acquisition","bflag":null,"csvName":null,"desc":"Acquisition","difference":"00:00:01","dt":"21012026195951","exchdisstime":"21-Jan-2026 19:59:52","fileSize":"186.96 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106503973","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-21 19:59:51","symbol":"BIOCON"},{"an_dt":"15-Jan-2026 09:16:54","attFileSize":"367.12 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15012026091618_Pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 14, 2026, titled \"Biocon Limited Concludes Rs 4,150 Crore (app USD 460 million) Equity Fundraise through a Qualified Institutions Placement (QIP)\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"15012026091654","exchdisstime":"15-Jan-2026 09:16:55","fileSize":"367.12 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106498000","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-15 09:16:54","symbol":"BIOCON"},{"an_dt":"14-Jan-2026 23:54:02","attFileSize":"402.09 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14012026235233_Allotment.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding allotment of 11,26,64,585 securities pursuant to Qualified Institution Placement at its meeting held on January 14, 2026","bflag":null,"csvName":null,"desc":"Allotment of Securities","difference":"00:00:00","dt":"14012026235402","exchdisstime":"14-Jan-2026 23:54:02","fileSize":"402.09 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106497977","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-14 23:54:02","symbol":"BIOCON"},{"an_dt":"14-Jan-2026 23:51:30","attFileSize":"402.09 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14012026235110_Allotment.pdf","attchmntText":"Biocon Limited has informed the Exchange about allotment under Qualified Institutions Placement","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"14012026235130","exchdisstime":"14-Jan-2026 23:51:31","fileSize":"402.09 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106497972","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-14 23:51:30","symbol":"BIOCON"},{"an_dt":"14-Jan-2026 22:31:38","attFileSize":"287.37 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14012026223106_Adoption_of_PD.pdf","attchmntText":"Biocon Limited has informed the Exchange about Qualified Institutions Placement - Approval and adoption of Placement Document","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"14012026223138","exchdisstime":"14-Jan-2026 22:31:39","fileSize":"287.37 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106497757","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-14 22:31:38","symbol":"BIOCON"},{"an_dt":"14-Jan-2026 22:16:38","attFileSize":"355.32 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14012026221502_Issue_Closing.pdf","attchmntText":"Biocon Limited has informed the Exchange about Qualified Institutions Placement - Issue Closure","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"14012026221638","exchdisstime":"14-Jan-2026 22:16:39","fileSize":"355.32 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106497752","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-14 22:16:38","symbol":"BIOCON"},{"an_dt":"12-Jan-2026 16:50:42","attFileSize":"3.08 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12012026165003_Issue_Opening.pdf","attchmntText":"Biocon Limited has informed the Exchange about Qualified Institutions Placement - Issue Opening","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:00","dt":"12012026165042","exchdisstime":"12-Jan-2026 16:50:42","fileSize":"3.08 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106494773","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-12 16:50:42","symbol":"BIOCON"},{"an_dt":"12-Jan-2026 16:10:52","attFileSize":"5.86 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12012026160941_Approval_of_Unaudited_Financial_Statement.pdf","attchmntText":"Biocon Limited has informed the Exchange about approval of Unaudited Condensed Consolidated Interim Financial Statements","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"12012026161052","exchdisstime":"12-Jan-2026 16:10:53","fileSize":"5.86 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106494717","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-12 16:10:52","symbol":"BIOCON"},{"an_dt":"12-Jan-2026 08:40:18","attFileSize":"2.99 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12012026083923_SE_notification_Everolimus_tablets-FOS_Approval_100126.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges '.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:00","dt":"12012026084018","exchdisstime":"12-Jan-2026 08:40:18","fileSize":"2.99 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106494091","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-12 08:40:18","symbol":"BIOCON"},{"an_dt":"08-Jan-2026 18:41:13","attFileSize":"3.19 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08012026184046_SEIntimationReg74.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:00","dt":"08012026184113","exchdisstime":"08-Jan-2026 18:41:13","fileSize":"3.19 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106491945","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-08 18:41:13","symbol":"BIOCON"},{"an_dt":"08-Jan-2026 13:56:36","attFileSize":"2.93 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08012026135548_SERecord_date.pdf","attchmntText":"Biocon Limited has informed the Exchange about  Record Date for Commercial Paper","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"08012026135636","exchdisstime":"08-Jan-2026 13:56:37","fileSize":"2.93 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106491518","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-08 13:56:36","symbol":"BIOCON"},{"an_dt":"06-Jan-2026 17:34:32","attFileSize":"3.13 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06012026173302_PressRelease06012026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 06, 2026, titled \"Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"06012026173432","exchdisstime":"06-Jan-2026 17:34:33","fileSize":"3.13 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106489151","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-06 17:34:32","symbol":"BIOCON"},{"an_dt":"05-Jan-2026 22:05:15","attFileSize":"2.97 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05012026220429_SE_disclosure__Biocon_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Acquisition of equity shares of Biocon Biologics Limited","bflag":null,"csvName":null,"desc":"Acquisition","difference":"00:00:01","dt":"05012026220515","exchdisstime":"05-Jan-2026 22:05:16","fileSize":"2.97 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106488059","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-05 22:05:15","symbol":"BIOCON"},{"an_dt":"05-Jan-2026 22:02:59","attFileSize":"2.97 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05012026215704_Montreal_-_SE_disclosure__Biocon_.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding allotment of 17,12,79,553 equity shares pursuant to Preferential Issue at its meeting held on January 05, 2026","bflag":null,"csvName":null,"desc":"Allotment of Securities","difference":"00:00:01","dt":"05012026220259","exchdisstime":"05-Jan-2026 22:03:00","fileSize":"2.97 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106488058","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-05 22:02:59","symbol":"BIOCON"},{"an_dt":"05-Jan-2026 12:34:55","attFileSize":"2.94 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05012026123426_Early_Redemption_of_NCDs_SE_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about early full redemption of NCDs by the Company","bflag":null,"csvName":null,"desc":"Redemption","difference":"00:00:01","dt":"05012026123455","exchdisstime":"05-Jan-2026 12:34:56","fileSize":"2.94 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106487419","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-05 12:34:55","symbol":"BIOCON"},{"an_dt":"02-Jan-2026 16:50:13","attFileSize":"3.01 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02012026164951_Intimation_for_allotment02012026.pdf","attchmntText":"Biocon Limited has informed the Exchange about Issue of Commercial Papers of Rs. 200 Crores","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"02012026165013","exchdisstime":"02-Jan-2026 16:50:14","fileSize":"3.01 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106486216","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-02 16:50:13","symbol":"BIOCON"},{"an_dt":"01-Jan-2026 11:13:15","attFileSize":"5.60 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01012026110923_BioconScrutinizerReportVotingResults.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Extraordinary General Meeting held on December 31, 2025. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"01012026111315","exchdisstime":"01-Jan-2026 11:13:16","fileSize":"5.60 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106485017","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2026-01-01 11:13:15","symbol":"BIOCON"},{"an_dt":"31-Dec-2025 18:12:14","attFileSize":"3.10 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31122025180728_Covering_Letter_EGM_Proceedings.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Proceedings of Extraordinary General Meeting held on December 31, 2025","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"31122025181214","exchdisstime":"31-Dec-2025 18:12:15","fileSize":"3.10 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106484302","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-31 18:12:14","symbol":"BIOCON"},{"an_dt":"26-Dec-2025 19:08:31","attFileSize":"2.93 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26122025190818_IntimationTradingWindow31122025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:01","dt":"26122025190831","exchdisstime":"26-Dec-2025 19:08:32","fileSize":"2.93 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106479118","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-26 19:08:31","symbol":"BIOCON"},{"an_dt":"24-Dec-2025 20:27:43","attFileSize":"2.98 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24122025202728_SERecord_date.pdf","attchmntText":"Biocon Limited has informed the Exchange about Intimation of Record Date for Commercial Paper","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"24122025202743","exchdisstime":"24-Dec-2025 20:27:44","fileSize":"2.98 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106476969","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-24 20:27:43","symbol":"BIOCON"},{"an_dt":"23-Dec-2025 17:34:31","attFileSize":"3.15 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23122025173405_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 23, 2025, titled \"Biocon Limited signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"23122025173431","exchdisstime":"23-Dec-2025 17:34:32","fileSize":"3.15 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106475371","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-23 17:34:31","symbol":"BIOCON"},{"an_dt":"23-Dec-2025 09:11:32","attFileSize":"3.11 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23122025090823_PressRelease_23122025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 23, 2025, titled \"Biocon Biologics Secures Full Global Rights to Biosimilar Adalimumab through Expanded FKB In-Licensing Agreement\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"23122025091132","exchdisstime":"23-Dec-2025 09:11:33","fileSize":"3.11 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106474530","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-23 09:11:32","symbol":"BIOCON"},{"an_dt":"22-Dec-2025 19:37:28","attFileSize":"3.01 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22122025193708_Intimation_for_allotment.pdf","attchmntText":"Biocon Limited has informed the Exchange about Issue of Commercial Papers","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"22122025193728","exchdisstime":"22-Dec-2025 19:37:29","fileSize":"3.01 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106474215","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-22 19:37:28","symbol":"BIOCON"},{"an_dt":"18-Dec-2025 17:44:21","attFileSize":"2.94 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18122025174345_Intimation_to_SE_US_FDA_EIR_BGI_Final_181225.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"18122025174421","exchdisstime":"18-Dec-2025 17:44:22","fileSize":"2.94 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106471533","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-18 17:44:21","symbol":"BIOCON"},{"an_dt":"17-Dec-2025 08:14:27","attFileSize":"3.08 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17122025081412_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 17, 2025, titled \"Biocon Biologics Recognized as Asia IP Elite for 2025 by IAM.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"17122025081427","exchdisstime":"17-Dec-2025 08:14:28","fileSize":"3.08 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106469940","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-17 08:14:27","symbol":"BIOCON"},{"an_dt":"16-Dec-2025 20:12:24","attFileSize":"3.28 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16122025201208_Cover_letter_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:02","dt":"16122025201224","exchdisstime":"16-Dec-2025 20:12:26","fileSize":"3.28 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106469668","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-16 20:12:24","symbol":"BIOCON"},{"an_dt":"16-Dec-2025 19:18:20","attFileSize":"3.49 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16122025191754_Cover_letter_Intimation-ICRA.pdf","attchmntText":"Biocon Limited has informed the Exchange about Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:02","dt":"16122025191820","exchdisstime":"16-Dec-2025 19:18:22","fileSize":"3.49 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106469630","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-16 19:18:20","symbol":"BIOCON"},{"an_dt":"15-Dec-2025 08:29:24","attFileSize":"362.75 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15122025082857_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 15, 2025, titled \"Biocon Limited launches its Glucagon-like Peptide-1 (GLP -1), Liraglutide, in the Netherlands\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"15122025082924","exchdisstime":"15-Dec-2025 08:29:25","fileSize":"362.75 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106467961","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-15 08:29:24","symbol":"BIOCON"},{"an_dt":"13-Dec-2025 13:40:56","attFileSize":"378.93 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13122025133818_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 13, 2025, titled \"Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"13122025134056","exchdisstime":"13-Dec-2025 13:40:57","fileSize":"378.93 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106467706","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-13 13:40:56","symbol":"BIOCON"},{"an_dt":"11-Dec-2025 13:15:59","attFileSize":"485.23 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11122025131526_SEIntimationSPPR11122025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 11, 2025, titled \"S&P Global Places Biocon Biologics on Positive CreditWatchOn Account of Accelerated Debt Reduction\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"11122025131559","exchdisstime":"11-Dec-2025 13:16:00","fileSize":"485.23 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106466018","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-11 13:15:59","symbol":"BIOCON"},{"an_dt":"10-Dec-2025 16:06:07","attFileSize":"2.94 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10122025160547_InvestorMeetingDecembe15192025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"10122025160607","exchdisstime":"10-Dec-2025 16:06:08","fileSize":"2.94 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106465112","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-10 16:06:07","symbol":"BIOCON"},{"an_dt":"10-Dec-2025 13:14:52","attFileSize":"3.03 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10122025131400_Intimation_of_Credit_Rating_India_Ratings-09122025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:01","dt":"10122025131452","exchdisstime":"10-Dec-2025 13:14:53","fileSize":"3.03 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106465013","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-10 13:14:52","symbol":"BIOCON"},{"an_dt":"09-Dec-2025 20:01:51","attFileSize":"5.08 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09122025200131_IR_PPT_Cover_Letter.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:00","dt":"09122025200151","exchdisstime":"09-Dec-2025 20:01:51","fileSize":"5.08 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106464451","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-09 20:01:51","symbol":"BIOCON"},{"an_dt":"08-Dec-2025 16:48:53","attFileSize":"3.57 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08122025164835_Intimation_NewspaperAd.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"08122025164853","exchdisstime":"08-Dec-2025 16:48:54","fileSize":"3.57 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106463260","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-08 16:48:53","symbol":"BIOCON"},{"an_dt":"07-Dec-2025 14:21:20","attFileSize":"4.08 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07122025141941_Biocon_EGM_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on December 31, 2025","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"07122025142120","exchdisstime":"07-Dec-2025 14:21:21","fileSize":"4.08 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106462713","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-07 14:21:20","symbol":"BIOCON"},{"an_dt":"06-Dec-2025 11:30:51","attFileSize":"3.08 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06122025113033_BM_Outcome06122025.pdf","attchmntText":"Biocon Limited has informed the Exchange about fund raising through issuance of Commercial Papers","bflag":null,"csvName":null,"desc":"Issue of Securities","difference":"00:00:01","dt":"06122025113051","exchdisstime":"06-Dec-2025 11:30:52","fileSize":"3.08 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106462403","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-06 11:30:51","symbol":"BIOCON"},{"an_dt":"06-Dec-2025 11:27:20","attFileSize":"3.08 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06122025112658_BM_Outcome06122025.pdf","attchmntText":"Biocon Limited has informed the Exchange about raising of funds by way of issuance of any instrument or security","bflag":null,"csvName":null,"desc":"Issue of Securities","difference":"00:00:01","dt":"06122025112720","exchdisstime":"06-Dec-2025 11:27:21","fileSize":"3.08 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106462401","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-06 11:27:20","symbol":"BIOCON"},{"an_dt":"06-Dec-2025 11:20:07","attFileSize":"3.08 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06122025111949_BM_Outcome06122025.pdf","attchmntText":"Biocon Limited has informed the Exchange about issue of Securities on preferential basis","bflag":null,"csvName":null,"desc":"Issue of Securities","difference":"00:00:01","dt":"06122025112007","exchdisstime":"06-Dec-2025 11:20:08","fileSize":"3.08 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106462396","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-06 11:20:07","symbol":"BIOCON"},{"an_dt":"06-Dec-2025 11:00:48","attFileSize":"3.08 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06122025110020_BM_Outcome06122025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.","bflag":null,"csvName":null,"desc":"Amendment to AOA/MOA","difference":"00:00:01","dt":"06122025110048","exchdisstime":"06-Dec-2025 11:00:49","fileSize":"3.08 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106462384","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-06 11:00:48","symbol":"BIOCON"},{"an_dt":"06-Dec-2025 10:55:47","attFileSize":"3.08 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06122025105530_BM_Outcome06122025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Acquisition","bflag":null,"csvName":null,"desc":"Acquisition","difference":"00:00:01","dt":"06122025105547","exchdisstime":"06-Dec-2025 10:55:48","fileSize":"3.08 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106462383","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-06 10:55:47","symbol":"BIOCON"},{"an_dt":"06-Dec-2025 10:52:20","attFileSize":"3.08 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06122025105157_BM_Outcome06122025.pdf","attchmntText":"Biocon Limited has informed the Exchange about outcome of Board Meeting","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"06122025105220","exchdisstime":"06-Dec-2025 10:52:21","fileSize":"3.08 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106462382","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-06 10:52:20","symbol":"BIOCON"},{"an_dt":"06-Dec-2025 10:47:14","attFileSize":"5.80 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06122025104655_Analyst_Call.pdf","attchmntText":"Biocon Limited has informed the Exchange about Presentation","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:02","dt":"06122025104714","exchdisstime":"06-Dec-2025 10:47:16","fileSize":"5.80 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106462380","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-06 10:47:14","symbol":"BIOCON"},{"an_dt":"06-Dec-2025 10:45:48","attFileSize":"5.80 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06122025104528_Analyst_Call.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"06122025104548","exchdisstime":"06-Dec-2025 10:45:49","fileSize":"5.80 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106462379","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-06 10:45:48","symbol":"BIOCON"},{"an_dt":"06-Dec-2025 10:17:55","attFileSize":"3.13 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06122025101728_Press_Release06122025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 06, 2025, titled \"Biocon Limited to Integrate Biocon Biologics Limited to Create a Unified Global Biopharmaceutical Leader\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"06122025101755","exchdisstime":"06-Dec-2025 10:17:56","fileSize":"3.13 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106462377","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-06 10:17:55","symbol":"BIOCON"},{"an_dt":"06-Dec-2025 10:14:18","attFileSize":"3.08 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06122025101327_BM_Outcome06122025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on December 06, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"06122025101418","exchdisstime":"06-Dec-2025 10:14:19","fileSize":"3.08 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106462376","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-06 10:14:18","symbol":"BIOCON"},{"an_dt":"05-Dec-2025 18:05:08","attFileSize":"2.98 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05122025180446_SE_notification_Carbidopa-Levodopa_FDA_TA_051225_Final.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"05122025180508","exchdisstime":"05-Dec-2025 18:05:09","fileSize":"2.98 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106462054","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-05 18:05:08","symbol":"BIOCON"},{"an_dt":"05-Dec-2025 15:51:22","attFileSize":"2.98 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05122025155023_InvestorMeetingDecember10_and112025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"05122025155122","exchdisstime":"05-Dec-2025 15:51:22","fileSize":"2.98 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106461886","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-05 15:51:22","symbol":"BIOCON"},{"an_dt":"02-Dec-2025 09:04:33","attFileSize":"392.26 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02122025090356_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 02, 2025, titled \"Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World®\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"02122025090433","exchdisstime":"02-Dec-2025 09:04:34","fileSize":"392.26 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106458788","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-12-02 09:04:33","symbol":"BIOCON"},{"an_dt":"27-Nov-2025 08:23:13","attFileSize":"355.91 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_27112025082247_SEIntimation27112025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"27112025082313","exchdisstime":"27-Nov-2025 08:23:14","fileSize":"355.91 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106455494","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-27 08:23:13","symbol":"BIOCON"},{"an_dt":"19-Nov-2025 09:07:19","attFileSize":"242.78 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_19112025090703_SE_notification_Tofacitinib_approval-US_Final_181125_SIGNED.pdf","attchmntText":"Biocon Limited has informed the Exchange about Notification to Stock Exchanges","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"19112025090719","exchdisstime":"19-Nov-2025 09:07:20","fileSize":"242.78 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106449470","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-19 09:07:19","symbol":"BIOCON"},{"an_dt":"18-Nov-2025 16:58:17","attFileSize":"777.12 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_18112025165746_Cover_Letter_Transcript_Earnings_Call.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"18112025165817","exchdisstime":"18-Nov-2025 16:58:18","fileSize":"777.12 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106448825","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-18 16:58:17","symbol":"BIOCON"},{"an_dt":"14-Nov-2025 08:30:29","attFileSize":"276.19 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_14112025082957_Rumour_verification.pdf","attchmntText":"Biocon Limited has informed the Exchange about Rumour Verification - Regulation 30(11)","bflag":null,"csvName":null,"desc":"Rumour Verification - Regulation 30(11)","difference":"00:00:01","dt":"14112025083029","exchdisstime":"14-Nov-2025 08:30:30","fileSize":"276.19 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106443385","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-14 08:30:29","symbol":"BIOCON"},{"an_dt":"13-Nov-2025 16:40:02","attFileSize":"2.94 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_13112025163941_Covering_Letter.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"13112025164002","exchdisstime":"13-Nov-2025 16:40:03","fileSize":"2.94 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106441946","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-13 16:40:02","symbol":"BIOCON"},{"an_dt":"12-Nov-2025 15:07:31","attFileSize":"244.18 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_12112025150621_Cover_Letter_Earnings_Call_LINK.pdf","attchmntText":"Biocon Limited has informed the Exchange about Link of Recording","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"12112025150731","exchdisstime":"12-Nov-2025 15:07:32","fileSize":"244.18 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106439274","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-12 15:07:31","symbol":"BIOCON"},{"an_dt":"12-Nov-2025 08:25:22","attFileSize":"2.06 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_12112025082431_IR_PPT_Cover_Letter.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:01","dt":"12112025082522","exchdisstime":"12-Nov-2025 08:25:23","fileSize":"2.06 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106438564","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-12 08:25:22","symbol":"BIOCON"},{"an_dt":"11-Nov-2025 20:57:14","attFileSize":"3.69 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_11112025205644_SE_Intimation_-_Monitoring_Agency.pdf","attchmntText":"Monitoring Agency Report for the quarter ended on September 30, 2025","bflag":null,"csvName":null,"desc":"Monitoring Agency Report","difference":"00:00:01","dt":"11112025205714","exchdisstime":"11-Nov-2025 20:57:15","fileSize":"3.69 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106438141","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-11 20:57:14","symbol":"BIOCON"},{"an_dt":"11-Nov-2025 20:47:31","attFileSize":"1.13 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_11112025204534_Covering_Letter_Press_Release.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 11, 2025, titled \"Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%; PBT (before exceptional items) at Rs 183 Cr, Up 153%\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:02","dt":"11112025204731","exchdisstime":"11-Nov-2025 20:47:33","fileSize":"1.13 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106438124","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-11 20:47:31","symbol":"BIOCON"},{"an_dt":"11-Nov-2025 20:42:22","attFileSize":"8.41 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_11112025204130_Outcome_of_BM11112025.pdf","attchmntText":"Biocon Limited has informed the Exchange about issue of Securities through of Issuance of Commercial Papers","bflag":null,"csvName":null,"desc":"Issue of Securities","difference":"00:00:01","dt":"11112025204222","exchdisstime":"11-Nov-2025 20:42:23","fileSize":"8.41 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106438109","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-11 20:42:22","symbol":"BIOCON"},{"an_dt":"11-Nov-2025 20:39:26","attFileSize":"8.41 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_11112025203851_Outcome_of_BM11112025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Agreements","bflag":null,"csvName":null,"desc":"Agreements","difference":"00:00:01","dt":"11112025203926","exchdisstime":"11-Nov-2025 20:39:27","fileSize":"8.41 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106438100","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-11 20:39:26","symbol":"BIOCON"},{"an_dt":"11-Nov-2025 20:37:22","attFileSize":"8.41 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_11112025203652_Outcome_of_BM11112025.pdf","attchmntText":"Biocon Limited has informed the Exchange about  outcome of the Board Meeting-Early full redemption of Non-Convertible Debentures","bflag":null,"csvName":null,"desc":"Redemption","difference":"00:00:01","dt":"11112025203722","exchdisstime":"11-Nov-2025 20:37:23","fileSize":"8.41 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106438092","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-11 20:37:22","symbol":"BIOCON"},{"an_dt":"11-Nov-2025 20:34:17","attFileSize":"8.41 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_11112025203157_Outcome_of_BM11112025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on November 11, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"11112025203417","exchdisstime":"11-Nov-2025 20:34:18","fileSize":"8.41 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106438086","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-11 20:34:17","symbol":"BIOCON"},{"an_dt":"11-Nov-2025 20:28:48","attFileSize":"8.41 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_11112025202622_Outcome_of_BM11112025.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"11112025202848","exchdisstime":"11-Nov-2025 20:28:49","fileSize":"8.41 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106438078","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-11 20:28:48","symbol":"BIOCON"},{"an_dt":"08-Nov-2025 18:00:43","attFileSize":"245.99 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_08112025180009_Intimation_to_SE_FDA_inspection_Site_6_Final_0811255.pdf","attchmntText":"Biocon Limited has informed the Exchange about Notification to Stock Exchange","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"08112025180043","exchdisstime":"08-Nov-2025 18:00:44","fileSize":"245.99 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106433756","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-08 18:00:43","symbol":"BIOCON"},{"an_dt":"04-Nov-2025 15:08:29","attFileSize":"423.81 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_04112025150748_Earning_call_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:02","dt":"04112025150829","exchdisstime":"04-Nov-2025 15:08:31","fileSize":"423.81 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106426291","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-11-04 15:08:29","symbol":"BIOCON"},{"an_dt":"30-Oct-2025 20:37:26","attFileSize":"856.24 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_30102025203707_Cover_letter_Intimation-ICRA.pdf","attchmntText":"Biocon Limited has informed the Exchange about Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:01","dt":"30102025203726","exchdisstime":"30-Oct-2025 20:37:27","fileSize":"856.24 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106421436","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-10-30 20:37:26","symbol":"BIOCON"},{"an_dt":"30-Oct-2025 15:47:49","attFileSize":"232.93 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_30102025154723_Name_change_of_subsidiaries.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Intimation of change in status and name of step-down subsidiary of the Company'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"30102025154749","exchdisstime":"30-Oct-2025 15:47:50","fileSize":"232.93 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106420823","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-10-30 15:47:49","symbol":"BIOCON"},{"an_dt":"23-Oct-2025 18:34:03","attFileSize":"3.16 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_23102025183242_Intimation_Name_change_of_subsidiaries.pdf","attchmntText":"Biocon Limited has informed the Exchange about change in name of step-down subsidiaries of the Company","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"23102025183403","exchdisstime":"23-Oct-2025 18:34:04","fileSize":"3.16 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106414505","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-10-23 18:34:03","symbol":"BIOCON"},{"an_dt":"23-Oct-2025 08:13:27","attFileSize":"3.40 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_23102025081252_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 23, 2025, titled \"Biocon Biologics Receives Health Canada Approval for Yesintek  and Yesintek  I.V. (ustekinumab), a Biosimilar to Stelara®\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"23102025081327","exchdisstime":"23-Oct-2025 08:13:28","fileSize":"3.40 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106413955","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-10-23 08:13:27","symbol":"BIOCON"},{"an_dt":"16-Oct-2025 15:50:47","attFileSize":"3.55 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_16102025155008_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 16, 2025, titled \"Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"16102025155047","exchdisstime":"16-Oct-2025 15:50:48","fileSize":"3.55 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106409731","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-10-16 15:50:47","symbol":"BIOCON"},{"an_dt":"13-Oct-2025 18:18:55","attFileSize":"2.84 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_13102025181809_Reg_745Biocon30092025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:01","dt":"13102025181855","exchdisstime":"13-Oct-2025 18:18:56","fileSize":"2.84 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106406021","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-10-13 18:18:55","symbol":"BIOCON"},{"an_dt":"11-Oct-2025 20:43:18","attFileSize":"2.64 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_11102025204303_Cranbury_Inspection_FDA.pdf","attchmntText":"Biocon Limited has informed the Exchange about Company Statement","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:02","dt":"11102025204318","exchdisstime":"11-Oct-2025 20:43:20","fileSize":"2.64 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106405074","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-10-11 20:43:18","symbol":"BIOCON"},{"an_dt":"09-Oct-2025 16:53:44","attFileSize":"2.62 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_09102025165235_InvestorMeeting17102025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"09102025165344","exchdisstime":"09-Oct-2025 16:53:45","fileSize":"2.62 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106402783","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-10-09 16:53:44","symbol":"BIOCON"},{"an_dt":"09-Oct-2025 13:16:26","attFileSize":"2.86 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_09102025131535_SE_Intimation_on_amendment_in_Trust_Deed.pdf","attchmntText":"Biocon Limited has informed the Exchange about General Updates","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"09102025131626","exchdisstime":"09-Oct-2025 13:16:27","fileSize":"2.86 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106402363","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-10-09 13:16:26","symbol":"BIOCON"},{"an_dt":"07-Oct-2025 08:05:29","attFileSize":"260.51 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_07102025080506_Notification_to_SE07102025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Notification to Stock Exchanges","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"07102025080529","exchdisstime":"07-Oct-2025 08:05:30","fileSize":"260.51 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106399097","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-10-07 08:05:29","symbol":"BIOCON"},{"an_dt":"01-Oct-2025 20:10:02","attFileSize":"216.83 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_01102025200501_NCDEarlyRedemption.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on October 01, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"01102025201002","exchdisstime":"01-Oct-2025 20:10:03","fileSize":"216.83 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106395847","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-10-01 20:10:02","symbol":"BIOCON"},{"an_dt":"01-Oct-2025 09:01:30","attFileSize":"489.15 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_01102025090108_PressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 01, 2025, titled \"Biocon Biologics Secures U.S. Market Entry Date for Bosaya  and Aukelso , Denosumab Biosimilars\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"01102025090130","exchdisstime":"01-Oct-2025 09:01:31","fileSize":"489.15 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106394717","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-10-01 09:01:30","symbol":"BIOCON"},{"an_dt":"26-Sep-2025 17:54:15","attFileSize":"216.55 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_26092025175149_TWClosure30092025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:01","dt":"26092025175415","exchdisstime":"26-Sep-2025 17:54:16","fileSize":"216.55 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106387601","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-26 17:54:15","symbol":"BIOCON"},{"an_dt":"25-Sep-2025 17:23:02","attFileSize":"241.79 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_25092025172225_IntimationShowCauseNotice.pdf","attchmntText":"Biocon Limited has informed the Exchange about Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company","bflag":null,"csvName":null,"desc":"Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company","difference":"00:00:01","dt":"25092025172302","exchdisstime":"25-Sep-2025 17:23:03","fileSize":"241.79 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106384655","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-25 17:23:02","symbol":"BIOCON"},{"an_dt":"18-Sep-2025 16:24:30","attFileSize":"513.00 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_18092025162408_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 18, 2025, titled \"Biocon Biologics  Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"18092025162430","exchdisstime":"18-Sep-2025 16:24:31","fileSize":"513.00 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106377025","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-18 16:24:30","symbol":"BIOCON"},{"an_dt":"17-Sep-2025 19:06:38","attFileSize":"193.38 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_17092025190621_SERecorddate18092025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Intimation of record date for buy back of listed Commercial Paper issued by the Company","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"17092025190638","exchdisstime":"17-Sep-2025 19:06:39","fileSize":"193.38 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106376130","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-17 19:06:38","symbol":"BIOCON"},{"an_dt":"17-Sep-2025 16:14:37","attFileSize":"550.09 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_17092025161413_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 17, 2025, titled \"Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya  and Aukelso , Denosumab Biosimilars\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"17092025161437","exchdisstime":"17-Sep-2025 16:14:38","fileSize":"550.09 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106375827","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-17 16:14:37","symbol":"BIOCON"},{"an_dt":"13-Sep-2025 18:21:28","attFileSize":"640.80 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_13092025182025_SE_Intimation_Covering_Letter.pdf","attchmntText":"Biocon Limited has informed the Exchange about Letters to shareholders under 100 Days Campaign    Saksham Niveshak","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"13092025182128","exchdisstime":"13-Sep-2025 18:21:29","fileSize":"640.80 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106373062","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-13 18:21:28","symbol":"BIOCON"},{"an_dt":"12-Sep-2025 17:34:32","attFileSize":"467.79 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_12092025173401_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 12, 2025, titled \"Biocon Foundation Supports Government High School, Kicks off Construction of a New Building for 250 Students Dr C. N. Manjunath, M.P. Bengaluru Rural Constituency Performs the Groundbreaking Ceremony\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"12092025173432","exchdisstime":"12-Sep-2025 17:34:33","fileSize":"467.79 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106372366","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-12 17:34:32","symbol":"BIOCON"},{"an_dt":"12-Sep-2025 17:30:22","attFileSize":"467.79 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_12092025172911_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 12, 2025, titled \"Biocon Foundation Supports Government High School, Kicks off Construction of a New Building for 250 Students Dr C. N. Manjunath, M.P. Bengaluru Rural Constituency Performs the Groundbreaking Ceremony \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"12092025173022","exchdisstime":"12-Sep-2025 17:30:23","fileSize":"467.79 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106372362","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-12 17:30:22","symbol":"BIOCON"},{"an_dt":"11-Sep-2025 00:31:38","attFileSize":"315.13 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_11092025003115_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 10, 2025, titled \"Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:00","dt":"11092025003138","exchdisstime":"11-Sep-2025 00:31:38","fileSize":"315.13 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106370658","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-11 00:31:38","symbol":"BIOCON"},{"an_dt":"10-Sep-2025 20:11:29","attFileSize":"382.39 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_10092025201105_SEIntimationCovering_Letter.pdf","attchmntText":"Biocon Limited has informed the Exchange about Email communication to shareholders under 100 Days Campaign    Saksham Niveshak","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"10092025201129","exchdisstime":"10-Sep-2025 20:11:30","fileSize":"382.39 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106370398","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-10 20:11:29","symbol":"BIOCON"},{"an_dt":"09-Sep-2025 20:10:01","attFileSize":"316.05 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_09092025200940_SE_Intimation_on_CS_appointment.pdf","attchmntText":"Biocon Limited has informed the Exchange about Change in Company Secretary/Compliance Officer","bflag":null,"csvName":null,"desc":"Change in Company Secretary/Compliance Officer","difference":"00:00:01","dt":"09092025201001","exchdisstime":"09-Sep-2025 20:10:02","fileSize":"316.05 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106369324","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-09 20:10:01","symbol":"BIOCON"},{"an_dt":"09-Sep-2025 20:08:11","attFileSize":"316.05 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_09092025200708_SE_Intimation_on_CS_appointment.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on September 09, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"09092025200811","exchdisstime":"09-Sep-2025 20:08:12","fileSize":"316.05 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106369319","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-09 20:08:11","symbol":"BIOCON"},{"an_dt":"09-Sep-2025 14:42:38","attFileSize":"224.56 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_09092025144207_InvestorMeeting09092025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"09092025144238","exchdisstime":"09-Sep-2025 14:42:39","fileSize":"224.56 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106368875","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-09 14:42:38","symbol":"BIOCON"},{"an_dt":"05-Sep-2025 19:57:19","attFileSize":"224.25 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_05092025195649_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"05092025195719","exchdisstime":"05-Sep-2025 19:57:20","fileSize":"224.25 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106365533","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-05 19:57:19","symbol":"BIOCON"},{"an_dt":"04-Sep-2025 19:21:55","attFileSize":"269.13 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_04092025192140_SEIntimation04092025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Company Statement","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"04092025192155","exchdisstime":"04-Sep-2025 19:21:56","fileSize":"269.13 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106363770","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-04 19:21:55","symbol":"BIOCON"},{"an_dt":"02-Sep-2025 17:23:31","attFileSize":"538.16 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_02092025172305_InvestorMeeting05092025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"02092025172331","exchdisstime":"02-Sep-2025 17:23:32","fileSize":"538.16 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106360095","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-09-02 17:23:31","symbol":"BIOCON"},{"an_dt":"29-Aug-2025 19:56:16","attFileSize":"224.14 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_29082025195558_InvestorMeeting03092025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"29082025195616","exchdisstime":"29-Aug-2025 19:56:16","fileSize":"224.14 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106356251","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-29 19:56:16","symbol":"BIOCON"},{"an_dt":"26-Aug-2025 20:58:25","attFileSize":"233.58 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_26082025205808_SE26082025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Notification to Stock Exchanges","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:00","dt":"26082025205825","exchdisstime":"26-Aug-2025 20:58:25","fileSize":"233.58 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106352817","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-26 20:58:25","symbol":"BIOCON"},{"an_dt":"20-Aug-2025 19:19:27","attFileSize":"777.28 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_20082025191911_Newspaper_Ad.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"20082025191927","exchdisstime":"20-Aug-2025 19:19:28","fileSize":"777.28 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106346906","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-20 19:19:27","symbol":"BIOCON"},{"an_dt":"14-Aug-2025 19:48:33","attFileSize":"816.71 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_14082025194801_Cover_Letter_Transcript_Earnings_Call.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"14082025194833","exchdisstime":"14-Aug-2025 19:48:34","fileSize":"816.71 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106342539","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-14 19:48:33","symbol":"BIOCON"},{"an_dt":"14-Aug-2025 18:32:34","attFileSize":"223.90 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_14082025183149_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"14082025183234","exchdisstime":"14-Aug-2025 18:32:35","fileSize":"223.90 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106342262","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-14 18:32:34","symbol":"BIOCON"},{"an_dt":"11-Aug-2025 23:48:05","attFileSize":"1.62 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_11082025234705_SEVotingresults.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Annual General Meeting held on August 08, 2025. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"11082025234805","exchdisstime":"11-Aug-2025 23:48:06","fileSize":"1.62 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106335740","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-11 23:48:05","symbol":"BIOCON"},{"an_dt":"09-Aug-2025 14:37:09","attFileSize":"4.39 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_09082025143602_Covering_Letter.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"09082025143709","exchdisstime":"09-Aug-2025 14:37:10","fileSize":"4.39 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106333737","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-09 14:37:09","symbol":"BIOCON"},{"an_dt":"08-Aug-2025 19:04:56","attFileSize":"3.58 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_08082025190236_Covering_Letter_Chairman_speech.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Chairperson's Speech at the 47th Annual General Meeting of the Company.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"08082025190456","exchdisstime":"08-Aug-2025 19:04:57","fileSize":"3.58 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106332977","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-08 19:04:56","symbol":"BIOCON"},{"an_dt":"08-Aug-2025 18:56:38","attFileSize":"307.80 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_08082025185421_SEsIntimationDirector.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"00:00:01","dt":"08082025185638","exchdisstime":"08-Aug-2025 18:56:39","fileSize":"307.80 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106332944","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-08 18:56:38","symbol":"BIOCON"},{"an_dt":"08-Aug-2025 18:42:02","attFileSize":"408.03 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_08082025184012_SEAGMProceedings.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 08, 2025","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"08082025184202","exchdisstime":"08-Aug-2025 18:42:03","fileSize":"408.03 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106332881","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-08 18:42:02","symbol":"BIOCON"},{"an_dt":"08-Aug-2025 17:28:32","attFileSize":"263.26 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_08082025172728_CoverLetterEarningsCallLINK.pdf","attchmntText":"Biocon Limited has informed the Exchange about Link of Recording","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"08082025172832","exchdisstime":"08-Aug-2025 17:28:33","fileSize":"263.26 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106332518","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-08 17:28:32","symbol":"BIOCON"},{"an_dt":"08-Aug-2025 08:18:50","attFileSize":"1.96 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_08082025081826_IRPPTCoverLetter.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:01","dt":"08082025081850","exchdisstime":"08-Aug-2025 08:18:51","fileSize":"1.96 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106331271","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-08 08:18:50","symbol":"BIOCON"},{"an_dt":"07-Aug-2025 21:10:46","attFileSize":"2.31 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_07082025211019_SEIntimationMonitoringAgency.pdf","attchmntText":"Monitoring Agency Report","bflag":null,"csvName":null,"desc":"Monitoring Agency Report","difference":"00:00:01","dt":"07082025211046","exchdisstime":"07-Aug-2025 21:10:47","fileSize":"2.31 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106330917","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-07 21:10:46","symbol":"BIOCON"},{"an_dt":"07-Aug-2025 21:00:08","attFileSize":"236.33 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_07082025205937_SEIntimationAcquisitionFinalProzeal.pdf","attchmntText":"Biocon Limited has informed the Exchange about Acquisition","bflag":null,"csvName":null,"desc":"Acquisition","difference":"00:00:01","dt":"07082025210008","exchdisstime":"07-Aug-2025 21:00:09","fileSize":"236.33 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106330900","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-07 21:00:08","symbol":"BIOCON"},{"an_dt":"07-Aug-2025 20:49:09","attFileSize":"236.33 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_07082025204819_SEIntimationAcquisitionFinalProzeal.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on August 07, 2025 regarding Acquisition.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:02","dt":"07082025204909","exchdisstime":"07-Aug-2025 20:49:11","fileSize":"236.33 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106330872","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-07 20:49:09","symbol":"BIOCON"},{"an_dt":"07-Aug-2025 20:33:34","attFileSize":"1.14 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_07082025203305_CoveringLetterPressRelease07082025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 07, 2025, titled \"Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15%EBITDA at Rs 829 Cr; Up 19%*;PBT (before exceptional item) at Rs 97 Cr, Up 72%*Biosimilars Up 18%, CRDMO Up 11% and Generics Up 6%\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:02","dt":"07082025203334","exchdisstime":"07-Aug-2025 20:33:36","fileSize":"1.14 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106330847","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-07 20:33:34","symbol":"BIOCON"},{"an_dt":"07-Aug-2025 20:28:13","attFileSize":"8.02 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_07082025202612_OutcomeofBM07082025.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"07082025202813","exchdisstime":"07-Aug-2025 20:28:14","fileSize":"8.02 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106330828","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-08-07 20:28:13","symbol":"BIOCON"},{"an_dt":"28-Jul-2025 14:37:21","attFileSize":"466.67 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_28072025143627_PressRelease28072025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 28, 2025, titled \"Biocon Foundation and IISc Commemorate World Head & Neck Cancer Day\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"28072025143721","exchdisstime":"28-Jul-2025 14:37:22","fileSize":"466.67 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106314073","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-28 14:37:21","symbol":"BIOCON"},{"an_dt":"23-Jul-2025 12:33:25","attFileSize":"906.36 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_23072025123244_SEPressRelease23072025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 23, 2025, titled \"Deepali Naair Appointed as the Global Head - Brand &Corporate Communications at Biocon Biologics\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"23072025123325","exchdisstime":"23-Jul-2025 12:33:26","fileSize":"906.36 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106308777","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-23 12:33:25","symbol":"BIOCON"},{"an_dt":"23-Jul-2025 08:45:10","attFileSize":"391.92 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_23072025084427_SEIntimation23072025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Company Statement","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"23072025084510","exchdisstime":"23-Jul-2025 08:45:11","fileSize":"391.92 KB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106308473","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-23 08:45:10","symbol":"BIOCON"},{"an_dt":"18-Jul-2025 17:41:42","attFileSize":"1.55 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_18072025173919_SEIntimation18072025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:02","dt":"18072025174142","exchdisstime":"18-Jul-2025 17:41:44","fileSize":"1.55 MB","hasXbrl":true,"old_new":null,"orgid":null,"seq_id":"106304561","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-18 17:41:42","symbol":"BIOCON"},{"an_dt":"17-Jul-2025 14:08:45","attFileSize":"8.89 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_17072025140714_Biocon_AGM_Intimation_SEs.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 08, 2025","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"17072025140845","exchdisstime":"17-Jul-2025 14:08:46","fileSize":"8.89 MB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106302819","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-17 14:08:45","symbol":"BIOCON"},{"an_dt":"16-Jul-2025 00:00:38","attFileSize":"385.55 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_16072025000015_CoverLetterpressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 15, 2025, titled \"Biocon Biologics Expands Diabetes Portfolio with FDA Approvalof Kirsty , the First and Only Interchangeable Rapid-ActingInsulin Aspart in the United States\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"16072025000038","exchdisstime":"16-Jul-2025 00:00:39","fileSize":"385.55 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106301196","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-16 00:00:38","symbol":"BIOCON"},{"an_dt":"10-Jul-2025 18:56:42","attFileSize":"2.87 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_10072025185628_SE.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:02","dt":"10072025185642","exchdisstime":"10-Jul-2025 18:56:44","fileSize":"2.87 MB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106296171","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-10 18:56:42","symbol":"BIOCON"},{"an_dt":"10-Jul-2025 17:03:18","attFileSize":"3.07 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_10072025170251_CFOCertificateFundUtilizationJune302025.pdf","attchmntText":"Biocon Limited has informed the Exchange about the Certificate pursuant to SEBI Master Circular no. SEBI/HO/DDHS/PoD1/P/CIR/2024/54dated May 22, 2024.","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"10072025170318","exchdisstime":"10-Jul-2025 17:03:19","fileSize":"3.07 MB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106295957","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-10 17:03:18","symbol":"BIOCON"},{"an_dt":"09-Jul-2025 20:10:11","attFileSize":"227.82 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_09072025200945_SEIntimationonCSappoitment.pdf","attchmntText":"Biocon Limited has informed the Exchange about outcome of Board Meeting - Appointment of Interim Company Secretary and Compliance Officer","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"09072025201011","exchdisstime":"09-Jul-2025 20:10:12","fileSize":"227.82 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106294941","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-09 20:10:11","symbol":"BIOCON"},{"an_dt":"09-Jul-2025 20:08:02","attFileSize":"227.82 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_09072025200730_SEIntimationonCSappoitment.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Appointment of Ms Ekta Agarwal as Company Secretary & Compliance Officer of the company w.e.f. July 10, 2025.","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:01","dt":"09072025200802","exchdisstime":"09-Jul-2025 20:08:03","fileSize":"227.82 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106294938","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-09 20:08:02","symbol":"BIOCON"},{"an_dt":"09-Jul-2025 20:05:48","attFileSize":"227.82 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_09072025200504_SEIntimationonCSappoitment.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on July 09, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"09072025200548","exchdisstime":"09-Jul-2025 20:05:49","fileSize":"227.82 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106294935","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-09 20:05:48","symbol":"BIOCON"},{"an_dt":"08-Jul-2025 17:20:26","attFileSize":"362.50 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_08072025171935_BMIntimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"08072025172026","exchdisstime":"08-Jul-2025 17:20:26","fileSize":"362.50 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106293288","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-08 17:20:26","symbol":"BIOCON"},{"an_dt":"07-Jul-2025 08:07:36","attFileSize":"406.34 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_07072025080709_PR07072025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 07, 2025, titled \"Biocon Biologics Receives MHRA UK Approval for Vevzuo® and Evfraxy®, Denosumab Biosimilars\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"07072025080736","exchdisstime":"07-Jul-2025 08:07:37","fileSize":"406.34 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106291161","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-07 08:07:36","symbol":"BIOCON"},{"an_dt":"04-Jul-2025 14:27:50","attFileSize":"3.48 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_04072025142736_IntimationPriorAGM.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"04072025142750","exchdisstime":"04-Jul-2025 14:27:51","fileSize":"3.48 MB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106289908","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-04 14:27:50","symbol":"BIOCON"},{"an_dt":"03-Jul-2025 08:21:20","attFileSize":"286.46 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_03072025082035_PressRelease03072025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 03, 2025, titled \"Advancing Bone Health: European Commission ApprovesBiocon Biologics  Denosumab Biosimilars\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:02","dt":"03072025082120","exchdisstime":"03-Jul-2025 08:21:22","fileSize":"286.46 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106288441","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-07-03 08:21:20","symbol":"BIOCON"},{"an_dt":"30-Jun-2025 08:38:55","attFileSize":"801.19 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_30062025083708_PressRelease30062025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 30, 2025, titled \"Biocon Biologics Expands Insulin Access in Malaysia Over 100 Mn Cartridges of rh-Insulin Supplied to Health Ministry; 345,000+ patients served\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:02","dt":"30062025083855","exchdisstime":"30-Jun-2025 08:38:57","fileSize":"801.19 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106284195","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-30 08:38:55","symbol":"BIOCON"},{"an_dt":"27-Jun-2025 09:19:30","attFileSize":"502.63 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_27062025091834_SEIntimation27062025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 27, 2025, titled \"Biocon Biologics Receives Health Canada Approval for Yesafili  (aflibercept); First Global Launch Scheduled for July 2025\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"27062025091930","exchdisstime":"27-Jun-2025 09:19:31","fileSize":"502.63 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106281502","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-27 09:19:30","symbol":"BIOCON"},{"an_dt":"26-Jun-2025 20:19:23","attFileSize":"182.24 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_26062025201900_TradingWindow30062025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:01","dt":"26062025201923","exchdisstime":"26-Jun-2025 20:19:24","fileSize":"182.24 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106281155","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-26 20:19:23","symbol":"BIOCON"},{"an_dt":"26-Jun-2025 20:05:35","attFileSize":"233.37 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_26062025200241_SEintimationBM26062025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Agreements","bflag":null,"csvName":null,"desc":"Agreements","difference":"00:00:01","dt":"26062025200535","exchdisstime":"26-Jun-2025 20:05:36","fileSize":"233.37 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106281141","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-26 20:05:35","symbol":"BIOCON"},{"an_dt":"26-Jun-2025 20:00:40","attFileSize":"233.37 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_26062025195856_SEintimationBM26062025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on Jun 26, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"26062025200040","exchdisstime":"26-Jun-2025 20:00:41","fileSize":"233.37 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106281137","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-26 20:00:40","symbol":"BIOCON"},{"an_dt":"26-Jun-2025 08:42:57","attFileSize":"369.75 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_26062025084212_SEIntimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Communication to the shareholders w.r.t. TDS on Final Dividend","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"26062025084257","exchdisstime":"26-Jun-2025 08:42:58","fileSize":"369.75 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106279155","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-26 08:42:57","symbol":"BIOCON"},{"an_dt":"24-Jun-2025 08:55:44","attFileSize":"399.83 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_24062025085406_SEPressrelase-24062025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 24, 2025, titled \"Biocon Biologics Collaborates with National Cancer Society MalaysiaRolls Out Patient Assistance Program to Expand Affordable Access to Biosimilars\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"24062025085544","exchdisstime":"24-Jun-2025 08:55:45","fileSize":"399.83 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106276242","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-24 08:55:44","symbol":"BIOCON"},{"an_dt":"20-Jun-2025 18:45:45","attFileSize":"1.00 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_20062025184520_PR20062025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 20, 2025, titled \"Biocon Limited Concludes a Rs 4,500 Crore (USD 523million1) Equity Fundraise through a Qualified Institutions Placement (QIP)\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"20062025184545","exchdisstime":"20-Jun-2025 18:45:46","fileSize":"1.00 MB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106274237","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-20 18:45:45","symbol":"BIOCON"},{"an_dt":"20-Jun-2025 00:04:55","attFileSize":"276.74 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_20062025000424_Intimationofallotment.pdf","attchmntText":"Biocon Limited has informed the Exchange about General Updates","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"20062025000455","exchdisstime":"20-Jun-2025 00:04:56","fileSize":"276.74 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106273511","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-20 00:04:55","symbol":"BIOCON"},{"an_dt":"19-Jun-2025 22:36:40","attFileSize":"236.38 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_19062025223617_4IntimationofPDapproval.pdf","attchmntText":"Biocon Limited has informed the Exchange about Qualified Institutions Placement - Approval and adoption the Placement Document dated June 19, 2025","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:02","dt":"19062025223640","exchdisstime":"19-Jun-2025 22:36:42","fileSize":"236.38 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106273354","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-19 22:36:40","symbol":"BIOCON"},{"an_dt":"19-Jun-2025 19:51:17","attFileSize":"280.23 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_19062025195045_3IntimationofissueClosing.pdf","attchmntText":"Biocon Limited has informed the Exchange about Qualified Institutions Placement","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"19062025195117","exchdisstime":"19-Jun-2025 19:51:18","fileSize":"280.23 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106273211","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-19 19:51:17","symbol":"BIOCON"},{"an_dt":"18-Jun-2025 00:27:13","attFileSize":"752.03 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_18062025002537_SECreditrating18062025.pdf","attchmntText":"Biocon Limited has informed the Exchange about General Updates","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:02","dt":"18062025002713","exchdisstime":"18-Jun-2025 00:27:15","fileSize":"752.03 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106271520","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-18 00:27:13","symbol":"BIOCON"},{"an_dt":"16-Jun-2025 18:46:02","attFileSize":"260.49 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_16062025184550_QIPLaunch.pdf","attchmntText":"Biocon Limited has informed the Exchange about Qualified Institutions Placement of equity shares","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:00","dt":"16062025184602","exchdisstime":"16-Jun-2025 18:46:02","fileSize":"260.49 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106270294","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-16 18:46:02","symbol":"BIOCON"},{"an_dt":"16-Jun-2025 09:39:02","attFileSize":"7.69 MB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_16062025093824_SEIntimation16062025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Intimation of the approval of the audited consolidated financial statements for the financial year March 31, 2025","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"16062025093902","exchdisstime":"16-Jun-2025 09:39:03","fileSize":"7.69 MB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106269765","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-16 09:39:02","symbol":"BIOCON"},{"an_dt":"09-Jun-2025 16:57:44","attFileSize":"472.37 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_09062025165711_PressRelease09062025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 09, 2025, titled \"Biocon Foundation in Partnership with NCBS and BeST Cluster Launches BioWISE Program - to Empower Women in STEM\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"09062025165744","exchdisstime":"09-Jun-2025 16:57:45","fileSize":"472.37 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106265206","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-09 16:57:44","symbol":"BIOCON"},{"an_dt":"04-Jun-2025 22:05:06","attFileSize":"895.18 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_04062025220233_SEIntimationPostalBallot.pdf","attchmntText":"Biocon Limited has informed the Exchange about Shareholders meeting","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"04062025220506","exchdisstime":"04-Jun-2025 22:05:07","fileSize":"895.18 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106262228","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-04 22:05:06","symbol":"BIOCON"},{"an_dt":"02-Jun-2025 19:30:32","attFileSize":"404.24 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_02062025193002_SEIntimation02062025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Press Release","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"02062025193032","exchdisstime":"02-Jun-2025 19:30:33","fileSize":"404.24 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106260154","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-06-02 19:30:32","symbol":"BIOCON"},{"an_dt":"27-May-2025 21:58:52","attFileSize":"309.39 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_27052025215824_Intimation2025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Reminder Letter sent to holders of physical securities for furnishing of KYC details","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"27052025215852","exchdisstime":"27-May-2025 21:58:53","fileSize":"309.39 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106251120","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-27 21:58:52","symbol":"BIOCON"},{"an_dt":"25-May-2025 13:56:40","attFileSize":"371.70 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_25052025135613_SEIntimation25052025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Company Statement","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"25052025135640","exchdisstime":"25-May-2025 13:56:41","fileSize":"371.70 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106247746","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-25 13:56:40","symbol":"BIOCON"},{"an_dt":"22-May-2025 08:42:19","attFileSize":"354.43 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_22052025084200_SEIntimation22052025.pdf","attchmntText":"Biocon Limited has informed Company Statement","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"22052025084219","exchdisstime":"22-May-2025 08:42:20","fileSize":"354.43 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106242812","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-22 08:42:19","symbol":"BIOCON"},{"an_dt":"21-May-2025 08:02:30","attFileSize":"403.70 KB","attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_21052025080204_SEIntimation21052025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Company Statement","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:02","dt":"21052025080230","exchdisstime":"21-May-2025 08:02:32","fileSize":"403.70 KB","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106240836","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-21 08:02:30","symbol":"BIOCON"},{"an_dt":"15-May-2025 22:36:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_15052025223549_SETranscriptEarningsCall.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"15052025223614","exchdisstime":"15-May-2025 22:36:14","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106234392","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-15 22:36:14","symbol":"BIOCON"},{"an_dt":"15-May-2025 19:14:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_15052025191316_SEIntimation15052025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Notification to Stock Exchange","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"15052025191401","exchdisstime":"15-May-2025 19:14:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106233908","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-15 19:14:01","symbol":"BIOCON"},{"an_dt":"14-May-2025 18:01:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_14052025180113_IntimationIEPF.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"14052025180126","exchdisstime":"14-May-2025 18:01:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106231621","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-14 18:01:26","symbol":"BIOCON"},{"an_dt":"13-May-2025 19:53:04","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_13052025195158_IntimationIEPF.pdf","attchmntText":"Biocon Limited has informed the Exchange about General Reminder Letter issued to shareholders to claim unclaimed dividends","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"13052025195304","exchdisstime":"13-May-2025 19:53:05","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106230154","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-13 19:53:04","symbol":"BIOCON"},{"an_dt":"12-May-2025 10:43:11","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_12052025104245_SEPresentation12052025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:00","dt":"12052025104311","exchdisstime":"12-May-2025 10:43:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106227572","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-12 10:43:11","symbol":"BIOCON"},{"an_dt":"10-May-2025 16:01:24","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_10052025160040_NewspaperAd10052025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"10052025160124","exchdisstime":"10-May-2025 16:01:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106227144","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-10 16:01:24","symbol":"BIOCON"},{"an_dt":"09-May-2025 17:12:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_09052025171138_CoverLetterEarningsCallLINK.pdf","attchmntText":"Biocon Limited has informed the Exchange about Link of Recording","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"09052025171215","exchdisstime":"09-May-2025 17:12:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106226222","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-09 17:12:15","symbol":"BIOCON"},{"an_dt":"09-May-2025 08:12:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_09052025081203_IR09052025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:00","dt":"09052025081234","exchdisstime":"09-May-2025 08:12:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106225342","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-09 08:12:34","symbol":"BIOCON"},{"an_dt":"08-May-2025 20:05:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08052025200413_OutcomeofBM08052025.pdf","attchmntText":"Biocon Limited has informed the Exchange that Board of Directors at its meeting held on May 08, 2025, recommended Final Dividend of Rs. 0.50 per equity share.","bflag":null,"csvName":null,"desc":"Dividend","difference":"00:00:00","dt":"08052025200508","exchdisstime":"08-May-2025 20:05:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106224947","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-08 20:05:08","symbol":"BIOCON"},{"an_dt":"08-May-2025 19:58:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08052025195659_OutcomeofBM08052025.pdf","attchmntText":"Biocon Limited has informed the Exchange that Record date for the purpose of Dividend  is 04-Jul-2025.","bflag":null,"csvName":null,"desc":"Record Date","difference":"00:00:01","dt":"08052025195821","exchdisstime":"08-May-2025 19:58:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106224932","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-08 19:58:21","symbol":"BIOCON"},{"an_dt":"08-May-2025 19:55:45","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08052025195418_OutcomeofBM08052025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on May 08, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:00","dt":"08052025195545","exchdisstime":"08-May-2025 19:55:45","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106224929","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-08 19:55:45","symbol":"BIOCON"},{"an_dt":"08-May-2025 19:47:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_08052025194632_PressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 08, 2025, titled \"Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA atRs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% FY25 Revenue at Rs 16,470 Cr; EBITDA at Rs 4,374Cr; Net Profit at Rs 1,013 Cr\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:00","dt":"08052025194701","exchdisstime":"08-May-2025 19:47:01","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106224914","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-08 19:47:01","symbol":"BIOCON"},{"an_dt":"08-May-2025 19:44:53","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08052025194232_OutcomeofBM08052025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on May 08, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:00","dt":"08052025194453","exchdisstime":"08-May-2025 19:44:53","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106224910","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-08 19:44:53","symbol":"BIOCON"},{"an_dt":"06-May-2025 14:53:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_06052025145341_IntimationNewspaperAd.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:00","dt":"06052025145357","exchdisstime":"06-May-2025 14:53:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106221377","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-06 14:53:57","symbol":"BIOCON"},{"an_dt":"05-May-2025 15:25:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_05052025152513_Intimation_to_SE_Postal_Ballot_Notice.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Postal Ballot","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"05052025152556","exchdisstime":"05-May-2025 15:25:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106220039","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-05 15:25:56","symbol":"BIOCON"},{"an_dt":"05-May-2025 08:38:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_05052025083747_SE05052025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 05, 2025, titled \"Biocon Biologics Secures Strong Market Access Coverage for Yesintek  in the United States Covering 100+ Million Lives\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"05052025083826","exchdisstime":"05-May-2025 08:38:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106219589","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-05-05 08:38:26","symbol":"BIOCON"},{"an_dt":"30-Apr-2025 20:03:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_30042025200257_SE30042025.pdf","attchmntText":"Biocon Limited has informed the Exchange about the record date for Commercial Papers","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:00","dt":"30042025200327","exchdisstime":"30-Apr-2025 20:03:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106217038","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-30 20:03:27","symbol":"BIOCON"},{"an_dt":"29-Apr-2025 19:55:19","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_29042025195452_SE29042025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Redemption of Commercial Papers","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:00","dt":"29042025195519","exchdisstime":"29-Apr-2025 19:55:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106215568","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-29 19:55:19","symbol":"BIOCON"},{"an_dt":"26-Apr-2025 11:24:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_26042025112427_SEIntimation26042025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Company Statement dated April 26, 2025","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:00","dt":"26042025112457","exchdisstime":"26-Apr-2025 11:24:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106212868","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-26 11:24:57","symbol":"BIOCON"},{"an_dt":"23-Apr-2025 20:11:05","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_23042025201033_SE.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on April 23, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:00","dt":"23042025201105","exchdisstime":"23-Apr-2025 20:11:05","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106209702","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-23 20:11:05","symbol":"BIOCON"},{"an_dt":"22-Apr-2025 20:15:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_22042025201532_Intimation_for_allotment.pdf","attchmntText":"Biocon Limited has informed the Exchange about issue of Commercial Papers","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"22042025201552","exchdisstime":"22-Apr-2025 20:15:53","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106208423","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-22 20:15:52","symbol":"BIOCON"},{"an_dt":"15-Apr-2025 19:53:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_15042025195331_SE.pdf","attchmntText":"Biocon Limited has informed the Exchange about Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:01","dt":"15042025195342","exchdisstime":"15-Apr-2025 19:53:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106202775","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-15 19:53:42","symbol":"BIOCON"},{"an_dt":"15-Apr-2025 08:18:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_15042025081734_Press_Release.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 15, 2025, titled \"Biocon Biologics Secures Market Entry Date for Yesafili , an Interchangeable Biosimilar to Eylea?, in the U.S.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"15042025081801","exchdisstime":"15-Apr-2025 08:18:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106201897","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-15 08:18:01","symbol":"BIOCON"},{"an_dt":"14-Apr-2025 16:34:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_14042025163347_SE.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:01","dt":"14042025163406","exchdisstime":"14-Apr-2025 16:34:07","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106201617","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-14 16:34:06","symbol":"BIOCON"},{"an_dt":"10-Apr-2025 22:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_10042025220237_IntimationtoSEUSFDAApprovalEverolimusTablets100425.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"10042025220400","exchdisstime":"10-Apr-2025 22:04:01","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106199965","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-10 22:04:00","symbol":"BIOCON"},{"an_dt":"10-Apr-2025 18:00:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon2_10042025175934_CFOCertificateFundUtilizationMarch312025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Certificate pursuant to SEBI Master Circular no. SEBI/HO/DDHS/PoD1/P/CIR/2024/54dated May 22, 2024.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"10042025180014","exchdisstime":"10-Apr-2025 18:00:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106199784","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-10 18:00:14","symbol":"BIOCON"},{"an_dt":"10-Apr-2025 08:35:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_10042025083324_PressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 10, 2025, titled \"Biocon Biologics Announces U.S. FDA Approval for Jobevne , Biosimilar Bevacizumab, Expanding Its Oncology Portfolio\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"10042025083527","exchdisstime":"10-Apr-2025 08:35:28","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106199436","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-10 08:35:27","symbol":"BIOCON"},{"an_dt":"08-Apr-2025 16:24:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/team_sandeshc_03042025171311_Annual11.pdf","attchmntText":"Kiran Mazumdar Shaw has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"00:00:01","dt":"08042025162409","exchdisstime":"08-Apr-2025 16:24:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106193290","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-08 16:24:09","symbol":"BIOCON"},{"an_dt":"04-Apr-2025 20:56:20","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_04042025205225_BM_Outcome_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on April 04, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:00","dt":"04042025205620","exchdisstime":"04-Apr-2025 20:56:20","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106194714","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-04 20:56:20","symbol":"BIOCON"},{"an_dt":"02-Apr-2025 17:19:59","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_02042025171941_BMIntimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"02042025171959","exchdisstime":"02-Apr-2025 17:19:59","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106192182","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-02 17:19:59","symbol":"BIOCON"},{"an_dt":"02-Apr-2025 15:51:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_02042025154948_Voting_Results_signed.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Postal Ballot. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:00","dt":"02042025155100","exchdisstime":"02-Apr-2025 15:51:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106192057","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-02 15:51:00","symbol":"BIOCON"},{"an_dt":"01-Apr-2025 22:42:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_01042025224235_SE_Intimation_SMP_Resignation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Cessation of Mr Peter Bains as Other of the company w.e.f. April 01, 2025.","bflag":null,"csvName":null,"desc":"Cessation","difference":"00:00:00","dt":"01042025224251","exchdisstime":"01-Apr-2025 22:42:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106191399","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-04-01 22:42:51","symbol":"BIOCON"},{"an_dt":"29-Mar-2025 15:26:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON1_29032025152448_Intimation_under_Regulation_30-Cautionary_email.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding cautionary emails received from NSE and BSE dated March 28, 2025.","bflag":null,"csvName":null,"desc":"Action(s) taken or orders passed","difference":"00:00:01","dt":"29032025152606","exchdisstime":"29-Mar-2025 15:26:07","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106188817","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-03-29 15:26:06","symbol":"BIOCON"},{"an_dt":"28-Mar-2025 18:05:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_28032025180540_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Reminder Letter to shareholders for claiming Unclaimed dividend and Updation of KYCInformation'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:02","dt":"28032025180549","exchdisstime":"28-Mar-2025 18:05:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106187897","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-03-28 18:05:49","symbol":"BIOCON"},{"an_dt":"28-Mar-2025 15:34:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_28032025153355_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:01","dt":"28032025153408","exchdisstime":"28-Mar-2025 15:34:09","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106187472","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-03-28 15:34:08","symbol":"BIOCON"},{"an_dt":"24-Mar-2025 08:52:25","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_24032025085156_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchange'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:00","dt":"24032025085225","exchdisstime":"24-Mar-2025 08:52:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106179028","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-03-24 08:52:25","symbol":"BIOCON"},{"an_dt":"07-Mar-2025 18:39:25","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_07032025183914_Pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 07, 2025, titled \"Biocon Biologics Announces Positive Results from Phase 3 Study of Yesintek  Biosimilar to Ustekinumab for Chronic Plaque Psoriasis\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"07032025183925","exchdisstime":"07-Mar-2025 18:39:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106168185","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-03-07 18:39:25","symbol":"BIOCON"},{"an_dt":"06-Mar-2025 17:32:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_06032025173219_Pressrelease_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 06, 2025, titled \"Biocon Biologics and Civica, Inc. Collaborate to ExpandInsulin Aspart Access in the United States\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"06032025173230","exchdisstime":"06-Mar-2025 17:32:31","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106167100","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-03-06 17:32:30","symbol":"BIOCON"},{"an_dt":"06-Mar-2025 12:42:46","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_06032025124203_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"06032025124246","exchdisstime":"06-Mar-2025 12:42:47","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106166892","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-03-06 12:42:46","symbol":"BIOCON"},{"an_dt":"04-Mar-2025 18:26:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_04032025182602_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about General Updates","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"04032025182618","exchdisstime":"04-Mar-2025 18:26:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106165273","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-03-04 18:26:18","symbol":"BIOCON"},{"an_dt":"04-Mar-2025 11:26:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_04032025112606_PressRelease_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 04, 2025, titled \"Biocon Academy Conducts its 9th Graduation Day \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"04032025112627","exchdisstime":"04-Mar-2025 11:26:28","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106164893","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-03-04 11:26:27","symbol":"BIOCON"},{"an_dt":"28-Feb-2025 18:05:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_28022025180457_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 28, 2025, titled \"Biocon Foundation Marks 20 Years of Transforming LivesThrough Impactful Social Initiatives\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"28022025180507","exchdisstime":"28-Feb-2025 18:05:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106162826","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-28 18:05:07","symbol":"BIOCON"},{"an_dt":"28-Feb-2025 14:25:22","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_28022025142450_Intimation_Newspaper_Ad.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"28022025142522","exchdisstime":"28-Feb-2025 14:25:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106162500","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-28 14:25:22","symbol":"BIOCON"},{"an_dt":"28-Feb-2025 08:52:37","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_28022025085136_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 28, 2025, titled \"Biocon Limited launches its Glucagon-like peptide-1 (GLP -1), Liraglutide, in the United Kingdom\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"28022025085237","exchdisstime":"28-Feb-2025 08:52:38","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106162174","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-28 08:52:37","symbol":"BIOCON"},{"an_dt":"27-Feb-2025 18:45:04","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_27022025184450_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Postal Ballot","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"27022025184504","exchdisstime":"27-Feb-2025 18:45:05","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106161841","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-27 18:45:04","symbol":"BIOCON"},{"an_dt":"25-Feb-2025 15:48:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_25022025154739_Reg30.pdf","attchmntText":"Biocon Limited has informed the Exchange about General Updates","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"25022025154821","exchdisstime":"25-Feb-2025 15:48:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106160335","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-25 15:48:21","symbol":"BIOCON"},{"an_dt":"24-Feb-2025 17:00:38","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_24022025170016_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 24, 2025, titled \"Biocon Biologics Launches Yesintek  (ustekinumab-kfce) Biosimilar to Stelara? in the United States\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"24022025170038","exchdisstime":"24-Feb-2025 17:00:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106159444","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-24 17:00:38","symbol":"BIOCON"},{"an_dt":"18-Feb-2025 08:37:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_18022025083630_SIGNEDNotification18022025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchange'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"18022025083700","exchdisstime":"18-Feb-2025 08:37:01","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106154834","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-18 08:37:00","symbol":"BIOCON"},{"an_dt":"17-Feb-2025 16:56:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_17022025165612_SIGNEDRecordDateCP.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Record Date Intimation for Commercial Papers'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"17022025165630","exchdisstime":"17-Feb-2025 16:56:31","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106154196","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-17 16:56:30","symbol":"BIOCON"},{"an_dt":"11-Feb-2025 15:11:25","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_11022025151111_SIGNEDPR11022025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 11, 2025, titled \"Biocon Foundation Dedicates Metro Pillars Public ArtProject to  Everyday Champions  of Bengaluru\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"11022025151125","exchdisstime":"11-Feb-2025 15:11:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106146114","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-11 15:11:25","symbol":"BIOCON"},{"an_dt":"07-Feb-2025 17:15:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_07022025171405_SIGNEDMeeting1317.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"07022025171514","exchdisstime":"07-Feb-2025 17:15:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106142069","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-07 17:15:14","symbol":"BIOCON"},{"an_dt":"07-Feb-2025 15:46:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_07022025154443_SIGNEDSELetterTranscript.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"07022025154634","exchdisstime":"07-Feb-2025 15:46:35","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106141751","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-07 15:46:34","symbol":"BIOCON"},{"an_dt":"06-Feb-2025 18:38:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_06022025183816_SIGNEDpr06022025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 06, 2025, titled \"Equillium Inc. and Biocon Limited Announce Positive Data from Phase 2 Study Evaluating Itolizumab in Patients with Moderate to Severe Ulcerative Colitis\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"06022025183844","exchdisstime":"06-Feb-2025 18:38:45","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106140415","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-06 18:38:44","symbol":"BIOCON"},{"an_dt":"03-Feb-2025 13:45:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_03022025134422_SIGNEDCorpPres.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Corporate Presentation'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"03022025134501","exchdisstime":"03-Feb-2025 13:45:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106134279","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-03 13:45:01","symbol":"BIOCON"},{"an_dt":"01-Feb-2025 14:57:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_01022025145719_SIGNEDNewspaperPubl.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"01022025145734","exchdisstime":"01-Feb-2025 14:57:35","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106133344","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-01 14:57:34","symbol":"BIOCON"},{"an_dt":"01-Feb-2025 13:28:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_01022025132734_SIGNEDReg30Order.pdf","attchmntText":"Biocon Limited has informed the Exchange about Disclosure under Regulation 30 of SEBI(LODR) Regulations, 2015","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"01022025132808","exchdisstime":"01-Feb-2025 13:28:09","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106133293","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-02-01 13:28:08","symbol":"BIOCON"},{"an_dt":"31-Jan-2025 19:41:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_31012025194120_Reg30_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about General Updates","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"31012025194130","exchdisstime":"31-Jan-2025 19:41:31","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106132609","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-31 19:41:30","symbol":"BIOCON"},{"an_dt":"31-Jan-2025 16:18:31","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_31012025161817_SIGNEDIntegratedFin.pdf","attchmntText":"Integrated Filing (Financials) for the quarter and nine months ended December 31, 2024","bflag":null,"csvName":null,"desc":"Integrated Filing- Financial","difference":"00:00:01","dt":"31012025161831","exchdisstime":"31-Jan-2025 16:18:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106132084","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-31 16:18:31","symbol":"BIOCON"},{"an_dt":"31-Jan-2025 15:51:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_31012025155042_SIGNEDLink.pdf","attchmntText":"Biocon Limited has informed the Exchange about Link of Recording","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"31012025155132","exchdisstime":"31-Jan-2025 15:51:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106132000","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-31 15:51:32","symbol":"BIOCON"},{"an_dt":"31-Jan-2025 08:39:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_31012025083844_SignedIRPPT.pdf","attchmntText":"Biocon Limited has informed the Exchange about Presentation","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"31012025083901","exchdisstime":"31-Jan-2025 08:39:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106131325","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-31 08:39:01","symbol":"BIOCON"},{"an_dt":"30-Jan-2025 21:48:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_30012025214748_FINALOUTCOMESIGNED.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'amendment of Code of Practices  and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI)'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"30012025214829","exchdisstime":"30-Jan-2025 21:48:30","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106131021","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-30 21:48:29","symbol":"BIOCON"},{"an_dt":"30-Jan-2025 20:47:53","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/FINALOUTCOMESIGNED_30012025204753.pdf","attchmntText":" Biocon Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:00:00","dt":"30012025204753","exchdisstime":"30-Jan-2025 20:47:53","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"168896","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-30 20:47:53","symbol":"BIOCON"},{"an_dt":"30-Jan-2025 20:39:23","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_30012025203908_SE_Intimation_Resignation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Resignation of Mr Mayank verma as Company Secretary & Compliance Officer of the company w.e.f. April 14, 2025.","bflag":null,"csvName":null,"desc":"Resignation","difference":"00:00:00","dt":"30012025203923","exchdisstime":"30-Jan-2025 20:39:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106130979","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-30 20:39:23","symbol":"BIOCON"},{"an_dt":"30-Jan-2025 20:34:12","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_30012025203401_Outcome_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about General Updates","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"30012025203412","exchdisstime":"30-Jan-2025 20:34:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106130969","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-30 20:34:12","symbol":"BIOCON"},{"an_dt":"30-Jan-2025 20:22:46","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_30012025202115_SIGNEDPressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 30, 2025, titled \"Biocon Q3FY25 Revenue atRs 3,856 Cr, Up 7% EBITDA at Rs 787 Cr, Up 16%; Net Profit at Rs 25 Cr\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"30012025202246","exchdisstime":"30-Jan-2025 20:22:47","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106130960","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-30 20:22:46","symbol":"BIOCON"},{"an_dt":"30-Jan-2025 20:09:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_30012025200831_FINALOUTCOMESIGNED.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on January 30, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"30012025200910","exchdisstime":"30-Jan-2025 20:09:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106130947","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-30 20:09:10","symbol":"BIOCON"},{"an_dt":"29-Jan-2025 21:00:11","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_29012025205851_BM_Intimation_for_allotment_Biocon_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about General Updates","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"29012025210011","exchdisstime":"29-Jan-2025 21:00:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106129365","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-29 21:00:11","symbol":"BIOCON"},{"an_dt":"28-Jan-2025 16:10:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_28012025161004_SIGNEDInvestorMeetingFeb2025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"28012025161027","exchdisstime":"28-Jan-2025 16:10:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106127171","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-28 16:10:27","symbol":"BIOCON"},{"an_dt":"27-Jan-2025 09:33:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_27012025093242_Outcome27012025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on January 27, 2025.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"27012025093314","exchdisstime":"27-Jan-2025 09:33:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106125210","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-27 09:33:14","symbol":"BIOCON"},{"an_dt":"27-Jan-2025 08:40:22","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_27012025083957_SIGNEDPR27012025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 27, 2025, titled \"Biocon s S&P Global ESG Score Improves to 69 for 2024; Biocon Biologics Debuts with S&P Global ESG Score of 53\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"27012025084022","exchdisstime":"27-Jan-2025 08:40:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106125205","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-27 08:40:22","symbol":"BIOCON"},{"an_dt":"22-Jan-2025 22:44:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_22012025224411_SIGNEDIntimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:01","dt":"22012025224442","exchdisstime":"22-Jan-2025 22:44:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106121886","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-22 22:44:42","symbol":"BIOCON"},{"an_dt":"12-Jan-2025 11:58:40","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_12012025115802_SIGNEDNotification12012025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchange'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"12012025115840","exchdisstime":"12-Jan-2025 11:58:41","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106111820","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-12 11:58:40","symbol":"BIOCON"},{"an_dt":"09-Jan-2025 18:08:12","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_09012025180755_Pressreleasesigned.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 09, 2025, titled \"Biocon Biologics to Present at the 43rd Annual J.P. Morgan Healthcare Conference\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"09012025180812","exchdisstime":"09-Jan-2025 18:08:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106109736","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-09 18:08:12","symbol":"BIOCON"},{"an_dt":"09-Jan-2025 13:19:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_09012025131846_SIGNED31122024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:01","dt":"09012025131918","exchdisstime":"09-Jan-2025 13:19:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106109347","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-09 13:19:18","symbol":"BIOCON"},{"an_dt":"08-Jan-2025 19:13:46","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_08012025191300_SIGNEDInvestorMeeting08012025.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investor / Research Analyst","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"08012025191346","exchdisstime":"08-Jan-2025 19:13:46","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106108591","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-08 19:13:46","symbol":"BIOCON"},{"an_dt":"07-Jan-2025 12:01:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_07012025120057_SIGNEDPR07012025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 07, 2025, titled \"Biocon Biologics Completes One Year as an Integrated Global Biosimilars Enterprise\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:00","dt":"07012025120127","exchdisstime":"07-Jan-2025 12:01:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106106508","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-07 12:01:27","symbol":"BIOCON"},{"an_dt":"07-Jan-2025 08:15:38","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_07012025081522_SIGNEDIntimation07012025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchange'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"07012025081538","exchdisstime":"07-Jan-2025 08:15:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106106207","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-07 08:15:38","symbol":"BIOCON"},{"an_dt":"03-Jan-2025 15:23:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_03012025152247_SIGNEDINTIMATION.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"03012025152318","exchdisstime":"03-Jan-2025 15:23:18","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106104133","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-03 15:23:18","symbol":"BIOCON"},{"an_dt":"02-Jan-2025 17:57:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_02012025175734_Signed_Notification02012025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchange'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"02012025175750","exchdisstime":"02-Jan-2025 17:57:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106103320","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2025-01-02 17:57:50","symbol":"BIOCON"},{"an_dt":"30-Dec-2024 20:45:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_30122024204457_SIGNEDTradingWindowClosure_Q3.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:01","dt":"30122024204532","exchdisstime":"30-Dec-2024 20:45:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106099847","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-12-30 20:45:32","symbol":"BIOCON"},{"an_dt":"30-Dec-2024 09:04:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_30122024090334_SIGNEDNotification_30122024.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchange'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:00","dt":"30122024090430","exchdisstime":"30-Dec-2024 09:04:30","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106098618","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-12-30 09:04:30","symbol":"BIOCON"},{"an_dt":"24-Dec-2024 15:22:40","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_24122024152015_SEIntimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about General Updates","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"24122024152240","exchdisstime":"24-Dec-2024 15:22:41","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106093312","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-12-24 15:22:40","symbol":"BIOCON"},{"an_dt":"24-Dec-2024 08:16:13","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconlimited_24122024081514_SEIntimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"24122024081613","exchdisstime":"24-Dec-2024 08:16:14","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106092759","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-12-24 08:16:13","symbol":"BIOCON"},{"an_dt":"18-Dec-2024 18:34:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18122024183452_SIGNEDInvestorMeeting18122024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investor / Research Analyst","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"18122024183452","exchdisstime":"18-Dec-2024 18:34:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106088832","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-12-18 18:34:52","symbol":"BIOCON"},{"an_dt":"17-Dec-2024 16:14:38","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17122024161438_SIGNED_InvestorMeeting17122024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investor / Research Analyst","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"17122024161438","exchdisstime":"17-Dec-2024 16:14:38","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106087573","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-12-17 16:14:38","symbol":"BIOCON"},{"an_dt":"15-Dec-2024 14:00:39","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15122024140039_SIGNEDIntimation15122024SIGN.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchange'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"15122024140039","exchdisstime":"15-Dec-2024 14:00:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106086075","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-12-15 14:00:39","symbol":"BIOCON"},{"an_dt":"14-Dec-2024 14:24:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14122024142415_SIGNEDPressNote14122024.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Press Note'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"14122024142415","exchdisstime":"14-Dec-2024 14:24:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106085778","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-12-14 14:24:15","symbol":"BIOCON"},{"an_dt":"11-Dec-2024 15:52:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11122024155214_SIGNEDInvestorMeeting11122024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors / Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"11122024155214","exchdisstime":"11-Dec-2024 15:52:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106082661","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-12-11 15:52:14","symbol":"BIOCON"},{"an_dt":"11-Dec-2024 08:39:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11122024083914_SIGNEDPR11122024.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 11, 2024, titled \"Biocon Biologics Recognized as Asia IP Elite for 2024 by IAM, Cementing Leadership in Intellectual Property Excellence\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"11122024083914","exchdisstime":"11-Dec-2024 08:39:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106082168","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-12-11 08:39:14","symbol":"BIOCON"},{"an_dt":"10-Dec-2024 16:57:11","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10122024165711_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about General Updates","bflag":null,"csvName":null,"desc":"General Updates","difference":"00:00:01","dt":"10122024165711","exchdisstime":"10-Dec-2024 16:57:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106081648","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-12-10 16:57:11","symbol":"BIOCON"},{"an_dt":"07-Dec-2024 20:16:35","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07122024201635_Notification07122024.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchange'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"07122024201635","exchdisstime":"07-Dec-2024 20:16:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106079954","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-12-07 20:16:35","symbol":"BIOCON"},{"an_dt":"01-Dec-2024 13:29:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01122024132954_NotificationtoSE01122024.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"01122024132954","exchdisstime":"01-Dec-2024 13:29:55","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106074197","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-12-01 13:29:54","symbol":"BIOCON"},{"an_dt":"29-Nov-2024 17:40:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29112024174008_SIGNEDPRessNote29112024.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Press Note'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"29112024174008","exchdisstime":"29-Nov-2024 17:40:09","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106073226","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-29 17:40:08","symbol":"BIOCON"},{"an_dt":"28-Nov-2024 16:33:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28112024163326_SIGNEDInvestorMeeting28112024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investor / Research Analyst","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"28112024163326","exchdisstime":"28-Nov-2024 16:33:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106072003","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-28 16:33:26","symbol":"BIOCON"},{"an_dt":"27-Nov-2024 16:16:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27112024161632_SIGNEDPressrelease27112024.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 27, 2024, titled \"Biocon Biologics Supports Diabetes Africa to Drive Progress in Embedding Specialist Nurses in Diabetes Care in Ethiopia\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"27112024161632","exchdisstime":"27-Nov-2024 16:16:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106070875","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-27 16:16:32","symbol":"BIOCON"},{"an_dt":"27-Nov-2024 15:19:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27112024151943_SIGNEDInvestorMeeting27112024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors / Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"27112024151942","exchdisstime":"27-Nov-2024 15:19:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106070830","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-27 15:19:42","symbol":"BIOCON"},{"an_dt":"26-Nov-2024 16:43:46","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26112024164347_SIGNEDInvestorMeeting26112024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors / Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"26112024164346","exchdisstime":"26-Nov-2024 16:43:47","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106069749","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-26 16:43:46","symbol":"BIOCON"},{"an_dt":"26-Nov-2024 16:22:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26112024162227_SIGNEDIntimationCRISIL.pdf","attchmntText":"Biocon Limited has informed the Exchange about Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:01","dt":"26112024162227","exchdisstime":"26-Nov-2024 16:22:28","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106069708","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-26 16:22:27","symbol":"BIOCON"},{"an_dt":"25-Nov-2024 14:21:47","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25112024142147_SIGNED_InvestorMeeting25112024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors / Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"25112024142147","exchdisstime":"25-Nov-2024 14:21:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106068553","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-25 14:21:47","symbol":"BIOCON"},{"an_dt":"22-Nov-2024 19:44:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22112024194407_SIGNEDInvestorMeeting22112024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investor / Research Analyst","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"22112024194407","exchdisstime":"22-Nov-2024 19:44:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106067603","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-22 19:44:07","symbol":"BIOCON"},{"an_dt":"19-Nov-2024 17:16:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19112024171649_SIGNEDInvestorMeeting19112024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investor / Research Analyst","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"19112024171648","exchdisstime":"19-Nov-2024 17:16:49","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106064534","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-19 17:16:48","symbol":"BIOCON"},{"an_dt":"18-Nov-2024 19:06:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18112024190650_InvestorMeeting21112024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"18112024190650","exchdisstime":"18-Nov-2024 19:06:50","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106063535","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-18 19:06:50","symbol":"BIOCON"},{"an_dt":"14-Nov-2024 12:40:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14112024124042_PressNote14112024_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Press Note'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"14112024124042","exchdisstime":"14-Nov-2024 12:40:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106059123","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-14 12:40:42","symbol":"BIOCON"},{"an_dt":"10-Nov-2024 12:46:17","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10112024124617_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"10112024124617","exchdisstime":"10-Nov-2024 12:46:18","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106052474","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-10 12:46:17","symbol":"BIOCON"},{"an_dt":"07-Nov-2024 21:27:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07112024212744_TranscriptEarningsCallQ2FY25.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"07112024212744","exchdisstime":"07-Nov-2024 21:27:45","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106049653","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-07 21:27:44","symbol":"BIOCON"},{"an_dt":"07-Nov-2024 19:49:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07112024194950_InvestorMeeting13112024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"07112024194950","exchdisstime":"07-Nov-2024 19:49:50","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106049559","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-07 19:49:50","symbol":"BIOCON"},{"an_dt":"07-Nov-2024 16:05:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07112024160532_InvestorMeeting07112024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"07112024160532","exchdisstime":"07-Nov-2024 16:05:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106048910","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-07 16:05:32","symbol":"BIOCON"},{"an_dt":"01-Nov-2024 13:57:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01112024135742_NewspaperPublication_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:00","dt":"01112024135742","exchdisstime":"01-Nov-2024 13:57:42","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106042518","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-11-01 13:57:42","symbol":"BIOCON"},{"an_dt":"31-Oct-2024 09:11:24","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31102024091124_Cover_Letter_Earnings_Call_LINK.pdf","attchmntText":"Biocon Limited has informed the Exchange about Link of Recording","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"31102024091124","exchdisstime":"31-Oct-2024 09:11:24","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106041591","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-10-31 09:11:24","symbol":"BIOCON"},{"an_dt":"30-Oct-2024 23:01:41","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30102024230141_PresentationSignedEarningsCall.pdf","attchmntText":"Biocon Limited has informed the Exchange about Presentation","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"30102024230141","exchdisstime":"30-Oct-2024 23:01:41","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106041438","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-10-30 23:01:41","symbol":"BIOCON"},{"an_dt":"30-Oct-2024 17:49:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30102024174933_PressRelease_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 30, 2024, titled \"Press Release on Financial Results for the quarter ended September 30, 2024\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"30102024174933","exchdisstime":"30-Oct-2024 17:49:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106041010","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-10-30 17:49:33","symbol":"BIOCON"},{"an_dt":"30-Oct-2024 17:30:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Outcome_signed_30102024173052.pdf","attchmntText":" Biocon Limited has submitted to the Exchange, the financial results for the period ended September 30, 2024.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:00:00","dt":"30102024173052","exchdisstime":"30-Oct-2024 17:30:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"166400","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-10-30 17:30:52","symbol":"BIOCON"},{"an_dt":"30-Oct-2024 17:28:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30102024172855_Outcome_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on October 30, 2024.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"30102024172855","exchdisstime":"30-Oct-2024 17:28:56","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106040950","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-10-30 17:28:55","symbol":"BIOCON"},{"an_dt":"30-Oct-2024 16:22:16","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30102024162216_PR30102024.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 30, 2024, titled \"Biocon Biologics  Drug Substance Facility in Bengaluru Classified as Voluntary Action Indicated (VAI)\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:00","dt":"30102024162216","exchdisstime":"30-Oct-2024 16:22:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106040746","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-10-30 16:22:16","symbol":"BIOCON"},{"an_dt":"28-Oct-2024 17:06:05","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28102024170605_PressRelease28102024.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 28, 2024, titled \"Biocon Continues to be Among Science Magazine s Top 10 Global Employers List\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"28102024170605","exchdisstime":"28-Oct-2024 17:06:06","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106037276","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-10-28 17:06:05","symbol":"BIOCON"},{"an_dt":"25-Oct-2024 13:34:28","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25102024133428_PR25102024.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 25, 2024, titled \"Biocon Foundation Honored with  Doing Good for Bharat Awards 2024  in  Healthcare Category  for  eLAJ Smart Clinics  by the CSR Box\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"25102024133428","exchdisstime":"25-Oct-2024 13:34:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106034650","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-10-25 13:34:28","symbol":"BIOCON"},{"an_dt":"14-Oct-2024 16:50:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14102024165042_Reg74DP.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:01","dt":"14102024165042","exchdisstime":"14-Oct-2024 16:50:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106021832","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-10-14 16:50:42","symbol":"BIOCON"},{"an_dt":"09-Oct-2024 21:28:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09102024212834_Intimation_final.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"09102024212833","exchdisstime":"09-Oct-2024 21:28:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106018046","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-10-09 21:28:33","symbol":"BIOCON"},{"an_dt":"08-Oct-2024 11:49:22","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08102024114923_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 08, 2024, titled \"Biocon Biologics  Commissioned Report Highlights Pathways to Increase Adoption of Biosimilars in LMICs; GaBI Publishes Peer-Reviewed Article\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"08102024114922","exchdisstime":"08-Oct-2024 11:49:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106015755","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-10-08 11:49:22","symbol":"BIOCON"},{"an_dt":"03-Oct-2024 08:04:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03102024080444_Cover_Letter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 03, 2024, titled \"Biocon Biologics Refinances USD 1.1 Billion (INR 93,468 million) Long Term Debt through USD Bonds and New Syndicated Facility\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"03102024080444","exchdisstime":"03-Oct-2024 08:04:45","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106011297","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-10-03 08:04:44","symbol":"BIOCON"},{"an_dt":"01-Oct-2024 17:56:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01102024175633_Letter_of_Confirmation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Issue of Letter of Confirmation","bflag":null,"csvName":null,"desc":"Issue of Duplicate Share Certificate","difference":"00:00:01","dt":"01102024175632","exchdisstime":"01-Oct-2024 17:56:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106010282","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-10-01 17:56:32","symbol":"BIOCON"},{"an_dt":"28-Sep-2024 17:17:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28092024171721_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"28092024171721","exchdisstime":"28-Sep-2024 17:17:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106005941","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-28 17:17:21","symbol":"BIOCON"},{"an_dt":"28-Sep-2024 15:22:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28092024152251_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:00","dt":"28092024152251","exchdisstime":"28-Sep-2024 15:22:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106005751","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-28 15:22:51","symbol":"BIOCON"},{"an_dt":"27-Sep-2024 17:23:23","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27092024172323_TradingWindow.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:01","dt":"27092024172323","exchdisstime":"27-Sep-2024 17:23:24","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106004193","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-27 17:23:23","symbol":"BIOCON"},{"an_dt":"26-Sep-2024 16:30:53","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26092024163054_PressRelease_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 26, 2024, titled \"Biocon Limited partners with Tabuk Pharmaceuticals to commercialize its Glucagon-like peptide-1 (GLP -1) products in the Middle East region\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"26092024163053","exchdisstime":"26-Sep-2024 16:30:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106001355","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-26 16:30:53","symbol":"BIOCON"},{"an_dt":"25-Sep-2024 10:36:05","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25092024103605_PressRelease_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 25, 2024, titled \"Biocon Biologics Announces New Dermatology Data to be Presented at EADV Congress 2024\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"25092024103605","exchdisstime":"25-Sep-2024 10:36:06","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105998358","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-25 10:36:05","symbol":"BIOCON"},{"an_dt":"24-Sep-2024 00:22:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24092024002209_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure under Reg 30'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"24092024002209","exchdisstime":"24-Sep-2024 00:22:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105996825","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-24 00:22:09","symbol":"BIOCON"},{"an_dt":"23-Sep-2024 17:20:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23092024172049_InvestorMeeting23092024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"23092024172048","exchdisstime":"23-Sep-2024 17:20:49","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105996228","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-23 17:20:48","symbol":"BIOCON"},{"an_dt":"23-Sep-2024 08:46:13","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23092024084613_CorporatePresentation_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Corporate Presentation'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"23092024084613","exchdisstime":"23-Sep-2024 08:46:14","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105995605","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-23 08:46:13","symbol":"BIOCON"},{"an_dt":"23-Sep-2024 08:39:31","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23092024083931_Voting_Results_signed.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Postal Ballot. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"23092024083931","exchdisstime":"23-Sep-2024 08:39:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105995604","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-23 08:39:31","symbol":"BIOCON"},{"an_dt":"21-Sep-2024 20:48:35","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21092024204836_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"21092024204835","exchdisstime":"21-Sep-2024 20:48:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105995461","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-21 20:48:35","symbol":"BIOCON"},{"an_dt":"17-Sep-2024 18:39:36","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17092024183936_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"17092024183936","exchdisstime":"17-Sep-2024 18:39:37","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105990877","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-17 18:39:36","symbol":"BIOCON"},{"an_dt":"13-Sep-2024 15:54:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13092024155401_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"13092024155401","exchdisstime":"13-Sep-2024 15:54:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105987845","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-13 15:54:01","symbol":"BIOCON"},{"an_dt":"12-Sep-2024 17:21:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12092024172133_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"12092024172133","exchdisstime":"12-Sep-2024 17:21:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105986789","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-12 17:21:33","symbol":"BIOCON"},{"an_dt":"06-Sep-2024 16:40:22","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06092024164022_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"06092024164022","exchdisstime":"06-Sep-2024 16:40:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105981106","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-06 16:40:22","symbol":"BIOCON"},{"an_dt":"05-Sep-2024 20:37:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05092024203757_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"05092024203757","exchdisstime":"05-Sep-2024 20:37:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105979876","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-05 20:37:57","symbol":"BIOCON"},{"an_dt":"03-Sep-2024 18:40:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03092024184018_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Loss of Share Certificates","bflag":null,"csvName":null,"desc":"Loss of Share Certificates","difference":"00:00:01","dt":"03092024184018","exchdisstime":"03-Sep-2024 18:40:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105976113","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-03 18:40:18","symbol":"BIOCON"},{"an_dt":"03-Sep-2024 12:53:22","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03092024125322_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"03092024125322","exchdisstime":"03-Sep-2024 12:53:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105975337","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-03 12:53:22","symbol":"BIOCON"},{"an_dt":"01-Sep-2024 15:38:36","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01092024153836_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchange'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"01092024153836","exchdisstime":"01-Sep-2024 15:38:37","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105973310","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-09-01 15:38:36","symbol":"BIOCON"},{"an_dt":"31-Aug-2024 16:15:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31082024161514_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure under Reg 30'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"31082024161514","exchdisstime":"31-Aug-2024 16:15:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105972658","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-31 16:15:14","symbol":"BIOCON"},{"an_dt":"30-Aug-2024 18:56:13","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30082024185613_SEIntimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:01","dt":"30082024185613","exchdisstime":"30-Aug-2024 18:56:14","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105971788","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-30 18:56:13","symbol":"BIOCON"},{"an_dt":"30-Aug-2024 17:27:58","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30082024172758_IntimationtoSE_2.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"30082024172758","exchdisstime":"30-Aug-2024 17:27:59","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105971538","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-30 17:27:58","symbol":"BIOCON"},{"an_dt":"30-Aug-2024 17:23:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30082024172352_IntimationtoSE_1.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"30082024172352","exchdisstime":"30-Aug-2024 17:23:53","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105971517","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-30 17:23:52","symbol":"BIOCON"},{"an_dt":"29-Aug-2024 17:36:16","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29082024173616_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"29082024173616","exchdisstime":"29-Aug-2024 17:36:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105969954","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-29 17:36:16","symbol":"BIOCON"},{"an_dt":"29-Aug-2024 08:15:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29082024081506_CoverLetter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 29, 2024, titled \"Press Release titled  Biocon Biologics Secures Market Entry for Bmab 1200, a Proposed Biosimilar to Stelara?, in Europe, UK, Canada, and Japan \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:00","dt":"29082024081506","exchdisstime":"29-Aug-2024 08:15:06","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105969074","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-29 08:15:06","symbol":"BIOCON"},{"an_dt":"28-Aug-2024 18:36:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28082024183608_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Intimation under reg 30 of SEBI Listing Regulations'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"28082024183608","exchdisstime":"28-Aug-2024 18:36:09","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105968551","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-28 18:36:08","symbol":"BIOCON"},{"an_dt":"24-Aug-2024 16:12:35","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24082024161235_Intimation_NewspaperAd.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:00","dt":"24082024161235","exchdisstime":"24-Aug-2024 16:12:35","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105964813","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-24 16:12:35","symbol":"BIOCON"},{"an_dt":"23-Aug-2024 18:37:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23082024183750_CoverLetter_LetterofConfirmation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Intimation regarding Issuance of  Letter of Confirmation '.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"23082024183750","exchdisstime":"23-Aug-2024 18:37:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105964131","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-23 18:37:50","symbol":"BIOCON"},{"an_dt":"23-Aug-2024 13:03:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23082024130307_PostalBallotNotice_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Postal Ballot","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"23082024130307","exchdisstime":"23-Aug-2024 13:03:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105963574","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-23 13:03:07","symbol":"BIOCON"},{"an_dt":"23-Aug-2024 12:03:38","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23082024120338_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"23082024120338","exchdisstime":"23-Aug-2024 12:03:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105963481","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-23 12:03:38","symbol":"BIOCON"},{"an_dt":"19-Aug-2024 17:28:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19082024172815_CoverLetter_TranscriptEarningsCall.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"19082024172815","exchdisstime":"19-Aug-2024 17:28:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105958741","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-19 17:28:15","symbol":"BIOCON"},{"an_dt":"19-Aug-2024 12:08:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19082024120834_IRPresentation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Corporate Presentation'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:00","dt":"19082024120834","exchdisstime":"19-Aug-2024 12:08:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105958483","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-19 12:08:34","symbol":"BIOCON"},{"an_dt":"18-Aug-2024 15:35:43","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18082024153543_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Meeting conducted with Institutional Investors/ Research Analysts'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:00","dt":"18082024153543","exchdisstime":"18-Aug-2024 15:35:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105958169","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-18 15:35:43","symbol":"BIOCON"},{"an_dt":"13-Aug-2024 19:27:05","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13082024192705_SEIntimation_signed.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Annual General Meeting held on August 09, 2024. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:00","dt":"13082024192705","exchdisstime":"13-Aug-2024 19:27:05","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105952932","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-13 19:27:05","symbol":"BIOCON"},{"an_dt":"13-Aug-2024 13:12:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13082024131233_Outcome_revised.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Outcome of the Board Meeting'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"13082024131233","exchdisstime":"13-Aug-2024 13:12:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105951670","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-13 13:12:33","symbol":"BIOCON"},{"an_dt":"10-Aug-2024 18:15:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10082024181533_CoveringLetter_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"10082024181533","exchdisstime":"10-Aug-2024 18:15:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105949207","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-10 18:15:33","symbol":"BIOCON"},{"an_dt":"10-Aug-2024 14:23:38","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10082024142338_CoverLetter_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Presentation and Link of Recording","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"10082024142338","exchdisstime":"10-Aug-2024 14:23:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105948870","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-10 14:23:38","symbol":"BIOCON"},{"an_dt":"09-Aug-2024 18:56:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09082024185601_DirectorAppointments.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"00:00:01","dt":"09082024185600","exchdisstime":"09-Aug-2024 18:56:01","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105948109","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-09 18:56:00","symbol":"BIOCON"},{"an_dt":"09-Aug-2024 18:37:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09082024183732_AGMProceedingssigned.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on August 09, 2024","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:01","dt":"09082024183732","exchdisstime":"09-Aug-2024 18:37:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105948048","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-09 18:37:32","symbol":"BIOCON"},{"an_dt":"08-Aug-2024 19:30:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08082024193010_PressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 08, 2024, titled \"Biocon Q1FY25 Revenue up 30% at Rs 4,567 Cr EBITDA up 117% at Rs 1,755 Cr Net Profit at Rs 660 Cr\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"08082024193009","exchdisstime":"08-Aug-2024 19:30:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105946123","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-08 19:30:09","symbol":"BIOCON"},{"an_dt":"08-Aug-2024 18:32:31","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Outcome_08082024183231.pdf","attchmntText":" Biocon Limited has submitted to the Exchange, the financial results for the period ended June 30, 2024.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:00:01","dt":"08082024183231","exchdisstime":"08-Aug-2024 18:32:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"164602","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-08 18:32:31","symbol":"BIOCON"},{"an_dt":"08-Aug-2024 18:30:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08082024183010_Outcome.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on August 08, 2024.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:01","dt":"08082024183010","exchdisstime":"08-Aug-2024 18:30:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105945919","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-08 18:30:10","symbol":"BIOCON"},{"an_dt":"05-Aug-2024 17:04:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05082024170452_Intimation_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:00","dt":"05082024170452","exchdisstime":"05-Aug-2024 17:04:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105939524","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-08-05 17:04:52","symbol":"BIOCON"},{"an_dt":"27-Jul-2024 19:24:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27072024192401_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchange'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:00","dt":"27072024192401","exchdisstime":"27-Jul-2024 19:24:01","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105928817","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-07-27 19:24:01","symbol":"BIOCON"},{"an_dt":"27-Jul-2024 18:45:36","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27072024184536_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"27072024184536","exchdisstime":"27-Jul-2024 18:45:37","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105928806","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-07-27 18:45:36","symbol":"BIOCON"},{"an_dt":"25-Jul-2024 18:12:13","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25072024181213_SE_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Cessation of Mr Meleveetil Damodaran as Independent Director of the company w.e.f. July 25, 2024.","bflag":null,"csvName":null,"desc":"Cessation","difference":"00:00:00","dt":"25072024181213","exchdisstime":"25-Jul-2024 18:12:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105926269","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-07-25 18:12:13","symbol":"BIOCON"},{"an_dt":"19-Jul-2024 20:12:11","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19072024201211_Intimation_2024_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding ''.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"19072024201211","exchdisstime":"19-Jul-2024 20:12:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105920133","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-07-19 20:12:11","symbol":"BIOCON"},{"an_dt":"19-Jul-2024 18:39:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19072024183908_Intimation_NewspaperAd_19072024.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"19072024183908","exchdisstime":"19-Jul-2024 18:39:09","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105919968","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-07-19 18:39:08","symbol":"BIOCON"},{"an_dt":"18-Jul-2024 21:43:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18072024214326_Biocon_AGM_Intimation_SEs.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 09, 2024","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:00","dt":"18072024214326","exchdisstime":"18-Jul-2024 21:43:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105918776","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-07-18 21:43:26","symbol":"BIOCON"},{"an_dt":"16-Jul-2024 18:50:31","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16072024185031_Reg_74_5__Biocon_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:01","dt":"16072024185031","exchdisstime":"16-Jul-2024 18:50:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105916370","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-07-16 18:50:31","symbol":"BIOCON"},{"an_dt":"04-Jul-2024 19:22:35","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04072024192235_Intimation_PriorAGM.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"04072024192235","exchdisstime":"04-Jul-2024 19:22:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105903922","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-07-04 19:22:35","symbol":"BIOCON"},{"an_dt":"03-Jul-2024 21:41:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03072024214107_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:00","dt":"03072024214107","exchdisstime":"03-Jul-2024 21:41:07","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105902680","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-07-03 21:41:07","symbol":"BIOCON"},{"an_dt":"28-Jun-2024 18:15:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28062024181510_SE_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Communication to the shareholders w.r.t. TDS on Final Dividend'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"28062024181510","exchdisstime":"28-Jun-2024 18:15:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105897407","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-28 18:15:10","symbol":"BIOCON"},{"an_dt":"28-Jun-2024 17:07:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28062024170742_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"28062024170742","exchdisstime":"28-Jun-2024 17:07:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105897071","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-28 17:07:42","symbol":"BIOCON"},{"an_dt":"27-Jun-2024 18:41:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27062024184121_IR_PPT_CoverLetter.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:00","dt":"27062024184121","exchdisstime":"27-Jun-2024 18:41:21","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105895302","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-27 18:41:21","symbol":"BIOCON"},{"an_dt":"27-Jun-2024 17:30:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27062024173018_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:01","dt":"27062024173018","exchdisstime":"27-Jun-2024 17:30:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105895014","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-27 17:30:18","symbol":"BIOCON"},{"an_dt":"26-Jun-2024 19:50:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26062024195014_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"26062024195014","exchdisstime":"26-Jun-2024 19:50:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105893379","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-26 19:50:14","symbol":"BIOCON"},{"an_dt":"24-Jun-2024 08:13:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24062024081348_SEIntimation2406.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement dated June 24, 2024'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"24062024081348","exchdisstime":"24-Jun-2024 08:13:49","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105888977","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-24 08:13:48","symbol":"BIOCON"},{"an_dt":"22-Jun-2024 12:43:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22062024124326_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:00","dt":"22062024124326","exchdisstime":"22-Jun-2024 12:43:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105888612","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-22 12:43:26","symbol":"BIOCON"},{"an_dt":"20-Jun-2024 12:35:38","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20062024123538_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"20062024123538","exchdisstime":"20-Jun-2024 12:35:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105886540","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-20 12:35:38","symbol":"BIOCON"},{"an_dt":"19-Jun-2024 22:50:28","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19062024225028_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Intimation under Regulation 30'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"19062024225028","exchdisstime":"19-Jun-2024 22:50:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105886133","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-19 22:50:28","symbol":"BIOCON"},{"an_dt":"19-Jun-2024 17:26:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19062024172614_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"19062024172614","exchdisstime":"19-Jun-2024 17:26:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105885705","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-19 17:26:14","symbol":"BIOCON"},{"an_dt":"15-Jun-2024 11:48:22","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15062024114822_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"15062024114822","exchdisstime":"15-Jun-2024 11:48:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105883275","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-15 11:48:22","symbol":"BIOCON"},{"an_dt":"14-Jun-2024 14:48:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14062024144827_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Loss of Share Certificates","bflag":null,"csvName":null,"desc":"Loss of Share Certificates","difference":"00:00:01","dt":"14062024144827","exchdisstime":"14-Jun-2024 14:48:28","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105882550","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-14 14:48:27","symbol":"BIOCON"},{"an_dt":"13-Jun-2024 17:17:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13062024171750_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"13062024171750","exchdisstime":"13-Jun-2024 17:17:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105881643","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-13 17:17:50","symbol":"BIOCON"},{"an_dt":"12-Jun-2024 19:36:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12062024193621_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"12062024193621","exchdisstime":"12-Jun-2024 19:36:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105880766","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-12 19:36:21","symbol":"BIOCON"},{"an_dt":"11-Jun-2024 15:10:47","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11062024151047_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Appointment of Interim CFO'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"11062024151047","exchdisstime":"11-Jun-2024 15:10:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105879342","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-11 15:10:47","symbol":"BIOCON"},{"an_dt":"06-Jun-2024 15:20:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06062024152010_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:02","dt":"06062024152010","exchdisstime":"06-Jun-2024 15:20:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105875846","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-06 15:20:10","symbol":"BIOCON"},{"an_dt":"04-Jun-2024 17:36:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04062024173609_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"04062024173609","exchdisstime":"04-Jun-2024 17:36:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105873762","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-04 17:36:09","symbol":"BIOCON"},{"an_dt":"03-Jun-2024 16:12:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03062024161255_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:00","dt":"03062024161255","exchdisstime":"03-Jun-2024 16:12:55","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105872541","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-06-03 16:12:55","symbol":"BIOCON"},{"an_dt":"31-May-2024 20:52:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31052024205202_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:01","dt":"31052024205202","exchdisstime":"31-May-2024 20:52:03","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105871278","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-31 20:52:02","symbol":"BIOCON"},{"an_dt":"31-May-2024 17:12:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31052024171210_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:02","dt":"31052024171210","exchdisstime":"31-May-2024 17:12:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105870875","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-31 17:12:10","symbol":"BIOCON"},{"an_dt":"31-May-2024 11:38:03","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31052024113803_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"31052024113803","exchdisstime":"31-May-2024 11:38:04","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105870355","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-31 11:38:03","symbol":"BIOCON"},{"an_dt":"27-May-2024 17:13:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27052024171318_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"27052024171318","exchdisstime":"27-May-2024 17:13:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105862907","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-27 17:13:18","symbol":"BIOCON"},{"an_dt":"24-May-2024 08:18:35","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24052024081835_PressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 24, 2024, titled \"Biocon Limited signs exclusive licensing and supply deal for the commercialization of Liraglutide in South Korea with Handok Inc.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:00","dt":"24052024081835","exchdisstime":"24-May-2024 08:18:35","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105859566","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-24 08:18:35","symbol":"BIOCON"},{"an_dt":"23-May-2024 16:05:22","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23052024160522_Intimation_IEPF.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"23052024160522","exchdisstime":"23-May-2024 16:05:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105858604","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-23 16:05:22","symbol":"BIOCON"},{"an_dt":"23-May-2024 16:04:43","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23052024160443_Intimation_IEPF.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Reminder Letter to shareholders to claim unclaimed dividends and Newspaper Advertisementin this regard.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:00","dt":"23052024160443","exchdisstime":"23-May-2024 16:04:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105858601","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-23 16:04:43","symbol":"BIOCON"},{"an_dt":"23-May-2024 15:15:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23052024151509_CoverLetter_TranscriptEarningsCall.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"23052024151509","exchdisstime":"23-May-2024 15:15:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105858459","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-23 15:15:09","symbol":"BIOCON"},{"an_dt":"23-May-2024 14:52:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23052024145251_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/ Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:01","dt":"23052024145251","exchdisstime":"23-May-2024 14:52:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105858398","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-23 14:52:51","symbol":"BIOCON"},{"an_dt":"21-May-2024 07:59:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21052024075952_CoverLetter_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 21, 2024, titled \"Biocon Biologics  Obtains U.S. FDA Approval for Biosimilar Aflibercept for Yesafili . Enters U.S. Ophthalmology Market\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:01","dt":"21052024075952","exchdisstime":"21-May-2024 07:59:53","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105853950","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-21 07:59:52","symbol":"BIOCON"},{"an_dt":"19-May-2024 17:26:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19052024172629_SEIntimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:01","dt":"19052024172629","exchdisstime":"19-May-2024 17:26:30","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105852935","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-19 17:26:29","symbol":"BIOCON"},{"an_dt":"17-May-2024 16:14:11","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17052024161411_Intimationn_EarningsCallPresentation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Presentation and Link of Recording","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:07","dt":"17052024161411","exchdisstime":"17-May-2024 16:14:18","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105851075","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-17 16:14:11","symbol":"BIOCON"},{"an_dt":"16-May-2024 17:58:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16052024175855_PressRelease_160524_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 16, 2024, titled \"  Biocon Q4FY24 Revenue at Rs 3,966 Cr, EBITDA at Rs 964 Cr; Net Profit (before exceptional items) at Rs 144 Cr; FY24 Revenue at Rs 15,621 Cr, Up 35%; EBITDA at Rs 4,164 Cr, Up 44%; Net Profit (before exceptional items) at Rs 1,030 Cr, Up 31%; Biosimilars Revenue in FY24 Crosses USD 1 Bn\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:22","dt":"16052024175855","exchdisstime":"16-May-2024 17:59:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105849572","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-16 17:58:55","symbol":"BIOCON"},{"an_dt":"16-May-2024 17:23:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16052024172300_BMOutcome_160524_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Declaration for audit reports with unmodified opinion(s)","bflag":null,"csvName":null,"desc":"Declaration for audit reports with unmodified opinion(s)","difference":"00:00:05","dt":"16052024172300","exchdisstime":"16-May-2024 17:23:05","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105849435","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-16 17:23:00","symbol":"BIOCON"},{"an_dt":"16-May-2024 17:21:39","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16052024172141_BMOutcome_160524_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Appointment of Mr Siddharth Mittal as Managing Director & CEO of the company w.e.f. December 01, 2024.","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:21","dt":"16052024172139","exchdisstime":"16-May-2024 17:22:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105849431","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-16 17:21:39","symbol":"BIOCON"},{"an_dt":"16-May-2024 17:21:39","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16052024172139_BMOutcome_160524_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Appointment of Mr Atul Dhawan as Independent Director of the company w.e.f. May 16, 2024.","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:05","dt":"16052024172139","exchdisstime":"16-May-2024 17:21:44","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105849429","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-16 17:21:39","symbol":"BIOCON"},{"an_dt":"16-May-2024 17:21:39","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16052024172140_BMOutcome_160524_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Appointment of Ms Kiran Mazumdar Shaw as Chairman of the company w.e.f. April 01, 2025.","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:14","dt":"16052024172139","exchdisstime":"16-May-2024 17:21:53","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105849430","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-16 17:21:39","symbol":"BIOCON"},{"an_dt":"16-May-2024 17:17:45","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16052024171746_BMOutcome_160524_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange that Record date for the purpose of Dividend  is 05-Jul-2024.","bflag":null,"csvName":null,"desc":"Record Date","difference":"00:00:22","dt":"16052024171745","exchdisstime":"16-May-2024 17:18:07","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105849416","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-16 17:17:45","symbol":"BIOCON"},{"an_dt":"16-May-2024 17:15:53","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16052024171553_BMOutcome_160524_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Date of payment of dividend","bflag":null,"csvName":null,"desc":"Date of payment of dividend","difference":"00:00:05","dt":"16052024171553","exchdisstime":"16-May-2024 17:15:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105849406","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-16 17:15:53","symbol":"BIOCON"},{"an_dt":"16-May-2024 17:14:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16052024171457_BMOutcome_160524_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Dividend Updates","bflag":null,"csvName":null,"desc":"Dividend Updates","difference":"00:00:05","dt":"16052024171457","exchdisstime":"16-May-2024 17:15:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105849403","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-16 17:14:57","symbol":"BIOCON"},{"an_dt":"16-May-2024 17:12:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16052024171242_BMOutcome_160524_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange that Board of Directors at its meeting held on May 16, 2024, recommended Final Dividend of 10 per equity share.","bflag":null,"csvName":null,"desc":"Dividend","difference":"00:00:10","dt":"16052024171242","exchdisstime":"16-May-2024 17:12:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105849399","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-16 17:12:42","symbol":"BIOCON"},{"an_dt":"16-May-2024 17:10:46","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BMOutcome_160524_signed_16052024171046.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended March 31, 2024.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:00:04","dt":"16052024171046","exchdisstime":"16-May-2024 17:10:50","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"161881","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-16 17:10:46","symbol":"BIOCON"},{"an_dt":"13-May-2024 07:53:24","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13052024075324_PressRelease_130524_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 13, 2024, titled \"Biocon Limited signs semi-exclusive distribution and supply deal for the commercialization of generic Saxenda�� (Liraglutide) in Mexico with Medix\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:06","dt":"13052024075324","exchdisstime":"13-May-2024 07:53:30","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105843301","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-13 07:53:24","symbol":"BIOCON"},{"an_dt":"01-May-2024 13:48:04","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01052024134804_IntimationRegulation30_010524_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Intimation of receipt of Demand Orders.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:04","dt":"01052024134804","exchdisstime":"01-May-2024 13:48:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105830940","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-05-01 13:48:04","symbol":"BIOCON"},{"an_dt":"30-Apr-2024 18:42:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30042024184242_IntimationRegulation30_300424_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Receipt of Demand Orders'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:14","dt":"30042024184242","exchdisstime":"30-Apr-2024 18:42:56","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105830199","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-30 18:42:42","symbol":"BIOCON"},{"an_dt":"25-Apr-2024 17:22:17","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25042024172217_Disclosure.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:08","dt":"25042024172217","exchdisstime":"25-Apr-2024 17:22:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105825229","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-25 17:22:17","symbol":"BIOCON"},{"an_dt":"23-Apr-2024 19:18:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23042024191850_VotingResults_230424_signed.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Postal Ballot. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:12","dt":"23042024191850","exchdisstime":"23-Apr-2024 19:19:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105822833","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-23 19:18:50","symbol":"BIOCON"},{"an_dt":"23-Apr-2024 12:29:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23042024122927_InvestorMeeting_230424_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"23042024122927","exchdisstime":"23-Apr-2024 12:29:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105822290","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-23 12:29:27","symbol":"BIOCON"},{"an_dt":"20-Apr-2024 11:29:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20042024112915_Notification_200424_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:07","dt":"20042024112915","exchdisstime":"20-Apr-2024 11:29:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105820385","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-20 11:29:15","symbol":"BIOCON"},{"an_dt":"17-Apr-2024 18:30:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17042024183011_PressRelease_170424_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 17, 2024, titled \"Biocon Limited signs an exclusive licensing and supply agreement for generic Ozempic (Semaglutide) commercialization in Brazil with Biomm S.A.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:06","dt":"17042024183010","exchdisstime":"17-Apr-2024 18:30:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105817822","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-17 18:30:10","symbol":"BIOCON"},{"an_dt":"17-Apr-2024 11:51:16","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17042024115116_InvestorMeeting_170424_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:07","dt":"17042024115116","exchdisstime":"17-Apr-2024 11:51:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105817426","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-17 11:51:16","symbol":"BIOCON"},{"an_dt":"15-Apr-2024 16:57:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15042024165735_Intimation_Reg74_310324.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:08","dt":"15042024165734","exchdisstime":"15-Apr-2024 16:57:42","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105815467","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-15 16:57:34","symbol":"BIOCON"},{"an_dt":"12-Apr-2024 13:33:45","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12042024133345_Intimation_LetterOfConfirmation_120424_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Loss of Share Certificates","bflag":null,"csvName":null,"desc":"Loss of Share Certificates","difference":"00:00:08","dt":"12042024133345","exchdisstime":"12-Apr-2024 13:33:53","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105813710","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-12 13:33:45","symbol":"BIOCON"},{"an_dt":"10-Apr-2024 23:15:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10042024231502_Intimation_EC_100424_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"10042024231502","exchdisstime":"10-Apr-2024 23:15:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105812671","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-10 23:15:02","symbol":"BIOCON"},{"an_dt":"08-Apr-2024 19:23:05","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08042024192305_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Meeting conducted with Institutional Investors/Research Analysts'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:07","dt":"08042024192305","exchdisstime":"08-Apr-2024 19:23:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105810033","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-08 19:23:05","symbol":"BIOCON"},{"an_dt":"03-Apr-2024 16:21:45","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03042024162145_BIOCON.pdf","attchmntText":"Kiran Mazumdar Shaw has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"00:00:44","dt":"03042024162145","exchdisstime":"03-Apr-2024 16:22:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105804467","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-03 16:21:45","symbol":"BIOCON"},{"an_dt":"02-Apr-2024 18:47:45","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02042024184746_InvestorMeeting_020424.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"02042024184745","exchdisstime":"02-Apr-2024 18:47:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105803870","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-02 18:47:45","symbol":"BIOCON"},{"an_dt":"02-Apr-2024 18:00:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02042024180048_Intimation_Reg30_020424_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon Biologics Limited, subsidiary of Biocon Limited, has completed the transaction of transfer of its branded formulations business in India, to Eris Lifesciences Limited on a slump sale basis.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"02042024180048","exchdisstime":"02-Apr-2024 18:00:53","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105803787","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-02 18:00:48","symbol":"BIOCON"},{"an_dt":"01-Apr-2024 08:30:13","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01042024083013_Notification_010424_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:04","dt":"01042024083013","exchdisstime":"01-Apr-2024 08:30:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105801565","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-04-01 08:30:13","symbol":"BIOCON"},{"an_dt":"28-Mar-2024 13:24:35","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28032024132435_TradingWindowClosure_280324_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:06","dt":"28032024132435","exchdisstime":"28-Mar-2024 13:24:41","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105797114","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-28 13:24:35","symbol":"BIOCON"},{"an_dt":"27-Mar-2024 22:53:46","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27032024225346_PressRelease_270324_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 27, 2024, titled \"Biocon is the first generics Company to obtain approval for diabetes drug, Liraglutide, in the U.K.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:06","dt":"27032024225346","exchdisstime":"27-Mar-2024 22:53:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105796341","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-27 22:53:46","symbol":"BIOCON"},{"an_dt":"25-Mar-2024 18:03:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25032024180302_InvestorMeeting_.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"25032024180302","exchdisstime":"25-Mar-2024 18:03:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105792663","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-25 18:03:02","symbol":"BIOCON"},{"an_dt":"23-Mar-2024 01:43:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23032024014332_Intimation_NewspaperAd_230324_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:07","dt":"23032024014332","exchdisstime":"23-Mar-2024 01:43:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105792001","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-23 01:43:32","symbol":"BIOCON"},{"an_dt":"22-Mar-2024 17:08:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22032024170857_SEIntimation22032024.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI (Listing Regulations and Disclosure Requirements) Regulations, 2015'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"22032024170857","exchdisstime":"22-Mar-2024 17:09:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105791573","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-22 17:08:57","symbol":"BIOCON"},{"an_dt":"21-Mar-2024 18:26:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21032024182609_PostalBallotNotice_Intimation_signed_210324.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Postal Ballot","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:06","dt":"21032024182609","exchdisstime":"21-Mar-2024 18:26:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105790349","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-21 18:26:09","symbol":"BIOCON"},{"an_dt":"21-Mar-2024 13:45:46","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21032024134546_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"21032024134546","exchdisstime":"21-Mar-2024 13:45:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105789824","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-21 13:45:46","symbol":"BIOCON"},{"an_dt":"16-Mar-2024 12:46:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16032024124621_LossOfShareCertificate_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Loss of Share Certificates","bflag":null,"csvName":null,"desc":"Loss of Share Certificates","difference":"00:00:05","dt":"16032024124621","exchdisstime":"16-Mar-2024 12:46:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105785629","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-16 12:46:21","symbol":"BIOCON"},{"an_dt":"14-Mar-2024 22:27:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14032024222729_Intimation_KMP_Authorisation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Updated list of KMPs who are authorized to determine materiality of an event or information and make necessary disclosures to the Stock Exchange(s).'","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"14032024222729","exchdisstime":"14-Mar-2024 22:27:35","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105784204","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-14 22:27:29","symbol":"BIOCON"},{"an_dt":"14-Mar-2024 18:59:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14032024185933_Intimation_140324_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Resignation of Mr Indranil Sen as Chief Financial Officer of the company w.e.f. March 14, 2024.","bflag":null,"csvName":null,"desc":"Resignation","difference":"00:00:16","dt":"14032024185933","exchdisstime":"14-Mar-2024 18:59:49","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105784123","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-14 18:59:33","symbol":"BIOCON"},{"an_dt":"14-Mar-2024 15:13:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14032024151357_Intimation_Regulation30_140324_signed_2.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon Biologics Limited, a subsidiary of Biocon Limited has approved the sale of businesses in relation to its branded formulations in India, comprising, inter alia, of Metabolics, Oncology And Critical Care Diagnostic  ( BFI Business ) to Eris Lifesciences Limited on a  slump sale  basis.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"14032024151356","exchdisstime":"14-Mar-2024 15:14:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105783758","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-14 15:13:56","symbol":"BIOCON"},{"an_dt":"04-Mar-2024 19:24:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04032024192430_Intimation_SMP_Appointment_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Appointment of Mr Amit Kaptain as Other of the company w.e.f. March 04, 2024.","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:12","dt":"04032024192429","exchdisstime":"04-Mar-2024 19:24:41","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105775590","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-04 19:24:29","symbol":"BIOCON"},{"an_dt":"04-Mar-2024 19:24:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04032024192429_Intimation_SMP_Appointment_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Appointment of Mr Vishal Nayyar as Other of the company w.e.f. March 04, 2024.","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:04","dt":"04032024192429","exchdisstime":"04-Mar-2024 19:24:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105775589","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-04 19:24:29","symbol":"BIOCON"},{"an_dt":"04-Mar-2024 08:26:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04032024082607_Intimation_040324_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"04032024082607","exchdisstime":"04-Mar-2024 08:26:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105774999","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-03-04 08:26:07","symbol":"BIOCON"},{"an_dt":"29-Feb-2024 18:53:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29022024185306_pressrelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 29, 2024, titled \"Press Release titled  Biocon Biologics Secures US Market Entry Date for Bmab 1200, a Proposed Biosimilar to Stelara��\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:11","dt":"29022024185306","exchdisstime":"29-Feb-2024 18:53:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105773009","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-29 18:53:06","symbol":"BIOCON"},{"an_dt":"29-Feb-2024 16:39:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29022024163950_CompanyStatement_290224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:04","dt":"29022024163950","exchdisstime":"29-Feb-2024 16:39:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105772746","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-29 16:39:50","symbol":"BIOCON"},{"an_dt":"27-Feb-2024 10:35:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27022024103502_InvestorMeeting_270224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"27022024103502","exchdisstime":"27-Feb-2024 10:35:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105770138","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-27 10:35:02","symbol":"BIOCON"},{"an_dt":"23-Feb-2024 21:07:47","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23022024210747_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"23022024210747","exchdisstime":"23-Feb-2024 21:07:53","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105768519","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-23 21:07:47","symbol":"BIOCON"},{"an_dt":"23-Feb-2024 20:45:39","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23022024204539_Intimation_underRegulation_30_CorporateGuarantee_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Issuance of Corporate Guarantee on behalf of Biocon Generics Inc, wholly owned step down subsidiary of the Company'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"23022024204539","exchdisstime":"23-Feb-2024 20:45:45","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105768512","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-23 20:45:39","symbol":"BIOCON"},{"an_dt":"23-Feb-2024 14:45:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23022024144529_IntimationunderRegulation30_Order_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Order dated February 22, 2024, from the Office of Deputy Commissioner of Commercial Taxes, Divisional GST Office, Bangalore. '.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:04","dt":"23022024144529","exchdisstime":"23-Feb-2024 14:45:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105768033","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-23 14:45:29","symbol":"BIOCON"},{"an_dt":"21-Feb-2024 13:20:47","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21022024132047_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:07","dt":"21022024132047","exchdisstime":"21-Feb-2024 13:20:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105765780","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-21 13:20:47","symbol":"BIOCON"},{"an_dt":"20-Feb-2024 11:26:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20022024112614_InvestorMeeting_200224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"20022024112614","exchdisstime":"20-Feb-2024 11:26:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105764581","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-20 11:26:14","symbol":"BIOCON"},{"an_dt":"20-Feb-2024 11:08:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20022024110849_PressRelease_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 20, 2024, titled \"Biocon Included in S&P Global Sustainability Yearbook 2024; S&P Global ESG Score at 63; Inducted in Dow Jones Sustainability Emerging Markets Index for 3rd Year in a Row\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:06","dt":"20022024110849","exchdisstime":"20-Feb-2024 11:08:55","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105764503","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-20 11:08:49","symbol":"BIOCON"},{"an_dt":"16-Feb-2024 22:19:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16022024221949_Transcript_160224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"16022024221949","exchdisstime":"16-Feb-2024 22:19:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105762821","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-16 22:19:49","symbol":"BIOCON"},{"an_dt":"13-Feb-2024 22:50:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13022024225006_InvestorMeeting_130224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"13022024225006","exchdisstime":"13-Feb-2024 22:50:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105758659","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-13 22:50:06","symbol":"BIOCON"},{"an_dt":"11-Feb-2024 22:05:03","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11022024220503_NewspaperAd_110224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:07","dt":"11022024220503","exchdisstime":"11-Feb-2024 22:05:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105755572","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-11 22:05:03","symbol":"BIOCON"},{"an_dt":"09-Feb-2024 15:12:46","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09022024151246_EarningsCall_090224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Presentation and Link of Recording","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"09022024151246","exchdisstime":"09-Feb-2024 15:12:50","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105753802","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-09 15:12:46","symbol":"BIOCON"},{"an_dt":"09-Feb-2024 14:36:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09022024143655_InvestorPresentation_090224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:06","dt":"09022024143655","exchdisstime":"09-Feb-2024 14:37:01","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105753715","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-09 14:36:55","symbol":"BIOCON"},{"an_dt":"09-Feb-2024 08:00:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09022024080050_PressRelease_090224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 09, 2024, titled \"Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:07","dt":"09022024080049","exchdisstime":"09-Feb-2024 08:00:56","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105753121","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-09 08:00:49","symbol":"BIOCON"},{"an_dt":"09-Feb-2024 07:09:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09022024070930_CompanyStatement_090224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"09022024070930","exchdisstime":"09-Feb-2024 07:09:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105753120","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-09 07:09:30","symbol":"BIOCON"},{"an_dt":"08-Feb-2024 20:34:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08022024203450_PressRelease_080224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 08, 2024, titled \"Biocon Q3FY24 Revenue at Rs 4,519 Cr, Up 50%; Biosimilars Up 65%; Research Services Up 9%; EBITDA at Rs 1,492 Cr, Up 106%; Net Profit at Rs 660 Cr; Pre-Paid USD 200 Mn towards Debt Reduction\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:07","dt":"08022024203450","exchdisstime":"08-Feb-2024 20:34:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105752789","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-08 20:34:50","symbol":"BIOCON"},{"an_dt":"08-Feb-2024 19:16:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08022024191657_Resgination_Intimation_Final_080224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Resignation of Mr Nehal Vora as Senior Management Personnel of the company w.e.f. March 31, 2024.","bflag":null,"csvName":null,"desc":"Resignation","difference":"00:00:14","dt":"08022024191656","exchdisstime":"08-Feb-2024 19:17:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105752677","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-08 19:16:56","symbol":"BIOCON"},{"an_dt":"08-Feb-2024 19:16:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08022024191656_Resgination_Intimation_Final_080224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Resignation of Mr Indranil Sen as Chief Financial Officer of the company w.e.f. March 15, 2024.","bflag":null,"csvName":null,"desc":"Resignation","difference":"00:00:06","dt":"08022024191656","exchdisstime":"08-Feb-2024 19:17:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105752676","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-08 19:16:56","symbol":"BIOCON"},{"an_dt":"08-Feb-2024 19:09:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08022024190951_Outcome_BoardMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on February 08, 2024.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:06","dt":"08022024190951","exchdisstime":"08-Feb-2024 19:09:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105752656","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-08 19:09:51","symbol":"BIOCON"},{"an_dt":"08-Feb-2024 19:06:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Outcome_BoardMeeting_signed_08022024190618.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended December 31, 2023.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:00:07","dt":"08022024190618","exchdisstime":"08-Feb-2024 19:06:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"160075","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-08 19:06:18","symbol":"BIOCON"},{"an_dt":"08-Feb-2024 19:04:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08022024190414_Outcome_BoardMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on February 08, 2024.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:05","dt":"08022024190414","exchdisstime":"08-Feb-2024 19:04:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105752648","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-08 19:04:14","symbol":"BIOCON"},{"an_dt":"08-Feb-2024 15:09:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08022024150926_InvestorMeeting_080224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:07","dt":"08022024150926","exchdisstime":"08-Feb-2024 15:09:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105751990","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-08 15:09:26","symbol":"BIOCON"},{"an_dt":"07-Feb-2024 16:19:36","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07022024161936_CreditRating_070224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:07","dt":"07022024161936","exchdisstime":"07-Feb-2024 16:19:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105750400","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-07 16:19:36","symbol":"BIOCON"},{"an_dt":"07-Feb-2024 11:10:19","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07022024111019_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:23","dt":"07022024111019","exchdisstime":"07-Feb-2024 11:10:42","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105749765","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-07 11:10:19","symbol":"BIOCON"},{"an_dt":"06-Feb-2024 16:02:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06022024160227_Notification_060224_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:07","dt":"06022024160227","exchdisstime":"06-Feb-2024 16:02:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105748658","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-06 16:02:27","symbol":"BIOCON"},{"an_dt":"05-Feb-2024 13:13:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05022024131342_PressRelease_05022024_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 05, 2024, titled \"Oral Cancer Task Force's Consensus Guidelines for Head & Neck Cancer Recognized Among 13 Worldwide Clinical Practice Guidelines\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:07","dt":"05022024131342","exchdisstime":"05-Feb-2024 13:13:49","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105746705","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-02-05 13:13:42","symbol":"BIOCON"},{"an_dt":"31-Jan-2024 17:00:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31012024170050_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Reminder Letter to shareholders for claiming Unclaimed dividend and updation of KYCInformation'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"31012024170050","exchdisstime":"31-Jan-2024 17:00:56","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105741007","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-01-31 17:00:50","symbol":"BIOCON"},{"an_dt":"11-Jan-2024 18:41:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11012024184156_Certificate.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:16","dt":"11012024184156","exchdisstime":"11-Jan-2024 18:42:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105722997","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-01-11 18:41:56","symbol":"BIOCON"},{"an_dt":"11-Jan-2024 13:06:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11012024130654_InvestorMeeting_011124_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"11012024130654","exchdisstime":"11-Jan-2024 13:06:59","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105722470","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-01-11 13:06:54","symbol":"BIOCON"},{"an_dt":"10-Jan-2024 17:17:04","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10012024171704_EarningsCall.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"10012024171704","exchdisstime":"10-Jan-2024 17:17:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105721608","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2024-01-10 17:17:04","symbol":"BIOCON"},{"an_dt":"29-Dec-2023 15:39:20","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29122023153920_Intimation_TradingWindow_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:07","dt":"29122023153920","exchdisstime":"29-Dec-2023 15:39:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105710345","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-29 15:39:20","symbol":"BIOCON"},{"an_dt":"29-Dec-2023 11:24:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29122023112429_CompanyStatement_291223_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:07","dt":"29122023112429","exchdisstime":"29-Dec-2023 11:24:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105709737","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-29 11:24:29","symbol":"BIOCON"},{"an_dt":"22-Dec-2023 16:01:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22122023160149_PressRelease22122023.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 22, 2023, titled \"Biocon Biologics Partners with Sandoz for the Distribution of  Adalimumab BS Subcutaneous Injection [FKB]\" in Japan\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"22122023160149","exchdisstime":"22-Dec-2023 16:01:53","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105703516","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-22 16:01:49","symbol":"BIOCON"},{"an_dt":"21-Dec-2023 19:01:28","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21122023190128_Intiamtion_LetterOfConfirmation_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Loss of Share Certificates","bflag":null,"csvName":null,"desc":"Loss of Share Certificates","difference":"00:00:05","dt":"21122023190128","exchdisstime":"21-Dec-2023 19:01:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105702693","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-21 19:01:28","symbol":"BIOCON"},{"an_dt":"20-Dec-2023 13:20:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20122023132001_Intimation_Resignation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Resignation of Mr Prasad Deshpande as Other of the company w.e.f. January 16, 2024.","bflag":null,"csvName":null,"desc":"Resignation","difference":"00:00:07","dt":"20122023132001","exchdisstime":"20-Dec-2023 13:20:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105701212","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-20 13:20:01","symbol":"BIOCON"},{"an_dt":"19-Dec-2023 15:23:41","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19122023152341_PressRelease_191223_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 19, 2023, titled \"Biocon Academy Conducts its 8th Graduation Day, 112 Students with 77% Females across Four Programs Participate\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"19122023152341","exchdisstime":"19-Dec-2023 15:23:46","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105700226","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-19 15:23:41","symbol":"BIOCON"},{"an_dt":"19-Dec-2023 11:21:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19122023112148_biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 18, 2023, titled \"Biocon Biologics Concludes Integration of Acquired Biosimilars Business in approx 120 countries,  10+ Emerging Markets, Japan and ANZ Transition in Final Phase\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"19122023112148","exchdisstime":"19-Dec-2023 11:21:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105700042","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-19 11:21:48","symbol":"BIOCON"},{"an_dt":"19-Dec-2023 10:51:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19122023105121_BIOCON.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 18, 2023, titled \"Biocon Biologics Recognized as an Asia IP Elite for 2023, IPR Teamadjudged as the Team of the Year\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:07","dt":"19122023105121","exchdisstime":"19-Dec-2023 10:51:28","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105700003","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-19 10:51:21","symbol":"BIOCON"},{"an_dt":"15-Dec-2023 12:54:20","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15122023125420_Intimation_NewsClarification_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement on news article published in the Economic Times on December 15, 2023'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"15122023125420","exchdisstime":"15-Dec-2023 12:54:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105697738","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-15 12:54:20","symbol":"BIOCON"},{"an_dt":"15-Dec-2023 11:14:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15122023111457_Intimation_PressRelease_151223_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 15, 2023, titled \"Biocon Biologics Recognized as an Asia IP Elite for 2023,IPR Team adjudged as the Team of the Year\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:06","dt":"15122023111457","exchdisstime":"15-Dec-2023 11:15:03","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105697665","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-15 11:14:57","symbol":"BIOCON"},{"an_dt":"14-Dec-2023 16:25:36","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14122023162536_InvestorMeeting_141223_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"14122023162536","exchdisstime":"14-Dec-2023 16:25:42","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105696889","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-14 16:25:36","symbol":"BIOCON"},{"an_dt":"13-Dec-2023 16:56:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13122023165650_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding ' Bicara Therapeutics Inc. ( Bicara ), an associate company of Biocon Limited, has on December 12, 2023, completed its US$165 Million Series C financing. The proceeds of the funding shall be used to support the continued advancement of Bicara s lead product candidate, BCA101, a first-in-class bifunctional EGFR/TGF-β inhibitor that is currently in clinical development for multiple cancer types. The media release made by Bicara in this regard can be accessed at https://www.bicara.com/bicara-therapeutics-announces-oversubscribed-165-million-series-c-financing/.Consequent to this infusion of Series C funding and post allotment of shares by Bicara, the Company s shareholding in Bicara on fully diluted basis will fall below 20% and thereby, Bicara will cease to be an associate company of Biocon Limited.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:04","dt":"13122023165650","exchdisstime":"13-Dec-2023 16:56:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105695806","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-13 16:56:50","symbol":"BIOCON"},{"an_dt":"12-Dec-2023 16:09:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12122023160902_InvestorMeeting_121223_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:11","dt":"12122023160902","exchdisstime":"12-Dec-2023 16:09:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105694759","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-12 16:09:02","symbol":"BIOCON"},{"an_dt":"05-Dec-2023 21:57:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05122023215715_InvestorMeeting_051223_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"05122023215715","exchdisstime":"05-Dec-2023 21:57:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105690151","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-05 21:57:15","symbol":"BIOCON"},{"an_dt":"04-Dec-2023 17:41:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04122023174152_Intimation_LetterOfConfirmation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Loss of Share Certificates","bflag":null,"csvName":null,"desc":"Loss of Share Certificates","difference":"00:00:06","dt":"04122023174152","exchdisstime":"04-Dec-2023 17:41:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105689152","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-12-04 17:41:52","symbol":"BIOCON"},{"an_dt":"30-Nov-2023 16:36:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30112023163607_InvestorMeeting_30112023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:07","dt":"30112023163607","exchdisstime":"30-Nov-2023 16:36:14","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105686786","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-30 16:36:07","symbol":"BIOCON"},{"an_dt":"30-Nov-2023 15:40:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30112023154007_Intimation_CreditRating_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:09","dt":"30112023154007","exchdisstime":"30-Nov-2023 15:40:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105686735","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-30 15:40:07","symbol":"BIOCON"},{"an_dt":"30-Nov-2023 15:30:20","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30112023153020_Intimation_PressRelase_301123_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 30, 2023, titled \"Biocon Biologics Successfully Completes Integration of Viatris  Biosimilar Business in 31 Countries in Europe\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:18","dt":"30112023153020","exchdisstime":"30-Nov-2023 15:30:38","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105686726","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-30 15:30:20","symbol":"BIOCON"},{"an_dt":"29-Nov-2023 19:26:28","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29112023192628_Intimation_LossOfShareCertificate_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Intimation for Loss of share certificate'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"29112023192628","exchdisstime":"29-Nov-2023 19:26:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105685961","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-29 19:26:28","symbol":"BIOCON"},{"an_dt":"29-Nov-2023 19:03:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29112023190310_Intimation_Results_ScrutinizerReport_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"00:00:05","dt":"29112023190310","exchdisstime":"29-Nov-2023 19:03:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105685927","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-29 19:03:10","symbol":"BIOCON"},{"an_dt":"29-Nov-2023 19:00:38","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29112023190038_Intimation_Results_ScrutinizerReport_signed.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Postal Ballot. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:07","dt":"29112023190038","exchdisstime":"29-Nov-2023 19:00:45","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105685921","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-29 19:00:38","symbol":"BIOCON"},{"an_dt":"27-Nov-2023 18:01:36","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27112023180136_InvestorMeeting_27112023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:07","dt":"27112023180136","exchdisstime":"27-Nov-2023 18:01:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105684274","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-27 18:01:36","symbol":"BIOCON"},{"an_dt":"22-Nov-2023 17:01:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22112023170118_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"22112023170118","exchdisstime":"22-Nov-2023 17:01:24","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105681396","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-22 17:01:18","symbol":"BIOCON"},{"an_dt":"20-Nov-2023 21:43:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20112023214334_TranscriptEarningCall_10112023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"20112023214334","exchdisstime":"20-Nov-2023 21:43:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105679764","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-20 21:43:34","symbol":"BIOCON"},{"an_dt":"20-Nov-2023 17:25:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20112023172534_InvestorMeeting_20112023.pdf","attchmntText":"Biocon Limited has informed the Exchange about details of meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:07","dt":"20112023172534","exchdisstime":"20-Nov-2023 17:25:41","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105679570","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-20 17:25:34","symbol":"BIOCON"},{"an_dt":"17-Nov-2023 18:33:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17112023183355_InvestorPresentation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Investor Presentation'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"17112023183355","exchdisstime":"17-Nov-2023 18:34:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105678567","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-17 18:33:55","symbol":"BIOCON"},{"an_dt":"17-Nov-2023 18:11:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17112023181118_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"17112023181118","exchdisstime":"17-Nov-2023 18:11:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105678538","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-17 18:11:18","symbol":"BIOCON"},{"an_dt":"13-Nov-2023 16:00:39","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13112023160039_SEIntimation_13112023.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:09","dt":"13112023160039","exchdisstime":"13-Nov-2023 16:00:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105675137","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-13 16:00:39","symbol":"BIOCON"},{"an_dt":"11-Nov-2023 21:21:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11112023212156_CoverLetter_Lossofsharecertificate_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Loss of Share Certificates","bflag":null,"csvName":null,"desc":"Loss of Share Certificates","difference":"00:00:07","dt":"11112023212156","exchdisstime":"11-Nov-2023 21:22:03","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105674625","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-11 21:21:56","symbol":"BIOCON"},{"an_dt":"11-Nov-2023 15:57:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11112023155727_NewspaperPublication_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:09","dt":"11112023155727","exchdisstime":"11-Nov-2023 15:57:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105674491","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-11 15:57:27","symbol":"BIOCON"},{"an_dt":"11-Nov-2023 15:54:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11112023155418_EarningsCall_Presentation_final.pdf","attchmntText":"Biocon Limited has informed the Exchange about Presentation","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:08","dt":"11112023155418","exchdisstime":"11-Nov-2023 15:54:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105674487","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-11 15:54:18","symbol":"BIOCON"},{"an_dt":"11-Nov-2023 15:54:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11112023155420_EarningsCall_Presentation_final.pdf","attchmntText":"Biocon Limited has informed the Exchange about Link of Recording","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:16","dt":"11112023155418","exchdisstime":"11-Nov-2023 15:54:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105674488","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-11 15:54:18","symbol":"BIOCON"},{"an_dt":"10-Nov-2023 17:38:58","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10112023173858_RPT_300923_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about related Party Transactions","bflag":null,"csvName":null,"desc":"Related Party Transactions","difference":"00:00:12","dt":"10112023173858","exchdisstime":"10-Nov-2023 17:39:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105673539","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-10 17:38:58","symbol":"BIOCON"},{"an_dt":"10-Nov-2023 17:17:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10112023171756_PressRelease_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 10, 2023, titled \"Biocon Q2FY24 Revenue at Rs 3,620 Cr, Up 52%; Biosimilars Up 97%; Research Services Up 18%; EBITDA at Rs 900 Cr, Up 68%; Core EBITDA at Rs 1,100 Cr, Up 35%;Net Profit at Rs 126 Cr, Up 168%\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:11","dt":"10112023171756","exchdisstime":"10-Nov-2023 17:18:07","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105673457","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-10 17:17:56","symbol":"BIOCON"},{"an_dt":"10-Nov-2023 16:27:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10112023162756_Intimation_ChangeInPolicy_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure under Regulation 30(5) of SEBI LODR'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:07","dt":"10112023162756","exchdisstime":"10-Nov-2023 16:28:03","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105673300","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-10 16:27:56","symbol":"BIOCON"},{"an_dt":"10-Nov-2023 16:24:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10112023162449_Intimation_Outcome_BM_Results_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on November 10, 2023.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:13","dt":"10112023162449","exchdisstime":"10-Nov-2023 16:25:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105673289","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-10 16:24:49","symbol":"BIOCON"},{"an_dt":"10-Nov-2023 16:23:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Intimation_Outcome_BM_Results_signed_10112023162326.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended September 30, 2023.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:00:05","dt":"10112023162326","exchdisstime":"10-Nov-2023 16:23:31","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"158510","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-10 16:23:26","symbol":"BIOCON"},{"an_dt":"10-Nov-2023 12:01:17","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10112023120117_Intimation_Reg30_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Revised Filing w.r.t. Biocon Biologics Limited, a subsidiary of Biocon Limited has divested the businesses in relation to its non-core branded formulations in India, comprising, inter alia, of generic dermatology and nephrology small molecule formulations ( BFI Non-Core Business ) to Eris Lifesciences Limited on a  slump sale  basis.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:09","dt":"10112023120117","exchdisstime":"10-Nov-2023 12:01:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105672693","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-10 12:01:17","symbol":"BIOCON"},{"an_dt":"10-Nov-2023 11:32:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10112023113226_Intimation_Reg30_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon Biologics Limited, a subsidiary of Biocon Limited has divested the businesses in relation to its non-core branded formulations in India, comprising, inter alia, of generic dermatology and nephrology small molecule formulations ( BFI Non-Core Business ) to Eris Lifesciences Limited on a  slump sale  basis.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:17","dt":"10112023113226","exchdisstime":"10-Nov-2023 11:32:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105672625","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-10 11:32:26","symbol":"BIOCON"},{"an_dt":"08-Nov-2023 16:14:59","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08112023161459_Intmation_Regulation30_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 08, 2023, titled \"Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations - India Business Units\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:10","dt":"08112023161459","exchdisstime":"08-Nov-2023 16:15:09","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105669526","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-08 16:14:59","symbol":"BIOCON"},{"an_dt":"08-Nov-2023 16:09:39","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08112023160939_Intmation_Regulation30_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI Listing Regulations.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:21","dt":"08112023160939","exchdisstime":"08-Nov-2023 16:10:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105669510","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-11-08 16:09:39","symbol":"BIOCON"},{"an_dt":"31-Oct-2023 15:48:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31102023154855_PressRelease_311023_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 31, 2023, titled \"Biocon Ranked No. 8 Among Science Magazine s Best Employers in Global Biotech and Pharma Sector\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:07","dt":"31102023154855","exchdisstime":"31-Oct-2023 15:49:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105659009","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-31 15:48:55","symbol":"BIOCON"},{"an_dt":"28-Oct-2023 23:47:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28102023234749_NewspaperAdIntimation_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:06","dt":"28102023234748","exchdisstime":"28-Oct-2023 23:47:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105656549","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-28 23:47:48","symbol":"BIOCON"},{"an_dt":"27-Oct-2023 19:12:16","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27102023191216_PostalBallotNotice_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Postal Ballot","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:06","dt":"27102023191216","exchdisstime":"27-Oct-2023 19:12:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105655782","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-27 19:12:16","symbol":"BIOCON"},{"an_dt":"19-Oct-2023 15:07:59","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19102023150759_PressRelease_191023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 19, 2023, titled \"Finance Leadership Update at Biocon Biologics: Kedar Upadhye Appointed as New CFO of Biocon Biologics; Current CFO MB Chinappa to take on a Strategic Finance role at Biocon Group.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:10","dt":"19102023150759","exchdisstime":"19-Oct-2023 15:08:09","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105648605","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-19 15:07:59","symbol":"BIOCON"},{"an_dt":"18-Oct-2023 05:25:05","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18102023052505_CompanyStatement_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement w.r.t.  Update on U.S. FDA Inspection at Biocon Biologics  Manufacturing Facility in Johor, Malaysia. '.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"18102023052505","exchdisstime":"18-Oct-2023 05:25:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105646970","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-18 05:25:05","symbol":"BIOCON"},{"an_dt":"16-Oct-2023 20:13:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16102023201315_Certificate_Reg74_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:06","dt":"16102023201315","exchdisstime":"16-Oct-2023 20:13:21","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105645534","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-16 20:13:15","symbol":"BIOCON"},{"an_dt":"13-Oct-2023 19:05:04","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13102023190504_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"13102023190504","exchdisstime":"13-Oct-2023 19:05:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105644085","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-13 19:05:04","symbol":"BIOCON"},{"an_dt":"11-Oct-2023 22:47:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11102023224734_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:22","dt":"11102023224733","exchdisstime":"11-Oct-2023 22:47:55","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105642143","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-11 22:47:33","symbol":"BIOCON"},{"an_dt":"11-Oct-2023 22:47:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11102023224735_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:29","dt":"11102023224733","exchdisstime":"11-Oct-2023 22:48:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105642144","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-11 22:47:33","symbol":"BIOCON"},{"an_dt":"11-Oct-2023 22:47:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11102023224733_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:15","dt":"11102023224733","exchdisstime":"11-Oct-2023 22:47:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105642142","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-11 22:47:33","symbol":"BIOCON"},{"an_dt":"11-Oct-2023 22:47:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11102023224733_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:08","dt":"11102023224733","exchdisstime":"11-Oct-2023 22:47:41","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105642141","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-11 22:47:33","symbol":"BIOCON"},{"an_dt":"11-Oct-2023 09:12:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11102023091251_InvestorMeeting_111023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"11102023091251","exchdisstime":"11-Oct-2023 09:12:56","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105641112","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-11 09:12:51","symbol":"BIOCON"},{"an_dt":"09-Oct-2023 17:23:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09102023172332_Intmation_SMP_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about change in Management","bflag":null,"csvName":null,"desc":"Change in Management","difference":"00:00:07","dt":"09102023172332","exchdisstime":"09-Oct-2023 17:23:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105639439","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-09 17:23:32","symbol":"BIOCON"},{"an_dt":"09-Oct-2023 17:08:53","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09102023170853_EarningsCall_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"09102023170853","exchdisstime":"09-Oct-2023 17:08:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105639413","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-09 17:08:53","symbol":"BIOCON"},{"an_dt":"09-Oct-2023 09:03:41","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09102023090341_Biocon_company.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Company Statement w.r.t. \"Biocon Biologics Receives Complete Response Letter from US FDA for Biosimilar Insulin Aspart.\"","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"09102023090341","exchdisstime":"09-Oct-2023 09:03:47","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105638781","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-09 09:03:41","symbol":"BIOCON"},{"an_dt":"06-Oct-2023 16:04:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06102023160451_PressRelease_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 06, 2023, titled \"Biocon Limited signs commercialization agreement with Juno Pharmaceuticals in Canada\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:01:49","dt":"06102023160451","exchdisstime":"06-Oct-2023 16:06:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105637695","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-10-06 16:04:51","symbol":"BIOCON"},{"an_dt":"29-Sep-2023 19:00:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29092023190021_Intimation_TradingWindow_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:04","dt":"29092023190021","exchdisstime":"29-Sep-2023 19:00:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105631963","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-29 19:00:21","symbol":"BIOCON"},{"an_dt":"22-Sep-2023 19:13:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22092023191306_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:09","dt":"22092023191306","exchdisstime":"22-Sep-2023 19:13:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105624402","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-22 19:13:06","symbol":"BIOCON"},{"an_dt":"22-Sep-2023 19:11:45","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22092023191145_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"22092023191145","exchdisstime":"22-Sep-2023 19:11:49","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105624394","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-22 19:11:45","symbol":"BIOCON"},{"an_dt":"22-Sep-2023 16:02:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22092023160206_SEIntimation_signed2.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure under Regulation 30'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:09","dt":"22092023160206","exchdisstime":"22-Sep-2023 16:02:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105624066","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-22 16:02:06","symbol":"BIOCON"},{"an_dt":"22-Sep-2023 08:57:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22092023085715_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"22092023085715","exchdisstime":"22-Sep-2023 08:57:20","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105623646","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-22 08:57:15","symbol":"BIOCON"},{"an_dt":"20-Sep-2023 15:59:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20092023155908_CompanyStatement_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"20092023155908","exchdisstime":"20-Sep-2023 15:59:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105622105","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-20 15:59:08","symbol":"BIOCON"},{"an_dt":"18-Sep-2023 20:39:58","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18092023203958_BIOCON_ROID_10549_KMP_Doc_18092023203958.zip","attchmntText":"BIOCON LIMITED has informed the Exchange about Resignation of Independent director.","bflag":null,"csvName":null,"desc":"Resignation of Independent director","difference":"00:00:02","dt":"18092023203958","exchdisstime":"18-Sep-2023 20:40:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105621185","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-18 20:39:58","symbol":"BIOCON"},{"an_dt":"18-Sep-2023 18:12:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18092023181208_PressRelease_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 18, 2023, titled \"Biocon Board Appoints Peter Bains as Group CEO\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"18092023181208","exchdisstime":"18-Sep-2023 18:12:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105621085","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-18 18:12:08","symbol":"BIOCON"},{"an_dt":"18-Sep-2023 18:10:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18092023181022_ChangeInManagement_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Appointment of Mr Peter Bains as Biocon Group Chief Executive Officer of the Company, being a Senior Management Personnel w.e.f. September 18, 2023.","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:08","dt":"18092023181021","exchdisstime":"18-Sep-2023 18:10:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105621083","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-18 18:10:21","symbol":"BIOCON"},{"an_dt":"18-Sep-2023 18:06:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18092023180621_ChangeInManagement_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Resignation of Mr Peter Bains as Non- Executive Independent Director of the company w.e.f. September 18, 2023.","bflag":null,"csvName":null,"desc":"Resignation","difference":"00:00:06","dt":"18092023180621","exchdisstime":"18-Sep-2023 18:06:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105621080","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-18 18:06:21","symbol":"BIOCON"},{"an_dt":"13-Sep-2023 11:52:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13092023115201_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:13","dt":"13092023115201","exchdisstime":"13-Sep-2023 11:52:14","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105617569","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-13 11:52:01","symbol":"BIOCON"},{"an_dt":"07-Sep-2023 16:35:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07092023163554_PressNote_070923_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 07, 2023, titled \"Kiran Mazumdar-Shaw appointed as member of the Court of Regents at the Royal College of Surgeons of Edinburgh\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"07092023163554","exchdisstime":"07-Sep-2023 16:35:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105613314","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-07 16:35:54","symbol":"BIOCON"},{"an_dt":"06-Sep-2023 15:59:19","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06092023155919_PressRelease_060923_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 06, 2023, titled \"Biocon Biologics Continues to Expand Global Footprint, Completes Integration of Viatris Biosimilars  Business In North America, Ahead of Schedule\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:06","dt":"06092023155919","exchdisstime":"06-Sep-2023 15:59:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105611837","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-06 15:59:19","symbol":"BIOCON"},{"an_dt":"02-Sep-2023 14:52:41","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02092023145241_SEIntimationPressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 01, 2023, titled \"Biocon Limited announces the acquisition of a manufacturing facility of Eywa Pharma Inc.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"02092023145241","exchdisstime":"02-Sep-2023 14:52:46","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105607609","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-02 14:52:41","symbol":"BIOCON"},{"an_dt":"01-Sep-2023 11:35:23","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01092023113523_SEIntimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Appointment of Mr Nicholas Robert Haggar as Non- Executive Independent Director of the company w.e.f. September 01, 2023.","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:06","dt":"01092023113523","exchdisstime":"01-Sep-2023 11:35:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105606270","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-09-01 11:35:23","symbol":"BIOCON"},{"an_dt":"31-Aug-2023 07:35:45","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31082023073545_InvestorMeeting_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about 1-1 Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"31082023073545","exchdisstime":"31-Aug-2023 07:35:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105604699","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-31 07:35:45","symbol":"BIOCON"},{"an_dt":"25-Aug-2023 18:17:16","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25082023181716_SEInitimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Reporting of violations under SEBI (Prohibition of Insider Trading) Regulations, 2015.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:03","dt":"25082023181716","exchdisstime":"25-Aug-2023 18:17:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105600037","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-25 18:17:16","symbol":"BIOCON"},{"an_dt":"25-Aug-2023 17:12:22","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25082023171222_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"25082023171222","exchdisstime":"25-Aug-2023 17:12:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105599833","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-25 17:12:22","symbol":"BIOCON"},{"an_dt":"24-Aug-2023 11:25:19","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24082023112519_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"24082023112519","exchdisstime":"24-Aug-2023 11:25:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105598327","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-24 11:25:19","symbol":"BIOCON"},{"an_dt":"21-Aug-2023 21:14:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21082023211415_Intimation_Reg30_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30(4) of SEBI Listing Regulations'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:25","dt":"21082023211415","exchdisstime":"21-Aug-2023 21:14:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105595484","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-21 21:14:15","symbol":"BIOCON"},{"an_dt":"21-Aug-2023 13:46:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21082023134622_EarningsCallTranscript_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:09","dt":"21082023134621","exchdisstime":"21-Aug-2023 13:46:30","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105594971","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-21 13:46:21","symbol":"BIOCON"},{"an_dt":"16-Aug-2023 12:33:37","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16082023123337_45thAGM_VotingResult_ScrutiniserReport_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Shareholders meeting","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:16","dt":"16082023123337","exchdisstime":"16-Aug-2023 12:33:53","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105591236","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-16 12:33:37","symbol":"BIOCON"},{"an_dt":"14-Aug-2023 13:48:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14082023134809_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:17","dt":"14082023134809","exchdisstime":"14-Aug-2023 13:48:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105589053","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-14 13:48:09","symbol":"BIOCON"},{"an_dt":"11-Aug-2023 15:06:12","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11082023150612_InvestorPresentation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:01:15","dt":"11082023150612","exchdisstime":"11-Aug-2023 15:07:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105586222","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-11 15:06:12","symbol":"BIOCON"},{"an_dt":"10-Aug-2023 22:40:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10082023224042_RevisedPressRelease_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a revised press release dated August 10, 2023, titled \"Biocon Q1FY24 Revenue at Rs 3,516 Cr, Up 59%; Biosimilars Up 106%; Research Services Up 25%; EBITDA at Rs 808 Cr, Up 69%; Net Profit at Rs 101 Cr\".","bflag":null,"csvName":null,"desc":"Press Release (Revised)","difference":"00:00:19","dt":"10082023224042","exchdisstime":"10-Aug-2023 22:41:01","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105585335","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-10 22:40:42","symbol":"BIOCON"},{"an_dt":"10-Aug-2023 20:50:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10082023205007_PressRelease_100823_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 10, 2023, titled \"Biocon Q1FY24 Revenue at Rs 3,516 Cr, Up 59%;Biosimilars Up 106%; Research Services Up 25%; EBITDA at Rs 808 Cr, Up 69%; Net Profit at Rs 101 Cr\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:15","dt":"10082023205007","exchdisstime":"10-Aug-2023 20:50:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105585170","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-10 20:50:07","symbol":"BIOCON"},{"an_dt":"10-Aug-2023 19:53:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10082023195351_Outcome_BM_100823_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'appointment of Mr. Nicholas Robert Haggar (DIN: 08518863) as an AdditionalDirector (Category: Non-Executive, Independent Director) of the Company subject to registrationof his name in the Independent Director s databank maintained by the Indian Institute of CorporateAffairs (IICA), and accordingly, his appointment on the Board will be effective from such date'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:21","dt":"10082023195351","exchdisstime":"10-Aug-2023 19:54:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105585106","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-10 19:53:51","symbol":"BIOCON"},{"an_dt":"10-Aug-2023 19:51:16","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10082023195116_Outcome_BM_100823_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on August 10, 2023.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:11","dt":"10082023195116","exchdisstime":"10-Aug-2023 19:51:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105585100","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-10 19:51:16","symbol":"BIOCON"},{"an_dt":"10-Aug-2023 19:50:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Outcome_BM_100823_signed_10082023195006.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended June 30, 2023.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:00:10","dt":"10082023195006","exchdisstime":"10-Aug-2023 19:50:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"155924","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-10 19:50:06","symbol":"BIOCON"},{"an_dt":"10-Aug-2023 08:38:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10082023083818_PressRelease_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 10, 2023, titled \"Biocon Foundation and Shakti Sustainable Energy Foundation organize Cities and Climate Action Workshop\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:08","dt":"10082023083818","exchdisstime":"10-Aug-2023 08:38:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105583737","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-10 08:38:18","symbol":"BIOCON"},{"an_dt":"05-Aug-2023 14:03:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05082023140330_Intimation_CreditRating.pdf","attchmntText":"Biocon Limited has informed the Exchange about Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"33:32:38","dt":"05082023140330","exchdisstime":"06-Aug-2023 23:36:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105578521","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-05 14:03:30","symbol":"BIOCON"},{"an_dt":"04-Aug-2023 16:08:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04082023160801_PressRelease_040823_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 04, 2023, titled \"Biocon Biologics Announces Key Leadership Appointments\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:13","dt":"04082023160801","exchdisstime":"04-Aug-2023 16:08:14","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105577381","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-08-04 16:08:01","symbol":"BIOCON"},{"an_dt":"29-Jul-2023 18:36:53","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29072023183653_Intimation_NewspaperAd_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:12","dt":"29072023183653","exchdisstime":"29-Jul-2023 18:37:05","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105570447","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-29 18:36:53","symbol":"BIOCON"},{"an_dt":"28-Jul-2023 20:41:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28072023204157_Intimation_AddendumToNotice_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Addendum to Notice of 45th Annual general Meeting'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:07","dt":"28072023204157","exchdisstime":"28-Jul-2023 20:42:04","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105569668","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-28 20:41:57","symbol":"BIOCON"},{"an_dt":"28-Jul-2023 20:39:35","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28072023203935_Intimation_AddendumToNotice_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Addendum to Notice of 45th Annual General Meeting to be held on August 11, 2023.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:08","dt":"28072023203935","exchdisstime":"28-Jul-2023 20:39:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105569665","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-28 20:39:35","symbol":"BIOCON"},{"an_dt":"27-Jul-2023 16:02:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27072023160252_Intimation_PressRelease_signed_270723.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 27, 2023, titled \"Biocon Foundation Releases Second Edition of Consensus Guidelinesfor Head & Neck Cancer\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:13","dt":"27072023160252","exchdisstime":"27-Jul-2023 16:03:05","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105567713","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-27 16:02:52","symbol":"BIOCON"},{"an_dt":"26-Jul-2023 19:02:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26072023190252_Intimation_DirectorAppointment_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"00:00:07","dt":"26072023190252","exchdisstime":"26-Jul-2023 19:02:59","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105566630","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-26 19:02:52","symbol":"BIOCON"},{"an_dt":"26-Jul-2023 19:02:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26072023190253_Intimation_TenureCompletion_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"00:00:16","dt":"26072023190252","exchdisstime":"26-Jul-2023 19:03:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105566631","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-26 19:02:52","symbol":"BIOCON"},{"an_dt":"26-Jul-2023 18:57:13","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26072023185713_Intimation_TenureCompletion_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Cessation of Mr Vijay Kuchroo as Independent Director of the company w.e.f. July 26, 2023.","bflag":null,"csvName":null,"desc":"Cessation","difference":"00:00:07","dt":"26072023185713","exchdisstime":"26-Jul-2023 18:57:20","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105566614","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-26 18:57:13","symbol":"BIOCON"},{"an_dt":"26-Jul-2023 18:52:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26072023185212_Intimation_DirectorAppointment_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Appointment of Ms Rekha Mehrotra Menon as Independent Director of the company w.e.f. July 26, 2023.","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:20","dt":"26072023185210","exchdisstime":"26-Jul-2023 18:52:30","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105566605","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-26 18:52:10","symbol":"BIOCON"},{"an_dt":"26-Jul-2023 18:52:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26072023185211_Intimation_DirectorAppointment_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Appointment of Ms Rekha Mehrotra Menon as Non- Executive Independent Director of the company w.e.f. July 26, 2023.","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:08","dt":"26072023185210","exchdisstime":"26-Jul-2023 18:52:18","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105566604","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-26 18:52:10","symbol":"BIOCON"},{"an_dt":"24-Jul-2023 23:36:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24072023233649_PostalBallot_Results_signed.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Postal Ballot. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:07","dt":"24072023233649","exchdisstime":"24-Jul-2023 23:36:56","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105564513","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-24 23:36:49","symbol":"BIOCON"},{"an_dt":"24-Jul-2023 08:00:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24072023080030_PressRelease_signed_240723.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 24, 2023, titled \"Biocon Biologics Announces Positive CHMP Opinion for YESAFILI��, Biosimilar Aflibercept \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:08","dt":"24072023080030","exchdisstime":"24-Jul-2023 08:00:38","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105563304","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-24 08:00:30","symbol":"BIOCON"},{"an_dt":"21-Jul-2023 17:29:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21072023172918_CompanyStatement_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement w.r.t.  U.S. FDA Completes Two cGMP Inspections atBiocon Biologics  Insulins Facility in Malaysia .'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:08","dt":"21072023172918","exchdisstime":"21-Jul-2023 17:29:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105562347","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-21 17:29:18","symbol":"BIOCON"},{"an_dt":"21-Jul-2023 16:51:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21072023165110_Intimation_NewspaperAd_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:15","dt":"21072023165110","exchdisstime":"21-Jul-2023 16:51:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105562280","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-21 16:51:10","symbol":"BIOCON"},{"an_dt":"21-Jul-2023 12:49:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21072023124949_EarningsCallIntimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:08","dt":"21072023124949","exchdisstime":"21-Jul-2023 12:49:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105562016","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-21 12:49:49","symbol":"BIOCON"},{"an_dt":"20-Jul-2023 21:49:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20072023214944_Intimation_BRSR_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Business Responsibility and Sustainability Report for the FY 2022-23'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:07","dt":"20072023214944","exchdisstime":"20-Jul-2023 21:49:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105561411","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-20 21:49:44","symbol":"BIOCON"},{"an_dt":"20-Jul-2023 21:47:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20072023214700_Biocon_NoticeAR_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on August 11, 2023","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:12","dt":"20072023214700","exchdisstime":"20-Jul-2023 21:47:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105561410","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-20 21:47:00","symbol":"BIOCON"},{"an_dt":"18-Jul-2023 22:24:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18072023222457_Intimation_NewspaperAd_18072023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:06","dt":"18072023222457","exchdisstime":"18-Jul-2023 22:25:03","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105559009","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-18 22:24:57","symbol":"BIOCON"},{"an_dt":"12-Jul-2023 19:22:58","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12072023192258_Certificate_Reg74_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2023'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:09","dt":"12072023192258","exchdisstime":"12-Jul-2023 19:23:07","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105553766","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-12 19:22:58","symbol":"BIOCON"},{"an_dt":"10-Jul-2023 22:15:45","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10072023221545_Communication_to_shareholder_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Communication to the shareholders w.r.t. TDS on Final Dividend'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:09","dt":"10072023221545","exchdisstime":"10-Jul-2023 22:15:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105551484","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-10 22:15:45","symbol":"BIOCON"},{"an_dt":"06-Jul-2023 19:16:19","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06072023191619_InvestorMeeting_060723_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:09","dt":"06072023191619","exchdisstime":"06-Jul-2023 19:16:28","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105548618","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-06 19:16:19","symbol":"BIOCON"},{"an_dt":"05-Jul-2023 17:17:40","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05072023171740_PressRelease_050723_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 05, 2023, titled \"Biocon Biologics Expands Footprint in Emerging Markets; Takes Over the Commercialization of Biosimilars Business from Viatris in 70+ countries\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:07","dt":"05072023171740","exchdisstime":"05-Jul-2023 17:17:47","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105547288","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-05 17:17:40","symbol":"BIOCON"},{"an_dt":"04-Jul-2023 11:02:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04072023110249_InvestorMeeting_040723.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:09","dt":"04072023110249","exchdisstime":"04-Jul-2023 11:02:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105545896","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-04 11:02:49","symbol":"BIOCON"},{"an_dt":"03-Jul-2023 21:44:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03072023214407_PressRelease_030723.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 03, 2023, titled \"After Five Years of Successful Experience Internationally, Biocon Biologics  Hulio�� Biosimilar to Humira��, Now Available in the United States\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:08","dt":"03072023214407","exchdisstime":"03-Jul-2023 21:44:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105545419","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-07-03 21:44:07","symbol":"BIOCON"},{"an_dt":"30-Jun-2023 19:38:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30062023193814_PressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 30, 2023, titled \"Biocon Group concluded the month-long sustainability initiatives commemorating  World Environment Day  initiated with  Nature Positive  Campaign\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:09","dt":"30062023193814","exchdisstime":"30-Jun-2023 19:38:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105543941","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-30 19:38:14","symbol":"BIOCON"},{"an_dt":"30-Jun-2023 17:00:37","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30062023170037_Intimation_TradingWindow_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:02","dt":"30062023170037","exchdisstime":"30-Jun-2023 17:00:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105543558","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-30 17:00:37","symbol":"BIOCON"},{"an_dt":"26-Jun-2023 17:52:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26062023175249_InvestorMeeting_26062023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"26062023175249","exchdisstime":"26-Jun-2023 17:52:55","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105538722","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-26 17:52:49","symbol":"BIOCON"},{"an_dt":"23-Jun-2023 11:38:25","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23062023113825_InvestorMeeting_22062023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:02","dt":"23062023113825","exchdisstime":"23-Jun-2023 11:38:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105537130","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-23 11:38:25","symbol":"BIOCON"},{"an_dt":"21-Jun-2023 18:53:20","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21062023185320_Intimation_NewspaperAd_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:14","dt":"21062023185320","exchdisstime":"21-Jun-2023 18:53:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105535561","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-21 18:53:20","symbol":"BIOCON"},{"an_dt":"20-Jun-2023 19:49:20","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20062023194921_PostalBallotNotice.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Postal Ballot","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:04","dt":"20062023194920","exchdisstime":"20-Jun-2023 19:49:24","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105534664","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-20 19:49:20","symbol":"BIOCON"},{"an_dt":"20-Jun-2023 17:57:45","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20062023175745_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"20062023175745","exchdisstime":"20-Jun-2023 17:57:49","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105534562","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-20 17:57:45","symbol":"BIOCON"},{"an_dt":"15-Jun-2023 17:16:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15062023171626_InvestorMeeting_15062023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"15062023171626","exchdisstime":"15-Jun-2023 17:16:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105531193","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-15 17:16:26","symbol":"BIOCON"},{"an_dt":"13-Jun-2023 17:06:12","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13062023170612_InvestorMeeting_13062023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:12","dt":"13062023170612","exchdisstime":"13-Jun-2023 17:06:24","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105529413","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-13 17:06:12","symbol":"BIOCON"},{"an_dt":"08-Jun-2023 16:05:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08062023160510_Notification_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to stock exchange'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"08062023160510","exchdisstime":"08-Jun-2023 16:05:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105526484","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-08 16:05:10","symbol":"BIOCON"},{"an_dt":"08-Jun-2023 15:58:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08062023155844_InvestorMeeting_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"08062023155844","exchdisstime":"08-Jun-2023 15:58:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105526478","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-08 15:58:44","symbol":"BIOCON"},{"an_dt":"07-Jun-2023 16:57:20","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07062023165720_InvestorMeeting_07062023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"07062023165720","exchdisstime":"07-Jun-2023 16:57:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105525589","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-07 16:57:20","symbol":"BIOCON"},{"an_dt":"03-Jun-2023 14:00:17","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03062023140017_Notification030623_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchange'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:07","dt":"03062023140017","exchdisstime":"03-Jun-2023 14:00:24","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105522967","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-03 14:00:17","symbol":"BIOCON"},{"an_dt":"02-Jun-2023 14:51:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02062023145118_InvestorMeeting_01062023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"02062023145118","exchdisstime":"02-Jun-2023 14:51:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105522260","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-06-02 14:51:18","symbol":"BIOCON"},{"an_dt":"31-May-2023 17:14:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31052023171455_TranscriptEarningsCall_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:02","dt":"31052023171455","exchdisstime":"31-May-2023 17:14:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105520020","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-31 17:14:55","symbol":"BIOCON"},{"an_dt":"31-May-2023 14:44:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31052023144415_InvestorMeeting_31052023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:16","dt":"31052023144415","exchdisstime":"31-May-2023 14:44:31","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105519765","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-31 14:44:15","symbol":"BIOCON"},{"an_dt":"26-May-2023 16:32:53","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26052023163253_RelatedPartyTransaction_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about related Party Transactions","bflag":null,"csvName":null,"desc":"Related Party Transactions","difference":"00:00:05","dt":"26052023163253","exchdisstime":"26-May-2023 16:32:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105512189","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-26 16:32:53","symbol":"BIOCON"},{"an_dt":"25-May-2023 17:59:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25052023175926_AnnualSecretarialComplianceReport2023.pdf","attchmntText":"Pursuant to Regulation 24A of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, read with CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2022-23 dated May 23, 2023, issued by Mr. Pradeep B. Kulkarni, Partner of M/s. V. Sreedharan and Associates, Practicing Company Secretaries, Bengaluru.","bflag":null,"csvName":null,"desc":"Annual Secretarial Compliance Report","difference":"00:00:03","dt":"25052023175926","exchdisstime":"25-May-2023 17:59:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105510586","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-25 17:59:26","symbol":"BIOCON"},{"an_dt":"25-May-2023 17:55:20","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25052023175520_NewspaperPublication.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:03","dt":"25052023175520","exchdisstime":"25-May-2023 17:55:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105510571","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-25 17:55:20","symbol":"BIOCON"},{"an_dt":"25-May-2023 14:03:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25052023140303_InvestorMeeting_25052023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:09","dt":"25052023140302","exchdisstime":"25-May-2023 14:03:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105509946","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-25 14:03:02","symbol":"BIOCON"},{"an_dt":"24-May-2023 16:39:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24052023163950_EarningsCallIntimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Earnings Call Presentation and Link of Recording","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"24052023163950","exchdisstime":"24-May-2023 16:39:55","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105508602","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-24 16:39:50","symbol":"BIOCON"},{"an_dt":"24-May-2023 16:05:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24052023160532_InvestorPresentationQ4_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:05","dt":"24052023160532","exchdisstime":"24-May-2023 16:05:37","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105508533","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-24 16:05:32","symbol":"BIOCON"},{"an_dt":"23-May-2023 23:19:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23052023231956_RelatedPartyTransaction_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about related Party Transactions","bflag":null,"csvName":null,"desc":"Related Party Transactions","difference":"00:00:04","dt":"23052023231956","exchdisstime":"23-May-2023 23:20:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105507900","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-23 23:19:56","symbol":"BIOCON"},{"an_dt":"23-May-2023 21:13:40","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23052023211340_PressRelease_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 23, 2023, titled \"Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31%; EBITDA at Rs 1,152 Cr, Up 75%; Net Profit (before exceptional Items) at Rs 335 Cr, Up 28%\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:17","dt":"23052023211340","exchdisstime":"23-May-2023 21:13:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105507605","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-23 21:13:40","symbol":"BIOCON"},{"an_dt":"23-May-2023 20:08:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23052023200803_Outcome_BM_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange that Record date for the purpose of Dividend  is 07-Jul-2023.","bflag":null,"csvName":null,"desc":"Record Date","difference":"00:00:10","dt":"23052023200802","exchdisstime":"23-May-2023 20:08:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105507527","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-23 20:08:02","symbol":"BIOCON"},{"an_dt":"23-May-2023 20:07:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23052023200700_Outcome_BM_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on May 23, 2023.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:04","dt":"23052023200700","exchdisstime":"23-May-2023 20:07:04","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105507525","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-23 20:07:00","symbol":"BIOCON"},{"an_dt":"23-May-2023 20:05:53","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Outcome_BM_signed_23052023200553.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended March 31, 2023.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:00:04","dt":"23052023200553","exchdisstime":"23-May-2023 20:05:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"153516","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-23 20:05:53","symbol":"BIOCON"},{"an_dt":"20-May-2023 14:22:11","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20052023142211_Notification_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchange'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:11","dt":"20052023142211","exchdisstime":"20-May-2023 14:22:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105504081","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-20 14:22:11","symbol":"BIOCON"},{"an_dt":"19-May-2023 17:55:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19052023175532_AllotmentIntimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding allotment of 50000 securities pursuant to Non Convertible Securities at its meeting held on May 19, 2023","bflag":null,"csvName":null,"desc":"Allotment of Securities","difference":"00:00:04","dt":"19052023175532","exchdisstime":"19-May-2023 17:55:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105503239","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-19 17:55:32","symbol":"BIOCON"},{"an_dt":"16-May-2023 22:11:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16052023221144_KYCReminderLetter.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Reminder Letter to holders of physical securities for furnishing of PAN, KYC details andNomination details'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:03","dt":"16052023221144","exchdisstime":"16-May-2023 22:11:47","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105498960","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-16 22:11:44","symbol":"BIOCON"},{"an_dt":"16-May-2023 18:44:43","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16052023184443_EarningsCallIntimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:10","dt":"16052023184443","exchdisstime":"16-May-2023 18:44:53","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105498744","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-05-16 18:44:43","symbol":"BIOCON"},{"an_dt":"28-Apr-2023 18:12:17","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042023181217_InvestorMeeting_28042023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"28042023181217","exchdisstime":"28-Apr-2023 18:12:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105481815","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-28 18:12:17","symbol":"BIOCON"},{"an_dt":"28-Apr-2023 17:35:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042023173507_CompanyStatement_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:09","dt":"28042023173507","exchdisstime":"28-Apr-2023 17:35:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105481753","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-28 17:35:07","symbol":"BIOCON"},{"an_dt":"28-Apr-2023 09:26:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042023092644_InvestorMeeting_27042023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"28042023092644","exchdisstime":"28-Apr-2023 09:26:47","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105481032","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-28 09:26:44","symbol":"BIOCON"},{"an_dt":"26-Apr-2023 21:37:16","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26042023213716_Outcome_BM_260423.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on April 26, 2023.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:02","dt":"26042023213716","exchdisstime":"26-Apr-2023 21:37:18","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105479381","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-26 21:37:16","symbol":"BIOCON"},{"an_dt":"26-Apr-2023 21:29:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26042023212908_Outcome_BM_260423.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on April 26, 2023.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:05","dt":"26042023212908","exchdisstime":"26-Apr-2023 21:29:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105479377","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-26 21:29:08","symbol":"BIOCON"},{"an_dt":"25-Apr-2023 12:42:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25042023124201_Annual2.pdf","attchmntText":"Kiran Mazumdar Shaw has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"00:00:06","dt":"25042023124201","exchdisstime":"25-Apr-2023 12:42:07","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105471510","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-25 12:42:01","symbol":"BIOCON"},{"an_dt":"25-Apr-2023 08:29:53","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25042023082953_Notification.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification titled  Serum & Biocon Biologics Agree to Restructure Equity Investment .'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:41:02","dt":"25042023082953","exchdisstime":"25-Apr-2023 09:10:55","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105477250","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-25 08:29:53","symbol":"BIOCON"},{"an_dt":"21-Apr-2023 23:25:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21042023232514_CoverLetter_BL_ESOP_TrustDeed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Submission of amended Biocon India Limited Employees Welfare Trust Deed'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:02","dt":"21042023232514","exchdisstime":"21-Apr-2023 23:25:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105475665","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-21 23:25:14","symbol":"BIOCON"},{"an_dt":"20-Apr-2023 16:41:03","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20042023164103_InvestorMeeting_20042023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"20042023164103","exchdisstime":"20-Apr-2023 16:41:07","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105473985","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-20 16:41:03","symbol":"BIOCON"},{"an_dt":"20-Apr-2023 11:35:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20042023113550_BMIntimation.pdf","attchmntText":"Pursuant to Regulation 29(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 23, 2023, inter alia, to approve and take on record the audited standalone and consolidated financial results of the Company for the quarter and financial year ended March 31, 2023 and to consider recommendation of dividend, if any, amongst other routine matters.","bflag":null,"csvName":null,"desc":"Board Meeting Intimation","difference":"00:00:02","dt":"20042023113550","exchdisstime":"20-Apr-2023 11:35:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105473703","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-20 11:35:50","symbol":"BIOCON"},{"an_dt":"18-Apr-2023 20:57:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18042023205727_InvestorMeeting_18042023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"18042023205727","exchdisstime":"18-Apr-2023 20:57:30","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105472085","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-18 20:57:27","symbol":"BIOCON"},{"an_dt":"18-Apr-2023 19:25:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18042023192527_Regulation_74_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter  ended March 31,2023'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:04","dt":"18042023192527","exchdisstime":"18-Apr-2023 19:25:31","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105472053","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-18 19:25:27","symbol":"BIOCON"},{"an_dt":"17-Apr-2023 17:16:12","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17042023171612_InvestorMeeting_17042023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"17042023171612","exchdisstime":"17-Apr-2023 17:16:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105470904","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-17 17:16:12","symbol":"BIOCON"},{"an_dt":"14-Apr-2023 17:07:47","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14042023170747_InvestorMeeting_14042023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"14042023170747","exchdisstime":"14-Apr-2023 17:07:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105469826","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-14 17:07:47","symbol":"BIOCON"},{"an_dt":"12-Apr-2023 16:27:11","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12042023162711_InvestorMeeting_12042023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"12042023162711","exchdisstime":"12-Apr-2023 16:27:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105467873","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-12 16:27:11","symbol":"BIOCON"},{"an_dt":"11-Apr-2023 15:58:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11042023155800_InvestorMeeting_10042023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"11042023155800","exchdisstime":"11-Apr-2023 15:58:05","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105466618","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-11 15:58:00","symbol":"BIOCON"},{"an_dt":"06-Apr-2023 10:55:25","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06042023105525_InvestorMeeting_05042023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"06042023105525","exchdisstime":"06-Apr-2023 10:55:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105462972","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-06 10:55:25","symbol":"BIOCON"},{"an_dt":"05-Apr-2023 16:18:28","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05042023161828_PressRelease_050423_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 05, 2023, titled \"Biocon Academy Conducted Graduation Ceremony for 185 Students across Four Programs\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"05042023161828","exchdisstime":"05-Apr-2023 16:18:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105462261","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-05 16:18:28","symbol":"BIOCON"},{"an_dt":"03-Apr-2023 17:03:20","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03042023170320_InvestorMeeting_03042023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"03042023170320","exchdisstime":"03-Apr-2023 17:03:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105460909","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-03 17:03:20","symbol":"BIOCON"},{"an_dt":"03-Apr-2023 11:37:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03042023113729_PressRelease_030423_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 03, 2023, titled \"Biocon Awarded a Silver Medal by EcoVadis for its Sustainability Accomplishments\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"03042023113729","exchdisstime":"03-Apr-2023 11:37:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105460667","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-04-03 11:37:29","symbol":"BIOCON"},{"an_dt":"31-Mar-2023 16:44:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31032023164415_IntimationTradingWindow.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:05","dt":"31032023164415","exchdisstime":"31-Mar-2023 16:44:20","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105459001","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-03-31 16:44:15","symbol":"BIOCON"},{"an_dt":"31-Mar-2023 16:26:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31032023162656_InvestorMeeting_31032023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"31032023162656","exchdisstime":"31-Mar-2023 16:27:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105458950","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-03-31 16:26:56","symbol":"BIOCON"},{"an_dt":"30-Mar-2023 17:14:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30032023171414_InvestorMeeting_30032023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"30032023171414","exchdisstime":"30-Mar-2023 17:14:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105457740","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-03-30 17:14:14","symbol":"BIOCON"},{"an_dt":"30-Mar-2023 17:13:11","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30032023171311_InvestorMeeting_29032023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"30032023171311","exchdisstime":"30-Mar-2023 17:13:14","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105457735","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-03-30 17:13:11","symbol":"BIOCON"},{"an_dt":"28-Mar-2023 12:11:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28032023121129_PressRelease_280323.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 28, 2023, titled \"Biocon Biologics Wins the  ABEA : Bioprocessing Excellence in South Asia  Award\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:03","dt":"28032023121129","exchdisstime":"28-Mar-2023 12:11:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105455139","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-03-28 12:11:29","symbol":"BIOCON"},{"an_dt":"21-Mar-2023 23:51:05","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21032023235105_InvestorMeeting_21032023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"21032023235105","exchdisstime":"21-Mar-2023 23:51:09","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105451040","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-03-21 23:51:05","symbol":"BIOCON"},{"an_dt":"20-Mar-2023 16:40:11","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20032023164011_InvestorMeeting_20032023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:04:05","dt":"20032023164011","exchdisstime":"20-Mar-2023 16:44:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105449670","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-03-20 16:40:11","symbol":"BIOCON"},{"an_dt":"16-Mar-2023 15:12:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16032023151221_InvestorMeeting_16032023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"16032023151221","exchdisstime":"16-Mar-2023 15:12:24","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105447496","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-03-16 15:12:21","symbol":"BIOCON"},{"an_dt":"13-Mar-2023 16:57:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13032023165707_InvestorMeeting_13032023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:33","dt":"13032023165707","exchdisstime":"13-Mar-2023 16:57:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105445057","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-03-13 16:57:07","symbol":"BIOCON"},{"an_dt":"07-Mar-2023 14:16:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07032023141609_InvestorMeeting_07032023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:02","dt":"07032023141609","exchdisstime":"07-Mar-2023 14:16:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105441779","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-03-07 14:16:09","symbol":"BIOCON"},{"an_dt":"03-Mar-2023 11:24:28","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03032023112428_InvestorMeeting_02032023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:11","dt":"03032023112428","exchdisstime":"03-Mar-2023 11:24:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105439911","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-03-03 11:24:28","symbol":"BIOCON"},{"an_dt":"02-Mar-2023 10:44:41","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02032023104441_InvestorMeeting_01032023_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:07","dt":"02032023104441","exchdisstime":"02-Mar-2023 10:44:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105439078","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-03-02 10:44:41","symbol":"BIOCON"},{"an_dt":"01-Mar-2023 11:59:04","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01032023115904_InvestorMeeting_28022023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:07","dt":"01032023115904","exchdisstime":"01-Mar-2023 11:59:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105438248","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-03-01 11:59:04","symbol":"BIOCON"},{"an_dt":"24-Feb-2023 18:29:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24022023182914_InvestorMeeting_24022023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meetings conducted with Institutional Investors/Research Analysts.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"24022023182914","exchdisstime":"24-Feb-2023 18:29:18","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105435593","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-24 18:29:14","symbol":"BIOCON"},{"an_dt":"23-Feb-2023 14:07:41","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23022023140741_InvestorMeeting_23022023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meetings conducted with Institutional Investors/Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:10","dt":"23022023140741","exchdisstime":"23-Feb-2023 14:07:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105434525","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-23 14:07:41","symbol":"BIOCON"},{"an_dt":"23-Feb-2023 14:02:45","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23022023140245_InvestorMeeting_22022023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meetings conducted with Institutional Investors/Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:09","dt":"23022023140245","exchdisstime":"23-Feb-2023 14:02:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105434524","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-23 14:02:45","symbol":"BIOCON"},{"an_dt":"22-Feb-2023 19:26:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22022023192601_CPRedemption.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Redemption of Commercial Papers'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:04","dt":"22022023192601","exchdisstime":"22-Feb-2023 19:26:05","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105433949","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-22 19:26:01","symbol":"BIOCON"},{"an_dt":"22-Feb-2023 10:18:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22022023101855_TranscriptEarningscallFeb23.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Transcript of Earnings Call Q3 FY23'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"22022023101855","exchdisstime":"22-Feb-2023 10:19:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105433476","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-22 10:18:55","symbol":"BIOCON"},{"an_dt":"21-Feb-2023 18:19:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21022023181954_SEIntimation21022023.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding allotment of 107000 securities pursuant to Non Convertible Securities at its meeting held on February 21, 2023","bflag":null,"csvName":null,"desc":"Allotment of Securities","difference":"00:00:04","dt":"21022023181954","exchdisstime":"21-Feb-2023 18:19:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105432988","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-21 18:19:54","symbol":"BIOCON"},{"an_dt":"21-Feb-2023 17:47:43","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21022023174743_InvestorMeeting_21022023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meetings conducted with Institutional Investors/Research Analysts.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"21022023174743","exchdisstime":"21-Feb-2023 17:47:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105432943","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-21 17:47:43","symbol":"BIOCON"},{"an_dt":"20-Feb-2023 18:35:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20022023183527_InvestorMeeting_20022023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Intimation under Regulation 30 (6) of SEBI Listing Obligations and Disclosure Requirements (LODR) Regulations, 2015.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"20022023183527","exchdisstime":"20-Feb-2023 18:35:30","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105432139","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-20 18:35:27","symbol":"BIOCON"},{"an_dt":"18-Feb-2023 20:50:58","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18022023205058_InvestorMeeting17022023.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"18022023205058","exchdisstime":"18-Feb-2023 20:51:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105431399","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-18 20:50:58","symbol":"BIOCON"},{"an_dt":"17-Feb-2023 19:02:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17022023190248_InvestorPresentation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:05","dt":"17022023190248","exchdisstime":"17-Feb-2023 19:02:53","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105430983","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-17 19:02:48","symbol":"BIOCON"},{"an_dt":"16-Feb-2023 16:29:23","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16022023162923_NewspaperPublication.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:02","dt":"16022023162923","exchdisstime":"16-Feb-2023 16:29:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105429868","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-16 16:29:23","symbol":"BIOCON"},{"an_dt":"15-Feb-2023 22:04:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15022023220453_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Reminder Letter to holders of physical securities for furnishing of PAN, KYC details and nomination'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:02","dt":"15022023220454","exchdisstime":"15-Feb-2023 22:04:56","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105429089","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-15 22:04:54","symbol":"BIOCON"},{"an_dt":"15-Feb-2023 17:59:23","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15022023175923_Intimation_EarningsCall.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Presentation and Video Recording of Q3 FY23 Earnings Call'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:04","dt":"15022023175923","exchdisstime":"15-Feb-2023 17:59:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105428938","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-15 17:59:23","symbol":"BIOCON"},{"an_dt":"14-Feb-2023 19:50:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14022023195034_PressRelease_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 14, 2023, titled \"Biocon Q3FY23 Revenue at Rs 3,020 Cr, Up 36%; Biosimilars Up 54%; Research Services Up 23%; Generics Up 18%; EBITDA at Rs 723 Cr, Up 35%; Core EBITDA at Rs 1,069 Cr, Up 49%; Net Profit (excluding exceptional items) at Rs 140 Cr\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"14022023195034","exchdisstime":"14-Feb-2023 19:50:38","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105427869","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-14 19:50:34","symbol":"BIOCON"},{"an_dt":"14-Feb-2023 19:20:59","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14022023192059_Initmation_Change_in_policy_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure under Regulation 30 of SEBI Listing Regulations, 2015'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:03","dt":"14022023192059","exchdisstime":"14-Feb-2023 19:21:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105427822","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-14 19:20:59","symbol":"BIOCON"},{"an_dt":"14-Feb-2023 19:13:12","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Initmation_BM_Outcome_signed_14022023191312.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended December 31, 2022.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:00:07","dt":"14022023191312","exchdisstime":"14-Feb-2023 19:13:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"152329","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-14 19:13:12","symbol":"BIOCON"},{"an_dt":"13-Feb-2023 21:20:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13022023212050_Intimation_CP_proceeds.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Certificate pursuant to SEBI Circular no. SEBI/HO/DDHS/P/CIR/2021/613 dated 10th August 2021'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:02","dt":"13022023212050","exchdisstime":"13-Feb-2023 21:20:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105426274","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-13 21:20:50","symbol":"BIOCON"},{"an_dt":"12-Feb-2023 11:59:22","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12022023115922_CompanyStatement.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:03","dt":"12022023115922","exchdisstime":"12-Feb-2023 11:59:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105425084","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-12 11:59:22","symbol":"BIOCON"},{"an_dt":"09-Feb-2023 22:32:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09022023223251_IntimationRecordDate.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Record date intimation for commercial papers'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:04","dt":"09022023223251","exchdisstime":"09-Feb-2023 22:32:55","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105423065","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-09 22:32:51","symbol":"BIOCON"},{"an_dt":"08-Feb-2023 16:22:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08022023162210_CreditRatingIntimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:03","dt":"08022023162210","exchdisstime":"08-Feb-2023 16:22:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105421389","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-02-08 16:22:10","symbol":"BIOCON"},{"an_dt":"24-Jan-2023 09:55:58","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24012023095558_PressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 24, 2023, titled \"Biocon Foundation Wins the Prestigious  IHW Gold Award for Diseases Screening Initiative of the Year  for 2022\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:09","dt":"24012023095558","exchdisstime":"24-Jan-2023 09:56:07","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105407274","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-01-24 09:55:58","symbol":"BIOCON"},{"an_dt":"23-Jan-2023 19:32:31","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23012023193231_PostalBallotResult_signed.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Postal Ballot. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:05","dt":"23012023193231","exchdisstime":"23-Jan-2023 19:32:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105406817","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-01-23 19:32:31","symbol":"BIOCON"},{"an_dt":"16-Jan-2023 22:32:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16012023223207_Regulation74.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2022'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"16012023223207","exchdisstime":"16-Jan-2023 22:32:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105401784","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-01-16 22:32:07","symbol":"BIOCON"},{"an_dt":"07-Jan-2023 11:25:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07012023112515_ComapnyStatement.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:02","dt":"07012023112515","exchdisstime":"07-Jan-2023 11:25:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105395511","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-01-07 11:25:15","symbol":"BIOCON"},{"an_dt":"06-Jan-2023 16:10:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06012023161044_AnalystMeet.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"06012023161044","exchdisstime":"06-Jan-2023 16:10:47","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105394933","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-01-06 16:10:44","symbol":"BIOCON"},{"an_dt":"06-Jan-2023 16:08:03","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06012023160803_TradingWindowClosure.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015","bflag":null,"csvName":null,"desc":"Trading Window","difference":"00:00:07","dt":"06012023160803","exchdisstime":"06-Jan-2023 16:08:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105394932","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2023-01-06 16:08:03","symbol":"BIOCON"},{"an_dt":"30-Dec-2022 15:41:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30122022154132_Intimation_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Reminder Letter to shareholders for claiming unclaimed dividends.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:02","dt":"30122022154132","exchdisstime":"30-Dec-2022 15:41:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105389721","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-30 15:41:32","symbol":"BIOCON"},{"an_dt":"23-Dec-2022 18:49:04","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23122022184904_InvestorMeeting_23122022_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about  Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:09","dt":"23122022184904","exchdisstime":"23-Dec-2022 18:49:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105384843","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-23 18:49:04","symbol":"BIOCON"},{"an_dt":"22-Dec-2022 18:23:40","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22122022182340_Notification.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon Limited has been issued a Good Manufacturing Practice (GMP) Certificate of Compliance by the European Directorate for the Quality of Medicines & HealthCare (EDQM), for our Active Pharmaceutical Ingredient (API) manufacturing facility in Bangalore. This certification is based on a GMP inspection of the site that was conducted between the 12th and 14th of September 2022'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:03","dt":"22122022182340","exchdisstime":"22-Dec-2022 18:23:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105383946","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-22 18:23:40","symbol":"BIOCON"},{"an_dt":"22-Dec-2022 15:14:25","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22122022151425_IntimationPressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 22, 2022, titled \"Biocon Biologics Recognized as a Company with Great Managers; Two Managers conferred with individual   Great Managers Award 2022  \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:15","dt":"22122022151425","exchdisstime":"22-Dec-2022 15:14:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105383795","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-22 15:14:25","symbol":"BIOCON"},{"an_dt":"22-Dec-2022 13:15:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22122022131555_InvestorMeeting_21122022.pdf","attchmntText":"Biocon Limited has informed the Exchange about  Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"22122022131555","exchdisstime":"22-Dec-2022 13:15:59","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105383745","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-22 13:15:55","symbol":"BIOCON"},{"an_dt":"21-Dec-2022 19:43:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21122022194333_IntimationNewspaperAd.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:02","dt":"21122022194333","exchdisstime":"21-Dec-2022 19:43:35","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105383192","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-21 19:43:33","symbol":"BIOCON"},{"an_dt":"21-Dec-2022 10:33:59","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21122022103359_InvestorMeeting_20122022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Meeting conducted with Institutional Investors/Research Analysts","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:08","dt":"21122022103359","exchdisstime":"21-Dec-2022 10:34:07","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105382707","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-21 10:33:59","symbol":"BIOCON"},{"an_dt":"20-Dec-2022 18:47:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20122022184755_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Postal Ballot","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:04","dt":"20122022184755","exchdisstime":"20-Dec-2022 18:47:59","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105382394","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-20 18:47:55","symbol":"BIOCON"},{"an_dt":"16-Dec-2022 16:09:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16122022160900_InvestorMeeting_16122022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:05","dt":"16122022160900","exchdisstime":"16-Dec-2022 16:09:05","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5131318","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-16 16:09:00","symbol":"BIOCON"},{"an_dt":"15-Dec-2022 19:12:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15122022191206_Intimation_IEPFReminderLetterNewspaperAd_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Newspaper Advertisements for claiming unclaimed dividends and equity shares liable to be transferred to IEPF.","bflag":null,"csvName":null,"desc":"Newspaper Advertisements","difference":"00:00:05","dt":"15122022191206","exchdisstime":"15-Dec-2022 19:12:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5131107","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-15 19:12:06","symbol":"BIOCON"},{"an_dt":"15-Dec-2022 19:09:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15122022190957_Intimation_IEPFReminderLetterNewspaperAd_signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about communication to shareholders as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding Reminder Letter for claiming unclaimed dividends, whose equity shares are liable to be transferred to IEPF.","bflag":null,"csvName":null,"desc":"Communication to shareholders as per Reg 30","difference":"00:00:03","dt":"15122022190957","exchdisstime":"15-Dec-2022 19:10:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5131105","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-15 19:09:57","symbol":"BIOCON"},{"an_dt":"14-Dec-2022 16:40:31","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14122022164030_CoverletterIntimation_PressRelease_.pdf","attchmntText":"Dear Sir/Madam,Please find enclosed the press release titled ���Biocon Limited initiates clinical study of Itolizumab for Ulcerative Colitis in India���.The above information will also be available on the website of the Company at www.biocon.com.Kindly take the same on record and acknowledge.","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:03","dt":"14122022164031","exchdisstime":"14-Dec-2022 16:40:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5130606","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-14 16:40:31","symbol":"BIOCON"},{"an_dt":"12-Dec-2022 19:27:36","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12122022192736_CoveringLetter_NSE.pdf","attchmntText":"Biocon Limited  has informed the Exchange about appointment of Peter Bains as Independent Director of the company w.e.f. 12-Dec-2022","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:03","dt":"12122022192736","exchdisstime":"12-Dec-2022 19:27:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5130095","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-12 19:27:36","symbol":"BIOCON"},{"an_dt":"08-Dec-2022 15:51:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08122022155130_InvestorMeeting_08122022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:03","dt":"08122022155130","exchdisstime":"08-Dec-2022 15:51:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5129180","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-08 15:51:30","symbol":"BIOCON"},{"an_dt":"05-Dec-2022 13:36:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05122022133600_Intimaiton_PressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 05-Dec-2022 titled \"Shreehas Tambe Appointed as Managing Director & CEO of Biocon Biologics Limited.\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"05122022133600","exchdisstime":"05-Dec-2022 13:36:04","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5127982","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-05 13:36:00","symbol":"BIOCON"},{"an_dt":"02-Dec-2022 16:45:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02122022164521_InvestorMeeting_02122022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:05","dt":"02122022164521","exchdisstime":"02-Dec-2022 16:45:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5127587","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-02 16:45:21","symbol":"BIOCON"},{"an_dt":"01-Dec-2022 15:23:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01122022152342_InvestorMeeting_01122022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:06","dt":"01122022152342","exchdisstime":"01-Dec-2022 15:23:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5127189","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-01 15:23:42","symbol":"BIOCON"},{"an_dt":"01-Dec-2022 12:40:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01122022124051_Intimation_CreditRating.pdf","attchmntText":"Biocon Limited has informed the Exchange about Affirmation of Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:10","dt":"01122022124051","exchdisstime":"01-Dec-2022 12:41:01","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5127138","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-01 12:40:51","symbol":"BIOCON"},{"an_dt":"01-Dec-2022 11:27:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01122022112730_InvestorMeeting_01122022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:02","dt":"01122022112730","exchdisstime":"01-Dec-2022 11:27:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5127067","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-12-01 11:27:30","symbol":"BIOCON"},{"an_dt":"29-Nov-2022 18:32:12","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29112022183212_PressRelease_29112022.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 29-Nov-2022 titled \"Biocon Biologics Completes Acquisition of Viatris��� Global Biosimilars Business\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"29112022183212","exchdisstime":"29-Nov-2022 18:32:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5126604","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-29 18:32:12","symbol":"BIOCON"},{"an_dt":"28-Nov-2022 19:17:12","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28112022191712_RPTDisclosure_Sept2022.pdf","attchmntText":"Biocon Limited has informed the Exchange about related party transaction for the period ended September 2022","bflag":null,"csvName":null,"desc":"Related Party Transaction","difference":"00:00:03","dt":"28112022191712","exchdisstime":"28-Nov-2022 19:17:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5126195","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-28 19:17:12","symbol":"BIOCON"},{"an_dt":"24-Nov-2022 16:09:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24112022160909_StakeAcquisitioninBBL_2205Cr.pdf","attchmntText":"Biocon Limited has informed the Exchange about Disclosure pursuant to Regulation 30 ","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:09","dt":"24112022160909","exchdisstime":"24-Nov-2022 16:09:18","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5124809","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-24 16:09:09","symbol":"BIOCON"},{"an_dt":"24-Nov-2022 11:49:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24112022114957_Intimation_IssueofCP.pdf","attchmntText":"Biocon Limited has informed the Exchange about Issue of Commercial Papers of Rs. 2,250 Crores","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:02","dt":"24112022114957","exchdisstime":"24-Nov-2022 11:49:59","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5124687","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-24 11:49:57","symbol":"BIOCON"},{"an_dt":"23-Nov-2022 22:09:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23112022220921_Intimation_PressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 23-Nov-2022 titled Press Release titled ���Biocon Limited enters into a commercialization agreement with Zentiva in Europe���","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:02","dt":"23112022220921","exchdisstime":"23-Nov-2022 22:09:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5124633","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-23 22:09:21","symbol":"BIOCON"},{"an_dt":"23-Nov-2022 12:58:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23112022125833_InvestorMeeting_22112022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:06","dt":"23112022125833","exchdisstime":"23-Nov-2022 12:58:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5124237","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-23 12:58:33","symbol":"BIOCON"},{"an_dt":"22-Nov-2022 18:48:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22112022184851_EarningsCall_Transcript.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Transcript of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:03","dt":"22112022184851","exchdisstime":"22-Nov-2022 18:48:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5124061","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-22 18:48:51","symbol":"BIOCON"},{"an_dt":"21-Nov-2022 19:40:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21112022194006_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Disclosure pursuant to Regulation 30 ","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:04","dt":"21112022194006","exchdisstime":"21-Nov-2022 19:40:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5123563","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-21 19:40:06","symbol":"BIOCON"},{"an_dt":"17-Nov-2022 22:12:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17112022221209_StakeAcquisitioninBBL.pdf","attchmntText":"Biocon Limited has informed the Exchange about Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (���SEBI Listing Regulations���).","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:05","dt":"17112022221209","exchdisstime":"17-Nov-2022 22:12:14","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5122437","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-17 22:12:09","symbol":"BIOCON"},{"an_dt":"17-Nov-2022 19:37:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17112022193709_CreditratingIntimation_17112022.pdf","attchmntText":"Dear Sir/Madam,We wish to inform you that the Company has received rating letter dated November 17, 2022 from ICRA Limited (ICRA), wherein ICRA has assigned a short-term credit rating of [ICRA]A1+ to the Commercial Paper (to be issued) of Rs. 2,250 crore. The rating letter received in this regard is enclosed as Annexure-A.Further, in respect of Rs. 450 crore bank facilities of the Company, ICRA vide its letter dated November 17, 2022, has decided to continue the long-term rating of [ICRA]AA+ on watch with developing implications, and has removed the short-term rating from watch with developing implications and reaffirmed the short-term rating at [ICRA]A1+. The rating letter received in this regard is enclosed as Annexure-B.The above information will also be available on the website of the Company at www.biocon.com.","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:03","dt":"17112022193709","exchdisstime":"17-Nov-2022 19:37:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5122395","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-17 19:37:09","symbol":"BIOCON"},{"an_dt":"17-Nov-2022 18:02:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17112022180230_InvestorMeeting_17112022.pdf","attchmntText":"Pursuant to Regulation 30 (6) of the SEBI LODR Regulations, 2015, we hereby inform you that the a meeting was conducted with GIC, Singapore, Institutional Investor/ Research Analysts on November 17, 2022.","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:02","dt":"17112022180230","exchdisstime":"17-Nov-2022 18:02:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5122299","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-17 18:02:30","symbol":"BIOCON"},{"an_dt":"17-Nov-2022 18:00:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17112022180015_BL_Response_NSE_Clarification.pdf","attchmntText":"BIOCON : The Exchange has sought clarification from Biocon Limited with respect to recent news item captioned Biocon Biologics secures regulatory approvals for acquisition of Viatris biosimilar business.  The response from the Company is attached.","bflag":null,"csvName":null,"desc":"News Verification","difference":"00:00:06","dt":"17112022180015","exchdisstime":"17-Nov-2022 18:00:21","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5122281","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-17 18:00:15","symbol":"BIOCON"},{"an_dt":"17-Nov-2022 15:16:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17112022151651_InvestorMeeting_17112022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:07","dt":"17112022151651","exchdisstime":"17-Nov-2022 15:16:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5122085","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-17 15:16:51","symbol":"BIOCON"},{"an_dt":"17-Nov-2022 12:47:12","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17112022124712_InvestorMeeting_17112022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:04","dt":"17112022124712","exchdisstime":"17-Nov-2022 12:47:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5122031","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-17 12:47:12","symbol":"BIOCON"},{"an_dt":"16-Nov-2022 22:17:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16112022221733_Intimation_CreditRating.pdf","attchmntText":"Biocon Limited has informed the Exchange about Assignment of Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:03","dt":"16112022221733","exchdisstime":"16-Nov-2022 22:17:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5121881","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-16 22:17:33","symbol":"BIOCON"},{"an_dt":"16-Nov-2022 17:53:54","attFileSize":null,"attchmntFile":"-","attchmntText":"BIOCON : The Exchange has sought clarification from Biocon Limited with respect to recent news item captioned Biocon Biologics secures regulatory approvals for acquisition of Viatris biosimilar business.  The response from the Company is awaited.","bflag":null,"csvName":null,"desc":"News Verification","difference":"00:00:04","dt":"16112022175354","exchdisstime":"16-Nov-2022 17:53:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5121713","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-16 17:53:54","symbol":"BIOCON"},{"an_dt":"16-Nov-2022 16:11:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16112022161157_NewspaperPublication.pdf","attchmntText":"Biocon Limited has informed the Exchange about Newspaper Advertisements","bflag":null,"csvName":null,"desc":"Newspaper Advertisements","difference":"00:00:03","dt":"16112022161157","exchdisstime":"16-Nov-2022 16:12:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5121581","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-16 16:11:57","symbol":"BIOCON"},{"an_dt":"15-Nov-2022 23:10:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15112022231000_EarningsCall.pdf","attchmntText":"Biocon Limited has informed the Exchange about Presentation and Video Recording of Q2 FY23 Earnings Call","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:10","dt":"15112022231000","exchdisstime":"15-Nov-2022 23:10:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5121214","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-15 23:10:00","symbol":"BIOCON"},{"an_dt":"15-Nov-2022 11:35:03","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15112022113503_InvestorPresentation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:09","dt":"15112022113503","exchdisstime":"15-Nov-2022 11:35:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5120512","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-15 11:35:03","symbol":"BIOCON"},{"an_dt":"14-Nov-2022 21:03:12","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14112022210312_PressRelease141122022.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 14-Nov-2022 titled \"Biocon Q2FY23 Revenue at Rs 2,384 Cr, Up 23%; Core EBITDA at Rs 816 Cr, Up 34% ; Gross R&D Spend at Rs 252 Crore, Up 52%; Biosimilars Up 34%; Research Services Up 26%; Generics Up 18%.\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"14112022210312","exchdisstime":"14-Nov-2022 21:03:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5120305","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-14 21:03:12","symbol":"BIOCON"},{"an_dt":"14-Nov-2022 20:19:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14112022201942_OutcomeofBM.pdf","attchmntText":"Biocon Limited has informed the Exchange about Appointment of Director","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:04","dt":"14112022201942","exchdisstime":"14-Nov-2022 20:19:46","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5120251","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-14 20:19:42","symbol":"BIOCON"},{"an_dt":"14-Nov-2022 20:18:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14112022201854_OutcomeofBM.pdf","attchmntText":"Biocon Limited has informed the Exchange about Board Meeting held on 14-Nov-2022 to consider financial statements for the period ended September 2022, Fund raising and Other business matters.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:06","dt":"14112022201854","exchdisstime":"14-Nov-2022 20:19:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5120239","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-14 20:18:54","symbol":"BIOCON"},{"an_dt":"11-Nov-2022 12:07:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11112022120742_PressRelease_11112022.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 11-Nov-2022 titled \"Biocon Biologics features in the prestigious ASIA IP ELITE List for 2022���","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:02","dt":"11112022120742","exchdisstime":"11-Nov-2022 12:07:44","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5117229","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-11 12:07:42","symbol":"BIOCON"},{"an_dt":"09-Nov-2022 21:18:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09112022211830_BM_Intimation_Biocon_Nov2022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Prior Intimation pursuant to Regulation 29(1)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:02","dt":"09112022211830","exchdisstime":"09-Nov-2022 21:18:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5116029","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-11-09 21:18:30","symbol":"BIOCON"},{"an_dt":"31-Oct-2022 16:54:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31102022165430_PressRelease_31.10.2022.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 31-Oct-2022 titled Biocon Ranks at No. 8 in ���Global Top Employers��� List by the U.S. Science Magazine","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"31102022165430","exchdisstime":"31-Oct-2022 16:54:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5110167","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-10-31 16:54:30","symbol":"BIOCON"},{"an_dt":"21-Oct-2022 17:51:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21102022175154_CompanyStatement_21102022.pdf","attchmntText":"Dear Sir/Madam,Please find enclosed a Company Statement.The above information will also be available on the website of the Company at www.biocon.com.Kindly take the same on record and acknowledge.Thanking You,","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:04","dt":"21102022175154","exchdisstime":"21-Oct-2022 17:51:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5107861","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-10-21 17:51:54","symbol":"BIOCON"},{"an_dt":"20-Oct-2022 22:43:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20102022224306_Intimation_closure_of_trading_window.pdf","attchmntText":"Biocon Limited has informed the Exchange about Closure of trading window from October 1, 2022 to November 16, 2022 (both days inclusive).","bflag":null,"csvName":null,"desc":"Closure of trading window","difference":"00:00:02","dt":"20102022224306","exchdisstime":"20-Oct-2022 22:43:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5107258","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-10-20 22:43:06","symbol":"BIOCON"},{"an_dt":"20-Oct-2022 22:30:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20102022223042_schedule_analystmeet.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:02","dt":"20102022223042","exchdisstime":"20-Oct-2022 22:30:44","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5107256","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-10-20 22:30:42","symbol":"BIOCON"},{"an_dt":"17-Oct-2022 22:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17102022221600_Reg745_Biocon_30092022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2022.","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:12","dt":"17102022221600","exchdisstime":"17-Oct-2022 22:16:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5105405","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-10-17 22:16:00","symbol":"BIOCON"},{"an_dt":"17-Oct-2022 08:30:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17102022083057_Intimation_PressRelease_17102022.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 17-Oct-2022 titled \"Biocon Biologics Out-Licenses Two Biosimilar Assets to Yoshindo for Commercialization in Japan\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:03","dt":"17102022083057","exchdisstime":"17-Oct-2022 08:31:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5105167","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-10-17 08:30:57","symbol":"BIOCON"},{"an_dt":"07-Oct-2022 16:40:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07102022164048_PressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 07-Oct-2022 titled Biocon Foundation Receives ���Mahatma Award 2022 for Excellence in Social Good","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:03","dt":"07102022164048","exchdisstime":"07-Oct-2022 16:40:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5101720","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-10-07 16:40:48","symbol":"BIOCON"},{"an_dt":"06-Oct-2022 21:54:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06102022215454_SEIntimation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Notification","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:05","dt":"06102022215454","exchdisstime":"06-Oct-2022 21:54:59","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5101441","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-10-06 21:54:54","symbol":"BIOCON"},{"an_dt":"30-Sep-2022 11:25:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30092022112542_InvestorMeeting_29092022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:12","dt":"30092022112542","exchdisstime":"30-Sep-2022 11:25:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5097891","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-09-30 11:25:42","symbol":"BIOCON"},{"an_dt":"29-Sep-2022 13:39:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29092022133918_InvestorMeeting_28092022_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:05","dt":"29092022133918","exchdisstime":"29-Sep-2022 13:39:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5096900","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-09-29 13:39:18","symbol":"BIOCON"},{"an_dt":"27-Sep-2022 16:05:23","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27092022160523_InvestorMeeting_27092022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:06","dt":"27092022160523","exchdisstime":"27-Sep-2022 16:05:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5095425","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-09-27 16:05:23","symbol":"BIOCON"},{"an_dt":"24-Sep-2022 11:13:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24092022111302_PressRelease24thSept.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 24-Sep-2022 titled Kiran Mazumdar-Shaw Awarded with  H.K. Firodia Lifetime Achievement Award 2022 for Excellence in Science & Technology","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:19","dt":"24092022111302","exchdisstime":"24-Sep-2022 11:13:21","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5094453","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-09-24 11:13:02","symbol":"BIOCON"},{"an_dt":"22-Sep-2022 19:47:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22092022194751_InvestorMeeting_22092022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:03","dt":"22092022194751","exchdisstime":"22-Sep-2022 19:47:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5093909","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-09-22 19:47:51","symbol":"BIOCON"},{"an_dt":"20-Sep-2022 20:43:03","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20092022204303_InvestorMeeting_20092022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:02","dt":"20092022204303","exchdisstime":"20-Sep-2022 20:43:05","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5093080","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-09-20 20:43:03","symbol":"BIOCON"},{"an_dt":"16-Sep-2022 13:03:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16092022130354_InvestorMeeting_15092022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:02","dt":"16092022130354","exchdisstime":"16-Sep-2022 13:03:56","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5091753","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-09-16 13:03:54","symbol":"BIOCON"},{"an_dt":"13-Sep-2022 16:16:13","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13092022161613_InvestorMeeting_13092022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:26","dt":"13092022161613","exchdisstime":"13-Sep-2022 16:16:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5090570","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-09-13 16:16:13","symbol":"BIOCON"},{"an_dt":"01-Sep-2022 23:06:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01092022230633_InvestorMeeting_01092022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:03","dt":"01092022230633","exchdisstime":"01-Sep-2022 23:06:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5085135","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-09-01 23:06:33","symbol":"BIOCON"},{"an_dt":"31-Aug-2022 18:11:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31082022181100_CompannyStatement_31082022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Company Statement","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:07","dt":"31082022181100","exchdisstime":"31-Aug-2022 18:11:07","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5084454","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-08-31 18:11:00","symbol":"BIOCON"},{"an_dt":"25-Aug-2022 16:02:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25082022160206_InvestorMeeting_25082022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:05","dt":"25082022160206","exchdisstime":"25-Aug-2022 16:02:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5081889","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-08-25 16:02:06","symbol":"BIOCON"},{"an_dt":"24-Aug-2022 15:52:45","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24082022155245_InvestorMeeting_23082022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:03","dt":"24082022155245","exchdisstime":"24-Aug-2022 15:52:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5081292","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-08-24 15:52:45","symbol":"BIOCON"},{"an_dt":"18-Aug-2022 23:01:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18082022230148_InvestorMeeting_18082022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:04","dt":"18082022230148","exchdisstime":"18-Aug-2022 23:01:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5079556","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-08-18 23:01:48","symbol":"BIOCON"},{"an_dt":"10-Aug-2022 19:05:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10082022190533_InvestorMeeting_10082022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:02","dt":"10082022190533","exchdisstime":"10-Aug-2022 19:05:35","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5075180","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-08-10 19:05:33","symbol":"BIOCON"},{"an_dt":"05-Aug-2022 11:00:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05082022110021_PressRelease_Malaysia_Book_Records.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 05-Aug-2022 titled \"Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility���","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:02","dt":"05082022110021","exchdisstime":"05-Aug-2022 11:00:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5071022","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-08-05 11:00:21","symbol":"BIOCON"},{"an_dt":"03-Aug-2022 19:31:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03082022193118_Q1FY23_EarningsCallTranscript.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Transcript of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:04","dt":"03082022193118","exchdisstime":"03-Aug-2022 19:31:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5069926","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-08-03 19:31:18","symbol":"BIOCON"},{"an_dt":"29-Jul-2022 19:13:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29072022191354_ScrutiniserReportandResults.pdf","attchmntText":"Biocon Limited has informed the Exchange about Voting results and  Scrutinizer report of Annual General Meeting held on 28-Jul-2022","bflag":null,"csvName":null,"desc":"Annual General Meeting","difference":"00:00:03","dt":"29072022191354","exchdisstime":"29-Jul-2022 19:13:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5066921","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-29 19:13:54","symbol":"BIOCON"},{"an_dt":"29-Jul-2022 17:27:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29072022172754_SEIntimatinResultsNewspaper.pdf","attchmntText":"Biocon Limited has informed the Exchange about Newspaper Advertisements for Unaudited Financial Results for quarter ended June 30, 2022.","bflag":null,"csvName":null,"desc":"Newspaper Advertisements","difference":"00:00:06","dt":"29072022172754","exchdisstime":"29-Jul-2022 17:28:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5066728","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-29 17:27:54","symbol":"BIOCON"},{"an_dt":"29-Jul-2022 16:56:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29072022165642_SEsIntimation_Directors_Final.pdf","attchmntText":"Biocon Limited has informed the Exchange about Appointment/Re-appointment of Directors","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:05","dt":"29072022165642","exchdisstime":"29-Jul-2022 16:56:47","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5066668","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-29 16:56:42","symbol":"BIOCON"},{"an_dt":"29-Jul-2022 16:45:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29072022164557_AGMOutcome_2022.pdf","attchmntText":"Biocon Limited has informed the Exchange about  Proceedings of Annual General Meeting held on 28-Jul-2022","bflag":null,"csvName":null,"desc":"Annual General Meeting","difference":"00:00:04","dt":"29072022164557","exchdisstime":"29-Jul-2022 16:46:01","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5066641","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-29 16:45:57","symbol":"BIOCON"},{"an_dt":"28-Jul-2022 18:24:36","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28072022182436_InvestorMeeting_28072022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:02","dt":"28072022182436","exchdisstime":"28-Jul-2022 18:24:38","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5065961","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-28 18:24:36","symbol":"BIOCON"},{"an_dt":"28-Jul-2022 18:22:39","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28072022182239_Q1EarningsCall.pdf","attchmntText":"Biocon Limited has informed the Exchange about Presentation and video recording of Q1 FY23 Earnings Call","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:09","dt":"28072022182239","exchdisstime":"28-Jul-2022 18:22:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5065960","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-28 18:22:39","symbol":"BIOCON"},{"an_dt":"27-Jul-2022 19:44:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27072022194427_InvestorPresentation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:04","dt":"27072022194427","exchdisstime":"27-Jul-2022 19:44:31","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5065364","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-27 19:44:27","symbol":"BIOCON"},{"an_dt":"27-Jul-2022 19:33:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27072022193321_PressRelease.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 27-Jul-2022 titled Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%;   Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:03","dt":"27072022193321","exchdisstime":"27-Jul-2022 19:33:24","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5065343","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-27 19:33:21","symbol":"BIOCON"},{"an_dt":"27-Jul-2022 19:09:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27072022190921_OutcomeBM.pdf","attchmntText":"Biocon Limited  has informed the Exchange about cessation of Mary Harney and Mr. Daniel M Bradbury  as Independent Director of the company w.e.f. 27-Jul-2022","bflag":null,"csvName":null,"desc":"Cessation","difference":"00:00:04","dt":"27072022190921","exchdisstime":"27-Jul-2022 19:09:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5065352","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-27 19:09:21","symbol":"BIOCON"},{"an_dt":"27-Jul-2022 18:57:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27072022185748_OutcomeBM.pdf","attchmntText":"Biocon Limited  has informed the Exchange about Board Meeting held on 27-Jul-2022 to consider financial statements for the period ended June 2022 and Other business matters","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:04","dt":"27072022185748","exchdisstime":"27-Jul-2022 18:57:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5065325","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-27 18:57:48","symbol":"BIOCON"},{"an_dt":"21-Jul-2022 17:58:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21072022175815_IntimationtoSE_USFDAAuditSite3.pdf","attchmntText":"Biocon Limited has informed the Exchange about Notification to Stock Exchanges","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:03","dt":"21072022175815","exchdisstime":"21-Jul-2022 17:58:18","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5062463","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-21 17:58:15","symbol":"BIOCON"},{"an_dt":"14-Jul-2022 00:18:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14072022001809_Certificate_Reg745_BioconLimited_13072022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:08","dt":"14072022001809","exchdisstime":"14-Jul-2022 00:18:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5059020","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-14 00:18:09","symbol":"BIOCON"},{"an_dt":"06-Jul-2022 21:49:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06072022214948_NewspaperIntimation_0607202.pdf","attchmntText":"Biocon Limited has informed the Exchange about Newspaper Advertisements","bflag":null,"csvName":null,"desc":"Newspaper Advertisements","difference":"00:00:03","dt":"06072022214948","exchdisstime":"06-Jul-2022 21:49:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5056068","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-06 21:49:48","symbol":"BIOCON"},{"an_dt":"05-Jul-2022 22:47:31","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05072022224730_BioconIntimation_NoticeAndAnnualReport2022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Notice of Annual General Meeting to be held on 28-Jul-2022","bflag":null,"csvName":null,"desc":"Annual General Meeting","difference":"00:00:02","dt":"05072022224731","exchdisstime":"05-Jul-2022 22:47:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5055535","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-05 22:47:31","symbol":"BIOCON"},{"an_dt":"05-Jul-2022 18:33:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05072022183321_CompanyStatement_05072022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Company Statement titled ���Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru���","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:05","dt":"05072022183321","exchdisstime":"05-Jul-2022 18:33:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5055427","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-05 18:33:21","symbol":"BIOCON"},{"an_dt":"02-Jul-2022 19:50:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02072022195054_Intimation_PriorAGM_02072022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Newspaper Advertisements","bflag":null,"csvName":null,"desc":"Newspaper Advertisements","difference":"00:00:03","dt":"02072022195054","exchdisstime":"02-Jul-2022 19:50:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5054632","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-02 19:50:54","symbol":"BIOCON"},{"an_dt":"01-Jul-2022 20:43:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01072022204321_Bicon_Communication_to_shareholder.pdf","attchmntText":"Biocon Limited has informed the Exchange about communication to shareholders as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015","bflag":null,"csvName":null,"desc":"Communication to shareholders as per Reg 30","difference":"00:00:04","dt":"01072022204321","exchdisstime":"01-Jul-2022 20:43:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5054475","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-01 20:43:21","symbol":"BIOCON"},{"an_dt":"01-Jul-2022 17:06:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01072022170606_Schedule_of_analystmeet.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:05","dt":"01072022170606","exchdisstime":"01-Jul-2022 17:06:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5054281","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-01 17:06:06","symbol":"BIOCON"},{"an_dt":"01-Jul-2022 17:04:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01072022170454_Closure_of_trading_window.pdf","attchmntText":"Biocon Limited has informed the Exchange about Closure of trading window","bflag":null,"csvName":null,"desc":"Closure of trading window","difference":"00:00:02","dt":"01072022170454","exchdisstime":"01-Jul-2022 17:04:56","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5054280","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-01 17:04:54","symbol":"BIOCON"},{"an_dt":"01-Jul-2022 11:23:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01072022112330_Biocon_ChangeOfAGMdate.pdf","attchmntText":"With reference to our earlier letter dated April 28, 2022, we wish to inform you that the Board of Directors vide resolution passed through circulation on June 30, 2022 have approved for the change of date of 44th Annual General Meeting (AGM) of the Company from Friday, July 29, 2022 to Thursday, July 28, 2022.Accordingly, the 44th AGM of the Company will be held on Thursday, July 28, 2022 at 3:30 P.M. (IST) through Video Conferencing / Other AudioVisual Means (OAVM).A copy of the Notice convening the said AGM will be sent in due course.Kindly take the above information on record and acknowledge.","bflag":null,"csvName":null,"desc":"Annual General Meeting","difference":"00:00:09","dt":"01072022112330","exchdisstime":"01-Jul-2022 11:23:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5054016","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-07-01 11:23:30","symbol":"BIOCON"},{"an_dt":"29-Jun-2022 19:28:36","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29062022192836_AMPYR_StakeAcquisition.pdf","attchmntText":"Biocon Limited has informed the Exchange about Acquisition","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:03","dt":"29062022192836","exchdisstime":"29-Jun-2022 19:28:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5052523","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-06-29 19:28:36","symbol":"BIOCON"},{"an_dt":"22-Jun-2022 14:52:40","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22062022145239_InvestorMeeting_22062022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:06","dt":"22062022145240","exchdisstime":"22-Jun-2022 14:52:46","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5049286","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-06-22 14:52:40","symbol":"BIOCON"},{"an_dt":"22-Jun-2022 10:40:23","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22062022104022_BL_Clarification_NSE_Query_June_2022.pdf","attchmntText":"BIOCON : The Exchange has sought clarification from Biocon Limited with respect to recent news item captioned Biocon subsidiary caught offering bribe to waive off trial of new drug.  The response from the Company is attached.","bflag":null,"csvName":null,"desc":"News Verification","difference":"00:00:04","dt":"22062022104023","exchdisstime":"22-Jun-2022 10:40:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5049213","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-06-22 10:40:23","symbol":"BIOCON"},{"an_dt":"21-Jun-2022 18:26:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21062022182609_BioconBiologics_Statement_21062022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Company Statement","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:03","dt":"21062022182609","exchdisstime":"21-Jun-2022 18:26:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5049114","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-06-21 18:26:09","symbol":"BIOCON"},{"an_dt":"21-Jun-2022 17:44:32","attFileSize":null,"attchmntFile":"-","attchmntText":"BIOCON : The Exchange has sought clarification from Biocon Limited with respect to recent news item captioned Biocon subsidiary caught offering bribe to waive off trial of new drug.  The response from the Company is awaited.","bflag":null,"csvName":null,"desc":"News Verification","difference":"00:00:05","dt":"21062022174432","exchdisstime":"21-Jun-2022 17:44:37","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5049077","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-06-21 17:44:32","symbol":"BIOCON"},{"an_dt":"21-Jun-2022 17:17:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21062022171727_InvestorMeeting_17062022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:04","dt":"21062022171727","exchdisstime":"21-Jun-2022 17:17:31","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5049041","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-06-21 17:17:27","symbol":"BIOCON"},{"an_dt":"15-Jun-2022 17:07:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15062022170733_InvestorMeeting_15062022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:07","dt":"15062022170733","exchdisstime":"15-Jun-2022 17:07:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5046744","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-06-15 17:07:33","symbol":"BIOCON"},{"an_dt":"14-Jun-2022 10:31:58","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14062022103158_InvestorMeeting_13062022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:02","dt":"14062022103158","exchdisstime":"14-Jun-2022 10:32:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5045988","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-06-14 10:31:58","symbol":"BIOCON"},{"an_dt":"10-Jun-2022 20:22:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10062022202202_InvestorMeeting_10062022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:04","dt":"10062022202202","exchdisstime":"10-Jun-2022 20:22:06","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5045339","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-06-10 20:22:02","symbol":"BIOCON"},{"an_dt":"10-Jun-2022 17:16:28","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10062022171628_InvestorMeeting_09062022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:04","dt":"10062022171628","exchdisstime":"10-Jun-2022 17:16:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5045148","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-06-10 17:16:28","symbol":"BIOCON"},{"an_dt":"09-Jun-2022 16:35:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09062022163549_PressRelease_UniversityofGlasgowofficiallyOpensMazumdarShawAdvanceResearchCentre.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 09-Jun-2022 titled \"University of Glasgow Officially Opens Mazumdar Shaw Advance Research Centre\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:03","dt":"09062022163549","exchdisstime":"09-Jun-2022 16:35:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5044674","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-06-09 16:35:49","symbol":"BIOCON"},{"an_dt":"08-Jun-2022 17:13:20","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08062022171320_InvestorMeeting_08062022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:06","dt":"08062022171320","exchdisstime":"08-Jun-2022 17:13:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5044271","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-06-08 17:13:20","symbol":"BIOCON"},{"an_dt":"03-Jun-2022 16:40:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03062022164008_InvestorMeeting_03062022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:07","dt":"03062022164008","exchdisstime":"03-Jun-2022 16:40:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5042602","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-06-03 16:40:08","symbol":"BIOCON"},{"an_dt":"31-May-2022 16:30:13","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31052022163013_InvestorMeeting_31052022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:08","dt":"31052022163013","exchdisstime":"31-May-2022 16:30:21","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5040925","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-05-31 16:30:13","symbol":"BIOCON"},{"an_dt":"26-May-2022 18:41:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26052022184137_InvestorMeeting_26052022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:02","dt":"26052022184142","exchdisstime":"26-May-2022 18:41:44","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5036979","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-05-26 18:41:42","symbol":"BIOCON"},{"an_dt":"26-May-2022 18:39:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26052022183924_InvestorMeeting_25052022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call.","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:02","dt":"26052022183934","exchdisstime":"26-May-2022 18:39:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5036978","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-05-26 18:39:34","symbol":"BIOCON"},{"an_dt":"24-May-2022 16:34:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24052022163442_InvestorMeeting_24052022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:12","dt":"24052022163444","exchdisstime":"24-May-2022 16:34:56","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5034924","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-05-24 16:34:44","symbol":"BIOCON"},{"an_dt":"19-May-2022 16:30:24","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19052022163021_PressRelease_BBL_Viatris_Abevmy_Launch_Canada_19052022.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 19-May-2022 titled \"Biocon Biologics and Viatris Launch Abevmy�� (bBevacizumab), Their Third Oncology Biosimilar, in Canada\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:09","dt":"19052022163024","exchdisstime":"19-May-2022 16:30:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5032137","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-05-19 16:30:24","symbol":"BIOCON"},{"an_dt":"12-May-2022 18:12:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12052022181205_Biocon_RPT_March_31_2022.pdf","attchmntText":"Biocon Limited has informed the Exchange about related party transaction for the period ended March 2022.","bflag":null,"csvName":null,"desc":"Related Party Transaction","difference":"00:00:08","dt":"12052022181208","exchdisstime":"12-May-2022 18:12:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5028723","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-05-12 18:12:08","symbol":"BIOCON"},{"an_dt":"10-May-2022 14:35:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10052022143531_InvestorMeeting_10052022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:04","dt":"10052022143544","exchdisstime":"10-May-2022 14:35:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5027129","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-05-10 14:35:44","symbol":"BIOCON"},{"an_dt":"10-May-2022 11:59:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10052022115855_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about  Analysts/Institutional Investor Meet","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:05","dt":"10052022115901","exchdisstime":"10-May-2022 11:59:06","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5026988","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-05-10 11:59:01","symbol":"BIOCON"},{"an_dt":"06-May-2022 17:49:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06052022174949_Biocon_Transcript_EarningsCall.pdf","attchmntText":"Biocon Limited has informed the Exchange about Transcript of Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Transcript of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:03","dt":"06052022174954","exchdisstime":"06-May-2022 17:49:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5026042","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-05-06 17:49:54","symbol":"BIOCON"},{"an_dt":"03-May-2022 21:45:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03052022214534_Notification_Biocon_03052022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Notification to Stock Exchanges","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:05","dt":"03052022214549","exchdisstime":"03-May-2022 21:45:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5024707","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-05-03 21:45:49","symbol":"BIOCON"},{"an_dt":"01-May-2022 22:20:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01052022222004_Biocon_NewspaperAdvertisement.pdf","attchmntText":"Biocon Limited has informed the Exchange about Newspaper Advertisements","bflag":null,"csvName":null,"desc":"Newspaper Advertisements","difference":"00:00:05","dt":"01052022222008","exchdisstime":"01-May-2022 22:20:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5023952","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-05-01 22:20:08","symbol":"BIOCON"},{"an_dt":"29-Apr-2022 19:25:23","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29042022192520_Biocon_EarningsCall_29042022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Presentation and Video Recording of Q4 FY22 Earnings Call","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:03","dt":"29042022192523","exchdisstime":"29-Apr-2022 19:25:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5023612","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-04-29 19:25:23","symbol":"BIOCON"},{"an_dt":"29-Apr-2022 15:47:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29042022154715_Biocon_updatedQ4FY22_InvestorPresentation.pdf","attchmntText":"Biocon Limited has informed the Exchange about Updated Investor Presentation-Q4 FY22.","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:04","dt":"29042022154718","exchdisstime":"29-Apr-2022 15:47:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5023329","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-04-29 15:47:18","symbol":"BIOCON"},{"an_dt":"28-Apr-2022 21:41:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042022214153_InvestorPresentation_Q4FY22_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:02","dt":"28042022214156","exchdisstime":"28-Apr-2022 21:41:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5023143","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-04-28 21:41:56","symbol":"BIOCON"},{"an_dt":"28-Apr-2022 21:36:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042022213648_PressRelease_April2022_Biocon_28042022.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 28-Apr-2022 titled ���Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21%; Core EBITDA at Rs 815 Cr, Up 37% ; PBT(before Exceptional Items) at Rs 384 Cr, Up 9%; Biosimilars Up 48% at Rs 982 Cr; Generics Up 26% at Rs 717 Cr; Research Services Up 15% at Rs 758 Cr.\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"28042022213650","exchdisstime":"28-Apr-2022 21:36:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5023142","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-04-28 21:36:50","symbol":"BIOCON"},{"an_dt":"28-Apr-2022 21:02:31","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042022210223_Outcome_of_Biocon_Board_Meeting_28042022.pdf","attchmntText":"Biocon Limited  has informed the Exchange about appointment of Naina Lal Kidwai as Independent Director of the company w.e.f. 28-Apr-2022","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:04","dt":"28042022210231","exchdisstime":"28-Apr-2022 21:02:35","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5023138","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-04-28 21:02:31","symbol":"BIOCON"},{"an_dt":"28-Apr-2022 20:54:45","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Outcome_of_Biocon_Board_Meeting_28042022_28042022205445.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended March 31, 2022.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:01:17","dt":"28042022205445","exchdisstime":"28-Apr-2022 20:56:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"148455","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-04-28 20:54:45","symbol":"BIOCON"},{"an_dt":"28-Apr-2022 20:48:31","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042022204831_OutcomeofBioconBoardMeeting_28042022.pdf","attchmntText":"Biocon Limited  has informed the Exchange about Board Meeting held on 28-Apr-2022 to consider financial statements for the period ended March 2022, Dividend and Other business matters","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:04","dt":"28042022204831","exchdisstime":"28-Apr-2022 20:48:35","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5023165","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-04-28 20:48:31","symbol":"BIOCON"},{"an_dt":"28-Apr-2022 20:48:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042022204823_OutcomeofBioconBoardMeeting_28042022.pdf","attchmntText":"Biocon Limited has informed the Exchange that Board of Directors at its meeting held on 28-Apr-2022, declared Dividend of Rs. 0.50 per equity share.","bflag":null,"csvName":null,"desc":"Dividend","difference":"00:00:05","dt":"28042022204829","exchdisstime":"28-Apr-2022 20:48:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5023166","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-04-28 20:48:29","symbol":"BIOCON"},{"an_dt":"27-Apr-2022 16:48:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27042022164758_Biocon_RTA_NameChange.pdf","attchmntText":"Biocon Limited has informed the Exchange about Change in name of Company's Registrar and Share Transfer Agent","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:08","dt":"27042022164801","exchdisstime":"27-Apr-2022 16:48:09","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5022500","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-04-27 16:48:01","symbol":"BIOCON"},{"an_dt":"26-Apr-2022 08:32:13","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26042022083212_PressRelease_BioconBiologics���InsugenAwardedaThreeYearContractbyMinistryofHealthMalaysia_26042022.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 26-Apr-2022 titled Biocon Biologics��� Insugen�� Awarded a Three-Year Contract by Ministry of Health, Malaysia ","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"26042022083213","exchdisstime":"26-Apr-2022 08:32:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5021902","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-04-26 08:32:13","symbol":"BIOCON"},{"an_dt":"14-Apr-2022 19:00:31","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14042022190029_Certificate_Reg745_BioconLimited_14042022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI(Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"General updates","difference":"00:00:03","dt":"14042022190031","exchdisstime":"14-Apr-2022 19:00:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5018964","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-04-14 19:00:31","symbol":"BIOCON"},{"an_dt":"06-Apr-2022 15:46:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AN_O06042022154657.xlsx","attchmntText":"Promoter/Promoter Group of Biocon Limited has submitted a disclosure under Regulation 31(4) of SEBI Takeover Regulations for the year ended 31-Mar-2022","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"00:00:11","dt":"06042022154657","exchdisstime":"06-Apr-2022 15:47:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"200001352","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-04-06 15:46:57","symbol":"BIOCON"},{"an_dt":"01-Apr-2022 09:11:28","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01042022090135_PressRelease_CHMPInpremzia_01042022_Intimation_SEs.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 01-Apr-2022 titled 'Biocon Biologics��� Partner Receives Positive EU CHMP Opinion for Biosimilar Human Insulin for IV Infusion'.","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:12","dt":"01042022091128","exchdisstime":"01-Apr-2022 09:11:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5014010","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-04-01 09:11:28","symbol":"BIOCON"},{"an_dt":"31-Mar-2022 09:10:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31032022090958_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:11","dt":"31032022091000","exchdisstime":"31-Mar-2022 09:10:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5012798","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-31 09:10:00","symbol":"BIOCON"},{"an_dt":"29-Mar-2022 11:38:04","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29032022113756_PressRelease_KMS_JS_Galsgow_Univ_29032022_Intimation_SEs.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 29-Mar-2022 titled University of Glasgow Names their Flagship Research Centre After John Shaw and Kiran Mazumdar-Shaw","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:11","dt":"29032022113804","exchdisstime":"29-Mar-2022 11:38:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5011562","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-29 11:38:04","symbol":"BIOCON"},{"an_dt":"24-Mar-2022 14:57:12","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24032022145709_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:11","dt":"24032022145712","exchdisstime":"24-Mar-2022 14:57:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5010303","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-24 14:57:12","symbol":"BIOCON"},{"an_dt":"23-Mar-2022 19:27:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23032022192548_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:10","dt":"23032022192726","exchdisstime":"23-Mar-2022 19:27:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5010150","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-23 19:27:26","symbol":"BIOCON"},{"an_dt":"23-Mar-2022 18:35:16","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23032022183515_PressRelease_KMS_Biocon_23032022_Intimation_SEs.pdf","attchmntText":"Biocon Limited has informed the Exchange about press release dated 23-Mar-2022 titled Kiran Mazumdar-Shaw Elected as the Fellow of Royal Society of Edinburgh (RSE)","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"23032022183516","exchdisstime":"23-Mar-2022 18:35:21","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5010107","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-23 18:35:16","symbol":"BIOCON"},{"an_dt":"11-Mar-2022 17:21:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11032022172127_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Schedule of Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:19","dt":"11032022172132","exchdisstime":"11-Mar-2022 17:21:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5007273","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-11 17:21:32","symbol":"BIOCON"},{"an_dt":"11-Mar-2022 13:08:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11032022130806_Intimation_CreditRating_Biocon_11032022_ICRA.pdf","attchmntText":"Biocon Limited has informed the Exchange about Assignment of Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:05","dt":"11032022130821","exchdisstime":"11-Mar-2022 13:08:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5007146","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-11 13:08:21","symbol":"BIOCON"},{"an_dt":"10-Mar-2022 20:11:41","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10032022201136_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:04","dt":"10032022201141","exchdisstime":"10-Mar-2022 20:11:45","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5007061","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-10 20:11:41","symbol":"BIOCON"},{"an_dt":"09-Mar-2022 18:15:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09032022181508_Intimation_CreditRating_Biocon_09032022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Assignment of Credit Rating","bflag":null,"csvName":null,"desc":"Credit Rating","difference":"00:00:11","dt":"09032022181532","exchdisstime":"09-Mar-2022 18:15:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5006690","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-09 18:15:32","symbol":"BIOCON"},{"an_dt":"08-Mar-2022 21:40:47","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08032022214045_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:07","dt":"08032022214047","exchdisstime":"08-Mar-2022 21:40:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5006429","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-08 21:40:47","symbol":"BIOCON"},{"an_dt":"04-Mar-2022 19:10:25","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04032022190957_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call ","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:02","dt":"04032022191025","exchdisstime":"04-Mar-2022 19:10:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5005485","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-04 19:10:25","symbol":"BIOCON"},{"an_dt":"02-Mar-2022 15:36:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02032022153648_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call.","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:08","dt":"02032022153650","exchdisstime":"02-Mar-2022 15:36:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5004314","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-02 15:36:50","symbol":"BIOCON"},{"an_dt":"02-Mar-2022 10:26:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02032022102615_Stock_Exchange_Intimation_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange about Biocon Biologics to Acquire Viatris��� Biosimilars Assetsfor up to USD 3.335 billion in Stock and Cash","bflag":null,"csvName":null,"desc":"Acquisition","difference":"00:00:18","dt":"02032022102615","exchdisstime":"02-Mar-2022 10:26:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5003538","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-02 10:26:15","symbol":"BIOCON"},{"an_dt":"02-Mar-2022 08:31:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02032022083127_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call.","bflag":null,"csvName":null,"desc":"Schedule of Analysts/Institutional Investor Meet/Con. Call","difference":"00:00:11","dt":"02032022083130","exchdisstime":"02-Mar-2022 08:31:41","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5004175","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-02 08:31:30","symbol":"BIOCON"},{"an_dt":"01-Mar-2022 16:36:25","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01032022163625_IR_PPT_28022022_BBL_VIATRIS.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation on Biocon Biologics to acquire Viatris��� Biosimilars Business.","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:14","dt":"01032022163625","exchdisstime":"01-Mar-2022 16:36:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5003602","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-03-01 16:36:25","symbol":"BIOCON"},{"an_dt":"17-Feb-2022 15:31:25","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17022022153125_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meetings","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:08","dt":"17022022153125","exchdisstime":"17-Feb-2022 15:31:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105245319","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-02-17 15:31:25","symbol":"BIOCON"},{"an_dt":"15-Feb-2022 11:14:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15022022111407_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:11","dt":"15022022111407","exchdisstime":"15-Feb-2022 11:14:18","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105242268","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-02-15 11:14:07","symbol":"BIOCON"},{"an_dt":"08-Feb-2022 23:21:11","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08022022232111_Intimation_IEPF_08022022.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:07","dt":"08022022232111","exchdisstime":"08-Feb-2022 23:21:18","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105233587","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-02-08 23:21:11","symbol":"BIOCON"},{"an_dt":"07-Feb-2022 22:10:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07022022221057_Notification_SEs_Biocon_07022022.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to stock exchanges'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:11","dt":"07022022221057","exchdisstime":"07-Feb-2022 22:11:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105232274","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-02-07 22:10:57","symbol":"BIOCON"},{"an_dt":"28-Jan-2022 14:40:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28012022144051_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:09","dt":"28012022144051","exchdisstime":"28-Jan-2022 14:41:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105221180","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-01-28 14:40:51","symbol":"BIOCON"},{"an_dt":"27-Jan-2022 15:04:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27012022150418_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:11","dt":"27012022150418","exchdisstime":"27-Jan-2022 15:04:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105219590","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-01-27 15:04:18","symbol":"BIOCON"},{"an_dt":"20-Jan-2022 22:36:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20012022223609_InvestorPresentation_Q3FY22_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:08","dt":"20012022223609","exchdisstime":"20-Jan-2022 22:36:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105213148","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-01-20 22:36:09","symbol":"BIOCON"},{"an_dt":"20-Jan-2022 22:31:43","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20012022223143_PressRelease_Biocon_Q3FY22.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 20, 2022, titled \"Press Release on financial results for the quarter and nine months ended December 31, 2021\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:08","dt":"20012022223143","exchdisstime":"20-Jan-2022 22:31:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105213145","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-01-20 22:31:43","symbol":"BIOCON"},{"an_dt":"20-Jan-2022 21:57:20","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/OutcomeOfBM_Bioco_20012022215720.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended December 31, 2021.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:01:42","dt":"20012022215720","exchdisstime":"20-Jan-2022 21:59:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"146575","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-01-20 21:57:20","symbol":"BIOCON"},{"an_dt":"20-Jan-2022 21:55:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20012022215552_OutcomeOfBM_Bioco.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on January 20, 2022.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:05","dt":"20012022215552","exchdisstime":"20-Jan-2022 21:55:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105213135","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-01-20 21:55:52","symbol":"BIOCON"},{"an_dt":"12-Jan-2022 11:29:11","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12012022112911_Regulation74_5__Biocon_Dec2021.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:11","dt":"12012022112911","exchdisstime":"12-Jan-2022 11:29:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105203929","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-01-12 11:29:11","symbol":"BIOCON"},{"an_dt":"07-Jan-2022 20:28:40","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07012022202840_CompanyStatement_BBL_Biocon_07012022.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"07012022202840","exchdisstime":"07-Jan-2022 20:28:46","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105199549","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-01-07 20:28:40","symbol":"BIOCON"},{"an_dt":"03-Jan-2022 21:34:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03012022213421_Intimation_BBL_Merger_03012022.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"03012022213421","exchdisstime":"03-Jan-2022 21:34:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105193792","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2022-01-03 21:34:21","symbol":"BIOCON"},{"an_dt":"30-Dec-2021 16:22:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30122021162234_PressRelease_BBL_BL_30122021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 30, 2021, titled \"Biocon Biologics* Partner Viatris Wins U.S. Court Decisions on Sanofi Appeals for Lantus�� Device Patents\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:06","dt":"30122021162234","exchdisstime":"30-Dec-2021 16:22:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105189783","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-12-30 16:22:34","symbol":"BIOCON"},{"an_dt":"23-Dec-2021 16:31:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23122021163118_PressRelease_BBL_Biocon_Itolizumab.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 23, 2021, titled \"Clinical Study for Itolizumab in Lupus Nephritis Initiated in India, Post DCGIApproval\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"23122021163118","exchdisstime":"23-Dec-2021 16:31:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105182786","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-12-23 16:31:18","symbol":"BIOCON"},{"an_dt":"17-Dec-2021 12:18:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17122021121855_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:08","dt":"17122021121855","exchdisstime":"17-Dec-2021 12:19:03","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105177066","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-12-17 12:18:55","symbol":"BIOCON"},{"an_dt":"13-Dec-2021 08:44:35","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13122021084435_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"13122021084435","exchdisstime":"13-Dec-2021 08:44:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105171153","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-12-13 08:44:35","symbol":"BIOCON"},{"an_dt":"10-Dec-2021 11:16:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10122021111615_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"10122021111615","exchdisstime":"10-Dec-2021 11:16:21","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105169889","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-12-10 11:16:15","symbol":"BIOCON"},{"an_dt":"09-Dec-2021 13:43:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09122021134355_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"09122021134355","exchdisstime":"09-Dec-2021 13:44:01","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105168876","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-12-09 13:43:55","symbol":"BIOCON"},{"an_dt":"08-Dec-2021 13:56:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08122021135634_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"08122021135634","exchdisstime":"08-Dec-2021 13:56:38","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105167575","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-12-08 13:56:34","symbol":"BIOCON"},{"an_dt":"07-Dec-2021 08:41:23","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07122021084123_PressRelease_Biocon_Tabuk_07122021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 07, 2021, titled \"Biocon Ltd partners with Tabuk Pharmaceuticals to commercialise its speciality generic medicines in the Middle East\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"07122021084123","exchdisstime":"07-Dec-2021 08:41:28","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105165606","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-12-07 08:41:23","symbol":"BIOCON"},{"an_dt":"02-Dec-2021 19:36:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02122021193610_Notification_SEs_BPL_BL_02122021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notification to Stock Exchanges '.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:04","dt":"02122021193610","exchdisstime":"02-Dec-2021 19:36:14","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105161967","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-12-02 19:36:10","symbol":"BIOCON"},{"an_dt":"01-Dec-2021 14:22:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01122021142251_PressRelease_Biocon_01122021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 01, 2021, titled \"Biocon Enters Prestigious Dow Jones SustainabilityEmerging Markets Index\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"01122021142251","exchdisstime":"01-Dec-2021 14:22:56","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105160299","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-12-01 14:22:51","symbol":"BIOCON"},{"an_dt":"24-Nov-2021 13:27:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24112021132702_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"24112021132702","exchdisstime":"24-Nov-2021 13:27:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105153240","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-24 13:27:02","symbol":"BIOCON"},{"an_dt":"19-Nov-2021 10:45:16","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19112021104516_SE_Intimation_19112021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Corrigendum to our press release titled  Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargine-yfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club. '.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"19112021104516","exchdisstime":"19-Nov-2021 10:45:21","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105149315","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-19 10:45:16","symbol":"BIOCON"},{"an_dt":"19-Nov-2021 09:15:13","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19112021091513_Intimation_PressRelease_19112021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 19, 2021, titled \"Biocon Biologics and Viatris Announce Insulin Glargine (insulin glargineyfgn) Injection Will Be Offered Through the Walgreens Prescription Savings Club\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"19112021091513","exchdisstime":"19-Nov-2021 09:15:18","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105149309","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-19 09:15:13","symbol":"BIOCON"},{"an_dt":"19-Nov-2021 08:40:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19112021084054_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"19112021084054","exchdisstime":"19-Nov-2021 08:40:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105149307","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-19 08:40:54","symbol":"BIOCON"},{"an_dt":"18-Nov-2021 14:55:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18112021145518_SE_Intimation_ESOPDeed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding ''Submission of amended Biocon India Limited Employees Welfare Trust Deed.\"","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:07","dt":"18112021145518","exchdisstime":"18-Nov-2021 14:55:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105148513","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-18 14:55:18","symbol":"BIOCON"},{"an_dt":"18-Nov-2021 14:21:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18112021142130_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"18112021142130","exchdisstime":"18-Nov-2021 14:21:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105148494","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-18 14:21:30","symbol":"BIOCON"},{"an_dt":"17-Nov-2021 10:54:22","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17112021105422_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"17112021105422","exchdisstime":"17-Nov-2021 10:54:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105146918","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-17 10:54:22","symbol":"BIOCON"},{"an_dt":"16-Nov-2021 17:49:24","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16112021174924_PressRelease_BBL_Biocon_16112021_Viatris_Semglee.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 16, 2021, titled \"Biocon Biologics and Viatris Announce Launch of Interchangeable SEMGLEE�� (insulin glargine-yfgn) Injection and Insulin Glargine (insulin glargine-yfgn) Injection\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:07","dt":"16112021174924","exchdisstime":"16-Nov-2021 17:49:31","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105145787","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-16 17:49:24","symbol":"BIOCON"},{"an_dt":"16-Nov-2021 13:12:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16112021131249_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"16112021131249","exchdisstime":"16-Nov-2021 13:12:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105145576","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-16 13:12:49","symbol":"BIOCON"},{"an_dt":"15-Nov-2021 09:24:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15112021092408_PressRelease_BBL_Biocon_15112021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 15, 2021, titled \"Biocon Biologics Collaborates with RSSDI to Expand Access to its Insulins for Children with Type 1 Diabetes on World Diabetes Day\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:03:09","dt":"15112021092408","exchdisstime":"15-Nov-2021 09:27:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105143332","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-15 09:24:08","symbol":"BIOCON"},{"an_dt":"11-Nov-2021 16:31:37","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11112021163137_InvestorMeeting_Revised.pdf","attchmntText":"Biocon Limited has informed the Exchange about revised intimation on Investor Meeting held on November 10, 2021","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:07","dt":"11112021163137","exchdisstime":"11-Nov-2021 16:31:44","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105139504","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-11 16:31:37","symbol":"BIOCON"},{"an_dt":"11-Nov-2021 15:55:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11112021155549_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"11112021155549","exchdisstime":"11-Nov-2021 15:55:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105139446","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-11 15:55:49","symbol":"BIOCON"},{"an_dt":"04-Nov-2021 08:30:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04112021083033_Notification_BBL_Viatris_Glargine_04112021_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon Biologics and Viatris Announce Prime TherapeuticsPrefers First-Ever Interchangeable Insulin Biosimilar Semglee�� (insulin glargine-yfgn) Injection and InsulinGlargine (insulin glargine-yfgn) Injection on its National Formularies.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"04112021083033","exchdisstime":"04-Nov-2021 08:30:38","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105133072","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-04 08:30:33","symbol":"BIOCON"},{"an_dt":"03-Nov-2021 13:37:11","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03112021133711_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Meeting","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"03112021133711","exchdisstime":"03-Nov-2021 13:37:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105132030","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-03 13:37:11","symbol":"BIOCON"},{"an_dt":"02-Nov-2021 11:06:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02112021110632_IR_Biocon_02112021_Q2FY22.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:04","dt":"02112021110632","exchdisstime":"02-Nov-2021 11:06:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105129992","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-11-02 11:06:32","symbol":"BIOCON"},{"an_dt":"28-Oct-2021 13:18:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28102021131844_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Teleconference","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:08","dt":"28102021131844","exchdisstime":"28-Oct-2021 13:18:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105124461","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-10-28 13:18:44","symbol":"BIOCON"},{"an_dt":"21-Oct-2021 23:43:35","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21102021234335_Appointment_Eric_Biocon_21102021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"00:00:05","dt":"21102021234335","exchdisstime":"21-Oct-2021 23:43:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105117042","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-10-21 23:43:35","symbol":"BIOCON"},{"an_dt":"21-Oct-2021 23:41:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21102021234133_PressRelease_Biocon_21102021_Q2FY22.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 21, 2021, titled \"Biocon Q2FY22 Revenue up 10% at Rs 1,945 Cr; EBITDA up 35% at Rs 551 Cr; Net Profit (before exceptional items) up 11% at Rs 188 Cr.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"21102021234133","exchdisstime":"21-Oct-2021 23:41:38","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105117041","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-10-21 23:41:33","symbol":"BIOCON"},{"an_dt":"21-Oct-2021 23:15:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Outcome_BL_21102021231551.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended September 30, 2021.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:01:10","dt":"21102021231551","exchdisstime":"21-Oct-2021 23:17:01","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"144650","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-10-21 23:15:51","symbol":"BIOCON"},{"an_dt":"21-Oct-2021 23:14:24","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21102021231424_Outcome_BL.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on October 21, 2021.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:05","dt":"21102021231424","exchdisstime":"21-Oct-2021 23:14:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105116784","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-10-21 23:14:24","symbol":"BIOCON"},{"an_dt":"21-Oct-2021 09:05:12","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21102021090512_PressRelease_BBL_Biocon_21102021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 21, 2021, titled \"Biocon Biologics  First-Ever Interchangeable Biosimilar Insulin Glargine, Co-Developed with Commercial Partner Viatris, Preferred on Express Scripts  Largest Formulary in US.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"21102021090512","exchdisstime":"21-Oct-2021 09:05:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105115509","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-10-21 09:05:12","symbol":"BIOCON"},{"an_dt":"13-Oct-2021 17:06:28","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13102021170628_Reg74_Intimation_Biocon_sept2021.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:04","dt":"13102021170628","exchdisstime":"13-Oct-2021 17:06:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105109010","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-10-13 17:06:28","symbol":"BIOCON"},{"an_dt":"04-Oct-2021 21:22:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04102021212227_Notification_to_Stock_Exchanges_KMS_04102021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Kiran Mazumdar Shaw s Notification to Stock Exchanges '.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"04102021212227","exchdisstime":"04-Oct-2021 21:22:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105097866","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-10-04 21:22:27","symbol":"BIOCON"},{"an_dt":"04-Oct-2021 09:01:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04102021090132_PressRelease_Everolimus_Biocon_04102021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 04, 2021, titled \"Biocon expands its Generic Formulations portfolio with the launch of Everolimus tablets in the US.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:06","dt":"04102021090132","exchdisstime":"04-Oct-2021 09:01:38","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105096976","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-10-04 09:01:32","symbol":"BIOCON"},{"an_dt":"30-Sep-2021 18:15:46","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30092021181546_Response_NSE_Biocon_30092021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Query on announcement dated September 16, 2021, regarding merger of CovidshieldTechnologies Private Limited with, and into Biocon Biologics Limited.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"30092021181546","exchdisstime":"30-Sep-2021 18:15:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105093791","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-09-30 18:15:46","symbol":"BIOCON"},{"an_dt":"30-Sep-2021 09:13:40","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30092021091340_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"30092021091340","exchdisstime":"30-Sep-2021 09:13:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105091988","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-09-30 09:13:40","symbol":"BIOCON"},{"an_dt":"25-Sep-2021 12:31:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25092021123134_Intimation_to_SE_USFDA_Malaysia_BBL_25092021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"25092021123134","exchdisstime":"25-Sep-2021 12:31:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105085950","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-09-25 12:31:34","symbol":"BIOCON"},{"an_dt":"24-Sep-2021 17:03:16","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24092021170316_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"24092021170316","exchdisstime":"24-Sep-2021 17:03:20","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105085276","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-09-24 17:03:16","symbol":"BIOCON"},{"an_dt":"22-Sep-2021 11:25:35","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22092021112535_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"22092021112535","exchdisstime":"22-Sep-2021 11:25:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105081974","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-09-22 11:25:35","symbol":"BIOCON"},{"an_dt":"21-Sep-2021 16:21:39","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21092021162139_IR_Presentation_Sept2021.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:05","dt":"21092021162139","exchdisstime":"21-Sep-2021 16:21:44","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105080488","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-09-21 16:21:39","symbol":"BIOCON"},{"an_dt":"21-Sep-2021 09:00:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21092021090014_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"21092021090014","exchdisstime":"21-Sep-2021 09:00:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105079608","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-09-21 09:00:14","symbol":"BIOCON"},{"an_dt":"16-Sep-2021 21:34:36","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16092021213436_BioconSEintimationReg30.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 16, 2021, titled \"Biocon Biologics and Serum Institute Life Sciences Announce Strategic Alliance\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"16092021213436","exchdisstime":"16-Sep-2021 21:34:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105075851","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-09-16 21:34:36","symbol":"BIOCON"},{"an_dt":"15-Sep-2021 11:49:42","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15092021114942_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"15092021114942","exchdisstime":"15-Sep-2021 11:49:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105073892","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-09-15 11:49:42","symbol":"BIOCON"},{"an_dt":"08-Sep-2021 08:26:53","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08092021082653_CompanyStatement_Celgene_Biocon_08092021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement '.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:04","dt":"08092021082653","exchdisstime":"08-Sep-2021 08:26:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105066527","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-09-08 08:26:53","symbol":"BIOCON"},{"an_dt":"01-Sep-2021 09:38:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01092021093850_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"01092021093850","exchdisstime":"01-Sep-2021 09:38:55","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105056942","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-09-01 09:38:50","symbol":"BIOCON"},{"an_dt":"27-Aug-2021 13:00:19","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27082021130019_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"27082021130019","exchdisstime":"27-Aug-2021 13:00:24","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105052159","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-08-27 13:00:19","symbol":"BIOCON"},{"an_dt":"25-Aug-2021 10:17:40","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25082021101740_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"25082021101740","exchdisstime":"25-Aug-2021 10:17:46","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105048733","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-08-25 10:17:40","symbol":"BIOCON"},{"an_dt":"10-Aug-2021 11:19:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10082021111915_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"10082021111915","exchdisstime":"10-Aug-2021 11:19:20","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105029849","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-08-10 11:19:15","symbol":"BIOCON"},{"an_dt":"04-Aug-2021 18:36:45","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04082021183645_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:07","dt":"04082021183645","exchdisstime":"04-Aug-2021 18:36:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105022033","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-08-04 18:36:45","symbol":"BIOCON"},{"an_dt":"04-Aug-2021 14:05:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04082021140552_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"04082021140552","exchdisstime":"04-Aug-2021 14:05:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105021655","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-08-04 14:05:52","symbol":"BIOCON"},{"an_dt":"29-Jul-2021 16:00:35","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29072021160035_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:10","dt":"29072021160035","exchdisstime":"29-Jul-2021 16:00:45","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105013359","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-29 16:00:35","symbol":"BIOCON"},{"an_dt":"29-Jul-2021 10:36:41","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29072021103641_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"29072021103641","exchdisstime":"29-Jul-2021 10:36:47","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105013075","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-29 10:36:41","symbol":"BIOCON"},{"an_dt":"29-Jul-2021 09:33:28","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29072021093328_PressRelease_USFDA_BBL_Biocon_29072021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 29, 2021, titled \"Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee�� (insulin glargine-yfgn injection) for the Treatment of Diabetes.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"29072021093328","exchdisstime":"29-Jul-2021 09:33:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105012602","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-29 09:33:28","symbol":"BIOCON"},{"an_dt":"27-Jul-2021 17:08:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27072021170850_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:07","dt":"27072021170850","exchdisstime":"27-Jul-2021 17:08:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105009850","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-27 17:08:50","symbol":"BIOCON"},{"an_dt":"27-Jul-2021 17:08:47","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27072021170847_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"27072021170847","exchdisstime":"27-Jul-2021 17:08:52","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105009849","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-27 17:08:47","symbol":"BIOCON"},{"an_dt":"26-Jul-2021 18:32:58","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26072021183258_SE_Intimation_BL.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 26, 2021, titled \"Biocon Biologics Partners with Adagio Therapeutics to Advance Antibody for the Prevention and Treatment of COVID-19\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"26072021183258","exchdisstime":"26-Jul-2021 18:33:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105008159","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-26 18:32:58","symbol":"BIOCON"},{"an_dt":"24-Jul-2021 16:17:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24072021161749_SEs_Intimation_Directors.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"00:00:09","dt":"24072021161749","exchdisstime":"24-Jul-2021 16:17:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105006891","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-24 16:17:49","symbol":"BIOCON"},{"an_dt":"24-Jul-2021 15:22:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24072021152201_Biocon_AGM_VotingResults_2021.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Annual General Meeting held on July 23, 2021. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:07","dt":"24072021152201","exchdisstime":"24-Jul-2021 15:22:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105006866","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-24 15:22:01","symbol":"BIOCON"},{"an_dt":"24-Jul-2021 15:04:37","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24072021150437_Biocon_AGM_Outcome.pdf","attchmntText":"Proceedings of 43rd Annual General Meeting of the Company","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:05","dt":"24072021150437","exchdisstime":"24-Jul-2021 15:04:42","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105006859","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-24 15:04:37","symbol":"BIOCON"},{"an_dt":"23-Jul-2021 13:02:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23072021130244_Covering_Letter_Retire.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"00:00:06","dt":"23072021130244","exchdisstime":"23-Jul-2021 13:02:50","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105005467","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-23 13:02:44","symbol":"BIOCON"},{"an_dt":"22-Jul-2021 23:49:53","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22072021234953_PressRelease_Q1FY22.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 22, 2021, titled \"Biocon Q1FY22 Revenue at Rs 1,808 Cr, Up 6%; EBITDA at Rs 437 Cr; Biosimilars Up 10 % at Rs 758 Cr; Research Services Up 41 % at Rs 595 Cr.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"22072021234953","exchdisstime":"22-Jul-2021 23:49:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105004757","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-22 23:49:53","symbol":"BIOCON"},{"an_dt":"22-Jul-2021 23:37:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22072021233709_outcome_bm_s.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on July 22, 2021.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:06","dt":"22072021233709","exchdisstime":"22-Jul-2021 23:37:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"105004754","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-22 23:37:09","symbol":"BIOCON"},{"an_dt":"22-Jul-2021 23:34:16","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/outcome_bm_s_22072021233416.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended June 30, 2021.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:01:46","dt":"22072021233416","exchdisstime":"22-Jul-2021 23:36:02","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"142834","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-22 23:34:16","symbol":"BIOCON"},{"an_dt":"15-Jul-2021 17:15:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15072021171544_BBL_GS_Amendment_Biocon_SEs_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"15072021171544","exchdisstime":"15-Jul-2021 17:15:50","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104995923","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-15 17:15:44","symbol":"BIOCON"},{"an_dt":"12-Jul-2021 18:27:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12072021182709_Biocon_Reg74_June2021.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:06","dt":"12072021182709","exchdisstime":"12-Jul-2021 18:27:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104990516","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-12 18:27:09","symbol":"BIOCON"},{"an_dt":"02-Jul-2021 23:04:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02072021230407_Intimation_PriorAGM_02072021.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:08","dt":"02072021230407","exchdisstime":"02-Jul-2021 23:04:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104979701","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-07-02 23:04:07","symbol":"BIOCON"},{"an_dt":"30-Jun-2021 17:07:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30062021170754_Biocon_Annual_Report_2021_SE.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Updated Annual Report for the FY 2020-21.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"30062021170754","exchdisstime":"30-Jun-2021 17:08:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104975464","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-06-30 17:07:54","symbol":"BIOCON"},{"an_dt":"29-Jun-2021 22:34:43","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29062021223443_Biocon_AGM_Notice_Annual_Report_2021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 23, 2021","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"00:00:06","dt":"29062021223443","exchdisstime":"29-Jun-2021 22:34:49","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104973331","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-06-29 22:34:43","symbol":"BIOCON"},{"an_dt":"25-Jun-2021 18:29:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25062021182909_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:08","dt":"25062021182909","exchdisstime":"25-Jun-2021 18:29:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104967910","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-06-25 18:29:09","symbol":"BIOCON"},{"an_dt":"24-Jun-2021 21:37:04","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24062021213704_Intimation_PriorAGM_24062021.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:06","dt":"24062021213704","exchdisstime":"24-Jun-2021 21:37:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104966169","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-06-24 21:37:04","symbol":"BIOCON"},{"an_dt":"21-Jun-2021 21:21:59","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21062021212159_Intimation_IEPF_062021_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:08","dt":"21062021212159","exchdisstime":"21-Jun-2021 21:22:07","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104960375","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-06-21 21:21:59","symbol":"BIOCON"},{"an_dt":"18-Jun-2021 18:08:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18062021180856_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"18062021180856","exchdisstime":"18-Jun-2021 18:09:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104957729","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-06-18 18:08:56","symbol":"BIOCON"},{"an_dt":"15-Jun-2021 17:54:24","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15062021175424_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"15062021175424","exchdisstime":"15-Jun-2021 17:54:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104951828","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-06-15 17:54:24","symbol":"BIOCON"},{"an_dt":"10-Jun-2021 10:24:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10062021102456_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:08","dt":"10062021102456","exchdisstime":"10-Jun-2021 10:25:04","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104944942","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-06-10 10:24:56","symbol":"BIOCON"},{"an_dt":"08-Jun-2021 19:16:40","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08062021191640_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"08062021191640","exchdisstime":"08-Jun-2021 19:16:46","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104941446","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-06-08 19:16:40","symbol":"BIOCON"},{"an_dt":"03-Jun-2021 16:28:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03062021162834_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:08","dt":"03062021162834","exchdisstime":"03-Jun-2021 16:28:42","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104935137","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-06-03 16:28:34","symbol":"BIOCON"},{"an_dt":"02-Jun-2021 19:04:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02062021190406_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:07","dt":"02062021190406","exchdisstime":"02-Jun-2021 19:04:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104933377","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-06-02 19:04:06","symbol":"BIOCON"},{"an_dt":"28-May-2021 19:52:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28052021195220_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:12","dt":"28052021195221","exchdisstime":"28-May-2021 19:52:33","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104927073","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-05-28 19:52:21","symbol":"BIOCON"},{"an_dt":"26-May-2021 17:18:18","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26052021171818_RPT_Disclosure_Biocon_March2021.pdf","attchmntText":"Biocon Limited has informed the Exchange about related Party Transactions","bflag":null,"csvName":null,"desc":"Related Party Transactions","difference":"00:00:08","dt":"26052021171818","exchdisstime":"26-May-2021 17:18:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104923739","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-05-26 17:18:18","symbol":"BIOCON"},{"an_dt":"26-May-2021 12:09:05","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26052021120905_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:26","dt":"26052021120905","exchdisstime":"26-May-2021 12:09:31","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104923555","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-05-26 12:09:05","symbol":"BIOCON"},{"an_dt":"21-May-2021 17:33:59","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21052021173359_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:16","dt":"21052021173359","exchdisstime":"21-May-2021 17:34:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104917125","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-05-21 17:33:59","symbol":"BIOCON"},{"an_dt":"21-May-2021 09:13:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21052021091348_Intimation_21052021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Order passed by the Adjudicating Officer of Securities and Exchange Board of India ( SEBI ).'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:07","dt":"21052021091348","exchdisstime":"21-May-2021 09:13:55","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104916197","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-05-21 09:13:48","symbol":"BIOCON"},{"an_dt":"19-May-2021 11:39:59","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19052021113959_IR_Presentation_Biocon_19052021.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:20","dt":"19052021113959","exchdisstime":"19-May-2021 11:40:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104912853","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-05-19 11:39:59","symbol":"BIOCON"},{"an_dt":"03-May-2021 17:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03052021174400_Materiality_Policy_Amendment_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Change in the name and contact details of Key Managerial Personnel under the Policy for Determination of Materiality for Disclosures.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:16","dt":"03052021174400","exchdisstime":"03-May-2021 17:44:16","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104891188","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-05-03 17:44:00","symbol":"BIOCON"},{"an_dt":"29-Apr-2021 19:33:03","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29042021193303_DividendUpdated_Biocon_April2021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Update on declaration of dividend for FY21'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:12","dt":"29042021193303","exchdisstime":"29-Apr-2021 19:33:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104886851","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-29 19:33:03","symbol":"BIOCON"},{"an_dt":"29-Apr-2021 00:22:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29042021002244_AllotmentOfShares_Biocon_28042021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Allotment of equity shares to Biocon India Limited Employee Welfare Trust under Biocon Restricted Stock Unit Long Term Incentive Plan FY 2020-24.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:21","dt":"29042021002244","exchdisstime":"29-Apr-2021 00:23:05","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104885600","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-29 00:22:44","symbol":"BIOCON"},{"an_dt":"29-Apr-2021 00:19:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29042021001914_ChangeInKMP_Biocon_28042021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Change in Key Managerial Personnel of the Company'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:12","dt":"29042021001914","exchdisstime":"29-Apr-2021 00:19:26","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104885291","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-29 00:19:14","symbol":"BIOCON"},{"an_dt":"29-Apr-2021 00:03:28","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29042021000328_PressRelease_FY21_Biocon_28042021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 28, 2021, titled \"Biocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68% Net Profit (before exceptional item & discontinuing operations) at Rs 257 Cr; Biosimilars Up 53% at Rs 664Cr; Research Services Up 8% at Rs 659 Cr; Generics Up 3% at Rs 578 Cr., FY21 Revenue Up 14% at Rs 7,360 Cr; EBITDA Up 8% at Rs 1,907 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 754 Cr.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:12","dt":"29042021000328","exchdisstime":"29-Apr-2021 00:03:40","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104885290","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-29 00:03:28","symbol":"BIOCON"},{"an_dt":"28-Apr-2021 23:53:58","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042021235357_OutcomeOfBM_Biocon_28042021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on April 28, 2021.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:10","dt":"28042021235358","exchdisstime":"28-Apr-2021 23:54:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104885289","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-28 23:53:58","symbol":"BIOCON"},{"an_dt":"28-Apr-2021 23:50:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/OutcomeOfBM_Biocon_28042021_28042021235010.pdf","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended March 31, 2021.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:01:53","dt":"28042021235010","exchdisstime":"28-Apr-2021 23:52:03","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"140840","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-28 23:50:10","symbol":"BIOCON"},{"an_dt":"28-Apr-2021 15:40:28","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042021154028_PressRelease_BBL_Biocon_28042021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 28, 2021, titled \"Biocon Biologics  New Monoclonal Antibodies Manufacturing Facility Wins ISPE s 2021 Facility of the Year Honorable Mention Award\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:10","dt":"28042021154028","exchdisstime":"28-Apr-2021 15:40:38","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104884498","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-28 15:40:28","symbol":"BIOCON"},{"an_dt":"28-Apr-2021 11:30:28","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042021113028_CompanyStatement_KMS_Biocon_28042021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement - Kiran Mazumdar-Shaw Joins Board of Trustees of Memorial Sloan Kettering Cancer Center, U.S.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:13","dt":"28042021113028","exchdisstime":"28-Apr-2021 11:30:41","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104884284","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-28 11:30:28","symbol":"BIOCON"},{"an_dt":"26-Apr-2021 08:27:07","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26042021082707_CompanyStatement_26042021_Biocon_Biologics.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement - Biocon Biologics and Viatris Receive European Commission Approval for Biosimilar Bevacizumab. '.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:10","dt":"26042021082707","exchdisstime":"26-Apr-2021 08:27:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104879415","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-26 08:27:07","symbol":"BIOCON"},{"an_dt":"24-Apr-2021 08:04:46","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_24042021205133_Biocon_Large_Corporate_Confirmation_008.pdf","attchmntText":"Biocon Limited has submitted to the Exchange Annual Disclosure as per SEBI Circular dated November 26, 2018.","bflag":null,"csvName":null,"desc":"Annual Disclosure","difference":"12:47:03","dt":"24042021080446","exchdisstime":"24-Apr-2021 20:51:49","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104879329","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-24 08:04:46","symbol":"BIOCON"},{"an_dt":"19-Apr-2021 09:36:38","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19042021093638_BICON314_19042021093515.zip","attchmntText":"��Promoter/Member of the Promoter Group of the Company has informed the Exchange regarding disclosure under Regulation 30 and Regulation 31(4) of SEBI SAST Regulations 2011��as at March 31, 2021.��","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"00:00:04","dt":"19042021093638","exchdisstime":"19-Apr-2021 09:36:42","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104869753","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-19 09:36:38","symbol":"BIOCON"},{"an_dt":"16-Apr-2021 21:21:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16042021212144_Biocon_BM_Newspaper_Ad.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:04","dt":"16042021212144","exchdisstime":"16-Apr-2021 21:21:48","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104868171","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-16 21:21:44","symbol":"BIOCON"},{"an_dt":"12-Apr-2021 08:25:05","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12042021082505_Intimation_BPL_BL_GMP_12042021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon Pharma Limited, a wholly owned subsidiary of Biocon Limited, receives GMP compliance certificate from MHRA, UK.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:03","dt":"12042021082505","exchdisstime":"12-Apr-2021 08:25:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104859959","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-12 08:25:05","symbol":"BIOCON"},{"an_dt":"07-Apr-2021 19:26:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07042021192655_Certificate_Reg74_5__BioconLimited_07042021.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:04","dt":"07042021192655","exchdisstime":"07-Apr-2021 19:26:59","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104853248","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-07 19:26:55","symbol":"BIOCON"},{"an_dt":"01-Apr-2021 16:18:03","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01042021161803_IR_Biocon_01042021_SEs.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:10","dt":"01042021161803","exchdisstime":"01-Apr-2021 16:18:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104844777","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-04-01 16:18:03","symbol":"BIOCON"},{"an_dt":"29-Mar-2021 08:37:37","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29032021083737_PressRelease_BPL_Libbs_29032021_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 29, 2021, titled \"Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"29032021083737","exchdisstime":"29-Mar-2021 08:37:42","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104838016","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-03-29 08:37:37","symbol":"BIOCON"},{"an_dt":"19-Mar-2021 17:15:47","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19032021171547_Incorporation_of_New_WOS_Biofusion_Therapeutics_Limited.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Intimation for Incorporation of Wholly Owned Subsidiary Company - Biofusion Therapeutics Limited.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:04","dt":"19032021171547","exchdisstime":"19-Mar-2021 17:15:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104824291","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-03-19 17:15:47","symbol":"BIOCON"},{"an_dt":"09-Mar-2021 16:20:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09032021162026_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"09032021162026","exchdisstime":"09-Mar-2021 16:20:30","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104807667","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-03-09 16:20:26","symbol":"BIOCON"},{"an_dt":"08-Mar-2021 17:10:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08032021171056_BBL_Allotment_08032021_ASM.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( SEBI Listing Regulations ).'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"08032021171056","exchdisstime":"08-Mar-2021 17:11:01","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104805423","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-03-08 17:10:56","symbol":"BIOCON"},{"an_dt":"04-Mar-2021 15:44:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04032021154452_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"04032021154452","exchdisstime":"04-Mar-2021 15:44:56","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104800514","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-03-04 15:44:52","symbol":"BIOCON"},{"an_dt":"02-Mar-2021 11:48:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02032021114826_PressRelease_BioconBiologics_Biocon_02032021_CCO.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 02, 2021, titled \"Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"02032021114826","exchdisstime":"02-Mar-2021 11:48:31","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104794024","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-03-02 11:48:26","symbol":"BIOCON"},{"an_dt":"01-Mar-2021 15:06:59","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01032021150659_PressRelease_BioconBiologics_Biocon_01032021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 01, 2021, titled \"Biocon Biologics Promotes Shreehas Tambe to Deputy Chief Executive Officer\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"01032021150659","exchdisstime":"01-Mar-2021 15:07:04","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104792036","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-03-01 15:06:59","symbol":"BIOCON"},{"an_dt":"01-Mar-2021 08:31:22","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01032021083122_PressRelease_BioconBiologics_Biocon_01032021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 01, 2021, titled \"Biocon Biologics and Viatris Inc. Receive CHMP Nod for Abevmy��, a Biosimilar to Avastin�� (Bevacizumab)\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:03","dt":"01032021083122","exchdisstime":"01-Mar-2021 08:31:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104791232","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-03-01 08:31:22","symbol":"BIOCON"},{"an_dt":"18-Feb-2021 11:40:23","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18022021114023_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"18022021114023","exchdisstime":"18-Feb-2021 11:40:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104777988","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-02-18 11:40:23","symbol":"BIOCON"},{"an_dt":"17-Feb-2021 12:45:04","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17022021124504_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"17022021124504","exchdisstime":"17-Feb-2021 12:45:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104775708","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-02-17 12:45:04","symbol":"BIOCON"},{"an_dt":"16-Feb-2021 11:04:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16022021110410_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"16022021110410","exchdisstime":"16-Feb-2021 11:04:15","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104772774","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-02-16 11:04:10","symbol":"BIOCON"},{"an_dt":"16-Feb-2021 08:30:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16022021083029_PressRelease_BBL_Biocon_16022021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 16, 2021, titled \"Biocon Biologics Joins Hands with IDF in its Mission to Promote Diabetes Care, Prevention and effective Management Worldwide\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:03","dt":"16022021083029","exchdisstime":"16-Feb-2021 08:30:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104772427","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-02-16 08:30:29","symbol":"BIOCON"},{"an_dt":"12-Feb-2021 18:30:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12022021183055_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"12022021183055","exchdisstime":"12-Feb-2021 18:31:00","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104768103","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-02-12 18:30:55","symbol":"BIOCON"},{"an_dt":"12-Feb-2021 07:57:47","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12022021075747_CompanyStatement_12022021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement titled \"Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart .'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:04","dt":"12022021075747","exchdisstime":"12-Feb-2021 07:57:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104766127","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-02-12 07:57:47","symbol":"BIOCON"},{"an_dt":"09-Feb-2021 16:03:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09022021160334_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"09022021160334","exchdisstime":"09-Feb-2021 16:03:38","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104760043","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-02-09 16:03:34","symbol":"BIOCON"},{"an_dt":"06-Feb-2021 19:40:16","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06022021194016_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"06022021194016","exchdisstime":"06-Feb-2021 19:40:20","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104756046","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-02-06 19:40:16","symbol":"BIOCON"},{"an_dt":"05-Feb-2021 15:49:19","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05022021154919_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"05022021154919","exchdisstime":"05-Feb-2021 15:49:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104754130","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-02-05 15:49:19","symbol":"BIOCON"},{"an_dt":"04-Feb-2021 16:47:39","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04022021164739_PressRelease_BBL_Biocon_04022021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 04, 2021, titled \"Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries, Will enable access to Trastuzumab & Pegfilgrastim in Africa & Asia\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"04022021164739","exchdisstime":"04-Feb-2021 16:47:44","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104751539","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-02-04 16:47:39","symbol":"BIOCON"},{"an_dt":"04-Feb-2021 16:20:03","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04022021162003_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:10","dt":"04022021162003","exchdisstime":"04-Feb-2021 16:20:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104751504","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-02-04 16:20:03","symbol":"BIOCON"},{"an_dt":"03-Feb-2021 14:32:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03022021143248_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"03022021143248","exchdisstime":"03-Feb-2021 14:32:51","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104749043","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-02-03 14:32:48","symbol":"BIOCON"},{"an_dt":"02-Feb-2021 10:37:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02022021103715_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"02022021103715","exchdisstime":"02-Feb-2021 10:37:20","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104746006","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-02-02 10:37:15","symbol":"BIOCON"},{"an_dt":"21-Jan-2021 23:18:23","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21012021231823_PressRelease_Biocon_21012021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 21, 2021, titled \"Biocon Q3FY21 Revenue at ₹ 1,879 Crore, Up 7%; EBITDA at ₹427 Crore; Net Profit at ₹169 Crore; Biosimilars up 11% at ₹769 Crore; Research Services up 13% at ₹585 Crore; Generics down 3% at ₹561 Crore.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"21012021231823","exchdisstime":"21-Jan-2021 23:18:28","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104729002","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-01-21 23:18:23","symbol":"BIOCON"},{"an_dt":"21-Jan-2021 23:02:40","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/OutcomeOFBM_BL_21012021230240.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended December 31, 2020.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:01:23","dt":"21012021230240","exchdisstime":"21-Jan-2021 23:04:03","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"139087","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-01-21 23:02:40","symbol":"BIOCON"},{"an_dt":"21-Jan-2021 22:58:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21012021225814_OutcomeOFBM_BL.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on January 21, 2021.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:03","dt":"21012021225814","exchdisstime":"21-Jan-2021 22:58:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104728849","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-01-21 22:58:14","symbol":"BIOCON"},{"an_dt":"21-Jan-2021 13:30:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21012021133030_PressRelease_BBL_Appointment_ID_Biocon_21012021.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 21, 2021, titled \"Professor Peter Piot Joins the Board of Biocon Biologics Limited as an Independent Director.\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:02:04","dt":"21012021133030","exchdisstime":"21-Jan-2021 13:32:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104728119","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-01-21 13:30:30","symbol":"BIOCON"},{"an_dt":"07-Jan-2021 17:14:25","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07012021171425_PressRelease_BBL_ADQ_07012021_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 07, 2021, titled \"Biocon Biologics Receives Rs 555 Cr (USD 75 Million) CapitalInjection from ADQTransaction Values Biocon Biologics at ~USD 4.17 Billion\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:03","dt":"07012021171425","exchdisstime":"07-Jan-2021 17:14:28","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104704230","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-01-07 17:14:25","symbol":"BIOCON"},{"an_dt":"07-Jan-2021 16:07:01","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07012021160701_Biocon_BM_Newspaper_07012021.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:05","dt":"07012021160701","exchdisstime":"07-Jan-2021 16:07:06","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104704172","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-01-07 16:07:01","symbol":"BIOCON"},{"an_dt":"07-Jan-2021 16:03:59","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07012021160359_Biocon_ComplianceCertificate_Reg74_07012021.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:13","dt":"07012021160359","exchdisstime":"07-Jan-2021 16:04:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104704171","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2021-01-07 16:03:59","symbol":"BIOCON"},{"an_dt":"28-Dec-2020 16:02:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28122020160221_PressRelease_Biocon_Tacrolimus_28122020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 28, 2020, titled \"Biocon expands generic formulations portfolio with the launch of Tacrolimus capsules in the US\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:04","dt":"28122020160221","exchdisstime":"28-Dec-2020 16:02:25","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104684073","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-12-28 16:02:21","symbol":"BIOCON"},{"an_dt":"25-Dec-2020 11:07:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25122020110708_Intimation_25122020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon Biologics Statement on the Status of Bevacizumab FDA Action Date in Dec 2020 '.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"25122020110708","exchdisstime":"25-Dec-2020 11:07:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104681989","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-12-25 11:07:08","symbol":"BIOCON"},{"an_dt":"15-Dec-2020 17:30:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15122020173048_PressRelease_Biocon_BioconBiologics_Tanzania_15122020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 15, 2020, titled \"Biocon Biologics signs an MoU with CSSC in Tanzania for Mission 10 cents\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:06","dt":"15122020173048","exchdisstime":"15-Dec-2020 17:30:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104665146","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-12-15 17:30:48","symbol":"BIOCON"},{"an_dt":"14-Dec-2020 08:25:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14122020082529_Intimation_14122020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon Biologics and Mylan Receive CHMP Recommendation for Approval of Biosimilar Insulin Aspart'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:06","dt":"14122020082529","exchdisstime":"14-Dec-2020 08:25:35","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104661754","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-12-14 08:25:29","symbol":"BIOCON"},{"an_dt":"09-Dec-2020 15:22:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09122020152234_BBL_Allotment_122020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Further to our intimation dated November 7, 2020, in relation to execution of a Securities subscription agreement ( SSA ) and a shareholders  agreement ( SHA ) between Biocon Limited (the  Company ), Biocon Biologics Limited ( BBL ), existing investors of BBL and Goldman Sachs India AIF Scheme - 1, a scheme setup under Goldman Sachs India Alternative Investment Trust, acting through its investment manager, Goldman Sachs (India) Alternative Investment Management Private Limited (the  Investor ) as applicable, we wish to inform you that the subscription money aggregating to Rs. 1,125 Crores have been received by BBL from the Investor.Consequently, today the Board of BBL has approved the allotment of 1,125 Unlisted, Unsecured, Redeemable, Optionally Convertible Debentures (OCDs) at face value of Rs. 1,00,00,000 (Rupees One Crore) each aggregating to Rs. 1,125 Crores of BBL to the Investor.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:05","dt":"09122020152234","exchdisstime":"09-Dec-2020 15:22:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104655387","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-12-09 15:22:34","symbol":"BIOCON"},{"an_dt":"01-Dec-2020 17:50:40","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01122020175040_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"01122020175040","exchdisstime":"01-Dec-2020 17:50:43","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104640830","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-12-01 17:50:40","symbol":"BIOCON"},{"an_dt":"25-Nov-2020 21:09:59","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25112020210959_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:11","dt":"25112020210959","exchdisstime":"25-Nov-2020 21:10:10","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104633172","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-11-25 21:09:59","symbol":"BIOCON"},{"an_dt":"24-Nov-2020 11:22:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24112020112249_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"24112020112249","exchdisstime":"24-Nov-2020 11:22:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104630525","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-11-24 11:22:49","symbol":"BIOCON"},{"an_dt":"23-Nov-2020 15:07:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23112020150750_Hinduja_Energy_Stake_Acquisition_BioconLimited_Nov2020.pdf","attchmntText":"Biocon Limited has informed the Exchange about Acquisition","bflag":null,"csvName":null,"desc":"Acquisition","difference":"00:00:04","dt":"23112020150751","exchdisstime":"23-Nov-2020 15:07:55","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104628331","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-11-23 15:07:51","symbol":"BIOCON"},{"an_dt":"21-Nov-2020 21:17:05","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21112020211705_RPT_Disclosure_Biocon_AprToSept2020.pdf","attchmntText":"Biocon Limited has informed the Exchange about related Party Transactions","bflag":null,"csvName":null,"desc":"Related Party Transactions","difference":"00:00:03","dt":"21112020211705","exchdisstime":"21-Nov-2020 21:17:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104627182","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-11-21 21:17:05","symbol":"BIOCON"},{"an_dt":"20-Nov-2020 12:49:19","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20112020124919_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"20112020124919","exchdisstime":"20-Nov-2020 12:49:23","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104625477","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-11-20 12:49:19","symbol":"BIOCON"},{"an_dt":"17-Nov-2020 17:16:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17112020171629_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"17112020171629","exchdisstime":"17-Nov-2020 17:16:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104618643","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-11-17 17:16:29","symbol":"BIOCON"},{"an_dt":"13-Nov-2020 17:02:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13112020170256_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:02","dt":"13112020170256","exchdisstime":"13-Nov-2020 17:02:58","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104615589","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-11-13 17:02:56","symbol":"BIOCON"},{"an_dt":"11-Nov-2020 19:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11112020194800_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:09","dt":"11112020194800","exchdisstime":"11-Nov-2020 19:48:09","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104610292","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-11-11 19:48:00","symbol":"BIOCON"},{"an_dt":"09-Nov-2020 19:51:05","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09112020195105_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"09112020195105","exchdisstime":"09-Nov-2020 19:51:08","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104604909","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-11-09 19:51:05","symbol":"BIOCON"},{"an_dt":"07-Nov-2020 15:14:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07112020151451_SE_Intimation_BBL_Investment_GS_Nov2020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 07, 2020, titled \"Biocon Biologics Receives USD 150 MillionCapital Injection from Goldman Sachs, Transaction Values Biocon Biologics at USD 3.94 Billion\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:08","dt":"07112020151451","exchdisstime":"07-Nov-2020 15:14:59","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104603101","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-11-07 15:14:51","symbol":"BIOCON"},{"an_dt":"05-Nov-2020 16:03:15","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05112020160315_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"05112020160315","exchdisstime":"05-Nov-2020 16:03:21","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104598813","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-11-05 16:03:15","symbol":"BIOCON"},{"an_dt":"03-Nov-2020 21:25:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03112020212527_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"03112020212527","exchdisstime":"03-Nov-2020 21:25:31","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104593867","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-11-03 21:25:27","symbol":"BIOCON"},{"an_dt":"03-Nov-2020 11:52:40","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03112020115240_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"03112020115240","exchdisstime":"03-Nov-2020 11:52:45","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104593290","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-11-03 11:52:40","symbol":"BIOCON"},{"an_dt":"30-Oct-2020 11:34:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30102020113434_PressRelease_TopEmployer_Biocon_30102020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 30, 2020, titled \"Biocon Ranked Among Top 5 Biotech Employers Globally\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:08","dt":"30102020113434","exchdisstime":"30-Oct-2020 11:34:42","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104587900","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-10-30 11:34:34","symbol":"BIOCON"},{"an_dt":"28-Oct-2020 20:34:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28102020203433_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"28102020203433","exchdisstime":"28-Oct-2020 20:34:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104583621","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-10-28 20:34:33","symbol":"BIOCON"},{"an_dt":"23-Oct-2020 00:24:17","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23102020002417_PressRelease_Biocon_Q2FY21.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 22, 2020, titled \"Biocon Q2FY21 Revenue at Rs 1,760 Cr, Up 10%; EBITDA atRs 407 Cr; Net Profit (before exceptional item & discontinuing operations) at Rs 174 Cr; Generics Up 8% at Rs 599 Cr; Biosimilars Up 11% at Rs 676 Cr; Research Services Up 12% at Rs 520 Cr. \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:11","dt":"23102020002417","exchdisstime":"23-Oct-2020 00:24:28","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104574850","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-10-23 00:24:17","symbol":"BIOCON"},{"an_dt":"22-Oct-2020 23:54:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22102020235454_Outcome_Of_BM_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on October 22, 2020.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"00:00:05","dt":"22102020235454","exchdisstime":"22-Oct-2020 23:54:59","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104574300","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-10-22 23:54:54","symbol":"BIOCON"},{"an_dt":"22-Oct-2020 23:47:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Outcome_Of_BM_Biocon_22102020234702.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended September 30, 2020.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"00:01:59","dt":"22102020234702","exchdisstime":"22-Oct-2020 23:49:01","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"137219","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-10-22 23:47:02","symbol":"BIOCON"},{"an_dt":"13-Oct-2020 22:12:46","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13102020221245_Biocon_BM_Notice_Newspaper_Ad.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"00:00:04","dt":"13102020221246","exchdisstime":"13-Oct-2020 22:12:50","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104558144","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-10-13 22:12:46","symbol":"BIOCON"},{"an_dt":"13-Oct-2020 21:20:17","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13102020212017_Biocon_Reg74_ComplianceCertificate.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"00:00:05","dt":"13102020212017","exchdisstime":"13-Oct-2020 21:20:22","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104558108","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-10-13 21:20:17","symbol":"BIOCON"},{"an_dt":"08-Oct-2020 15:59:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08102020155929_PressRelease_BioconFoundation_BMRCL_08102020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 08, 2020, titled \"Biocon Foundation Signs MoU with Bangalore Metro to Contribute Towards Building Metro Station in Hebbagodi,\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:05","dt":"08102020155929","exchdisstime":"08-Oct-2020 15:59:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104551253","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-10-08 15:59:29","symbol":"BIOCON"},{"an_dt":"30-Sep-2020 21:03:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30092020210330_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"30092020210330","exchdisstime":"30-Sep-2020 21:03:35","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104539006","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-09-30 21:03:30","symbol":"BIOCON"},{"an_dt":"25-Sep-2020 19:20:17","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25092020192017_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"25092020192017","exchdisstime":"25-Sep-2020 19:20:20","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104531115","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-09-25 19:20:17","symbol":"BIOCON"},{"an_dt":"22-Sep-2020 20:30:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22092020203008_Intimation_appointment_CFO_Biocon_Sep2020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Appointment of Mr Anupam Jindal as Chief Financial Officer of the company w.e.f. September 22, 2020.","bflag":null,"csvName":null,"desc":"Appointment","difference":"00:00:05","dt":"22092020203008","exchdisstime":"22-Sep-2020 20:30:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104524563","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-09-22 20:30:08","symbol":"BIOCON"},{"an_dt":"21-Sep-2020 22:01:26","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21092020220126_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"21092020220126","exchdisstime":"21-Sep-2020 22:01:29","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104522443","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-09-21 22:01:26","symbol":"BIOCON"},{"an_dt":"18-Sep-2020 14:57:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18092020145727_Biocon_IR_BBIL_PPT_Sept_2020.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation on  Biocon Biologics Transforming Healthcare. Transforming Lives.","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"00:00:04","dt":"18092020145727","exchdisstime":"18-Sep-2020 14:57:31","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104519640","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-09-18 14:57:27","symbol":"BIOCON"},{"an_dt":"17-Sep-2020 11:05:39","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17092020110539_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"17092020110539","exchdisstime":"17-Sep-2020 11:05:45","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104517517","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-09-17 11:05:39","symbol":"BIOCON"},{"an_dt":"15-Sep-2020 18:28:50","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15092020182850_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"15092020182850","exchdisstime":"15-Sep-2020 18:28:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104513547","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-09-15 18:28:50","symbol":"BIOCON"},{"an_dt":"07-Sep-2020 21:59:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07092020215954_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"07092020215954","exchdisstime":"07-Sep-2020 21:59:57","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104499920","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-09-07 21:59:54","symbol":"BIOCON"},{"an_dt":"04-Sep-2020 21:27:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04092020212714_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"04092020212714","exchdisstime":"04-Sep-2020 21:27:19","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104497040","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-09-04 21:27:14","symbol":"BIOCON"},{"an_dt":"04-Sep-2020 00:42:32","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04092020004231_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:02","dt":"04092020004232","exchdisstime":"04-Sep-2020 00:42:34","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104495480","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-09-04 00:42:32","symbol":"BIOCON"},{"an_dt":"03-Sep-2020 21:11:41","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03092020211141_Allotment_BBIL.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Allotment of shares by Biocon Biologics India Limited (\"BBIL\") to Tata Capital Growth Fund II (\"the Investor\").'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:03","dt":"03092020211141","exchdisstime":"03-Sep-2020 21:11:44","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104494858","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-09-03 21:11:41","symbol":"BIOCON"},{"an_dt":"31-Aug-2020 15:33:04","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31082020153304_PressRelease_Biocon_BBIL_31082020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 31, 2020, titled \"Biocon Biologics and Mylan Announce Launch of Semglee  (insulin glargine injection) in the U.S. to Expand Access for Patients Living with Diabetes.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"00:00:03","dt":"31082020153304","exchdisstime":"31-Aug-2020 15:33:07","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104488285","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-08-31 15:33:04","symbol":"BIOCON"},{"an_dt":"21-Aug-2020 21:10:08","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21082020211008_Biocon_IntimationtoSEs_MOA_21082020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Amendment to MOA of the company.","bflag":null,"csvName":null,"desc":"Amendment to AOA/MOA","difference":"00:00:19","dt":"21082020211008","exchdisstime":"21-Aug-2020 21:10:27","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104473999","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-08-21 21:10:08","symbol":"BIOCON"},{"an_dt":"20-Aug-2020 13:17:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20082020131709_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:04","dt":"20082020131709","exchdisstime":"20-Aug-2020 13:17:13","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104471361","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-08-20 13:17:09","symbol":"BIOCON"},{"an_dt":"14-Aug-2020 18:20:29","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14082020182029_Impact_of_Covid19_Biocon_SEs_Intimation.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure pursuant to SEBI Circular No. SEBI/HO/CFD/CMD1 /CIR/P/2020/ 84 dated May 20, 2020 (\"SEBI Circular )   Impact of Covid-19 pandemic.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:03","dt":"14082020182029","exchdisstime":"14-Aug-2020 18:20:32","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104462203","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-08-14 18:20:29","symbol":"BIOCON"},{"an_dt":"14-Aug-2020 09:27:48","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14082020092748_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"14082020092748","exchdisstime":"14-Aug-2020 09:27:54","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104459761","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-08-14 09:27:48","symbol":"BIOCON"},{"an_dt":"12-Aug-2020 18:01:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12082020180102_Biocon_Intimation_to_SEs_PIT_12082020.pdf","attchmntText":"Biocon Limited has informed the Exchange about Code of Conduct under SEBI(PIT) Reg., 2015","bflag":null,"csvName":null,"desc":"Code of Conduct under SEBI(PIT) Reg., 2015","difference":"00:00:09","dt":"12082020180102","exchdisstime":"12-Aug-2020 18:01:11","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104456702","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-08-12 18:01:02","symbol":"BIOCON"},{"an_dt":"12-Aug-2020 12:35:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12082020123556_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:16","dt":"12082020123556","exchdisstime":"12-Aug-2020 12:36:12","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104456396","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-08-12 12:35:56","symbol":"BIOCON"},{"an_dt":"10-Aug-2020 22:32:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10082020223233_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:06","dt":"10082020223233","exchdisstime":"10-Aug-2020 22:32:39","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104452478","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-08-10 22:32:33","symbol":"BIOCON"},{"an_dt":"05-Aug-2020 22:59:31","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05082020225931_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:05","dt":"05082020225931","exchdisstime":"05-Aug-2020 22:59:36","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104445810","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-08-05 22:59:31","symbol":"BIOCON"},{"an_dt":"04-Aug-2020 20:45:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04082020204514_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"00:00:03","dt":"04082020204514","exchdisstime":"04-Aug-2020 20:45:17","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104443823","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-08-04 20:45:14","symbol":"BIOCON"},{"an_dt":"03-Aug-2020 19:12:13","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03082020191213_BBIL_SHA_SSA_Signed.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Execution of SHA and SSA with Tata Capital Growth Fund II - Disclosure pursuant to Regulation 30 of SEBI Regulations, 2015'.","bflag":null,"csvName":null,"desc":"Updates","difference":"00:00:08","dt":"03082020191213","exchdisstime":"03-Aug-2020 19:12:21","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104441603","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-08-03 19:12:13","symbol":"BIOCON"},{"an_dt":"31-Jul-2020 09:41:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31072020094136_biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange about Press release titled Press Rele  Tata Capital Growth Fund to Invest USD 30 Million i.e. Rs 225 Crore in Biocon Biologics for an Equity Stake of 0.85%, Deal Values Biocon Biologics at USD 3.5 Billion\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"31072020094100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104437850","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-07-31 09:41:00","symbol":"BIOCON"},{"an_dt":"25-Jul-2020 19:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25072020194239_VotingResults_AGM_Biocon_SE.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Annual General Meeting held on July 24, 2020. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"25072020194200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104427942","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-07-25 19:42:00","symbol":"BIOCON"},{"an_dt":"25-Jul-2020 13:52:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25072020135233_Biocon_AGM_Proceedings_July2020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 24, 2020","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"25072020135200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104427655","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-07-25 13:52:00","symbol":"BIOCON"},{"an_dt":"23-Jul-2020 23:32:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23072020233248_PressRelease_Biocon_Q1FY21.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 23, 2020, titled \"Biocon Q1FY21 Revenue Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit (from continuing ops) at Rs 153 Cr, Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr,\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"23072020233200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104424961","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-07-23 23:32:00","symbol":"BIOCON"},{"an_dt":"23-Jul-2020 23:10:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23072020231001_OutcomeOfBM_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on July 23, 2020.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"23072020231000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104424551","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-07-23 23:10:00","symbol":"BIOCON"},{"an_dt":"23-Jul-2020 23:05:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/OutcomeOfBM_Biocon_23072020230556.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended June 30, 2020.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"23072020230556","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"135179","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-07-23 23:05:56","symbol":"BIOCON"},{"an_dt":"21-Jul-2020 08:30:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21072020083057_PressRelease_Biocon_21072020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 21, 2020, titled \"Biocon Biologics and Voluntis Join Hands for Global Collaboration on Digital Therapeutics for Insulins\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21072020083000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104418110","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-07-21 08:30:00","symbol":"BIOCON"},{"an_dt":"11-Jul-2020 14:58:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11072020145842_PressRelease_Biocon_11072020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 11, 2020, titled \"Biocon s Breakthrough Drug Itolizumab Receives DCGI Nod for its Use in Moderate to Severe COVID-19 Patients\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"11072020145800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104402484","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-07-11 14:58:00","symbol":"BIOCON"},{"an_dt":"09-Jul-2020 18:13:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09072020181317_Certificate_Intimation_74_5__Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018","bflag":null,"csvName":null,"desc":"Certificate under SEBI (Depositories and Participants) Regulations, 2018","difference":"-","dt":"09072020181300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104399468","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-07-09 18:13:00","symbol":"BIOCON"},{"an_dt":"09-Jul-2020 18:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09072020180409_Biocon_BM_Newspaper_Ad.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"-","dt":"09072020180400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104399461","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-07-09 18:04:00","symbol":"BIOCON"},{"an_dt":"02-Jul-2020 16:07:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02072020160744_Intimation_VC_AGM_Post_02072020.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"-","dt":"02072020160700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104387128","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-07-02 16:07:00","symbol":"BIOCON"},{"an_dt":"02-Jul-2020 12:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02072020124854_Corrigendum_CoveringLetter_AGM.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Corrigendum to Notice of Annual General Meeting to be held on July 24, 2020","bflag":null,"csvName":null,"desc":"Corrigendum","difference":"-","dt":"02072020124800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104386649","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-07-02 12:48:00","symbol":"BIOCON"},{"an_dt":"01-Jul-2020 18:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01072020184815_Biocon_AGM_Notice_AnnualReport_2020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 24, 2020","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"01072020184800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104384870","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-07-01 18:48:00","symbol":"BIOCON"},{"an_dt":"30-Jun-2020 21:49:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30062020214905_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"30062020214900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104382217","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-30 21:49:00","symbol":"BIOCON"},{"an_dt":"26-Jun-2020 22:25:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26062020222557_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"26062020222500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104375353","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-26 22:25:00","symbol":"BIOCON"},{"an_dt":"26-Jun-2020 18:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26062020183347_Intimation_VC_AGM_Prior_26062020.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication - Newspaper Advertisement - Notice - 42nd Annual General Meeting of Biocon Limited to be held through video conference or other audio visual means and remote e-voting facility.","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"-","dt":"26062020183300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104375153","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-26 18:33:00","symbol":"BIOCON"},{"an_dt":"25-Jun-2020 22:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25062020220042_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"25062020220000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104372695","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-25 22:00:00","symbol":"BIOCON"},{"an_dt":"24-Jun-2020 18:50:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24062020185039_Intimation_IEPF_23062020.pdf","attchmntText":"Biocon Limited has informed the Exchange about Copy of Newspaper Publication","bflag":null,"csvName":null,"desc":"Copy of Newspaper Publication","difference":"-","dt":"24062020185000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104369910","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-24 18:50:00","symbol":"BIOCON"},{"an_dt":"22-Jun-2020 08:22:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22062020082231_Biocon_PR_22062020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 22, 2020, titled \"Biocon Pharma and DKSH Collaborate to commercialize seven generic formulations in South East Asia markets.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"22062020082200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104363364","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-22 08:22:00","symbol":"BIOCON"},{"an_dt":"18-Jun-2020 16:21:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18062020162120_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"18062020162100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104359674","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-18 16:21:00","symbol":"BIOCON"},{"an_dt":"15-Jun-2020 16:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15062020161211_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"15062020161200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104352441","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-15 16:12:00","symbol":"BIOCON"},{"an_dt":"12-Jun-2020 16:38:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12062020163825_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"12062020163800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104349596","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-12 16:38:00","symbol":"BIOCON"},{"an_dt":"12-Jun-2020 07:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12062020074243_Intimation_PR_12062020_updated.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 12, 2020, titled \" Biocon and Mylan Announce U.S. FDA Approval of Semglee  (insulin                   glargine injection) \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"12062020074200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104348404","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-12 07:42:00","symbol":"BIOCON"},{"an_dt":"11-Jun-2020 16:19:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11062020161942_Biocon_RPT_Disclosure.pdf","attchmntText":"Biocon Limited has informed the Exchange about related Party Transactions","bflag":null,"csvName":null,"desc":"Related Party Transactions","difference":"-","dt":"11062020161900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104347228","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-11 16:19:00","symbol":"BIOCON"},{"an_dt":"11-Jun-2020 16:10:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11062020161045_IR_PPT.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"11062020161000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104347225","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-11 16:10:00","symbol":"BIOCON"},{"an_dt":"11-Jun-2020 16:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11062020160422_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"11062020160400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104347219","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-11 16:04:00","symbol":"BIOCON"},{"an_dt":"09-Jun-2020 21:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09062020213352_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange about Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"09062020213300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104342050","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-09 21:33:00","symbol":"BIOCON"},{"an_dt":"08-Jun-2020 21:37:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08062020213721_IR_PPT.pdf","attchmntText":"Biocon Limited has informed the Exchange about Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"08062020213700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104339773","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-08 21:37:00","symbol":"BIOCON"},{"an_dt":"05-Jun-2020 17:03:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05062020170339_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"05062020170300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104337050","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-05 17:03:00","symbol":"BIOCON"},{"an_dt":"05-Jun-2020 16:58:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05062020165825_Intimation_PR_05062020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 05, 2020, titled \"Kiran Mazumdar-Shaw Wins EY World Entrepreneur of the Year  2020 Award She is the First Woman Entrepreneur from India and Third Indian to Win this Title in WEOY Award s 20-year History  \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"05062020165800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104337042","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-05 16:58:00","symbol":"BIOCON"},{"an_dt":"03-Jun-2020 21:23:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03062020212304_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"03062020212300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104332765","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-03 21:23:00","symbol":"BIOCON"},{"an_dt":"02-Jun-2020 16:53:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02062020165303_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"02062020165300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104330174","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-02 16:53:00","symbol":"BIOCON"},{"an_dt":"01-Jun-2020 20:54:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01062020205405_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"01062020205400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104328245","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-01 20:54:00","symbol":"BIOCON"},{"an_dt":"01-Jun-2020 08:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01062020081214_PressRelease_Biocon_01062020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 01, 2020, titled \"Biocon s* Partner Mylan Receives Favourable Ruling from U.S. PTAB on Sanofi s Four Device Patents for Lantus�� SoloSTAR��.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"01062020081200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104326555","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-06-01 08:12:00","symbol":"BIOCON"},{"an_dt":"29-May-2020 19:38:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29052020193850_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"29052020193800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104324935","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-29 19:38:00","symbol":"BIOCON"},{"an_dt":"27-May-2020 13:59:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27052020135935_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"27052020135900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104319395","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-27 13:59:00","symbol":"BIOCON"},{"an_dt":"27-May-2020 08:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27052020080015_PressRelease_Biocon_27052020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 27, 2020, titled \"Biocon Biologics Receives DCGI Approval for Emergency Use of CytoSorb�� to Treat Critical COVID-19 Patients.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"27052020080000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104318348","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-27 08:00:00","symbol":"BIOCON"},{"an_dt":"21-May-2020 19:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21052020194855_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"21052020194800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104312050","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-21 19:48:00","symbol":"BIOCON"},{"an_dt":"20-May-2020 16:56:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20052020165624_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"20052020165600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104309701","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-20 16:56:00","symbol":"BIOCON"},{"an_dt":"19-May-2020 18:03:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19052020180315_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"19052020180300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104307415","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-19 18:03:00","symbol":"BIOCON"},{"an_dt":"19-May-2020 08:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19052020081224_Biocon_PressRelease_19052020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 19, 2020, titled \"Biocon Biologics Receives EU GMP Certification for Multiple Biosimilars Manufacturing Facilities in Bengaluru; Expands its Manufacturing Capacity\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"19052020081200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104306267","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-19 08:12:00","symbol":"BIOCON"},{"an_dt":"14-May-2020 23:39:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14052020233956_Appointment_Biocon_CFO_14052020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Appointment of Interim Chief Financial Officer ( Interim CFO ) and Key Managerial Personnel of the Company.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"14052020233900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104299966","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-14 23:39:00","symbol":"BIOCON"},{"an_dt":"14-May-2020 23:35:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14052020233539_PressRelease_BioconLimited_14052020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 14, 2020, titled \"Press Release on financial results for the quarter and year ended March 31, 2020.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"14052020233500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104299965","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-14 23:35:00","symbol":"BIOCON"},{"an_dt":"14-May-2020 23:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14052020230059_Outocome_of_BoardMeeting_Biocon_14052020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on May 14, 2020.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"14052020230000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104299964","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-14 23:00:00","symbol":"BIOCON"},{"an_dt":"14-May-2020 22:58:30","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Outocome_of_BoardMeeting_Biocon_14052020_14052020225830.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended March 31, 2020.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"14052020225830","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"133744","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-14 22:58:30","symbol":"BIOCON"},{"an_dt":"12-May-2020 08:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12052020082016_Intimation_12052020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 12, 2020, titled \"Biocon Biologics Drug Substance Facilities in Bengaluru Receive EU GMP Certification \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"12052020082000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104291745","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-12 08:20:00","symbol":"BIOCON"},{"an_dt":"08-May-2020 08:46:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08052020084635_Intimation_08052020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon's Receives EIR for Small Molecules API Manufacturing Facility for Pre -Approval and GMP U.S. FDA Inspection'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"08052020084600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104287279","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-08 08:46:00","symbol":"BIOCON"},{"an_dt":"07-May-2020 10:39:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07052020103908_KMS_Reg31_SEBI_SAST.pdf","attchmntText":"Promoter of Biocon Limited has informed the Exchange regarding Declaration under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"-","dt":"07052020103900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104284989","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-05-07 10:39:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2020 16:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042020162859_PressRelease_Biocon_28042020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 28, 2020, titled \"Biocon and Mylan Launch Fulphila��, Biosimilar Pegfilgrastim, in Canada.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"28042020162800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104271039","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-04-28 16:28:00","symbol":"BIOCON"},{"an_dt":"22-Apr-2020 08:46:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22042020084659_BIOCON_30.pdf","attchmntText":"Promoters of Biocon Limited has informed the Exchange regarding the disclosure pursuant to the provisions of Regulation 30 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as at 31st March, 2020","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"-","dt":"22042020084600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104256865","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-04-22 08:46:00","symbol":"BIOCON"},{"an_dt":"20-Apr-2020 22:07:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20042020220724_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"20042020220700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104254230","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-04-20 22:07:00","symbol":"BIOCON"},{"an_dt":"16-Apr-2020 08:11:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16042020081142_Intimation_16042020_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement - Biocon Biologics Receives EIR from U.S. FDA for Two Manufacturing Facilities, Inspection Stands Closed'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"16042020081100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104246509","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-04-16 08:11:00","symbol":"BIOCON"},{"an_dt":"15-Apr-2020 11:47:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15042020114705_BIOCON_30.pdf","attchmntText":"Promoters and Promoters Group of Biocon Limited has informed the Exchange regarding the disclosure pursuant to the provisions of Regulation 30 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as at 31st March, 2020","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"-","dt":"15042020114700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104242997","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-04-15 11:47:00","symbol":"BIOCON"},{"an_dt":"14-Apr-2020 08:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14042020082419_PressRelease_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 14, 2020, titled \"Biocon and Mylan Launch Fulphila��, Biosimilar Pegfilgrastim, in Australia\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"14042020082400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104243616","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-04-14 08:24:00","symbol":"BIOCON"},{"an_dt":"13-Apr-2020 22:15:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13042020221544_Biocon_Reg74_5__SE_April2020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2020'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"13042020221500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104242072","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-04-13 22:15:00","symbol":"BIOCON"},{"an_dt":"08-Apr-2020 20:55:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08042020205530_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"08042020205500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104234794","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-04-08 20:55:00","symbol":"BIOCON"},{"an_dt":"01-Apr-2020 22:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01042020222019_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"01042020222000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104227195","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-04-01 22:20:00","symbol":"BIOCON"},{"an_dt":"01-Apr-2020 08:06:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01042020080634_Intimation_01042020_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement - Biocon s Insulin Manufacturing Facility in Malaysia Receives EIR from U.S. FDA with Voluntary Action Indicated (VAI) Classification, Inspection Stands Closed'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"01042020080600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104225202","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-04-01 08:06:00","symbol":"BIOCON"},{"an_dt":"27-Mar-2020 08:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27032020081609_Intimation_PR_27032020_BIOCON.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 27, 2020, titled \"Biocon & Biocon Biologics Ensuring Manufacturing of Life-Saving Medicines for Patients, Partners and Customers.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"27032020081600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104215045","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-03-27 08:16:00","symbol":"BIOCON"},{"an_dt":"20-Mar-2020 08:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20032020082854_Biocon_Intimation_20032020_.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement - Biocon Receives EIR for Small Molecules API Manufacturing Facility for Post -Approval and GMP U.S. FDA Inspection.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"20032020082800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104200260","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-03-20 08:28:00","symbol":"BIOCON"},{"an_dt":"12-Mar-2020 17:38:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12032020173849_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"12032020173800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104184731","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-03-12 17:38:00","symbol":"BIOCON"},{"an_dt":"11-Mar-2020 16:49:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11032020164935_PressRelease_11032020_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 11, 2020, titled \"Biocon & Mylan Win Patent Litigation Asserted by Sanofi for Insulin Glargine Device Patent in U.S. \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"11032020164900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104182259","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-03-11 16:49:00","symbol":"BIOCON"},{"an_dt":"09-Mar-2020 17:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09032020172006_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"09032020172000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104178702","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-03-09 17:20:00","symbol":"BIOCON"},{"an_dt":"09-Mar-2020 08:25:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09032020082541_PressRelease_09032020_Biocon.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 09, 2020, titled \"U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"09032020082500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104176929","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-03-09 08:25:00","symbol":"BIOCON"},{"an_dt":"06-Mar-2020 18:27:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06032020182701_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"06032020182700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104175279","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-03-06 18:27:00","symbol":"BIOCON"},{"an_dt":"27-Feb-2020 08:19:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27022020081941_Intimation_Statement_Biocon_27022020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement - Biocon's Small Molecules API Manufacturing Facility Completes Post -Approval and GMP U.S. FDA Inspection'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"27022020081900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104154128","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-02-27 08:19:00","symbol":"BIOCON"},{"an_dt":"26-Feb-2020 16:34:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26022020163440_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"26022020163400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104153254","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-02-26 16:34:00","symbol":"BIOCON"},{"an_dt":"22-Feb-2020 12:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22022020124306_Intimation_Statement_Biocon_22022020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Company Statement - Biocon's Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"22022020124300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104145252","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-02-22 12:43:00","symbol":"BIOCON"},{"an_dt":"19-Feb-2020 18:21:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19022020182146_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"19022020182100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104142210","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-02-19 18:21:00","symbol":"BIOCON"},{"an_dt":"17-Feb-2020 17:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17022020171209_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"17022020171200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104135844","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-02-17 17:12:00","symbol":"BIOCON"},{"an_dt":"12-Feb-2020 12:56:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12022020125618_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"12022020125600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104124339","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-02-12 12:56:00","symbol":"BIOCON"},{"an_dt":"10-Feb-2020 17:19:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10022020171919_IR_Presentation_10022020.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"10022020171900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104117254","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-02-10 17:19:00","symbol":"BIOCON"},{"an_dt":"07-Feb-2020 20:05:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07022020200527_Merger_BRL_BBIL_SEs_07022020.pdf","attchmntText":"Biocon Limited has informed the Exchange about Amalgamation/Merger","bflag":null,"csvName":null,"desc":"Amalgamation/Merger","difference":"-","dt":"07022020200500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104114047","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-02-07 20:05:00","symbol":"BIOCON"},{"an_dt":"30-Jan-2020 17:58:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30012020175838_InvestorMeeting.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"30012020175800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104091322","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-30 17:58:00","symbol":"BIOCON"},{"an_dt":"27-Jan-2020 17:57:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_27012020175722_Biocon_Financials_SEs_Intimation_27012020_253.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Newspaper Advertisement - Q3 FY20 Financial Results'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"27012020175700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104082874","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-27 17:57:00","symbol":"BIOCON"},{"an_dt":"27-Jan-2020 09:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27012020090415_Intimation_013.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon's API Manufacturing Facility Completes Pre-Approval and GMP U.S. FDA inspection '.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"27012020090400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104081193","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-27 09:04:00","symbol":"BIOCON"},{"an_dt":"23-Jan-2020 20:39:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_23012020203907_ChangeInDirectorate_Biocon_Jan23_2020_317.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"-","dt":"23012020203900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104076396","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-23 20:39:00","symbol":"BIOCON"},{"an_dt":"23-Jan-2020 19:57:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_23012020195713_Materiality_Policy_ChangeInKMPs_304.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Change In Key Managerial Personnel (\"KMPs\") For Determination Of Materiality for Disclosures'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"23012020195700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104076369","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-23 19:57:00","symbol":"BIOCON"},{"an_dt":"23-Jan-2020 19:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_23012020192036_Press_Release_Biocon_Jan23012020_294.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 23, 2020, titled \"Press Release on Q3 FY20 Financial Results\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"23012020192000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104076357","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-23 19:20:00","symbol":"BIOCON"},{"an_dt":"23-Jan-2020 18:36:49","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/OutcomeOfBM_Biocon_Jan23012020_23012020183649.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended December 31, 2019.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"23012020183649","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"132083","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-23 18:36:49","symbol":"BIOCON"},{"an_dt":"23-Jan-2020 18:29:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_23012020182857_OutcomeOfBM_Biocon_Jan23012020_262.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on January 23, 2020.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"23012020182900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104076324","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-23 18:29:00","symbol":"BIOCON"},{"an_dt":"21-Jan-2020 19:13:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_21012020191339_BBIL_TrueNorth_Allotment_21012020_280.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Allotment Of Shares By Biocon Biologics India Limited (\"BBIL\") To Activ Pine LLP (An Affiliate Of True North Fund VI LLP)'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"21012020191300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104069928","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-21 19:13:00","symbol":"BIOCON"},{"an_dt":"20-Jan-2020 08:40:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_20012020084041_CompanyStatement_20012020_010.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon's Oral Solid Dosage Manufacturing Facility Completes Pre-Approval U.S. FDA inspection with Zero Observations.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"20012020084000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104065315","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-20 08:40:00","symbol":"BIOCON"},{"an_dt":"10-Jan-2020 20:03:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_10012020200331_ComplianceCertificate_Reg74_271.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Compliance Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended December 31, 2019.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"10012020200300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104047822","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-10 20:03:00","symbol":"BIOCON"},{"an_dt":"09-Jan-2020 17:32:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_09012020173150_BBIL_TrueNorth_SHA_SSA_Signed_Biocon_219.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Disclosure Under Regulation 30 Of The SEBI Listing Regulations - Execution Of SHA And SSA'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"09012020173200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104044520","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-09 17:32:00","symbol":"BIOCON"},{"an_dt":"06-Jan-2020 19:30:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_06012020193003_BBIL_CFO_Appointment_PR_BIOCON_300.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 06, 2020, titled \"Biocon Biologics Appoints M.B. Chinappa as Chief Financial Officer\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"06012020193000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104034852","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-06 19:30:00","symbol":"BIOCON"},{"an_dt":"06-Jan-2020 19:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_06012020192333_NewspaperAdvertisement_Biocon_299.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notice of Board Meeting - Newspaper Advertisement '.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"06012020192400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104034849","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-06 19:24:00","symbol":"BIOCON"},{"an_dt":"06-Jan-2020 14:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_06012020144739_PressRelease_Biocon_06012020_134.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 06, 2020, titled \"True North to Invest Rs. 536.25 Crore in Biocon Biologics for 2.44% Stake\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"06012020144800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104034676","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2020-01-06 14:48:00","symbol":"BIOCON"},{"an_dt":"26-Dec-2019 16:34:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_26122019163430_Incorporation_of_BBL_Covering_Letter_082.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Intimation for Incorporation of Biocon Biosphere Limited, Wholly Owned Subsidiary of the Company.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"26122019163400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104011939","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-26 16:34:00","symbol":"BIOCON"},{"an_dt":"13-Dec-2019 17:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_13122019174407_IntimationtoSE_200.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"13122019174400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103986075","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-13 17:44:00","symbol":"BIOCON"},{"an_dt":"12-Dec-2019 17:39:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_12122019173929_PressRelease_11122019_Biocon_208.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 12, 2019, titled \"Biocon & Equillium Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"12122019173900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103982900","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-12 17:39:00","symbol":"BIOCON"},{"an_dt":"12-Dec-2019 15:31:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_12122019153044_InvestorMeeting_110.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"12122019153100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103982819","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-12 15:31:00","symbol":"BIOCON"},{"an_dt":"12-Dec-2019 15:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_12122019152824_RTA_Name_Change_BIOCON_108.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Change in name of Company s Registrar and Share Transfer Agent '.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"12122019152800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103982817","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-12 15:28:00","symbol":"BIOCON"},{"an_dt":"11-Dec-2019 17:08:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_11122019170757_IR_Presentation_Final_216.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"11122019170800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103979687","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-11 17:08:00","symbol":"BIOCON"},{"an_dt":"11-Dec-2019 16:59:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_11122019165859_InvestorMeeting_209.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"11122019165900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103979679","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-11 16:59:00","symbol":"BIOCON"},{"an_dt":"10-Dec-2019 18:54:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_10122019185437_InvestorMeeting_324.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"10122019185400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103976526","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-10 18:54:00","symbol":"BIOCON"},{"an_dt":"06-Dec-2019 16:54:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_06122019165442_InvestorMeeting_172.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"06122019165400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103970004","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-06 16:54:00","symbol":"BIOCON"},{"an_dt":"05-Dec-2019 15:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_05122019151631_InvestorMeeting_151.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"05122019151600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103967259","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-05 15:16:00","symbol":"BIOCON"},{"an_dt":"04-Dec-2019 17:15:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_04122019171450_InvestorMeeting_210.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"04122019171500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103964648","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-04 17:15:00","symbol":"BIOCON"},{"an_dt":"03-Dec-2019 16:32:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_03122019163151_PR03122019ii_200.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 03, 2019, titled \"Biocon Biologics Takes Forward Its Mission to Unlock Universal Access to Insulins Globally\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"03122019163200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103961944","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-03 16:32:00","symbol":"BIOCON"},{"an_dt":"03-Dec-2019 11:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_03122019111559_PR3122019_039.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 03, 2019, titled \"Siddharth Mittal Takes Over as CEO and Joint Managing Director of Biocon Limited\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"03122019111600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103961801","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-03 11:16:00","symbol":"BIOCON"},{"an_dt":"02-Dec-2019 17:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_02122019173341_Biocon_PR_380.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 02, 2019, titled \"Biocon and Mylan Launch Trastuzumab Biosimilar, Ogivri  (trastuzumab-dkst), in the U.S.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"02122019173300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103959250","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-12-02 17:33:00","symbol":"BIOCON"},{"an_dt":"28-Nov-2019 17:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_28112019174416_InvestorMeeting_207.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"28112019174400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103953075","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-11-28 17:44:00","symbol":"BIOCON"},{"an_dt":"27-Nov-2019 08:31:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_27112019082943_PressRelease_Biocon_27112019_003.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 27, 2019, titled \"USFDA Approves Biocon s sBLA for Pegfilgrastim New Manufacturing Facility \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"27112019083100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103948210","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-11-27 08:31:00","symbol":"BIOCON"},{"an_dt":"21-Nov-2019 17:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_21112019165955_InvestorMeeting_186.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"21112019170000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103936519","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-11-21 17:00:00","symbol":"BIOCON"},{"an_dt":"21-Nov-2019 15:46:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract1_21112019154233_Biocon_RPT_Disclosure_145.pdf","attchmntText":"Biocon Limited has submitted to the Exchange a copy of Disclosure of Related Party Transactions for the half year ended September 30, 2019 pursuant to Regulation 23(9) of SEBI Listing Regulations.","bflag":null,"csvName":null,"desc":"Related Party Transactions","difference":"-","dt":"21112019154600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103936481","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-11-21 15:46:00","symbol":"BIOCON"},{"an_dt":"18-Nov-2019 19:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_18112019191517_PR_18112019_427.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 18, 2019, titled \"Kiran Mazumdar-Shaw Conferred with Lifetime Achievement Award by Indian Council of Medical Research\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18112019191600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103926979","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-11-18 19:16:00","symbol":"BIOCON"},{"an_dt":"12-Nov-2019 15:51:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_12112019155117_PR_Biocon_133.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 12, 2019, titled \"Biocon Features in the Prestigious ASIA IP ELITE List for the Fourth Consecutive Year\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"12112019155100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103915131","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-11-12 15:51:00","symbol":"BIOCON"},{"an_dt":"12-Nov-2019 15:15:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_12112019151539_InvestorMeeting_109.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"12112019151500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103915107","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-11-12 15:15:00","symbol":"BIOCON"},{"an_dt":"07-Nov-2019 11:29:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/zrizvi_07112019112854_Dr_Jeremy_Levin_Resignation_BIOCON_046.pdf","attchmntText":"BIOCON: The Exchange had sought clarification from Biocon Limited with respect to announcement dated 23-Oct-2019, regarding change in Director(s) of the company. On basis of above the Company was required to clarify following: 1. Confirmation from resigning independent director that there is no other material reasons other than provided. The response of the Company is attached.","bflag":null,"csvName":null,"desc":"Reply to Clarification Sought","difference":"-","dt":"07112019112900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103906119","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-11-07 11:29:00","symbol":"BIOCON"},{"an_dt":"07-Nov-2019 10:57:00","attFileSize":null,"attchmntFile":"-","attchmntText":"BIOCON: The Exchange has sought clarification from Biocon Limited with respect to announcement dated 23-Oct-2019, regarding change in Director(s) of the company. On basis of above the Company is required to clarify following: 1. Confirmation from resigning independent director that there is no other material reasons other than provided. The response of the Company is awaited.","bflag":null,"csvName":null,"desc":"Clarification","difference":"-","dt":"07112019105700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103905989","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-11-07 10:57:00","symbol":"BIOCON"},{"an_dt":"05-Nov-2019 17:13:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_05112019171316_InvestorMeeting_342.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"05112019171300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103900100","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-11-05 17:13:00","symbol":"BIOCON"},{"an_dt":"05-Nov-2019 08:34:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_05112019083421_PressRelease_Biocon_Nov2019_004.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 05, 2019, titled \"Biocon s Biologics Drug Products Facility in Bengaluru Receives EIR from U.S. FDA.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"05112019083400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103894186","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-11-05 08:34:00","symbol":"BIOCON"},{"an_dt":"31-Oct-2019 18:19:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_31102019181921_InvestorMeeting_314.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"31102019181900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103887332","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-10-31 18:19:00","symbol":"BIOCON"},{"an_dt":"28-Oct-2019 16:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28102019161909_PressRelease_025.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 28, 2019, titled \" Biocon Moves Up to Rank No. 6 on Science Careers  Top 20 Global Pharma & Biotech Employers List 2019 .\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"28102019162000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103880089","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-10-28 16:20:00","symbol":"BIOCON"},{"an_dt":"25-Oct-2019 16:58:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_25102019165846_Biocon_Financials_Ad_SE_279.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Newspaper Advertisement - Financial Results for the quarter and half year ended September 30, 2019.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"25102019165800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103878567","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-10-25 16:58:00","symbol":"BIOCON"},{"an_dt":"24-Oct-2019 16:35:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24102019163515_Dr_Jeremy_Levin_Resignation_BIOCON_238.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"-","dt":"24102019163500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103875820","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-10-24 16:35:00","symbol":"BIOCON"},{"an_dt":"23-Oct-2019 19:19:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_23102019191924_Press_Release_Biocon_393.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 23, 2019, titled \"Biocon Q2FY20 Earnings, Revenue at Rs. 1,611 Cr, Up 17 %; EBITDA at Rs. 441 Cr, Up 12%; Net Profit (excluding exceptional item) at Rs. 189 Cr, Up 3%\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"23102019191900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103872603","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-10-23 19:19:00","symbol":"BIOCON"},{"an_dt":"23-Oct-2019 19:17:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_23102019191659_Change_In_Directorate_BIOCON_392.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"-","dt":"23102019191700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103872602","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-10-23 19:17:00","symbol":"BIOCON"},{"an_dt":"23-Oct-2019 18:23:10","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/OutcomeOfBM_BIOCON_23102019182310.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended September 30, 2019.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"23102019182310","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"130313","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-10-23 18:23:10","symbol":"BIOCON"},{"an_dt":"23-Oct-2019 18:17:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_23102019181551_OutcomeOfBM_BIOCON_354.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on October 23, 2019.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"23102019181700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103872554","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-10-23 18:17:00","symbol":"BIOCON"},{"an_dt":"10-Oct-2019 17:31:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_10102019173055_Compliance_Certificate_Reg74_210.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2019'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"10102019173100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103847344","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-10-10 17:31:00","symbol":"BIOCON"},{"an_dt":"10-Oct-2019 17:18:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_10102019171800_Newspaper_BM_Notice_201.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notice of Board Meeting - Newspaper Advertisement '.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"10102019171800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103847333","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-10-10 17:18:00","symbol":"BIOCON"},{"an_dt":"10-Oct-2019 15:54:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_10102019155359_PressRelease_Biocon_10102019_150.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 10, 2019, titled \"Biocon Biologics & Just - Evotec Biologics Sign Licensing Deal for a Biosimilar Asset\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"10102019155400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103847281","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-10-10 15:54:00","symbol":"BIOCON"},{"an_dt":"03-Oct-2019 08:36:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03102019083557_Pressrelease3Oct2019_003.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 03, 2019, titled \"Biocon and Mylan Launch First Insulin Glargine Biosimilar, Semglee��, in Australia\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"03102019083600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103832816","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-10-03 08:36:00","symbol":"BIOCON"},{"an_dt":"01-Oct-2019 12:35:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01102019123457_InvestorMeeting_160.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"01102019123500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103831392","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-10-01 12:35:00","symbol":"BIOCON"},{"an_dt":"27-Sep-2019 18:13:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27092019181300_InvestorMeeting_515.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"27092019181300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103823720","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-27 18:13:00","symbol":"BIOCON"},{"an_dt":"25-Sep-2019 12:06:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/apandit_24092019200725_BIOCON_8482_reply_041.pdf","attchmntText":"The Exchange has sought clarification from Biocon Limited with respect to recent news item captioned Temasek, True North and CPPIB in investment talks for stake in Biocon arm: Report.  The response from the Company is attached.","bflag":null,"csvName":null,"desc":"News Verification","difference":"-","dt":"25092019120600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103815331","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-25 12:06:00","symbol":"BIOCON"},{"an_dt":"24-Sep-2019 16:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_24092019161242_Biocon_IR_meeting_Sept_24_131.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"24092019161200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103813474","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-24 16:12:00","symbol":"BIOCON"},{"an_dt":"24-Sep-2019 08:45:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_24092019084457_Biocon_Announcement_Sept_24_2019_004.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 24, 2019, titled \"Biocon Biologics Expands its R&D Footprint Through Acqusition.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"24092019084500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103811649","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-24 08:45:00","symbol":"BIOCON"},{"an_dt":"20-Sep-2019 18:54:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_20092019185406_Intimation_248.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'U.S. FDA Completes Pre-Approval Inspection of Two New Biocon Biologics Facilities in Bengaluru'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"20092019185400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103807140","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-20 18:54:00","symbol":"BIOCON"},{"an_dt":"19-Sep-2019 19:26:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_19092019192642_InvestorMeeting_230.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"19092019192600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103804429","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-19 19:26:00","symbol":"BIOCON"},{"an_dt":"12-Sep-2019 18:47:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_12092019184748_BioconPressRelease_134.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 12, 2019, titled \"Biocon Licenses Three Generic Formulation Products to China Medical System Holdings\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"12092019184700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103788891","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-12 18:47:00","symbol":"BIOCON"},{"an_dt":"12-Sep-2019 18:18:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12092019181825_InvestorMeeting_117.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"12092019181800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103788874","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-12 18:18:00","symbol":"BIOCON"},{"an_dt":"11-Sep-2019 17:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11092019171613_InvestorMeeting_210.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"11092019171600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103786069","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-11 17:16:00","symbol":"BIOCON"},{"an_dt":"11-Sep-2019 17:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11092019170421_IRPPT_205.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Investor Presentation_Revised","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"11092019170400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103786064","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-11 17:04:00","symbol":"BIOCON"},{"an_dt":"10-Sep-2019 19:50:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10092019195009_InvestorMeeting_152.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"10092019195000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103784400","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-10 19:50:00","symbol":"BIOCON"},{"an_dt":"09-Sep-2019 11:41:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09092019114109_IRPPT_127.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"09092019114100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103782158","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-09 11:41:00","symbol":"BIOCON"},{"an_dt":"06-Sep-2019 17:55:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06092019175538_InvestorMeeting_363.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"06092019175500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103778655","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-06 17:55:00","symbol":"BIOCON"},{"an_dt":"04-Sep-2019 17:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04092019172045_InvestorMeeting_318.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"04092019172000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103771737","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-09-04 17:20:00","symbol":"BIOCON"},{"an_dt":"31-Aug-2019 11:34:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31082019113427_Intimation_015.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'U.S. FDA Issues Complete Response Letter for New Drug Application for Insulin Glargine; Commercialization Plans Remain Unchanged  ��The U.S. FDA has issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for Insulin Glargine filed by our partner Mylan. The CRL has been issued pending completion of the Corrective And Preventive Actions (CAPAs) submitted to the U.S. FDA in response to the observations made at the conclusion of the pre-approval inspection of our insulin manufacturing facility in Malaysia in June 2019.   The CRL did not identify any outstanding scientific issues with the application. We remain confident of the quality of our application and do not anticipate any impact of this CRL on the commercial launch timing of our Insulin Glargine in the U.S. We remain committed to global standards of Quality & Compliance and are working closely with our Partner and the regulator to complete these CAPAs to the satisfaction of the U.S. FDA.��U.S. FDA completes surveillance (routine) cGMP inspection of one of our Biologics Drug Product facilities in Bengaluru ��The U.S. FDA conducted a cGMP inspection at one of our Biologics Drug Product facilities in Bengaluru from Aug 22 to Aug 30, 2019. The inspection concluded with four observations which we believe will not impact supplies from this facility. We are confident of addressing these observations through a Corrective and Preventive Action plan in a timely manner.��'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"31082019113400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103765773","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-08-31 11:34:00","symbol":"BIOCON"},{"an_dt":"29-Aug-2019 12:03:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_29082019120247_InvestorMeeting_041.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"29082019120300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103760636","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-08-29 12:03:00","symbol":"BIOCON"},{"an_dt":"27-Aug-2019 20:07:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27082019200713_InvestorMeeting_388.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"27082019200700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103754133","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-08-27 20:07:00","symbol":"BIOCON"},{"an_dt":"22-Aug-2019 16:35:00","attFileSize":null,"attchmntFile":"-","attchmntText":"The Exchange has sought clarification from Biocon Limited with respect to recent news item captioned Temasek, True North and CPPIB in investment talks for stake in Biocon arm: Report.  The response from the Company is awaited.","bflag":null,"csvName":null,"desc":"News Verification","difference":"-","dt":"22082019163500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103744765","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-08-22 16:35:00","symbol":"BIOCON"},{"an_dt":"22-Aug-2019 08:19:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22082019081858_PressRelease22Aug2019_001.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 22, 2019, titled \"��Biocon��s Malaysia Insulin Glargine Manufacturing Facility Receives EU GMP Certification, Provides Fillip to its Capacity��.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"22082019081900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103742894","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-08-22 08:19:00","symbol":"BIOCON"},{"an_dt":"21-Aug-2019 20:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21082019200405_InvestorMeeting_421.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"21082019200400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103742178","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-08-21 20:04:00","symbol":"BIOCON"},{"an_dt":"13-Aug-2019 17:55:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13082019175524_InvestorMeeting_071.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"13082019175500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103725751","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-08-13 17:55:00","symbol":"BIOCON"},{"an_dt":"08-Aug-2019 15:05:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_08082019150544_InvestorMeeting_200.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"08082019150500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103716984","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-08-08 15:05:00","symbol":"BIOCON"},{"an_dt":"03-Aug-2019 12:11:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03082019121142_Intimation_028.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Pursuant to Regulation 30(6) of the SEBI Listing Regulations, we hereby inform you that the following meetings were conducted with Institutional Investors/ Analysts:Sl. Date Name Type of Meeting Location1.  August 1, 2019 Arohi Asset Management Teleconference Bengaluru2.  August 2, 2019 Mission Holdings Teleconference Bengaluru The above information will also be available on the website of the Company at www.biocon.comWe request you to kindly take above intimation on record.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"03082019121100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103703499","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-08-03 12:11:00","symbol":"BIOCON"},{"an_dt":"01-Aug-2019 13:27:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_01082019132657_PressRelease_Mylan_Biocon_01082019_160.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 01, 2019, titled \"Mylan and Biocon Launch First Trastuzumab Biosimilar, Ogivri��, in Australia\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"01082019132700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103697983","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-08-01 13:27:00","symbol":"BIOCON"},{"an_dt":"31-Jul-2019 13:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_31072019132423_Investor_meeting_095.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"31072019132400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103694357","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-07-31 13:24:00","symbol":"BIOCON"},{"an_dt":"31-Jul-2019 13:22:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_31072019132206_CoveringLetter_Biocon_Directorate_092.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"-","dt":"31072019132200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103694354","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-07-31 13:22:00","symbol":"BIOCON"},{"an_dt":"30-Jul-2019 17:09:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30072019170913_InvestorMeeting_286.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"30072019170900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103690894","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-07-30 17:09:00","symbol":"BIOCON"},{"an_dt":"27-Jul-2019 17:21:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_27072019172127_VotingResutls_AGM_Biocon_Proceedings_097.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 26, 2019. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"27072019172100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103686001","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-07-27 17:21:00","symbol":"BIOCON"},{"an_dt":"25-Jul-2019 18:59:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_25072019185932_PressRelease_Biocon_336.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 25, 2019, titled \"Biocon Q1FY20 Revenue Rs 1,490 Cr, Up 25%;EBITDA Up 51% at Rs 462 Cr;Net Profit (excluding exceptional item) Up 86% at Rs 223 CrSmall Molecules up 20% at Rs 480 Cr, Biologics Up 96% at Rs 490 Cr\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25072019185900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103681398","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-07-25 18:59:00","symbol":"BIOCON"},{"an_dt":"25-Jul-2019 18:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25072019184200_Appointment_CS_Biocon_315.pdf","attchmntText":"Biocon Limited has informed the Exchange about appointment of Mr. Mayank Verma as Company Secretary and Compliance Officer of the Company","bflag":null,"csvName":null,"desc":"Change in Company Secretary/Compliance Officer","difference":"-","dt":"25072019184200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103681381","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-07-25 18:42:00","symbol":"BIOCON"},{"an_dt":"25-Jul-2019 18:26:51","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/OutcomeOfBM_Biocon_25072019182651.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended June 30, 2019.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"25072019182651","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"128634","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-07-25 18:26:51","symbol":"BIOCON"},{"an_dt":"25-Jul-2019 18:19:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_25072019181924_OutcomeOfBM_Biocon_302.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on July 25, 2019.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"25072019181900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103681366","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-07-25 18:19:00","symbol":"BIOCON"},{"an_dt":"08-Jul-2019 08:17:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08072019081705_Intimation_018.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding '��This is to inform you that Biocon Sdn Bhd��s Insulin Glargine Drug Substance, Drug Product and Device assembly facilities in Malaysia underwent a pre-approval inspection by the U.S. FDA between June 24 and July 5, 2019. The inspection across these 3 units concluded with 12 observations issued on the Form 483. We will respond to the FDA with a Corrective and Preventive Action Plan and are confident of addressing these observations expeditiously.  We do not expect any change to our commercialization plans for Insulin glargine in the U.S. Biocon remains committed to global standards of Quality and Compliance.��- Company Spokesperson'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"08072019081700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103635124","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-07-08 08:17:00","symbol":"BIOCON"},{"an_dt":"04-Jul-2019 19:51:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract3_47201919235_Biocon_Dividend_Updates_311.pdf","attchmntText":"Biocon Limited has informed the Exchange that the Board at its meeting held on April 25, 2019 had recommended a pre-bonus final dividend of Rs. 1/-per equity share of face value of Rs. 5/-each for the approval of the members at the ensuing AGM.","bflag":null,"csvName":null,"desc":"Dividend Updates","difference":"-","dt":"04072019195100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103630958","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-07-04 19:51:00","symbol":"BIOCON"},{"an_dt":"04-Jul-2019 12:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_04072019124300_BM_News_061.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Notice of Board Meeting- Newspaper advertisement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"04072019124300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103630745","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-07-04 12:43:00","symbol":"BIOCON"},{"an_dt":"04-Jul-2019 12:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_04072019123332_Intimation_SE_NewspaperAd_AGM_054.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Newspaper advertisement confirming dispatch of Notice of the 41st Annual General Meeting (' AGM') and the Annual Report for the FY 2018-19.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"04072019123300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103630740","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-07-04 12:33:00","symbol":"BIOCON"},{"an_dt":"28-Jun-2019 17:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_28062019170031_AGM_AnnualReport_Biocon_Intimation_490.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 26, 2019","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"28062019170000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103618144","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-28 17:00:00","symbol":"BIOCON"},{"an_dt":"28-Jun-2019 16:31:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLtd_28062019163039_InvestorMeeting_415.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"28062019163100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103618088","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-28 16:31:00","symbol":"BIOCON"},{"an_dt":"27-Jun-2019 17:11:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27062019171137_InvestorMeeting_259.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"27062019171100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103614931","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-27 17:11:00","symbol":"BIOCON"},{"an_dt":"19-Jun-2019 16:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19062019164415_Newspaper_Ad_TransferShares_IEPF_19062019_207.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Newspaper Advertisement for transfer of equity shares to IEPF'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"19062019164400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103593675","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-19 16:44:00","symbol":"BIOCON"},{"an_dt":"19-Jun-2019 11:40:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19062019114033_InvestorMeeting_052.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"19062019114000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103593508","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-19 11:40:00","symbol":"BIOCON"},{"an_dt":"17-Jun-2019 20:19:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17062019201921_Biocon_OutcomeofBoardMeeting_June17_393.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Outcome of Board Meeting - Sale of Branded Formulations India (BFI) Business of the Company on a ��going concern�� basis to Biocon Biologics India Limited (��BBIL��), a wholly owned subsidiary. '.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"17062019201900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103587482","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-17 20:19:00","symbol":"BIOCON"},{"an_dt":"17-Jun-2019 17:13:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17062019171252_InvestorMeeting_281.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"17062019171300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103587389","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-17 17:13:00","symbol":"BIOCON"},{"an_dt":"15-Jun-2019 12:56:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15062019125451_Disclosure_016.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding allotment of 600000000 securities pursuant to Bonus at its meeting held on Jun 15, 2019","bflag":null,"csvName":null,"desc":"Allotment of Securities","difference":"-","dt":"15062019125600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103585136","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-15 12:56:00","symbol":"BIOCON"},{"an_dt":"14-Jun-2019 14:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14062019141155_CompanyStatement_110.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon Biologics Facilities in Bengaluru Receive EU GMP Certification'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"14062019141200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103583452","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-14 14:12:00","symbol":"BIOCON"},{"an_dt":"14-Jun-2019 14:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14062019141155_CompanyStatement_110.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon Biologics Facilities in Bengaluru Receive EU GMP Certification'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"14062019141200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103583452","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-14 14:12:00","symbol":"BIOCON"},{"an_dt":"14-Jun-2019 14:03:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14062019140259_InvestorMeeting_106.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"14062019140300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103583448","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-14 14:03:00","symbol":"BIOCON"},{"an_dt":"14-Jun-2019 14:03:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14062019140259_InvestorMeeting_106.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"14062019140300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103583448","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-14 14:03:00","symbol":"BIOCON"},{"an_dt":"13-Jun-2019 17:01:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13062019165945_IR_PPT_228.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"13062019170100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103580112","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-13 17:01:00","symbol":"BIOCON"},{"an_dt":"12-Jun-2019 12:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12062019124846_InvestorMeeting_085.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"12062019124800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103576407","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-12 12:48:00","symbol":"BIOCON"},{"an_dt":"07-Jun-2019 13:08:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07062019130811_InvestorMeeting_082.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"07062019130800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103565748","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-07 13:08:00","symbol":"BIOCON"},{"an_dt":"04-Jun-2019 19:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04062019185902_InvestorMeeting_307.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"04062019190000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103558116","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-04 19:00:00","symbol":"BIOCON"},{"an_dt":"04-Jun-2019 13:30:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04062019132949_VotingResults_PostalBallot_04062019_087.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Postal Ballot. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"04062019133000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103557927","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-06-04 13:30:00","symbol":"BIOCON"},{"an_dt":"31-May-2019 19:58:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract3_3152019194117_Record_Date_Bonus_Biocon_532.pdf","attchmntText":"Biocon Limited has informed the Exchange that the Company has fixed Record Date as June 13, 2019 for the purpose of Issue of Bonus Shares","bflag":null,"csvName":null,"desc":"Record Date","difference":"-","dt":"31052019195800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103552078","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-31 19:58:00","symbol":"BIOCON"},{"an_dt":"30-May-2019 19:07:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30052019190635_InvestorMeeting_449.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"30052019190700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103548837","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-30 19:07:00","symbol":"BIOCON"},{"an_dt":"29-May-2019 13:40:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29052019133937_InvestorMeeting_Intimation_086.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"29052019134000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103543101","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-29 13:40:00","symbol":"BIOCON"},{"an_dt":"27-May-2019 13:10:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27052019130901_IR_Presentation_Disclosure_009.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"27052019131000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103536977","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-27 13:10:00","symbol":"BIOCON"},{"an_dt":"24-May-2019 19:41:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/zrizvi_245201919416_Biocon_RPT_Disclosure_24052019_279.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Disclosure of Related Party Transactions pursuant to Regulation 23(9) of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (\"SEBI Listing Regulation\").","bflag":null,"csvName":null,"desc":"Related Party Transactions","difference":"-","dt":"24052019194100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103533882","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-24 19:41:00","symbol":"BIOCON"},{"an_dt":"24-May-2019 19:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract3_245201919824_Revised_Financial_Results_254.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Standalone Financial Results for the year ended March 31, 2019 - Updation","bflag":null,"csvName":null,"desc":"Financial Results Updates","difference":"-","dt":"24052019191200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103533838","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-24 19:12:00","symbol":"BIOCON"},{"an_dt":"23-May-2019 19:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23052019190359_Biocon_LargeCorporateDisclosure_23052019_431.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Confirmation on Large Corporate as per SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"23052019190400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103530799","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-23 19:04:00","symbol":"BIOCON"},{"an_dt":"22-May-2019 17:02:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22052019170104_BioconPressRelease_358.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 22, 2019, titled \"Health Canada Approves Biocon and Mylan��s Ogivri��, the First Trastuzumab Biosimilar, for the Treatment of HER2-Positive Breast and Gastric Cancers.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"22052019170200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103527575","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-22 17:02:00","symbol":"BIOCON"},{"an_dt":"16-May-2019 12:46:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16052019124521_InvestorMeeting_084.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"16052019124600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103514130","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-16 12:46:00","symbol":"BIOCON"},{"an_dt":"16-May-2019 12:38:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16052019123718_BioconPressRelease_076.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 16, 2019, titled \"Biocon and Mylan to Present Final Overall Survival Data for Ogivri�� (trastuzumab-dkst), a biosimilar to Herceptin��, at the American Society of Clinical Oncology (ASCO) Annual Meeting.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"16052019123800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103514122","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-16 12:38:00","symbol":"BIOCON"},{"an_dt":"10-May-2019 19:52:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10052019195203_InvestorMeeting_393.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"10052019195200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103501198","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-10 19:52:00","symbol":"BIOCON"},{"an_dt":"09-May-2019 12:03:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09052019120239_InvestorMeeting_040.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"09052019120300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103497288","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-09 12:03:00","symbol":"BIOCON"},{"an_dt":"07-May-2019 20:27:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07052019202402_CompanyStatement_320.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Pursuant to Regulation 30 of the SEBI LODR Regulations, 2015, please find below the ��Company Statement�� on the subject matter.��Following the successful approval and European launch of Hulio��, (biosimilar Adalimumab) in-licensed by our partner Mylan from Fujifilm Kyowa Kirin Biologics, the commercialization rights have been extended from Europe to Global Markets. Biocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing arrangement and will gain a share of profits from Global Markets. Biocon is committed to enable patient access to affordable biosimilars and this partnership accelerates that process.�� - Biocon Spokesperson'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"07052019202700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103491188","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-07 20:27:00","symbol":"BIOCON"},{"an_dt":"07-May-2019 15:54:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07052019155420_Newspaper_Ad_Postal_Ballot_07052019_141.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Newspaper Advertisement for Notice of Postal Ballot'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"07052019155400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103490414","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-07 15:54:00","symbol":"BIOCON"},{"an_dt":"07-May-2019 13:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07052019133334_InvestorMeeting_042.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"07052019133300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103490245","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-07 13:33:00","symbol":"BIOCON"},{"an_dt":"03-May-2019 16:55:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03052019165459_Intimation_PostalBallot_SEs_03052019_218.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Postal Ballot","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"03052019165500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103483369","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-03 16:55:00","symbol":"BIOCON"},{"an_dt":"03-May-2019 15:11:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03052019151049_InvestorMeeting_142.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"03052019151100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103483292","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-05-03 15:11:00","symbol":"BIOCON"},{"an_dt":"30-Apr-2019 16:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30042019164342_InvestorMeeting_368.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"30042019164400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103477454","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-04-30 16:44:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2019 08:50:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract3_25042019203520_BIOCON_outcome_di_RD_Bonus_011.pdf","attchmntText":"Biocon Limited has informed the Exchange that the Company has fixed Record Date as July 19, 2019 for the purpose of Payment of Final dividned","bflag":null,"csvName":null,"desc":"Record Date","difference":"-","dt":"26042019085000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103470812","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-04-26 08:50:00","symbol":"BIOCON"},{"an_dt":"25-Apr-2019 20:38:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract3_25042019203444_BIOCON_outcome_di_RD_Bonus_899.pdf","attchmntText":"Biocon Limited has informed the Exchange that�� ��Board of Directors at its meeting held on April 25, 2019 has recommended the issue of Bonus shares by Capitalisation of free reserves in the ration of 1:1 i.e. 1(one) bonus equity share of Rs. 5/- each fully paid up for every 1(One) existing equity share of Rs. 5/-each.","bflag":null,"csvName":null,"desc":"Bonus","difference":"-","dt":"25042019203800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103470811","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-04-25 20:38:00","symbol":"BIOCON"},{"an_dt":"25-Apr-2019 20:36:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract3_25042019203157_BIOCON_outcome_di_RD_Bonus_898.pdf","attchmntText":"Biocon Limited has informed the Exchange that��Board of Directors at its meeting held on April 25, 2019 has recommended final dividend of Rs. 1 per equity share of face value of Rs. 5/- each( pre-bonus issue) for the financial year ended march 31, 2019","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"25042019203600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103470810","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-04-25 20:36:00","symbol":"BIOCON"},{"an_dt":"25-Apr-2019 20:35:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract3_25042019202948_BIOCON_outcome_di_RD_Bonus_897.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on April 25, 2019.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"25042019203500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103470809","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-04-25 20:35:00","symbol":"BIOCON"},{"an_dt":"25-Apr-2019 19:35:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25042019193525_PressReleaseBiocon_868.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 25, 2019, titled \"Biocon Q4FY19 Revenue Rs. 1,557 Cr, Up 26%; EBITDA Up 43% at Rs 431 Cr; Net Profit Up 64% at Rs 214 Cr, FY19 Revenue Up 31% at Rs 5,659 Cr; Net Profit Up 143% at Rs 905 Cr, Board Recommends 1: 1 Bonus Shares\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25042019193500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103470781","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-04-25 19:35:00","symbol":"BIOCON"},{"an_dt":"25-Apr-2019 19:08:54","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Outcome_Of_Board_Meeting_BIOCON_25042019190854.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended March 31, 2019.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"25042019190854","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"126657","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-04-25 19:08:54","symbol":"BIOCON"},{"an_dt":"25-Apr-2019 19:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25042019190341_Outcome_Of_Board_Meeting_BIOCON_846.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on April 25, 2019.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"25042019190400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103470767","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-04-25 19:04:00","symbol":"BIOCON"},{"an_dt":"25-Apr-2019 14:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract4_25042019105227_biocon_526.pdf","attchmntText":"The Promoter along with PAC has submitted to the Exchange a copy of Annual Disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011 as on March 31, 2019.","bflag":null,"csvName":null,"desc":"Disc. under Reg.30 of SEBI (SAST) Reg.2011","difference":"-","dt":"25042019144300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103470061","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-04-25 14:43:00","symbol":"BIOCON"},{"an_dt":"22-Apr-2019 19:46:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract3_224201919116_BoardMeeting_Bonus_513.pdf","attchmntText":"Biocon Limited has informed the Exchange that Intimation for proposal to consider and recommendation of Final Dividend and Bonus issue by the Company.","bflag":null,"csvName":null,"desc":"Bonus/Dividend","difference":"-","dt":"22042019194600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103461067","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-04-22 19:46:00","symbol":"BIOCON"},{"an_dt":"18-Apr-2019 18:10:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract1_18042019112636_BioconLimited_REG30_284.pdf","attchmntText":"The Promoter along with PAC has submitted to the Exchange a copy of Annual Disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares and Takeovers), Regulations, 2011 as on March 31, 2019.","bflag":null,"csvName":null,"desc":"Disc. under Reg.30 of SEBI (SAST) Reg.2011","difference":"-","dt":"18042019181000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103456909","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-04-18 18:10:00","symbol":"BIOCON"},{"an_dt":"02-Apr-2019 16:38:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02042019163751_StockExchangePIT02042019_242.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Revised Code of Conduct of Biocon Ltd., (��Company��) under the SEBI (Prohibition of Insider Trading) Regulations, 2015, with effect from April 1, 2019'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"02042019163800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103418047","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-04-02 16:38:00","symbol":"BIOCON"},{"an_dt":"29-Mar-2019 16:39:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29032019163835_Intimation29March2019_230.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"29032019163900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103411795","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-03-29 16:39:00","symbol":"BIOCON"},{"an_dt":"19-Mar-2019 11:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19032019111203_InvestorMeetMarch182019_026.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"19032019111200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103386774","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-03-19 11:12:00","symbol":"BIOCON"},{"an_dt":"18-Mar-2019 08:37:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract1_183201974018_StockExchangeIntimation16032019_016.pdf","attchmntText":"Biocon Limited has informed the Exchange that Mr. Satish Kumar SS, Company Secretary and Compliance Officer of the Company has resigned from his position, effective from closing business hours of March 15, 2019. Consequent to the resignation, Mr. Siddharth Mittal, President Finance and Chief Financial Officer will act as interim Compliance Officer of the Company in place of Mr. Satish Kumar SS, and authorised to make necessary communications and filings with the stock exchanges or any other regulatory authority (ies), till the appointment of new Company Secretary and Compliance Officer.","bflag":null,"csvName":null,"desc":"Change in Company Secretary/Compliance Officer","difference":"-","dt":"18032019083700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103380687","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-03-18 08:37:00","symbol":"BIOCON"},{"an_dt":"15-Mar-2019 16:06:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/ARJUN_15032019160338_InvestorMeeting15032019_090.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"15032019160600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103379671","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-03-15 16:06:00","symbol":"BIOCON"},{"an_dt":"13-Mar-2019 18:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/ARJUN_13032019183202_OutcomeofMeetingPostalBallot_167.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company.","bflag":null,"csvName":null,"desc":"Amendment to AOA/MOA","difference":"-","dt":"13032019183300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103372760","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-03-13 18:33:00","symbol":"BIOCON"},{"an_dt":"13-Mar-2019 16:10:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/ARJUN_13032019160649_ResultAnnouncementPostalBallot_107.pdf","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Postal Ballot. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"13032019161000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103372701","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-03-13 16:10:00","symbol":"BIOCON"},{"an_dt":"11-Mar-2019 16:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/ARJUN_11032019155946_InvestorMeetingMarch112019_136.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"11032019160000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103365552","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-03-11 16:00:00","symbol":"BIOCON"},{"an_dt":"07-Mar-2019 18:54:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/ARJUN_07032019185339_InvestorMeeting_168.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"07032019185400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103358722","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-03-07 18:54:00","symbol":"BIOCON"},{"an_dt":"06-Mar-2019 18:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06032019184804_InvestorMeeting06032019_238.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"06032019184800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103355890","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-03-06 18:48:00","symbol":"BIOCON"},{"an_dt":"06-Mar-2019 18:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06032019184230_CompanyStatement06032019_232.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon Facility Completes Pre Approval U.S. FDA Inspection'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"06032019184200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103355881","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-03-06 18:42:00","symbol":"BIOCON"},{"an_dt":"05-Mar-2019 13:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/ARJUN_05032019131955_investormeeting5mar2019_128.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"05032019132000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103352829","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-03-05 13:20:00","symbol":"BIOCON"},{"an_dt":"01-Mar-2019 18:49:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/ARJUN_01032019184835_BioconPressRelease01032019_242.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 01, 2019, titled \"Biocon Appoints Dr. Christiane Hamacher as CEO of Biocon Biologics India Limited\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"01032019184900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103349160","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-03-01 18:49:00","symbol":"BIOCON"},{"an_dt":"01-Mar-2019 17:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/ARJUN_01032019174200_InvestorMeet01032019_205.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"01032019174200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103349120","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-03-01 17:42:00","symbol":"BIOCON"},{"an_dt":"25-Feb-2019 17:38:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25022019173637_InvestormeetingFeb252019_187.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"25022019173800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103334555","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-02-25 17:38:00","symbol":"BIOCON"},{"an_dt":"18-Feb-2019 08:27:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_18022019082604_CompanyStatement1822019_019.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon Facilities complete Pre Approval U.S.FDA Inspection'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"18022019082700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103315982","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-02-18 08:27:00","symbol":"BIOCON"},{"an_dt":"15-Feb-2019 14:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15022019143302_investormeetingfeb142019_103.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"15022019143300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103313470","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-02-15 14:33:00","symbol":"BIOCON"},{"an_dt":"08-Feb-2019 17:32:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_08022019173108_Postalballotnotice_349.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Postal Ballot","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"08022019173200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103296908","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-02-08 17:32:00","symbol":"BIOCON"},{"an_dt":"06-Feb-2019 19:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06022019191318_BioconIRPPT31122018_489.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"06022019191600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103288664","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-02-06 19:16:00","symbol":"BIOCON"},{"an_dt":"04-Feb-2019 16:07:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_04022019160639_pressrelease4February2019_263.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 04, 2019, titled \"Cancer Task Force Recommends Guidelines for Cancer Care- Press Release\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"04022019160700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103280774","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-02-04 16:07:00","symbol":"BIOCON"},{"an_dt":"29-Jan-2019 12:01:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_29012019120020_Investorcall_043.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"29012019120100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103265369","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-01-29 12:01:00","symbol":"BIOCON"},{"an_dt":"24-Jan-2019 19:31:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24012019184838_BioconQ3FY19EarningsPressRelease_309.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 24, 2019, titled \"Biocon Q3 FY19 Earnings Press Release\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"24012019193100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103253960","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-01-24 19:31:00","symbol":"BIOCON"},{"an_dt":"24-Jan-2019 17:48:57","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/UnauditedFinancialResults31122018_24012019174857.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended December 31, 2018.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"24012019174857","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"125095","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-01-24 17:48:57","symbol":"BIOCON"},{"an_dt":"24-Jan-2019 17:38:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_24012019173724_Outcome24012019_243.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on January 24, 2019.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"24012019173800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103253912","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2019-01-24 17:38:00","symbol":"BIOCON"},{"an_dt":"20-Dec-2018 17:06:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20122018170608_investormeeting20Dec2018_147.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"20122018170600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103166519","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-12-20 17:06:00","symbol":"BIOCON"},{"an_dt":"19-Dec-2018 15:06:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19122018150425_InvestormeetingDec182018_072.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"19122018150600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103163623","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-12-19 15:06:00","symbol":"BIOCON"},{"an_dt":"19-Dec-2018 08:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_19122018075838_companystatement19dec2018_002.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biosimilar Trastuzumab Co-developed by Biocon Receives Approval in the EU'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"19122018080000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103161674","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-12-19 08:00:00","symbol":"BIOCON"},{"an_dt":"17-Dec-2018 08:01:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_17122018080128_companystatement17dec2018_001.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Regulation 30 of SEBI LODR Regulations 2015'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"17122018080100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103152960","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-12-17 08:01:00","symbol":"BIOCON"},{"an_dt":"14-Dec-2018 18:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14122018184149_InvestorMeetingDec142018_148.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Meetings conducted with Institutional Investors/Research Analysts. '.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"14122018184300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103150738","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-12-14 18:43:00","symbol":"BIOCON"},{"an_dt":"10-Dec-2018 17:45:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10122018174438_Investormeeting10Dec2018_151.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"10122018174500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103139120","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-12-10 17:45:00","symbol":"BIOCON"},{"an_dt":"03-Dec-2018 13:03:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03122018130233_ChangeinRTAname_148.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Change in name of Registrar & Share Transfer Agent -  Karvy Computershare Private Limited to Karvy Fintech Private Limited'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"03122018130300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103122690","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-12-03 13:03:00","symbol":"BIOCON"},{"an_dt":"02-Dec-2018 13:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02122018131149_Pressreleasebiocon2nddecember2018_060.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 02, 2018, titled \"Biocon Foundation dedicates rejuvenated Hebbagodi Lake and Children's Park to the community��\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"02122018131200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103120724","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-12-02 13:12:00","symbol":"BIOCON"},{"an_dt":"30-Nov-2018 16:25:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30112018162443_AnouncementdatedNov302018_165.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"30112018162500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103118989","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-11-30 16:25:00","symbol":"BIOCON"},{"an_dt":"27-Nov-2018 15:30:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27112018152013_Investormeet27Nov2018_110.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"27112018153000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103107661","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-11-27 15:30:00","symbol":"BIOCON"},{"an_dt":"26-Nov-2018 16:17:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_26112018161617_Reg30disclosureNov262018_141.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Change in the name and contact details of Key Managerial Personnel under the Policy for Determination of Materiality for disclosures'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"26112018161700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103104871","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-11-26 16:17:00","symbol":"BIOCON"},{"an_dt":"23-Nov-2018 15:32:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23112018153047_InvestormeetingNov232018_302.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"23112018153200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103102866","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-11-23 15:32:00","symbol":"BIOCON"},{"an_dt":"21-Nov-2018 20:21:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_21112018202007_Investormeeting21Nov2018_007.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"21112018202100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103099689","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-11-21 20:21:00","symbol":"BIOCON"},{"an_dt":"16-Nov-2018 17:59:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16112018175836_InvestorPresentationBiocon16Nov2018_602.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"16112018175900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103087243","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-11-16 17:59:00","symbol":"BIOCON"},{"an_dt":"16-Nov-2018 17:52:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_16112018175124_Investormeeting_16Nov2018_595.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"16112018175200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103087235","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-11-16 17:52:00","symbol":"BIOCON"},{"an_dt":"15-Nov-2018 19:22:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_15112018192147_meetingwithinvestors15Nov2018_332.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"15112018192200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103084398","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-11-15 19:22:00","symbol":"BIOCON"},{"an_dt":"12-Nov-2018 17:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12112018170308_meetingwithinvestor12Nov2018_197.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"12112018170400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103071871","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-11-12 17:04:00","symbol":"BIOCON"},{"an_dt":"12-Nov-2018 08:21:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_12112018082034_genericformulations12Nov2018_912.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon\"s Generic Formulations Facility in Bengaluru completes U.S. FDA Inspection with No 483 observations'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"12112018082100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103069704","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-11-12 08:21:00","symbol":"BIOCON"},{"an_dt":"09-Nov-2018 12:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_09112018124758_meetingwithinvestorsNovember2018_663.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"09112018124800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103068670","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-11-09 12:48:00","symbol":"BIOCON"},{"an_dt":"30-Oct-2018 13:27:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30102018132658_Pressrelease30october2018_085.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 30, 2018, titled \"Biocon ranked 7th on Top Global Pharma & Biotech Employers List 2018\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"30102018132700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103046527","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-10-30 13:27:00","symbol":"BIOCON"},{"an_dt":"30-Oct-2018 13:07:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30102018130648_Meetingswithinvestorsintimation30october2018_076.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"30102018130700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103046516","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-10-30 13:07:00","symbol":"BIOCON"},{"an_dt":"29-Oct-2018 20:22:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract3_29102018200916_Biocon_press_405.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 19, 2018, titled \"Biocon and Mylan Announce Positive CHMP Opinion for Ogivri, Biosimilar Trastuzumab.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"29102018202200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103043284","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-10-29 20:22:00","symbol":"BIOCON"},{"an_dt":"25-Oct-2018 18:53:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25102018185218_PressReleaseSep302018_845.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 25, 2018, titled \"Press Release \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25102018185300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103034890","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-10-25 18:53:00","symbol":"BIOCON"},{"an_dt":"25-Oct-2018 18:17:24","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/FinancialresultsSep302018_25102018181724.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended September 30, 2018.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"25102018181724","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"123129","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-10-25 18:17:24","symbol":"BIOCON"},{"an_dt":"25-Oct-2018 18:05:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25102018180520_OutcomeofBoardmeeting25102018_795.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on October 25, 2018.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"25102018180500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103034840","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-10-25 18:05:00","symbol":"BIOCON"},{"an_dt":"28-Sep-2018 08:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract1_28092018081554_Biocon_076.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"28092018084400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102967489","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-09-28 08:44:00","symbol":"BIOCON"},{"an_dt":"27-Sep-2018 11:19:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract1_27092018111650_Biocon_655.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 21, 2018, titled \"Biocon and Mylan Announce Positive CHMP Opinion for Fulphila��, Biosimilar Pegfilgrastim\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"27092018111900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102965560","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-09-27 11:19:00","symbol":"BIOCON"},{"an_dt":"22-Sep-2018 10:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_22092018101543_USFDAInspectionwithnoobservations_953.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding ' Biocon's Drug Substance Facility in Bangalore completes US FDA inspection with no observations.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"22092018101600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102952215","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-09-22 10:16:00","symbol":"BIOCON"},{"an_dt":"20-Sep-2018 18:06:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20092018180538_Announcementinvestormeeting20Sep2018_609.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"20092018180600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102949879","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-09-20 18:06:00","symbol":"BIOCON"},{"an_dt":"11-Sep-2018 20:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11092018203226_SASTDisclosureReg29_268.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding 'SEBI SAST Regulation 29 Announcement'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"11092018203300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102931888","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-09-11 20:33:00","symbol":"BIOCON"},{"an_dt":"11-Sep-2018 18:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_11092018184209_Announcementmeetingsep112018_206.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"11092018184200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102931832","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-09-11 18:42:00","symbol":"BIOCON"},{"an_dt":"10-Sep-2018 15:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_10092018154144_InvestorMeeting7thSep2018_383.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"10092018154200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102928432","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-09-10 15:42:00","symbol":"BIOCON"},{"an_dt":"07-Sep-2018 15:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07092018151958_InvestorMeeting6thSep2018_297.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"07092018152000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102924607","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-09-07 15:20:00","symbol":"BIOCON"},{"an_dt":"06-Sep-2018 14:57:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_06092018145648_Announcementinvestormeeting05092018_847.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"06092018145700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102920731","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-09-06 14:57:00","symbol":"BIOCON"},{"an_dt":"05-Sep-2018 17:19:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_05092018171859_MeetingannouncementRegulation30_sw_394.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"05092018171900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102917194","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-09-05 17:19:00","symbol":"BIOCON"},{"an_dt":"04-Sep-2018 07:22:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/listcontract1_04092018071642_BIOCON_124.pdf","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors in its meeting held on September 03, 2018, has appointed Mr. Satish Kumar SS as the Company Secretary and Compliance Officer of the Company.","bflag":null,"csvName":null,"desc":"Appointment of Company Secretary","difference":"-","dt":"04092018072200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102907653","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-09-04 07:22:00","symbol":"BIOCON"},{"an_dt":"02-Sep-2018 09:18:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_02092018091739_IRpresentationAnnouncementQ1_151.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"02092018091800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102907482","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-09-02 09:18:00","symbol":"BIOCON"},{"an_dt":"28-Aug-2018 15:46:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28082018154545_28082018AnnouncementInvestorMeetingandtelecon_190.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"28082018154600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102897201","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-08-28 15:46:00","symbol":"BIOCON"},{"an_dt":"23-Aug-2018 17:45:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_23082018174456_AnnouncementonteleconferenceandmeetingunderReg30_778.pdf","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"23082018174500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102886387","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-08-23 17:45:00","symbol":"BIOCON"},{"an_dt":"16-Aug-2018 17:15:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AnnouncementInvestorMeeting_16082018171514_254.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"16082018171500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102872259","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-08-16 17:15:00","symbol":"BIOCON"},{"an_dt":"14-Aug-2018 21:23:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/InvestorMeeting13August2018_14082018212309_826.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"14082018212300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102869366","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-08-14 21:23:00","symbol":"BIOCON"},{"an_dt":"09-Aug-2018 17:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AnnouncementinvestormeetingFinal_09082018174216_371.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"09082018174200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102857920","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-08-09 17:42:00","symbol":"BIOCON"},{"an_dt":"06-Aug-2018 20:54:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Intimationoninvestormeeting_sw_06082018205430_612.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"06082018205400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102848540","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-08-06 20:54:00","symbol":"BIOCON"},{"an_dt":"03-Aug-2018 15:22:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/03082018AnnouncementInvestorTelecon_03082018152249_199.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"03082018152200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102843798","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-08-03 15:22:00","symbol":"BIOCON"},{"an_dt":"01-Aug-2018 13:15:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Announcementonteleconference_01082018131534_174.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"01082018131500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102835664","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-08-01 13:15:00","symbol":"BIOCON"},{"an_dt":"29-Jul-2018 02:09:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AnnouncementonappointmentofBobbyParikh_29072018020926_733.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Change in Director(s) of the company.","bflag":null,"csvName":null,"desc":"Change in Director(s)","difference":"-","dt":"29072018020900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102825717","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-07-29 02:09:00","symbol":"BIOCON"},{"an_dt":"28-Jul-2018 19:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/IntimationonproceedingsofAGM_28072018191650_711.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 27, 2018. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"28072018191600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102825695","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-07-28 19:16:00","symbol":"BIOCON"},{"an_dt":"26-Jul-2018 19:26:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/OutcomeofBoardMeeting_26072018192644_187.zip","attchmntText":"Biocon Limited has informed the Exchange regarding  Board meeting held on July 26, 2018.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"26072018192600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102820497","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-07-26 19:26:00","symbol":"BIOCON"},{"an_dt":"26-Jul-2018 19:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_outcome_26072018192051.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on July 26, 2018.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"26072018192000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102820485","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-07-26 19:20:00","symbol":"BIOCON"},{"an_dt":"26-Jul-2018 19:02:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconQ1FY19EarningsPressRelease_26072018190232_158.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 26, 2018, titled \"Press Release \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"26072018190200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102820478","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-07-26 19:02:00","symbol":"BIOCON"},{"an_dt":"26-Jul-2018 18:56:09","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/OutcomeofBoardMeeting_26072018185609.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended June 30, 2018.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"26072018185609","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"121147","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-07-26 18:56:09","symbol":"BIOCON"},{"an_dt":"05-Jul-2018 19:19:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/DespatchofAGMNotice_05072018191933_378.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 27, 2018","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"05072018191900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102770893","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-07-05 19:19:00","symbol":"BIOCON"},{"an_dt":"04-Jul-2018 19:05:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/EUGMPcertification_04072018190543_608.zip","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon��s Sterile Drug Product facility receives EU GMP Certification'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"04072018190500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102767368","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-07-04 19:05:00","symbol":"BIOCON"},{"an_dt":"28-Jun-2018 21:30:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_28062018213046.zip","attchmntText":"Biocon Limited has informed the Exchange regarding teleconference conducted on June 27, 2018 with Institutional Investor/Research Analysts.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"28062018213000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102754207","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-06-28 21:30:00","symbol":"BIOCON"},{"an_dt":"28-Jun-2018 14:47:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/EtanerceptcollaborationwithMylan_28062018144745_074.zip","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon retains economic interest in Etanercept Collaboration with Mylan.'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"28062018144700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102754059","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-06-28 14:47:00","symbol":"BIOCON"},{"an_dt":"27-Jun-2018 17:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27062018170045.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"27062018170000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102751246","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-06-27 17:00:00","symbol":"BIOCON"},{"an_dt":"25-Jun-2018 08:45:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconsSterileDrugProductEIR_23062018_25062018084505_079.zip","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon��s Sterile Drug Product facility receives Establishment Inspection Report (EIR) from USFDA'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"25062018084500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102743596","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-06-25 08:45:00","symbol":"BIOCON"},{"an_dt":"22-Jun-2018 14:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/22062018AnnouncementInvestorteleconference_22062018144300_800.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"22062018144300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102741525","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-06-22 14:43:00","symbol":"BIOCON"},{"an_dt":"05-Jun-2018 18:39:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/05062018AnnouncementInvestorMeetingMumbai_05062018183912_994.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"05062018183900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102699818","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-06-05 18:39:00","symbol":"BIOCON"},{"an_dt":"05-Jun-2018 02:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconPressReleasePegfilUSFDAapprovalJune52018_05062018023342_666.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 05, 2018, titled \"U.S. FDA approves Mylan and Biocon��s Fulphila�� (pegfilgrastim-jmdb), the first Biosimilar to Neulasta�� -Press Release\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"05062018023300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102697485","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-06-05 02:33:00","symbol":"BIOCON"},{"an_dt":"04-Jun-2018 15:17:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconNimotuzumabStudyResultsatASCOPressReleaseFinal_04062018151734_382.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 04, 2018, titled \"Tata Memorial Hospital team presents Biocon's Nimotuzumab study results at AmericanSociety of Clinical Oncology (ASCO ) Annual Meeting 2018-Press Release\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"04062018151700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102696719","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-06-04 15:17:00","symbol":"BIOCON"},{"an_dt":"02-Jun-2018 13:54:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconMylanASCOPressRelease_02062018135423_036.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 02, 2018, titled \"Biocon and Mylan Press Release pertaining to presenting new data to American Society of Clinical Oncology (ASCO)\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"02062018135400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102694746","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-06-02 13:54:00","symbol":"BIOCON"},{"an_dt":"31-May-2018 16:57:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconLimitedInvestorppt310518_31052018165744_356.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"31052018165700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102690017","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-05-31 16:57:00","symbol":"BIOCON"},{"an_dt":"18-May-2018 11:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/SaleofEquitySharesoftheSyngeneInternationalLimited_18052018114303_086.zip","attchmntText":"Biocon Limited has informed the Exchange regarding 'Sale of Equity Shares of the Syngene International Limited'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"18052018114300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102655610","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-05-18 11:43:00","symbol":"BIOCON"},{"an_dt":"15-May-2018 18:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/15052018AnnouncementInvestorMeetingfinal_15052018184335_121.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"15052018184300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102646495","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-05-15 18:43:00","symbol":"BIOCON"},{"an_dt":"09-May-2018 17:50:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/09052018AnnouncementInvestorMeeting_09052018175047_847.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"09052018175000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102632249","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-05-09 17:50:00","symbol":"BIOCON"},{"an_dt":"08-May-2018 16:32:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/08052018AnnouncementInvestorMeeting_08052018163225_312.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"08052018163200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102628204","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-05-08 16:32:00","symbol":"BIOCON"},{"an_dt":"03-May-2018 08:26:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_03052018082645.zip","attchmntText":"Biocon Limited has informed the Exchange regarding 'Biocon Regulatory Audit Update'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"03052018082600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102615223","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-05-03 08:26:00","symbol":"BIOCON"},{"an_dt":"02-May-2018 18:59:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/02052018AnnouncementInvestorMeeting_02052018185949_500.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"02052018185900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102614084","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-05-02 18:59:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2018 20:06:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/RecorddateBiocon_26042018200619_308.zip","attchmntText":"Biocon Limited has informed the Exchange that the Company has fixed Record Date as July 20, 2018 for the purpose of declaration of dividend for the financial year 2017-18.","bflag":null,"csvName":null,"desc":"Record Date","difference":"-","dt":"26042018200600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102604621","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-04-26 20:06:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2018 19:51:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/OutcomeofBoardmeetingBiocon_26042018195142_301.zip","attchmntText":"Biocon Limited has informed the Exchange that Board of Directors at its meeting held on April 26, 2018, recommended Final Dividend of 1 per equity share.","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"26042018195100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102604622","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-04-26 19:51:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2018 19:41:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_outcome_dividend_26042018194154.zip","attchmntText":"Biocon Limited has informed the Exchange that Board of Directors at its meeting held on April 26, 2018 has proposed a final dividend of Rs. 1 per equity share.","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"26042018194100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102604610","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-04-26 19:41:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2018 19:40:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_outcome_dividend_26042018194050.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on April 26, 2018.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"26042018194000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102604609","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-04-26 19:40:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2018 19:30:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/PressReleaseBiocon_26042018193059_283.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 26, 2018, titled \"Press Release\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"26042018193000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102604607","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-04-26 19:30:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2018 19:17:23","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/FinancialResultsBiocon_26042018191723.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended March 31, 2018.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"26042018191723","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"118903","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-04-26 19:17:23","symbol":"BIOCON"},{"an_dt":"11-Apr-2018 19:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconFinal_11042018192442_543.zip","attchmntText":"Biocon Limited has informed the Exchange regarding 'Mylan and Biocon seek to accelerate introduction of Biosimilar adalimumab in EU'.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"11042018192400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102567423","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-04-11 19:24:00","symbol":"BIOCON"},{"an_dt":"09-Apr-2018 16:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_09042018162055.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.","bflag":null,"csvName":null,"desc":"Disc. under Reg.30 of SEBI (SAST) Reg.2011","difference":"-","dt":"09042018162000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102559688","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-04-09 16:20:00","symbol":"BIOCON"},{"an_dt":"28-Mar-2018 08:29:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_28032018082925_261.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 28, 2018, titled \"In compliance with the provisions of regulation 30 of SEBI (Listing Obligations and Disclosure Requirement) Regulations 2015Press Release titled ��Mylan and Biocon Receive Approvals from the European Commission and TGA Australia for Semglee��, Biosimilar Insulin Glargine�� \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"28032018082900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102536550","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-03-28 08:29:00","symbol":"BIOCON"},{"an_dt":"27-Mar-2018 16:47:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_27032018164741_104.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"27032018164700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102535852","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-03-27 16:47:00","symbol":"BIOCON"},{"an_dt":"20-Mar-2018 18:59:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_20032018185936_121.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"20032018185900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102519798","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-03-20 18:59:00","symbol":"BIOCON"},{"an_dt":"16-Mar-2018 17:14:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCONAIM_16032018171429_408.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"16032018171400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102513692","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-03-16 17:14:00","symbol":"BIOCON"},{"an_dt":"15-Mar-2018 17:41:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AIM_15032018174157_160.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"15032018174100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102511121","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-03-15 17:41:00","symbol":"BIOCON"},{"an_dt":"14-Mar-2018 15:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIO_14032018152406_096.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"14032018152400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102508231","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-03-14 15:24:00","symbol":"BIOCON"},{"an_dt":"13-Mar-2018 12:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/bio_13032018124825_858.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"13032018124800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102505139","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-03-13 12:48:00","symbol":"BIOCON"},{"an_dt":"08-Mar-2018 17:37:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIO_08032018173751_167.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"08032018173700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102496895","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-03-08 17:37:00","symbol":"BIOCON"},{"an_dt":"03-Mar-2018 17:50:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Intimation_03032018175059_072.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Resignation of Mr RAJIV BALAKRISHNAN as Company Secretary & Compliance Officer of the company w.e.f. March 02, 2018.","bflag":null,"csvName":null,"desc":"Resignation","difference":"-","dt":"03032018175000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102485747","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-03-03 17:50:00","symbol":"BIOCON"},{"an_dt":"03-Mar-2018 17:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_AIR_03032018174242_071.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"03032018174200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102485746","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-03-03 17:42:00","symbol":"BIOCON"},{"an_dt":"27-Feb-2018 11:52:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIO_AIR_27022018115246_817.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"27022018115200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102477919","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-02-27 11:52:00","symbol":"BIOCON"},{"an_dt":"22-Feb-2018 18:56:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIO_22022018185622_172.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"22022018185600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102467866","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-02-22 18:56:00","symbol":"BIOCON"},{"an_dt":"21-Feb-2018 08:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Intimation_21022018084859_914.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 21, 2018, titled \"Company Statement on US-FDA Inspection at Biocon Malaysia\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21022018084800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102462829","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-02-21 08:48:00","symbol":"BIOCON"},{"an_dt":"20-Feb-2018 19:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIO_20022018192844_887.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"20022018192800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102461779","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-02-20 19:28:00","symbol":"BIOCON"},{"an_dt":"15-Feb-2018 21:15:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_AIM_15022018211527_326.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"15022018211500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102453924","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-02-15 21:15:00","symbol":"BIOCON"},{"an_dt":"08-Feb-2018 19:46:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_08022018194634_118.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"08022018194600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102438390","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-02-08 19:46:00","symbol":"BIOCON"},{"an_dt":"08-Feb-2018 19:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_AIM_08022018194313_116.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"08022018194300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102438388","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-02-08 19:43:00","symbol":"BIOCON"},{"an_dt":"06-Feb-2018 16:47:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_AIM_06022018164723_484.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"06022018164700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102431534","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-02-06 16:47:00","symbol":"BIOCON"},{"an_dt":"05-Feb-2018 11:38:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_AR_05022018113821_108.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"05022018113800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102427504","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-02-05 11:38:00","symbol":"BIOCON"},{"an_dt":"01-Feb-2018 20:46:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_AM_01022018204635_839.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"01022018204600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102421258","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-02-01 20:46:00","symbol":"BIOCON"},{"an_dt":"30-Jan-2018 16:50:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_AIM_30012018165047_386.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"30012018165000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102414836","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-01-30 16:50:00","symbol":"BIOCON"},{"an_dt":"30-Jan-2018 16:36:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_AIM_30012018163643_360.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"30012018163600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102414822","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-01-30 16:36:00","symbol":"BIOCON"},{"an_dt":"29-Jan-2018 16:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/PR_29012018164826_541.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 29, 2018, titled \"Mylan and Biocon Receive Positive CHMP Opinion for SemgleeTM, Biosimilar Insulin Glargine\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"29012018164800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102411804","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-01-29 16:48:00","symbol":"BIOCON"},{"an_dt":"27-Jan-2018 13:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/InvestorMeeting_BIOCON_27012018132827_148.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"27012018132800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102409191","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-01-27 13:28:00","symbol":"BIOCON"},{"an_dt":"24-Jan-2018 19:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_outcome_24012018192428.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on January 24, 2018.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"24012018192400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102405097","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-01-24 19:24:00","symbol":"BIOCON"},{"an_dt":"24-Jan-2018 18:17:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Q3_Financials_BIOCON_DEC2017_24012018181734.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended December 31, 2017.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"24012018181734","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"117286","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-01-24 18:17:34","symbol":"BIOCON"},{"an_dt":"24-Jan-2018 08:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/0621_001_24012018082006_006.zip","attchmntText":"Biocon Limited has informed the Exchange that the Company has entered into a Business Transfer Agreement (BTA) with its step down wholly owned subsidiary, Biocon Biologics India Limited  (BBIL), i.e., January 22, 2018, for the transfer of its Biosimilars business to BBIL.","bflag":null,"csvName":null,"desc":"Diversification/Disinvestment","difference":"-","dt":"24012018082000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102402594","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-01-24 08:20:00","symbol":"BIOCON"},{"an_dt":"18-Jan-2018 15:47:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_18012018154702_148.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 18, 2018, titled \"��Biocon Announces Exclusive Global Collaboration with Sandoz on Next- Generation Biosimilars��\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18012018154700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102391003","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2018-01-18 15:47:00","symbol":"BIOCON"},{"an_dt":"29-Dec-2017 11:37:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_29122017113706_026.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 29, 2017, titled \"Press Release titled ��Biocon and Mylan��s Biosimilar Trastuzumab Receives Approval from ANVISA, Brazil Through Their Partner Libbs��\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"29122017113700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102349466","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-29 11:37:00","symbol":"BIOCON"},{"an_dt":"22-Dec-2017 18:02:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_IR_analysts_meet_22122017180259_206.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"22122017180200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102337632","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-22 18:02:00","symbol":"BIOCON"},{"an_dt":"21-Dec-2017 16:25:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_IR_Analysts_meet_21122017162545_903.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"21122017162500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102334856","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-21 16:25:00","symbol":"BIOCON"},{"an_dt":"20-Dec-2017 19:23:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_IR_Analysts_meet_20122017192337_756.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"20122017192300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102331615","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-20 19:23:00","symbol":"BIOCON"},{"an_dt":"19-Dec-2017 17:55:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_IR_Analyst_Meet_19122017175547_502.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"19122017175500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102328330","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-19 17:55:00","symbol":"BIOCON"},{"an_dt":"15-Dec-2017 15:03:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_IR_Analysts_meetings_15122017150315_504.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"15122017150300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102322806","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-15 15:03:00","symbol":"BIOCON"},{"an_dt":"14-Dec-2017 15:55:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_Investor_Analyst_meets_14122017155508_169.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"14122017155500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102319982","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-14 15:55:00","symbol":"BIOCON"},{"an_dt":"13-Dec-2017 12:09:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Statement_13122017120957_775.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 13, 2017, titled \"Biocon��s Clarification post media reports on ��Biocon on the FDA list for not paying facility fee��\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"13122017120900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102316607","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-13 12:09:00","symbol":"BIOCON"},{"an_dt":"08-Dec-2017 17:11:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analysts_Meet_08122017171159_866.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"08122017171100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102307495","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-08 17:11:00","symbol":"BIOCON"},{"an_dt":"07-Dec-2017 19:35:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Postal_Ballot_Results_Scrutiziners_Report_07122017193550_629.zip","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Postal Ballot. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"07122017193500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102304216","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-07 19:35:00","symbol":"BIOCON"},{"an_dt":"07-Dec-2017 15:22:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Analysts_meet_07122017152249_445.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"07122017152200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102304075","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-07 15:22:00","symbol":"BIOCON"},{"an_dt":"05-Dec-2017 15:39:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Investor_Analyst_Meets_05122017153933_399.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"05122017153900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102297455","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-05 15:39:00","symbol":"BIOCON"},{"an_dt":"01-Dec-2017 22:37:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Press_Release_Biocon_December_1_2017_01122017223756_742.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 01, 2017, titled \"Press Release titled ��U.S. FDA Approves Mylan and Biocon��s Ogivri�� the First Biosimilar for Trastuzumab, for the Treatment of HER2-Positive Breast and Gastric Cancers.��\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"01122017223700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102292019","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-01 22:37:00","symbol":"BIOCON"},{"an_dt":"01-Dec-2017 08:11:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Press_Release_Biocon_December_1_2017_01122017081137_354.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 01, 2017, titled \"European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocon��s Proposed Biosimilars Trastuzumab and Pegfilgrastim\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"01122017081100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102289403","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-12-01 08:11:00","symbol":"BIOCON"},{"an_dt":"23-Nov-2017 16:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Investor_Analysts_meet_Nov_23_2017_23112017160445_571.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"23112017160400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102274101","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-11-23 16:04:00","symbol":"BIOCON"},{"an_dt":"23-Nov-2017 10:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/PR_November_23_2017_23112017104406_459.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 23, 2017, titled \"\"Biocon Launches KRABEVA��- Biosimilar Bevacizumab for Treating Several Types of Cancer in India.��\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"23112017104400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102273240","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-11-23 10:44:00","symbol":"BIOCON"},{"an_dt":"20-Nov-2017 08:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Statement_Nov_20_2017_20112017081642_484.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 20, 2017, titled \"Biocon's Facility receives EIR with VAI status, Inspection Closed\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"20112017081600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102262454","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-11-20 08:16:00","symbol":"BIOCON"},{"an_dt":"15-Nov-2017 16:52:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analyst_meets_November_15_2017_15112017165232_560.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"15112017165200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102254341","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-11-15 16:52:00","symbol":"BIOCON"},{"an_dt":"14-Nov-2017 17:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analyst_Meets_November_14_2017_14112017172454_913.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"14112017172400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102250704","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-11-14 17:24:00","symbol":"BIOCON"},{"an_dt":"10-Nov-2017 09:40:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analyst_meet_Nov_10_2017_10112017094059_023.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"10112017094000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102240554","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-11-10 09:40:00","symbol":"BIOCON"},{"an_dt":"08-Nov-2017 19:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/SE_Declaration_Nov_8_2017_08112017194800_440.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Investor Presentation","bflag":null,"csvName":null,"desc":"Investor Presentation","difference":"-","dt":"08112017194800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102236024","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-11-08 19:48:00","symbol":"BIOCON"},{"an_dt":"07-Nov-2017 07:54:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Statement_November_7_2017_07112017075458_001.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 07, 2017, titled \"Company Statement on Resubmission of Biosimilar Trastuzumab and Pegfilgrastim Dossiers with EMA.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"07112017075400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102229936","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-11-07 07:54:00","symbol":"BIOCON"},{"an_dt":"03-Nov-2017 18:13:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Intimation_Postal_Ballot_Notice_dated_October_26_2017_03112017181322_596.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Postal Ballot","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"03112017181300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102224786","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-11-03 18:13:00","symbol":"BIOCON"},{"an_dt":"30-Oct-2017 15:35:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analyst_Meet_Oct_30_2017_30102017153504_139.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"30102017153500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102212459","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-10-30 15:35:00","symbol":"BIOCON"},{"an_dt":"27-Oct-2017 16:36:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/analyst_meet_27102017163628_652.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"27102017163600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102209450","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-10-27 16:36:00","symbol":"BIOCON"},{"an_dt":"26-Oct-2017 19:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_Outcome_26102017191247.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on October 26, 2017.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"26102017191200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102206072","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-10-26 19:12:00","symbol":"BIOCON"},{"an_dt":"26-Oct-2017 18:34:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Outcome_and_results_Q2_FY18_26102017183433.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended September 30, 2017.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"26102017183433","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"115469","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-10-26 18:34:33","symbol":"BIOCON"},{"an_dt":"25-Oct-2017 08:32:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_October_25_2017_25102017083251_332.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 25, 2017, titled \"Press Release titled ��Biocon Ranked Among Top 10 Global Pharma & Biotech Employers.��\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25102017083200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102200057","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-10-25 08:32:00","symbol":"BIOCON"},{"an_dt":"10-Oct-2017 09:07:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_PR_10102017090719.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 10, 2017, titled \"US FDA Issues Complete Response Letter for Proposed Biosimilar Pegfilgrastim \".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"10102017090700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102168218","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-10-10 09:07:00","symbol":"BIOCON"},{"an_dt":"21-Sep-2017 09:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_21092017094228_021.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"21092017094200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102125557","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-09-21 09:42:00","symbol":"BIOCON"},{"an_dt":"19-Sep-2017 16:36:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_19092017163622_228.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"19092017163600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102121007","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-09-19 16:36:00","symbol":"BIOCON"},{"an_dt":"18-Sep-2017 15:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/PressRelease_Biocon_18092017154411_046.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 18, 2017, titled \"Biocon��s Facility in Vishakhapatnam completes USFDA Inspection with no observations.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18092017154400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102117386","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-09-18 15:44:00","symbol":"BIOCON"},{"an_dt":"15-Sep-2017 16:54:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_15092017165406_494.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"15092017165400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102113753","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-09-15 16:54:00","symbol":"BIOCON"},{"an_dt":"08-Sep-2017 16:46:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Presentation_Biocon_08092017164623_321.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"08092017164600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102094989","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-09-08 16:46:00","symbol":"BIOCON"},{"an_dt":"07-Sep-2017 16:46:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/PressRelease_Biocon_07092017164614_343.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 07, 2017, titled \"Biocon s Insulins facility in Malaysia Receives EU GMP Compliance Certificate\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"07092017164600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102091210","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-09-07 16:46:00","symbol":"BIOCON"},{"an_dt":"06-Sep-2017 10:57:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Pressrelease_Biocon_06092017105743_017.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 06, 2017, titled \"JDRF Supports Biocon Study of Novel, Fast-acting Oral Insulin Tregopil for Type 1 Diabetes Treatment.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"06092017105700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102086880","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-09-06 10:57:00","symbol":"BIOCON"},{"an_dt":"05-Sep-2017 09:37:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_05092017093729_460.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"05092017093700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102080968","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-09-05 09:37:00","symbol":"BIOCON"},{"an_dt":"30-Aug-2017 16:01:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Pressrelease_30082017160107_314.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 30, 2017, titled \"USFDA Target Action Date for Trastuzumab reset to December 3, 2017.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"30082017160100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102067944","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-08-30 16:01:00","symbol":"BIOCON"},{"an_dt":"29-Aug-2017 10:30:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_29082017103009_034.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"29082017103000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102064740","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-08-29 10:30:00","symbol":"BIOCON"},{"an_dt":"23-Aug-2017 10:14:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_23082017101446_829.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"23082017101400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102053127","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-08-23 10:14:00","symbol":"BIOCON"},{"an_dt":"22-Aug-2017 10:09:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Anlaystmeet_Biocon_22082017100922_624.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"22082017100900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102048248","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-08-22 10:09:00","symbol":"BIOCON"},{"an_dt":"21-Aug-2017 19:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BM_Aug21_2017_21082017194300_579.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on 0 21, 017.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"21082017194300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102046480","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-08-21 19:43:00","symbol":"BIOCON"},{"an_dt":"17-Aug-2017 11:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_17082017110409_077.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"17082017110400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102039577","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-08-17 11:04:00","symbol":"BIOCON"},{"an_dt":"16-Aug-2017 11:29:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Statement_Aug16_16082017112914_494.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 16, 2017, titled \"Company Statement on Status of EMA Dossiers.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"16082017112900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102036681","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-08-16 11:29:00","symbol":"BIOCON"},{"an_dt":"11-Aug-2017 16:41:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_11082017164143_577.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"11082017164100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102028047","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-08-11 16:41:00","symbol":"BIOCON"},{"an_dt":"11-Aug-2017 11:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Incorporation_WOS_BHSB_11082017114251_130.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Incorporation of a Wholly Owned Subsidiary in Malaysia.","bflag":null,"csvName":null,"desc":"Acquisition","difference":"-","dt":"11082017114200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102027681","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-08-11 11:42:00","symbol":"BIOCON"},{"an_dt":"07-Aug-2017 11:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Anlaystmeet_Biocon_07082017114407_063.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"07082017114400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"102012509","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-08-07 11:44:00","symbol":"BIOCON"},{"an_dt":"31-Jul-2017 22:05:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Statement_July31_31072017220536_777.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 31, 2017, titled \"Company s statement in response to some media queries regarding the USFDA visit to Biocon in the month of May/June 2017.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"31072017220500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101994565","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-07-31 22:05:00","symbol":"BIOCON"},{"an_dt":"31-Jul-2017 18:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_July31_2017_31072017184426_662.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"31072017184400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101993775","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-07-31 18:44:00","symbol":"BIOCON"},{"an_dt":"29-Jul-2017 14:38:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AGM_Votingresults_Biocon_29072017143831_197.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on July 28, 2017. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"29072017143800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101990645","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-07-29 14:38:00","symbol":"BIOCON"},{"an_dt":"27-Jul-2017 19:27:25","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Results_June2017_27072017192725.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended June 30, 2017.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"27072017192725","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"113876","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-07-27 19:27:25","symbol":"BIOCON"},{"an_dt":"27-Jul-2017 19:27:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Results_June2017_27072017192747.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on July 27, 2017.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"27072017192700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101985473","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-07-27 19:27:00","symbol":"BIOCON"},{"an_dt":"14-Jul-2017 05:08:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Mylan_14072017050841_016.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 14, 2017, titled \"FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon s Proposed Biosimilar Trastuzumab\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"14072017050800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101948299","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-07-14 05:08:00","symbol":"BIOCON"},{"an_dt":"09-Jul-2017 09:26:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/ANSM_Biocon_Statement_9July17_09072017092651_881.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 09, 2017, titled \"Company s statement on the outcome of pre-approval inspection audits by ANSM on behalf of EMA.\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"09072017092600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101932601","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-07-09 09:26:00","symbol":"BIOCON"},{"an_dt":"06-Jul-2017 08:21:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AGM_Notice_Biocon_06072017082142_024.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on July 28, 2017","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"06072017082100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101925801","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-07-06 08:21:00","symbol":"BIOCON"},{"an_dt":"05-Jul-2017 08:40:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AGM_Ad_Biocon_05072017084050_128.zip","attchmntText":"Biocon Limited has submitted to the Exchange a Copy of Newspaper in connection with completion of dispatch of Notice and Annual report of the Annual General Meeting will be held on July 28, 2017.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"05072017084000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101921970","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-07-05 08:40:00","symbol":"BIOCON"},{"an_dt":"28-Jun-2017 11:02:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/IEPF_biocon_28062017110221_321.zip","attchmntText":"Biocon Limited has submitted to the Exchange a Copy of Newspaper Advertisement for transfer of equity shares of the Company to Investor Education and Protection Fund (IEPF).","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"28062017110200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101904360","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-06-28 11:02:00","symbol":"BIOCON"},{"an_dt":"23-Jun-2017 12:34:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Presentation_Biocon_23062017123457_337.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"23062017123400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101896289","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-06-23 12:34:00","symbol":"BIOCON"},{"an_dt":"22-Jun-2017 12:23:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AGM_Recorddate_BC_Biocon_22062017122352_072.zip","attchmntText":"Biocon Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from July 22, 2017 to July 28, 2017(both days inclusive) for the purpose of Annual General Meeting of the Company is scheduled to be held on July 28, 2017 & Dividend","bflag":null,"csvName":null,"desc":"AGM/Book Closure","difference":"-","dt":"22062017122300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101892423","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-06-22 12:23:00","symbol":"BIOCON"},{"an_dt":"20-Jun-2017 17:37:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AnalystsMeet_Biocon_20062017173701_480.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"20062017173700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101884916","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-06-20 17:37:00","symbol":"BIOCON"},{"an_dt":"19-Jun-2017 18:39:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bonus_allotment_Biocon_19062017183927_231.zip","attchmntText":"Biocon Limited has informed the Exchange regarding allotment of 400000000 securities pursuant to Bonus at its meeting held on Jun 19, 2017","bflag":null,"csvName":null,"desc":"Allotment of Securities","difference":"-","dt":"19062017183900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101881103","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-06-19 18:39:00","symbol":"BIOCON"},{"an_dt":"11-Jun-2017 10:50:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_MylanPR_June11_11062017105049_111.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated Jun 11, 2017, titled \"Mylan and Biocon Present Clinical Data on Insulin Glargine at the American Diabetes Association s 77th Scientific Sessions\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"11062017105000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101858478","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-06-11 10:50:00","symbol":"BIOCON"},{"an_dt":"07-Jun-2017 15:52:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Recorddate_bonus_07062017155224_538.zip","attchmntText":"Biocon Limited has informed the Exchange that the Company has fixed Record Date as June 17, 2017 to determine the eligible shareholders entitled to receive the Bonus Equity Shares.","bflag":null,"csvName":null,"desc":"Record Date","difference":"-","dt":"07062017155200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101848847","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-06-07 15:52:00","symbol":"BIOCON"},{"an_dt":"07-Jun-2017 15:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Votingsresults_Biocon_07062017152413_520.zip","attchmntText":"Biocon Limited has submitted the Exchange a copy Srutinizers report of  Postal Ballot. Further, the company has informed the Exchange regarding voting results.","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"07062017152400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101848839","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-06-07 15:24:00","symbol":"BIOCON"},{"an_dt":"01-Jun-2017 16:05:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_June01_2017_01062017160510_700.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"01062017160500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101832760","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-06-01 16:05:00","symbol":"BIOCON"},{"an_dt":"11-May-2017 18:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystsmeet_May11_11052017184249_860.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"11052017184200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101767153","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-05-11 18:42:00","symbol":"BIOCON"},{"an_dt":"10-May-2017 12:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconStatement_May10_10052017123334_971.zip","attchmntText":"Biocon Limited has informed the Exchange regarding \"Biocon statement in response to Media Reports on USFDA Form 483s for Biocon Limited\"","bflag":null,"csvName":null,"desc":"Clarification","difference":"-","dt":"10052017123300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101764608","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-05-10 12:33:00","symbol":"BIOCON"},{"an_dt":"05-May-2017 17:51:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Postalballot_Biocon_05052017175125_304.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Notice of Postal Ballot","bflag":null,"csvName":null,"desc":"Shareholders meeting","difference":"-","dt":"05052017175100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101752187","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-05-05 17:51:00","symbol":"BIOCON"},{"an_dt":"04-May-2017 18:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_04May2017_04052017184826_834.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"04052017184800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101747832","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-05-04 18:48:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2017 16:49:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_April28_28042017164918_287.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"28042017164900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101734840","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-04-28 16:49:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2017 16:47:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Presentation_March31_28042017164737_286.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"28042017164700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101734839","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-04-28 16:47:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2017 08:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042017084221.zip","attchmntText":"Biocon Limited has informed the Exchange that he Board of Directors of the Company at their meeting held on April 27, 2017, considered and approved the following: 1. Recommended a final dividend of Rs. 3/- per equity share of face value of Rs. 5/- each (Pre- bonus issue) for the financial year ended March 31, 2017.","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"28042017084200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101732207","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-04-28 08:42:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2017 08:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042017084242.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on April 27, 2017.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"28042017084200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101732208","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-04-28 08:42:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2017 08:37:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_28042017083744.zip","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on April 27, 2017, considered and approved the following: 1. Recommend issue of Bonus Shares in the proportion of 2:1 i.e. 2 (two) bonus equity shares of Rs. 5/- each for every 1(one) fully paid-up equity shares of Rs. 5/- each held as on record date, subject to the approval of the members of the Company. The record date for reckoning eligible shareholders entitled to receive bonus shares will be intimated to the stock exchanges in due course","bflag":null,"csvName":null,"desc":"Bonus","difference":"-","dt":"28042017083700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101732204","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-04-28 08:37:00","symbol":"BIOCON"},{"an_dt":"27-Apr-2017 20:33:55","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Results_27042017203355.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended March 31, 2017.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"27042017203355","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"112031","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-04-27 20:33:55","symbol":"BIOCON"},{"an_dt":"11-Apr-2017 11:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bicon_11042017114823.zip","attchmntText":"Kiran Mazumdar Shaw has submitted to the Exchange vide letter dated a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.","bflag":null,"csvName":null,"desc":"Disc. under Reg.30 of SEBI (SAST) Reg.2011","difference":"-","dt":"11042017114800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101685300","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-04-11 11:48:00","symbol":"BIOCON"},{"an_dt":"30-Mar-2017 12:55:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_30032017125546_153.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"30032017125500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101655550","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-03-30 12:55:00","symbol":"BIOCON"},{"an_dt":"27-Mar-2017 11:41:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Anlaystmeet_27032017114114_380.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"27032017114100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101644672","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-03-27 11:41:00","symbol":"BIOCON"},{"an_dt":"15-Mar-2017 12:31:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_analystmeet_15032017123128_271.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"15032017123100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101611233","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-03-15 12:31:00","symbol":"BIOCON"},{"an_dt":"14-Mar-2017 15:30:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Response_14032017153019_013.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Clarification in response to queries received from analysts/investors regarding Mylan s announcement related to its global settlement and license agreement with Genentech and Roche on Herceptin.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"14032017153000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101607714","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-03-14 15:30:00","symbol":"BIOCON"},{"an_dt":"06-Mar-2017 10:36:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AnalystMeet_Biocon_06032017103617_268.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"06032017103600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101586289","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-03-06 10:36:00","symbol":"BIOCON"},{"an_dt":"03-Mar-2017 19:59:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconStatement_Courtorder_03032017195938_158.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Biocon's statement in response to Delhi High Court Interim Order.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"03032017195900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101582073","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-03-03 19:59:00","symbol":"BIOCON"},{"an_dt":"02-Mar-2017 16:45:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AnalystMeet_Biocon_02032017164546_693.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"02032017164500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101578149","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-03-02 16:45:00","symbol":"BIOCON"},{"an_dt":"27-Feb-2017 09:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AnalystInvestor_Biocon_27022017094326_834.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"27022017094300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101564220","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-02-27 09:43:00","symbol":"BIOCON"},{"an_dt":"24-Feb-2017 10:40:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Anlaystmeet_Biocon_Feb23_24022017104012_440.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"24022017104000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101563568","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-02-24 10:40:00","symbol":"BIOCON"},{"an_dt":"22-Feb-2017 10:06:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_Feb22_22022017100643_635.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"22022017100600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101555949","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-02-22 10:06:00","symbol":"BIOCON"},{"an_dt":"16-Feb-2017 18:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_Feb16_16022017182840_319.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 16, 2017, titled \"U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon s Proposed Biosimilar Pegfilgrastim for Review\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"16022017182800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101541936","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-02-16 18:28:00","symbol":"BIOCON"},{"an_dt":"14-Feb-2017 10:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analyst_Biocon_14022017104228_822.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"14022017104200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101532794","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-02-14 10:42:00","symbol":"BIOCON"},{"an_dt":"13-Feb-2017 11:22:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Presentation_Biocon_13022017112207_080.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"13022017112200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101528424","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-02-13 11:22:00","symbol":"BIOCON"},{"an_dt":"07-Feb-2017 10:21:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Feb7_07022017102118_048.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"07022017102100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101509945","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-02-07 10:21:00","symbol":"BIOCON"},{"an_dt":"30-Jan-2017 12:57:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_Jan30_30012017125714_125.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"30012017125700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101485561","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-01-30 12:57:00","symbol":"BIOCON"},{"an_dt":"25-Jan-2017 16:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Reply_clarification_25012017164308.zip","attchmntText":"BIOCON: The Exchange had sought clarification from Biocon Limited with respect to announcement dated 25-Jan-2017, informing that based on the recommendation by the Nomination and Remuneration Committee, Mr. Rajiv Balakrishnan was appointed as the Company Secretary and Compliance Officer of the Company by the Board of Directors at their meeting held on January 24, 2017.On basis of above the Company was required to clarify following:1. Brief profile (in case of appointment);The response of the Company is attached.","bflag":null,"csvName":null,"desc":"Reply to Clarification Sought","difference":"-","dt":"25012017164300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101476667","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-01-25 16:43:00","symbol":"BIOCON"},{"an_dt":"25-Jan-2017 11:06:00","attFileSize":null,"attchmntFile":"-","attchmntText":"BIOCON: The Exchange has sought clarification from Biocon Limited with respect to announcement dated 25-Jan-2017, informing that based on the recommendation by the Nomination and Remuneration Committee, Mr. Rajiv Balakrishnan was appointed as the Company Secretary and Compliance Officer of the Company by the Board of Directors at their meeting held on January 24, 2017.On basis of above the Company is required to clarify following:1. Brief profile (in case of appointment);The response of the Company is awaited.","bflag":null,"csvName":null,"desc":"Clarification","difference":"-","dt":"25012017110600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101476201","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-01-25 11:06:00","symbol":"BIOCON"},{"an_dt":"25-Jan-2017 08:39:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Change_in_KMP_25012017083933_617.zip","attchmntText":"Biocon Limited has informed the Exchange that based on the recommendation by the Nomination and Remuneration Committee, Mr. Rajiv Balakrishnan was appointed as the Company Secretary and Compliance Officer of the Company by the Board of Directors at their meeting held on January 24, 2017.","bflag":null,"csvName":null,"desc":"Appointment of Company Secretary/Compliance Officer","difference":"-","dt":"25012017083900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101473915","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-01-25 08:39:00","symbol":"BIOCON"},{"an_dt":"25-Jan-2017 08:37:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25012017083702.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 24, 2017, titled \"Biocon Q3 FY17 Net Profit Up 65% at Rs.171 Crore\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25012017083700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101473916","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-01-25 08:37:00","symbol":"BIOCON"},{"an_dt":"25-Jan-2017 08:37:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_25012017083733.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Fact Sheet for December 2016.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"25012017083700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101473917","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-01-25 08:37:00","symbol":"BIOCON"},{"an_dt":"25-Jan-2017 07:25:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_MoH_25012017072503_603.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 25, 2017, titled \"Biocon Wins MYR 300 Million Contract for Insulin from MoH, Malaysia\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25012017072500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101473906","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-01-25 07:25:00","symbol":"BIOCON"},{"an_dt":"24-Jan-2017 20:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_results_24012017201644_579.zip","attchmntText":"Biocon Limited has informed the Exchange about Publication of Un-audited financial results for the quarter and period ended December 31, 2016.","bflag":null,"csvName":null,"desc":"Financial Results Updates","difference":"-","dt":"24012017201600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101472503","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-01-24 20:16:00","symbol":"BIOCON"},{"an_dt":"24-Jan-2017 19:46:52","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Results_Biocon_final_24012017194652.zip","attchmntText":"Biocon Limited has submitted to the Exchange, the financial results for the period ended December 31, 2016.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"24012017194652","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"110437","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-01-24 19:46:52","symbol":"BIOCON"},{"an_dt":"11-Jan-2017 18:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Jan11_Bio_Myl_PR_11012017182819_317.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 11, 2017, titled \"U.S. FDA Accepts Biologics License Application (BLA) for                              Mylan and Biocon s Proposed Biosimilar Trastuzumab\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"11012017182800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101434189","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2017-01-11 18:28:00","symbol":"BIOCON"},{"an_dt":"27-Dec-2016 12:11:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Dec27_PR_Biocon_27122016121122_325.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 27, 2016, titled \"Journal of the American Medical Association (JAMA) Publishes Mylan and Biocon s Proposed Biosimilar Trastuzumab Phase 3 Data\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"27122016121100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101390158","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-12-27 12:11:00","symbol":"BIOCON"},{"an_dt":"20-Dec-2016 16:53:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Bio_Dec20_20122016165311_612.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"20122016165300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101369210","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-12-20 16:53:00","symbol":"BIOCON"},{"an_dt":"19-Dec-2016 08:21:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Ad_IEPF_19122016082133_103.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of Newspaper Advertisement published in Newspaper in connection with Transfer of Shares to Investor Education Protection Fund (IEPF) suspense account\".","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"19122016082100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101361813","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-12-19 08:21:00","symbol":"BIOCON"},{"an_dt":"16-Dec-2016 19:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_KMP_16122016190449_627.zip","attchmntText":"Biocon Limited has informed the Exchange that Mr. Kiran Kumar, Company Secretary has been transferred to the Company's Subsidiary, M/s. Biocon Sdn Bhd, Malaysia as Vice President - Finance and hence ceased to be the Company Secretary and Compliance Officer of the Company effective December 15, 2016.","bflag":null,"csvName":null,"desc":"Change in Company Secretary/Compliance Officer","difference":"-","dt":"16122016190400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101360067","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-12-16 19:04:00","symbol":"BIOCON"},{"an_dt":"13-Dec-2016 18:07:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Bio_Dec13_13122016180720_057.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"13122016180700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101347901","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-12-13 18:07:00","symbol":"BIOCON"},{"an_dt":"13-Dec-2016 12:29:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_13122016122931.zip","attchmntText":"Biocon Limited has informed the Exchange that there was a fire last night within one of the laboratory buildings at Syngene International Limited, a subsidiary of the Company. The fire has since been bought under control and there has been no loss of life or any injury reported. Syngene is in the process of assessing the extent of damage to the building and equipment and also implementing a business continuity plan to minimize impact on operations. Other facilities at Syngene are not impacted and continue to operate as normal.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"13122016122900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101347787","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-12-13 12:29:00","symbol":"BIOCON"},{"an_dt":"09-Dec-2016 12:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_Dec09_09122016122855_092.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 09, 2016, titled \"Biocon Features in Asia IP Elite 2016 List  -The only Pharmaceutical Company from India to be recognized for IP-led Value Creation\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"09122016122800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101341972","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-12-09 12:28:00","symbol":"BIOCON"},{"an_dt":"06-Dec-2016 17:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_06122016171636_284.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"06122016171600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101329940","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-12-06 17:16:00","symbol":"BIOCON"},{"an_dt":"29-Nov-2016 16:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_Nov29_29112016160025_181.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 29, 2016, titled \"Biocon s Novel Diabetes Education Initiative for Medical Practitioners  ABIDE  Awarded by RSSDI\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"29112016160000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101308376","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-11-29 16:00:00","symbol":"BIOCON"},{"an_dt":"22-Nov-2016 14:11:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_22112016141122_552.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"22112016141100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101287893","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-11-22 14:11:00","symbol":"BIOCON"},{"an_dt":"17-Nov-2016 17:18:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Nov17_17112016171842_238.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"17112016171800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101274983","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-11-17 17:18:00","symbol":"BIOCON"},{"an_dt":"15-Nov-2016 12:05:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet-Nov15_15112016120510_280.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"15112016120500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101262039","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-11-15 12:05:00","symbol":"BIOCON"},{"an_dt":"12-Nov-2016 10:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_pr_12112016103327_272.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 11, 2016, titled \"Biocon Collaborates with Healthcare Professionals for a Public Awareness Campaign on Diabetes Prevention & Management across India\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"12112016103300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101261476","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-11-12 10:33:00","symbol":"BIOCON"},{"an_dt":"11-Nov-2016 12:41:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_11112016124131_716.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"11112016124100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101260762","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-11-11 12:41:00","symbol":"BIOCON"},{"an_dt":"09-Nov-2016 18:01:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_09112016180122_403.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investor Meet/Con. Call Updates","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"09112016180100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101252585","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-11-09 18:01:00","symbol":"BIOCON"},{"an_dt":"08-Nov-2016 17:49:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_Nov8_08112016174921_136.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 08, 2016, titled \"Mylan and Biocon Announce U.S. FDA Submission for Proposed Biosimilar Trastuzumab\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"08112016174900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101247990","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-11-08 17:49:00","symbol":"BIOCON"},{"an_dt":"03-Nov-2016 18:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_Nov3_03112016183316_605.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 03, 2016, titled \"Mylan and Biocon Announce Regulatory Submission for Insulin Glargine Accepted for Review by European\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"03112016183300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101235162","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-11-03 18:33:00","symbol":"BIOCON"},{"an_dt":"28-Oct-2016 18:52:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_Oct28_28102016185211_715.zip","attchmntText":"Biocon Limited has informed the Exchange regarding press release dated October 28, 2016 titled \" Biocon Ranked Among Global Top Ten Biotech Employers -The only Asian Company to Feature in 2016 Rankings .\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"28102016185200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101221738","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-10-28 18:52:00","symbol":"BIOCON"},{"an_dt":"24-Oct-2016 10:23:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_24102016102350_860.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Schedule of Analyst/Institutional Investor Meet.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"24102016102300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101202756","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-10-24 10:23:00","symbol":"BIOCON"},{"an_dt":"20-Oct-2016 19:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Results_PR_Biocon_Q2_20102016194217_450.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Press Release dated October 20, 2016 title \" Biocon Q2 FY17 Revenue Up 21%: EBITDA Up 45%.\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"20102016194200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101195112","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-10-20 19:42:00","symbol":"BIOCON"},{"an_dt":"20-Oct-2016 19:30:47","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Results_final_Biocon_Q2_20102016193047.zip","attchmntText":"Biocon Limited has submitted to the Exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended September 30, 2016.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"20102016193047","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"108654","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-10-20 19:30:47","symbol":"BIOCON"},{"an_dt":"28-Sep-2016 09:47:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_28092016094732_617.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investors meet.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"28092016094700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101128957","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-09-28 09:47:00","symbol":"BIOCON"},{"an_dt":"23-Sep-2016 13:14:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_23092016131437_162.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/ Institutional Investors meet.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"23092016131400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101118626","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-09-23 13:14:00","symbol":"BIOCON"},{"an_dt":"19-Sep-2016 09:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_19092016094449_299.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 19, 2016 \"Biocon Appoints Suresh Subramanian as Head of Branded Formulations (India) Business\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"19092016094400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101099372","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-09-19 09:44:00","symbol":"BIOCON"},{"an_dt":"14-Sep-2016 10:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AnlaystInvestormeet_14092016104311_966.zip","attchmntText":"Biocon Limited has informed the Exchange that regarding Analysts/Institutional Investor Meeting.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"14092016104300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101085681","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-09-14 10:43:00","symbol":"BIOCON"},{"an_dt":"07-Sep-2016 09:32:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_sep7_07092016093233_037.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Schedule of Analysts/ Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"07092016093200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101067819","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-09-07 09:32:00","symbol":"BIOCON"},{"an_dt":"01-Sep-2016 17:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_01092016170443_620.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/ Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"01092016170400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101057341","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-09-01 17:04:00","symbol":"BIOCON"},{"an_dt":"26-Aug-2016 15:59:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_26082016155934_794.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/ Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"26082016155900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101038776","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-08-26 15:59:00","symbol":"BIOCON"},{"an_dt":"25-Aug-2016 16:01:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/PR_Biocon_Mylan_25082016160139_304.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 25, 2016 titled \"Mylan and Biocon Announce Regulatory Submission for Proposed Biosimilar Trastuzumab Accepted for Review by European Medicines Agency\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25082016160100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101034409","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-08-25 16:01:00","symbol":"BIOCON"},{"an_dt":"24-Aug-2016 12:56:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon__24082016125654_134.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Intimation of  Analysts/ Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"24082016125600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101023765","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-08-24 12:56:00","symbol":"BIOCON"},{"an_dt":"17-Aug-2016 15:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_17082016154311_281.zip","attchmntText":"Biocon Limited has informed the Exchange that Intimation regarding Analysts/ Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"17082016154300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101008201","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-08-17 15:43:00","symbol":"BIOCON"},{"an_dt":"09-Aug-2016 16:01:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Analystmeet_09082016160103_349.zip","attchmntText":"Biocon Limited has informed the Exchange that Intimation regarding Analysts/ Institutional Investors Meet .","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"09082016160100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100981966","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-08-09 16:01:00","symbol":"BIOCON"},{"an_dt":"02-Aug-2016 15:23:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon-Aug_02082016152317_349.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analyst/ Institutional Investors Meet","bflag":null,"csvName":null,"desc":"Analysts/Institutional Investor Meet/Con. Call Updates","difference":"-","dt":"02082016152300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100957334","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-08-02 15:23:00","symbol":"BIOCON"},{"an_dt":"28-Jul-2016 10:35:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/PR_Biocon_28072016103548_069.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July  28, 2016  titled \"Biocon Initiates \"EK Prayaas\" Nationwide Awareness Program on Hepatitis C\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"28072016103500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100941252","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-07-28 10:35:00","symbol":"BIOCON"},{"an_dt":"21-Jul-2016 20:09:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Mylan_Biocon_PR_21072016200932_509.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Press release Dated July 21, 2016 Title \" Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency .\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21072016200900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100921072","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-07-21 20:09:00","symbol":"BIOCON"},{"an_dt":"21-Jul-2016 19:58:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconPR_factsheet_21072016195813_491.zip","attchmntText":"Biocon Limited has informed the Exchange regarding press release dated july 21, 2016 Title \" Bicon Reports & Strong Q1FY17.\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21072016195800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100921070","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-07-21 19:58:00","symbol":"BIOCON"},{"an_dt":"21-Jul-2016 19:05:59","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Results_Biocon_21072016190559.zip","attchmntText":"Biocon Limited has submitted to the Exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended June 30, 2016.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"21072016190559","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"106985","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-07-21 19:05:59","symbol":"BIOCON"},{"an_dt":"15-Jul-2016 09:06:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_June15_2016_15072016090637_011.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 15, 2016, titled \"Biocon's Insulin Glargine Launched in Japan\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"15072016090600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100898519","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-07-15 09:06:00","symbol":"BIOCON"},{"an_dt":"01-Jul-2016 19:07:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Votingresults_AGM_Biocon_01072016190701_527.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Voting Results for the Annual General Meeting of Company along with Scrutinizer report.","bflag":null,"csvName":null,"desc":"Regulation 44(3) of SEBI (LODR), Reg., 2015","difference":"-","dt":"01072016190700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100863152","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-07-01 19:07:00","symbol":"BIOCON"},{"an_dt":"01-Jul-2016 10:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/ChangeofAuditors_AGM2016_BIOCON_01072016103340_061.zip","attchmntText":"Biocon Limited has informed the Exchange vide letter dated June 30, 2016 \"Change in Statutory Auditors of the Company\".","bflag":null,"csvName":null,"desc":"Change in Auditors","difference":"-","dt":"01072016103300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100862483","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-07-01 10:33:00","symbol":"BIOCON"},{"an_dt":"01-Jul-2016 10:32:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AGMProceeding_Biocon_01072016103211_060.zip","attchmntText":"Biocon Limited has informed the Exchange regarding the proceeding of Annual General Meeting held on June 30, 2016.","bflag":null,"csvName":null,"desc":"Annual General Meeting Updates","difference":"-","dt":"01072016103200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100862484","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-07-01 10:32:00","symbol":"BIOCON"},{"an_dt":"27-Jun-2016 17:08:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_27062016170835_734.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Schedule for the Analyst/ Institutional Investor meetings.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"27062016170800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100845832","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-06-27 17:08:00","symbol":"BIOCON"},{"an_dt":"24-Jun-2016 10:09:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_24062016100945_919.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/ Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"24062016100900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100838955","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-06-24 10:09:00","symbol":"BIOCON"},{"an_dt":"23-Jun-2016 08:47:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_23062016084738_553.zip","attchmntText":"Biocon Limited has informed the Exchange that Intimation regarding Analysts/ Institutional Investors Meet - Pursuant to the regulation 30 (6) of the SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"23062016084700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100832727","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-06-23 08:47:00","symbol":"BIOCON"},{"an_dt":"23-Jun-2016 08:42:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Quark_PR_23062016084242_552.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated June 23, 2016 titled \"Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"23062016084200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100832726","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-06-23 08:42:00","symbol":"BIOCON"},{"an_dt":"20-Jun-2016 12:41:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_BioconJ20_20062016124159_624.zip","attchmntText":"Biocon Limited has informed the Exchange regarding the Analyst/Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"20062016124100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100822111","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-06-20 12:41:00","symbol":"BIOCON"},{"an_dt":"16-Jun-2016 16:31:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Analystmeet_16062016163108_863.zip","attchmntText":"Biocon Limited has informed the Exchange that Intimation regarding Analysts/ Institutional Investors Meet - Pursuant to the regulation 30 (6) of the SEBI (Listing Obligations & Disclosure Requirements), Regulations, 2015","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"16062016163100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100815063","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-06-16 16:31:00","symbol":"BIOCON"},{"an_dt":"10-Jun-2016 16:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_10062016164832_228.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/ Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"10062016164800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100796694","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-06-10 16:48:00","symbol":"BIOCON"},{"an_dt":"06-Jun-2016 08:29:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AGMNoticesubmission_Biocon_06062016082940_620.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of the notice of Annual General Meeting of the company scheduled on June 30, 2016.","bflag":null,"csvName":null,"desc":"Annual General Meeting Updates","difference":"-","dt":"06062016082900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100770440","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-06-06 08:29:00","symbol":"BIOCON"},{"an_dt":"06-Jun-2016 08:21:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/AGM_Bookclosure-BIOCON_06062016082105_598.zip","attchmntText":"Biocon Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from June 24, 2016 to June 30, 2016 (both days inclusive) for the purpose of Annual General Meeting of the Company scheduled to be held on June 30, 2016.","bflag":null,"csvName":null,"desc":"AGM/Book Closure","difference":"-","dt":"06062016082100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100770390","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-06-06 08:21:00","symbol":"BIOCON"},{"an_dt":"06-Jun-2016 08:10:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/PressRelease_Biocon_Final_06062016081014_583.zip","attchmntText":"Biocon Limited has informed the Exchange regarding press release Dated June 03, 2016 titled \" Mylan and Biocon to Present Phase 3 Trastuzumab Biosimilar Data at the American Society of Clinical Oncology (ASCO) Annual Meeting.\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"06062016081000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100770399","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-06-06 08:10:00","symbol":"BIOCON"},{"an_dt":"03-Jun-2016 12:01:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_03062016120156_105.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/ Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"03062016120100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100770228","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-06-03 12:01:00","symbol":"BIOCON"},{"an_dt":"02-Jun-2016 14:29:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_02062016142929_768.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/ Institutional Investors Meeting.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"02062016142900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100770062","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-06-02 14:29:00","symbol":"BIOCON"},{"an_dt":"30-May-2016 13:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_30052016134320_587.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/ Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"30052016134300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100756571","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-05-30 13:43:00","symbol":"BIOCON"},{"an_dt":"26-May-2016 17:26:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_2_26052016172640_484.zip","attchmntText":"Biocon Limited has informed the Exchange the Intimation regarding Analysts/ Institutional Investors Meet .","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"26052016172600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100747338","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-05-26 17:26:00","symbol":"BIOCON"},{"an_dt":"26-May-2016 12:59:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_26052016125927_183.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/ Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"26052016125900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100746226","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-05-26 12:59:00","symbol":"BIOCON"},{"an_dt":"18-May-2016 14:55:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_18052016145507_264.zip","attchmntText":"Biocon Limited has informed the Exchange vide letter dated May 18, 2016 regarding Analysts/ Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"18052016145500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100720572","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-05-18 14:55:00","symbol":"BIOCON"},{"an_dt":"12-May-2016 11:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_12052016113348_163.zip","attchmntText":"Biocon Limited has informed the Exchange vide letter dated May 12, 2016 regarding Intimation regarding Analysts/ Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"12052016113300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100702353","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-05-12 11:33:00","symbol":"BIOCON"},{"an_dt":"05-May-2016 10:54:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_05052016105449_070.zip","attchmntText":"Biocon Limited has informed the Exchange regarding schedule for the Analyst/Institutional Investor meetings.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"05052016105400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100677817","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-05-05 10:54:00","symbol":"BIOCON"},{"an_dt":"03-May-2016 09:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_Biocon_03052016094430_051.zip","attchmntText":"Biocon Limited has informed the Exchange vide letter dated May 03, 2016 regarding Analyst/Institutional Investor meet.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"03052016094400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100669673","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-05-03 09:44:00","symbol":"BIOCON"},{"an_dt":"27-Apr-2016 08:35:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_27042016083523.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of the Fact Sheet and press release with respect to the Financial Results for the quarter and year ended March 31, 2016.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"27042016083500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100651432","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-04-27 08:35:00","symbol":"BIOCON"},{"an_dt":"27-Apr-2016 08:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Intimation-AppointmentofDirector_27042016083327_664.zip","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors of the Company has appointed Mr. M. Damodaran as Additional Independent Director of the Company, at its meeting held on April 26, 2016.He will hold office upto date of ensuing Annual General Meeting where in his appointment as Director will be placed before the shareholders for Approval.","bflag":null,"csvName":null,"desc":"Appointment of Director","difference":"-","dt":"27042016083300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100651435","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-04-27 08:33:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2016 22:49:06","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Results_Biocon_26042016224906.zip","attchmntText":"Biocon Limited has submitted to the Exchange the standalone & consolidated financial results along with the Auditors Report for the period ended March 31, 2016.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"26042016224906","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"104911","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-04-26 22:49:06","symbol":"BIOCON"},{"an_dt":"20-Apr-2016 19:17:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon-BSENSE_20042016191705_470.zip","attchmntText":"Biocon Limited has informed the Exchange that the Class Ill recall for 5mg tablets of simvastatin pertains to a specific lot manufactured by Blu Caribe, Puerto Rico, USA for Blu Pharmaceuticals, Kentucky, USA (together 'Blu') long before Biocon acquired the simvastatin ANDA from Blu. The FDA notified Biocon as we are the current holders of the ANDA. Blu has successfully initiated and completed the recall. Biocon has not manufactured and supplied any simvastatin tablets to date.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"20042016191700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100634854","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-04-20 19:17:00","symbol":"BIOCON"},{"an_dt":"13-Apr-2016 08:49:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Duly_13042016084941.zip","attchmntText":"Biocon Limited has submitted to the Exchange vide letter dated April 7, 2016  a copy of disclosure under Regulation 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.","bflag":null,"csvName":null,"desc":"Disc. under Reg.30 of SEBI (SAST) Reg.2011","difference":"-","dt":"13042016084900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100621351","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-04-13 08:49:00","symbol":"BIOCON"},{"an_dt":"06-Apr-2016 17:02:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_6211_reply_06042016170221.zip","attchmntText":"Significant increase in volume has been observed in Biocon Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Biocon Limited has submitted their response.","bflag":null,"csvName":null,"desc":"Spurt in Volume","difference":"-","dt":"06042016170200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100607691","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-04-06 17:02:00","symbol":"BIOCON"},{"an_dt":"05-Apr-2016 16:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Bioconbdmeetapril26_05042016162858.zip","attchmntText":"Biocon Limited has informed the Exchange that the Company will organize a conference call for analysts and investors on April 27, 2016. The details of the call will be available on the Company's website closer to the scheduled event.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"05042016162800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100603311","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-04-05 16:28:00","symbol":"BIOCON"},{"an_dt":"29-Mar-2016 10:02:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_29032016100259_053.zip","attchmntText":"Biocon Limited has informed the Exchange regarding the \"Analysts/ Institutional Investors meet\".","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"29032016100200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100581257","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-03-29 10:02:00","symbol":"BIOCON"},{"an_dt":"28-Mar-2016 14:03:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/PR-Biocon_28032016140341_452.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 28, 2016 titled \" Biocon 's Insulin Glargine Receives Regulatory Approval in Japan\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"28032016140300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100581107","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-03-28 14:03:00","symbol":"BIOCON"},{"an_dt":"23-Mar-2016 11:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet-Biocon_23032016112000_044.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/ Institutional Investors meet.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"23032016112000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100576367","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-03-23 11:20:00","symbol":"BIOCON"},{"an_dt":"17-Mar-2016 12:03:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Pressrelease_17032016120326_098.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 17, 2016, titled \"Biocon Inks Co-Development & Commercialization Agreement with Lab PiSA for rh-Insulin in USA\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"17032016120300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100558786","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-03-17 12:03:00","symbol":"BIOCON"},{"an_dt":"17-Mar-2016 08:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_17032016084832_043.zip","attchmntText":"Biocon Limited has informed the Exchange vide letter dated March 17, 2016 regarding \"Agreement for development and commercialisation of rh-Insulin for US market\".","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"17032016084800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100556409","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-03-17 08:48:00","symbol":"BIOCON"},{"an_dt":"15-Mar-2016 12:55:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Analystmeet_15032016125537_574.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/Institutional Investors meet.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"15032016125500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100551144","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-03-15 12:55:00","symbol":"BIOCON"},{"an_dt":"11-Mar-2016 17:29:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Outcome_11032016172931_534.zip","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors of the Company at their meeting held on March 11, 2016, has approved the payment of Interim dividend at a rate of 100% i.e. (Rs. 5 per share) for the financial year 2015-16 vide circular resolution dated March 11, 2016. The said Interim dividend , will be paid on or before March 29, 2016.","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"11032016172900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100538149","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-03-11 17:29:00","symbol":"BIOCON"},{"an_dt":"08-Mar-2016 21:23:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/PriorIntimation-InterimdividendRecorddate_08032016212312_161.zip","attchmntText":"Biocon Limited has informed the Exchange that the Company has fixed Record Date as March 19, 2016 for the purpose of Interim Dividend for the financial year 2015-16.","bflag":null,"csvName":null,"desc":"Record Date","difference":"-","dt":"08032016212300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100529992","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-03-08 21:23:00","symbol":"BIOCON"},{"an_dt":"08-Mar-2016 19:17:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/PriorIntimation-InterimdividendRecorddate_08032016191749_115.zip","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors of the Company will consider declaration of Interim Dividend for the financial year 2015-16 through circular resolution on March 11, 2016.","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"08032016191700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100529990","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-03-08 19:17:00","symbol":"BIOCON"},{"an_dt":"08-Mar-2016 18:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconAnalystInvestormeet_08032016182400_078.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/ Institutional Investors meet.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"08032016182400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100529968","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-03-08 18:24:00","symbol":"BIOCON"},{"an_dt":"24-Feb-2016 15:40:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconAnalystsInstitutionalInvestorsMeet_24022016154042_411.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Analysts/ Institutional Investors Meet.","bflag":null,"csvName":null,"desc":"Analysts Meet","difference":"-","dt":"24022016154000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100494234","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-02-24 15:40:00","symbol":"BIOCON"},{"an_dt":"15-Feb-2016 11:01:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconapprovalforRosuvastatin_15022016110104_076.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 15, 2016 titled \"Biocon Gets its First Generic Formulation Approval in EU; On Track to Launch Rosuvastatin Tablets in FY 17\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"15022016110100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100463428","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-02-15 11:01:00","symbol":"BIOCON"},{"an_dt":"03-Feb-2016 12:51:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BioconPressrelease_03022016125102_652.zip","attchmntText":"Biocon Limited has informed the Exchange that Biocon regarding a press release dated February 03, 2016 titled \"Biocon Academy introduces First of its Kind Career Advancement Program in Quality Control Microbiology in Collaboration with BITS Pilani\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"03022016125100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100433096","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-02-03 12:51:00","symbol":"BIOCON"},{"an_dt":"21-Jan-2016 20:51:20","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Results_21012016205120.zip","attchmntText":"Biocon Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 31-Dec-2015.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"21012016205120","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"103313","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-01-21 20:51:20","symbol":"BIOCON"},{"an_dt":"21-Jan-2016 20:51:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/FactSheet_21012016205115.zip","attchmntText":"Biocon Limited has  submitted to the Exchange the Fact Sheet and press release with respect to the Financial Results for the quarter ended December 31, 2015.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21012016205100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100401147","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-01-21 20:51:00","symbol":"BIOCON"},{"an_dt":"21-Jan-2016 20:39:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon-InsulinTregopil_21012016203957_753.zip","attchmntText":"Biocon Limited has informed the Exchange regarding the press release dated January 21, 2016 titled, \"Biocon Announces Data from Key Studies for Insulin Tregopil.\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21012016203900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100401146","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2016-01-21 20:39:00","symbol":"BIOCON"},{"an_dt":"31-Dec-2015 16:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon-Policy-Materiality-Authorisation_31122015164814_590.zip","attchmntText":"Biocon Limited has informed the Exchange about the Adoption of Policy for determining materiality and authorised KMP s to determine and disclose material events under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"31122015164800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100342735","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-12-31 16:48:00","symbol":"BIOCON"},{"an_dt":"24-Dec-2015 09:39:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/NSEbioconpressrelease_24122015093921_287.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 24, 2015 titled \"Biocon Introduces CIMIVIR-L for Hepatitis-C in India\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"24122015093900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100324746","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-12-24 09:39:00","symbol":"BIOCON"},{"an_dt":"09-Dec-2015 15:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/NSEPressrelease_09122015152425_576.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a Press release dated December 09, 2015 titled ''NeoBiocon Partners with Novartis to offer Vildagliptin for Diabetics in UAE''","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"09122015152400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100289931","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-12-09 15:24:00","symbol":"BIOCON"},{"an_dt":"13-Nov-2015 18:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/NSEPressRelease_13112015180430_236.zip","attchmntText":"Biocon Limited has informed the Exchange that Press Release dated November 13, 2015 titled \"Biocon's Nationwide 'Winning with Diabetes' Campaign Raises Awareness on Disease Prevention & Management\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"13112015180400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100233426","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-11-13 18:04:00","symbol":"BIOCON"},{"an_dt":"03-Nov-2015 15:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/NSE_PR_NOV_BIOCON_03112015151233_605.zip","attchmntText":"Biocon Limited has informed the Exchange regarding the press release dated November 3, 2015 titled, \"Biocon is the Only Asian Company to be ranked in Top 20 Global Biotech Employers for 2015.\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"03112015151200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100219580","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-11-03 15:12:00","symbol":"BIOCON"},{"an_dt":"21-Oct-2015 08:36:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_press_21102015083621.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 20, 2015 titled \"Biocon Q2FY16 Revenues up 12%; Net Profit up 200% Syngene delivers 30% growth\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21102015083600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100193787","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-10-21 08:36:00","symbol":"BIOCON"},{"an_dt":"20-Oct-2015 20:54:59","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_Results_20102015205459.zip","attchmntText":"Biocon Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Sep-2015.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"20102015205459","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"101699","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-10-20 20:54:59","symbol":"BIOCON"},{"an_dt":"01-Oct-2015 18:33:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/NSE-1_01102015183323.zip","attchmntText":"Biocon Limited has informed the Exchange that the Company has acquired the business assets of the pharmaceutical manufacturing unit of M/s Acacia Lifesciences Private Limited located at Vishakapatnam with effect from October 1, 2015 on a going concern basis. This unit is presently manufacturing advanced intermediates of potent APls useful to business as well as for supply to third party customers .","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"01102015183300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100161427","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-10-01 18:33:00","symbol":"BIOCON"},{"an_dt":"21-Sep-2015 15:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BSE_NSE-_intimation_on_exercise_of_option_-_September_2015_21092015151616.zip","attchmntText":"Biocon Limited has informed the Exchange that 20850 options under Biocon Employee Stock Option Plan 2000 have been exercised by the option holders.Accordingly, Biocon India Limited Employee Welfare Trust has transferred 20850 equity shares of Rs. 5/- each from trust to the eligible option holders.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"21092015151600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100146133","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-09-21 15:16:00","symbol":"BIOCON"},{"an_dt":"15-Sep-2015 19:01:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_press1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 15, 2015 titled \"Biocon Inaugurates World Class Devices Facility & Introduces Basalog One\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"15092015190100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100140594","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-09-15 19:01:00","symbol":"BIOCON"},{"an_dt":"28-Aug-2015 12:06:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_01_28082015120607.zip","attchmntText":"Biocon Limited has informed the Exchange that 15450 options under Biocon Employee Stock Option Plan 2000 have been exercised by the option holders. Accordingly, Biocon India Limited Employee Welfare Trust has transferred 15450 equity shares of Rs 5/- each from trust to the eligible option holders.","bflag":null,"csvName":null,"desc":"ESOPs/ESOS/ESPS","difference":"-","dt":"28082015120600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100113151","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-08-28 12:06:00","symbol":"BIOCON"},{"an_dt":"25-Aug-2015 09:01:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_25082015090118.zip","attchmntText":"Biocon Limited has submitted to the Exchange a clarification on media report captioned \"USFDA observations not serious, say Biocon\". The Company has clarified that \"USFDA conducts audit at regular intervals. Biocon underwent such inspection in June 2015 wherein a few minor observations in the nature of recommendations were made by the regulatory team. All those have been considered by the company and closed out with the FDA. None of the USFDA observations were material in nature to have bearing on operation/performance of the Company or price sensitive in nature.\"","bflag":null,"csvName":null,"desc":"News Clarification","difference":"-","dt":"25082015090100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100102851","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-08-25 09:01:00","symbol":"BIOCON"},{"an_dt":"30-Jul-2015 20:27:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_code_30072015202730.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of the Code of Conduct for Prevention of Insider Trading and Code for Corporate disclosure practices.","bflag":null,"csvName":null,"desc":"Code of Conduct under SEBI(PIT) Reg., 2015","difference":"-","dt":"30072015202700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100057202","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-07-30 20:27:00","symbol":"BIOCON"},{"an_dt":"28-Jul-2015 08:30:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Scrut.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of disclosure of voting results at the Annual General Meeting of the Company held on July 24, 2015.","bflag":null,"csvName":null,"desc":"Disclosure of Voting Pattern - Clause 35A","difference":"-","dt":"28072015083000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100053856","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-07-28 08:30:00","symbol":"BIOCON"},{"an_dt":"28-Jul-2015 08:25:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PAGM_28072015082539.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of proceedings of the Annual General Meeting of the Company held on July 24, 2015.","bflag":null,"csvName":null,"desc":"Annual General Meeting Updates","difference":"-","dt":"28072015082500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100053855","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-07-28 08:25:00","symbol":"BIOCON"},{"an_dt":"24-Jul-2015 08:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_pr_24072015080427.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 23, 2015, titled \"Biocon's Earnings Surge in Q1FY16\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"24072015080400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100053077","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-07-24 08:04:00","symbol":"BIOCON"},{"an_dt":"24-Jul-2015 07:56:44","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_result_24072015075644.zip","attchmntText":"Biocon Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Jun-2015.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"24072015075644","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100174","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-07-24 07:56:44","symbol":"BIOCON"},{"an_dt":"16-Jul-2015 08:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_01_16072015082025.zip","attchmntText":"Biocon Limited has informed the Exchange vide letter dated July 15, 2015 that \"With reference to the earlier announcement dated April 22, 2015 in relation to the proposed public issue of Equity Shares of our subsidiary, Syngene international Limited (\"Syngene\"), the Company have been informed by Syngene that the Red Herring Prospectus filed by Syngene with the Registrar of Companies, Bangalore, has been approved on July 15, 2015. The Offer shall open for subscription to public on July 27, 2015 and shall close on July 29, 2015. The price band has been fixed between Rs. 240/- to Rs. 250 per Equity Share.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"16072015082000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"100051432","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-07-16 08:20:00","symbol":"BIOCON"},{"an_dt":"29-Jun-2015 15:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCOn_06292015152401_1.zip","attchmntText":"Biocon Limited has informed the Exchange that the Register of Members and Share Transfer Books of the Company shall remain closed from  July 18, 2015 to July 24, 2015 (both days inclusive) for the purpose of Annual General Meeting to be held on July 24, 2015.","bflag":null,"csvName":null,"desc":"AGM/Book Closure","difference":"-","dt":"29062015152400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1592211","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-06-29 15:24:00","symbol":"BIOCON"},{"an_dt":"07-May-2015 10:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_05072015100002_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 07, 2015 titled \"Biocon - Mylan Programs Make Progress\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"07052015100000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1498678","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-05-07 10:00:00","symbol":"BIOCON"},{"an_dt":"30-Apr-2015 08:35:03","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_results_04302015083501_.zip","attchmntText":"Biocon Limited has submitted to the exchange the standalone & consolidated financial results along with the Auditors Report for the period ended 31-Mar-2015.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"30042015083503","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"27387","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-04-30 08:35:03","symbol":"BIOCON"},{"an_dt":"30-Apr-2015 08:26:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_press_04302015082601_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 29, 2015 titled \"Biocon top line grows 15% in Q4 FY15\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"30042015082600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1489397","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-04-30 08:26:00","symbol":"BIOCON"},{"an_dt":"30-Apr-2015 08:26:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_factsheet_04302015082604_2.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of fact sheet for March 2015.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"30042015082600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1489398","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-04-30 08:26:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2015 21:41:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_pres_04282015214104_2.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 28, 2015 titled \"Biocon's CRO Arm Syngene Seeks Approval for IPO, Files DRHP\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"28042015214100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1486699","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-04-28 21:41:00","symbol":"BIOCON"},{"an_dt":"23-Apr-2015 08:19:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_Update_04232015081902_1.zip","attchmntText":"Biocon Limited has informed the Exchange that Syngene International Limited, a subsidiary of the Company has proposed public issue of its equity shares through 100% book building method in accordance with the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 and has filed a Draft Red Herring Prospectus with the Securities and Exchange Board of India on April 22, 2015. Under the proposed issue/ shares will be offered through an offer for sale (OFS) route by Biocon Limited upto 22,000,000 equity shares of face value of Rs 10 each for cash and at such premium as may be determined. The offer includes a reservation of 2,000,000 Equity Shares for Biocon Shareholders.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"23042015081900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1476221","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-04-23 08:19:00","symbol":"BIOCON"},{"an_dt":"20-Apr-2015 08:39:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01_04202015083902_1.zip","attchmntText":"Biocon Limited has informed the Exchange with reference to letter dated March 26, 2015, where in the Company have informed on the declaration of Interim Dividend at a rate of 100% i.e. (Rs 5/-per share) for the Financial Year 2014-15 and fixed the record date as April 10, 2015. The Company has now informed the Exchange that the Company has paid the interim dividend to eligible shareholders on April 15, 2015.","bflag":null,"csvName":null,"desc":"Date of payment of dividend","difference":"-","dt":"20042015083900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1469171","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-04-20 08:39:00","symbol":"BIOCON"},{"an_dt":"09-Apr-2015 17:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_PR_04092015172001_1.zip","attchmntText":"Biocon Limited regarding a press release dated April 09, 2015 titled \"Biocon Strengthens its Presence in Mexico; Receives Approval for Insulin Glargine through its partner PiSA Farmaceutica\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"09042015172000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1454312","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-04-09 17:20:00","symbol":"BIOCON"},{"an_dt":"08-Apr-2015 13:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_REG30_04082015134801_1.zip","attchmntText":"Biocon Limited has submitted to the Exchange vide letter dated April 06, 2015 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.","bflag":null,"csvName":null,"desc":"Disc. under Reg.30 of SEBI (SAST) Reg.2011","difference":"-","dt":"08042015134800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1450215","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-04-08 13:48:00","symbol":"BIOCON"},{"an_dt":"01-Apr-2015 12:35:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_update_04012015123502_1.zip","attchmntText":"Biocon Limited has informed the Exchange that our subsidiary M/s Syngene International Limited (Syngene) is in the process of acquiring approximately 40 acres of land on leasehold basis in the multi-product Special Economic Zone being developed by Mangalore SEZ Limited. This land will be used for setting up commercial scale facilities for manufacture of novel Active Pharmaceutical Ingredients, Advanced Intermediates and Agro Chemicals for Syngene's clients. In this regard, Syngene has also been granted status of Co-developer under the SEZ rules, for providing infrastructure facilities to its units.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"01042015123500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1444586","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-04-01 12:35:00","symbol":"BIOCON"},{"an_dt":"01-Apr-2015 08:14:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01_04012015081401_1.zip","attchmntText":"Biocon Limited has informed the Exchange that the Company Subsidiary M/s Syngene International Limited (Syngene) has appointed Mr Peter Bains, Director as the CEO of Syngene.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"01042015081400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1442530","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-04-01 08:14:00","symbol":"BIOCON"},{"an_dt":"27-Mar-2015 09:46:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the company will pay Interim Dividend within 30 days from March 26, 2015.","bflag":null,"csvName":null,"desc":"Date of payment of dividend","difference":"-","dt":"27032015094600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1434644","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-03-27 09:46:00","symbol":"BIOCON"},{"an_dt":"27-Mar-2015 09:23:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Company has fixed Record Date as April 10, 2015 for the purpose of declaration Interim dividend ","bflag":null,"csvName":null,"desc":"Record Date","difference":"-","dt":"27032015092300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1434641","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-03-27 09:23:00","symbol":"BIOCON"},{"an_dt":"27-Mar-2015 08:33:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board of Director vide its Circular resolution dated March 26, 2015 has approved the payment of Interim Dividend at a rate of 100% i.e. (Rs 5/- per share) for the Financial Year 2014-15.","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"27032015083300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1434638","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-03-27 08:33:00","symbol":"BIOCON"},{"an_dt":"23-Jan-2015 08:55:03","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31Dec2014_B_01232015085502_.zip","attchmntText":"Biocon Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 31-Dec-2014.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"23012015085503","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"25874","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-01-23 08:55:03","symbol":"BIOCON"},{"an_dt":"23-Jan-2015 08:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30_23012015082735.zip","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors at its meeting held on January 22, 2015 has appointed Mr. Jeremy Levin and Dr. Vijay Kumar Kuchroo as Additional Independent Directors of the Company. They will hold office up to the date of ensuing Annual General Meeting, wherein their appointment as Director will be placed before the shareholders for approval. Futther, the Company has submitted to the Exchange a copy of two press releases dated January 22, 2015 titled \"Dr Jeremy Levin joins Biocon's Board of Directors\" and \"Dr Vijay Kuchroo Joins Biocon's Board of Directors\".","bflag":null,"csvName":null,"desc":"Appointment of Director","difference":"-","dt":"23012015082800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1320282","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-01-23 08:28:00","symbol":"BIOCON"},{"an_dt":"23-Jan-2015 08:21:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01_01232015082003_.zip","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors at its meeting held on January 22, 2015 has approved to initiate the process to list its subsidiary, Syngene International Limited. The Company would offload 10%-15% of its stake through an offer for sale.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"23012015082100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1320280","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-01-23 08:21:00","symbol":"BIOCON"},{"an_dt":"23-Jan-2015 07:45:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_PR_23022015_01232015074502_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 22, 2015, titled \"Biocon Q3FY15 Revenues at Rs. 779 Crore, PAT at Rs. 91 Crore; Research Services delivers 20% growth; Board approves listing Syngene via offer for sale\" along with Fact Sheet.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"23012015074500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1320274","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-01-23 07:45:00","symbol":"BIOCON"},{"an_dt":"12-Jan-2015 21:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"The Exchange had sought clarification from Biocon Limited with respect to an announcement dated January 12, 2015, wherein the Company informed the Exchange that M/s Silver Leaf Oak (Mauritius) Limited has assigned its rights and obligations for acquisition of 10% stake in Syngene International Limited ('Syngene') to M/s IVF Trustee Company Private limited ('IVF'), a fund advised by India Value Fund Advisors. Biocon Research limited, a wholly owned subsidiary of the Company has concluded such sale to IVF. Post conclusion of the above, Biocon and BRL jointly hold 85.54% stake in Syngene. The Company has clarified as follows:  a) The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;   Company Response: Syngene International Limited is a subsidiary of the Company and the details of the turnover, income and networth are disclosed in the Statement under Section 212 of the Companies Act, 1956. The same formed part of our Annual Report (Page 156). The statement is attached herewith for your ready reference.  b) Date on which the agreement for sale has been entered into;  Company Response: The Agreement was entered into on September 18, 2014 (at which time the intimation to the exchange was made). On January 9, 2015, Silver Leaf Oak (Mauritius) Limited assigned its interest in the contract to IVF Trustee Company Private Limited. Post the said assignment, the consideration was received on January 12, 2015 by Biocon Research Limited, which has been intimation to the Exchange today.  c) Consideration received from such sale/disposal;  Company Response:The consideration was mentioned by us in the earlier communication to the Stock Exchange. Biocon Research Limited transferred 10% stake in Syngene at an enterprise valuation of Rs 3,800 Crores (the consideration thereby being Rs 380 Crores for the 10% stake)  d) Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm s length;  Company Response: The transaction has been made with an independent part (ie. IVF Trustee Company Private Limited).","bflag":null,"csvName":null,"desc":"Clarification","difference":"-","dt":"12012015210000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1304107","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-01-12 21:00:00","symbol":"BIOCON"},{"an_dt":"12-Jan-2015 20:48:00","attFileSize":null,"attchmntFile":"-","attchmntText":"The Exchange has sought clarification from Biocon Limited with respect to an announcement dated January 12, 2015, regarding press Release dated September 18, 2014, Company informed the Exchange that M/s Silver Leaf Oak (Mauritius) Limited has assigned its rights and obligations for acquisition of 10% stake in Syngene International Limited ('Syngene') to M/s IVF Trustee Company Private limited ('IVF'), a fund advised by India Value Fund Advisors. Biocon Research limited, a wholly owned subsidiary of the Company has concluded such sale to IVF. Post conclusion of the above, Biocon and BRL jointly hold 85.54% stake in Syngene . On basis of above Company is required to clarify following:  a) The amount and percentage of the turnover or revenue or income and net worth contributed by such unit or division of the listed entity during the last financial year;  b) Date on which the agreement for sale has been entered into  c) Consideration received from such sale/disposal;  d) Whether the transaction would fall within related party transactions? If yes, whether the same is done at arm s length.    Response from the Company is awaited. ","bflag":null,"csvName":null,"desc":"Clarification","difference":"-","dt":"12012015204800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1304105","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-01-12 20:48:00","symbol":"BIOCON"},{"an_dt":"12-Jan-2015 17:10:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_01122015171002_1.zip","attchmntText":"Biocon Limited has informed the Exchange that with reference to the Press Release dated September 18, 2014, Company wish to inform the Exchange that M/s Silver Leaf Oak (Mauritius) Limited has assigned its rights and obligations for acquisition of 10% stake in Syngene International Limited ('Syngene') to M/s IVF Trustee Company Private limited ('IVF'), a fund advised by India Value Fund Advisors. Biocon Research limited, a wholly owned subsidiary of the Company has concluded such sale to IVF. Post conclusion of the above, Biocon and BRL jointly hold 85.54% stake in Syngene.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"12012015171000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1303003","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2015-01-12 17:10:00","symbol":"BIOCON"},{"an_dt":"15-Dec-2014 18:31:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_12152014183102_1.zip","attchmntText":"The Exchange had sought clarification from Biocon Limited with respect to recent news item captioned  Biocon Plans to Set up Mfg Unit in Vizag .  In this regard, the Company, vide letter dated December 15, 2014 has clarified that:  \"The Company has been allotted land at Vizag in 2007 & the Company is yet to set up manufacturing facility. We will intimate the exchanges with appropriate details in future when the firm plan to set up a Bio-manufacturing facility is taken by the Company\".","bflag":null,"csvName":null,"desc":"News Clarification","difference":"-","dt":"15122014183100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1257160","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-12-15 18:31:00","symbol":"BIOCON"},{"an_dt":"15-Dec-2014 12:35:00","attFileSize":null,"attchmntFile":"-","attchmntText":"The Exchange has sought clarification from Biocon Limited with respect to recent news item captioned Biocon Plans to Set up Mfg Unit in Vizag.  In this regard, Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: \"a) Whether such event/negotiations/article stated in published news were taking place? If so, you are advised to provide the said information along with the sequence of events in chronological order and the material impact of this article on the Company. b) Whether company are aware of any information that has not been announced to the Exchanges under clause 36 of the Listing Agreement\". The response from the Company is awaited.","bflag":null,"csvName":null,"desc":"News Clarification","difference":"-","dt":"15122014123500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1256685","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-12-15 12:35:00","symbol":"BIOCON"},{"an_dt":"03-Nov-2014 17:52:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_press_11032014175201_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 03, 2014 titled \"Biocon Expands its Strategic Partnership with CytoSorbents for CytoSorb(R) to Treat SIRS and Cardiac Surgery Patients\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"03112014175200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1187314","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-11-03 17:52:00","symbol":"BIOCON"},{"an_dt":"22-Oct-2014 08:59:04","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30092014_B_LR_10222014085902_.zip","attchmntText":"Biocon Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Sep-2014.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"22102014085904","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"24355","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-10-22 08:59:04","symbol":"BIOCON"},{"an_dt":"22-Oct-2014 08:29:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Press_10222014082902_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 21, 2014 titled \"Biocon Q2 FY15 Revenues at Rs 773 Crore, PAT at Rs 102 Crore Branded Formulations Records Strong Growth of 17%\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"22102014082900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1168725","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-10-22 08:29:00","symbol":"BIOCON"},{"an_dt":"09-Sep-2014 19:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biaocn_Updates_09092014192402_3.zip","attchmntText":"Biocon Limited has informed the Exchange regarding purchase of shares in Syngene International Limited by Biocon Research Limited.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"09092014192400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1102295","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-09-09 19:24:00","symbol":"BIOCON"},{"an_dt":"11-Aug-2014 10:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_PR_08112014102402_1.zip","attchmntText":"Biocon Limited has informed the Exchange, vide letter dated August 11, 2014 regarding a press release dated August 10, 2014 titled \"Biocon to Mark a Decade of Excellence in Affordable Insulin Therapy\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"11082014102400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1054057","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-08-11 10:24:00","symbol":"BIOCON"},{"an_dt":"04-Aug-2014 09:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_29_08042014090401_1.zip","attchmntText":"Biocon Limited has submitted to the Exchange vide letter dated July 30, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011along with Disclosure under Regulation 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.","bflag":null,"csvName":null,"desc":"Discl. under SEBI Insider Trading and Takeover Regulation","difference":"-","dt":"04082014090400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1039040","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-08-04 09:04:00","symbol":"BIOCON"},{"an_dt":"30-Jul-2014 15:08:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_dis35A_07302014150802_2.zip","attchmntText":"Biocon Limited has informed the Exchange regarding the disclosure of voting results as per Clause 35A of the Listing Agreements with respect to the Annual General Meeting of the Company held on July 25, 2014.","bflag":null,"csvName":null,"desc":"Disclosure of Voting Pattern - Clause 35A","difference":"-","dt":"30072014150800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1033656","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-07-30 15:08:00","symbol":"BIOCON"},{"an_dt":"30-Jul-2014 15:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_AGM_07302014150401_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding Proceedings of the Annual General Meeting of the Company held on July 25, 2014.","bflag":null,"csvName":null,"desc":"Annual General Meeting Updates","difference":"-","dt":"30072014150400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1033653","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-07-30 15:04:00","symbol":"BIOCON"},{"an_dt":"30-Jul-2014 15:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the dividend of Rs. 5/- per equity share approved by the members of the Company at the Annual General Meeting held on July 25, 2014 will be paid out on July 31, 2014.","bflag":null,"csvName":null,"desc":"Date of payment of dividend","difference":"-","dt":"30072014150000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1033652","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-07-30 15:00:00","symbol":"BIOCON"},{"an_dt":"30-Jul-2014 08:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_REG_07302014084802_1.zip","attchmntText":"Franklin Templeton Investment Funds has submitted to the Exchange vide letter dated July 28, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"-","dt":"30072014084800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1031251","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-07-30 08:48:00","symbol":"BIOCON"},{"an_dt":"25-Jul-2014 08:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_PR_25072014_07252014082401_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 24, 2014, titled, \"Biocon announces Q1 FY15 results\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25072014082400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1025913","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-07-25 08:24:00","symbol":"BIOCON"},{"an_dt":"25-Jul-2014 08:07:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_07252014080701_.zip","attchmntText":"Biocon Limited has submitted to the exchange the standalone & consolidated financial results along with the Limited Review Report for the period ended 30-Jun-2014.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"25072014080702","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"22846","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-07-25 08:07:02","symbol":"BIOCON"},{"an_dt":"24-Jun-2014 09:52:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_06242014095201_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated June 23, 2014 titled \"Kiran Mazumdar-Shaw Awarded the '2014 Global Economy Prize' by the Kiel Institute for the World Economy\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"24062014095200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"969600","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-06-24 09:52:00","symbol":"BIOCON"},{"an_dt":"19-Jun-2014 09:44:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange the Annual General Meeting is scheduled to be held on July 25, 2014.","bflag":null,"csvName":null,"desc":"Annual General Meeting Updates","difference":"-","dt":"19062014094400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"963482","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-06-19 09:44:00","symbol":"BIOCON"},{"an_dt":"18-Jun-2014 18:56:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Company has fixed Book Closure from July 12, 2014 to July 25, 2014 for the purpose of Annual General Meeting & Declaration of Dividend.  ","bflag":null,"csvName":null,"desc":"AGM/Book Closure","difference":"-","dt":"18062014185600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"962259","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-06-18 18:56:00","symbol":"BIOCON"},{"an_dt":"03-Jun-2014 16:36:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_pr_06032014163602_2.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated June 3, 2014 titled \"Bristol-Myers Squibb and Syngene International Extend Research Collaboration\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"03062014163600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"934920","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-06-03 16:36:00","symbol":"BIOCON"},{"an_dt":"25-Apr-2014 10:15:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31mar2014_B_04252014101501_.zip","attchmntText":"Biocon Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Mar-2014.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"25042014101502","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"21229","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-04-25 10:15:02","symbol":"BIOCON"},{"an_dt":"25-Apr-2014 09:40:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_04252014094002_1.zip","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 24, 2014, has appointed Mr. Arun Suresh Chandavarkar as an Additional Director and designated him as CEO & Joint Managing Director of the Company.  In this regard, the Company has submitted to Exchange a copy of Press Release dated April 24, 2014 titled \"Dr Arun Chandavarkar appointed as CEO and Joint Managing Director of Biocon Ltd\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25042014094000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"873373","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-04-25 09:40:00","symbol":"BIOCON"},{"an_dt":"25-Apr-2014 09:36:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors at its meeting held on April 24, 2014 has recommended a final dividend of Rs 5/- per share (i.e. 100%) for the financial year 2013-14.    The declaration of dividend is subject to shareholders' approval at the ensuing Annual General Meeting of the company to be held during July 2014.","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"25042014093600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"873372","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-04-25 09:36:00","symbol":"BIOCON"},{"an_dt":"25-Apr-2014 09:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_pr_04252014092802_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 24, 2014 titled \"Broad-based business momentum helps Biocon deliver, 16% revenue growth in FY14, Board recommends a dividend of Rs 5/- share (100%)\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25042014092800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"873370","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-04-25 09:28:00","symbol":"BIOCON"},{"an_dt":"15-Apr-2014 17:31:00","attFileSize":null,"attchmntFile":"-","attchmntText":"News Verification : The media had reports that  \"Bonus Buzz in Biocon\". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Biocon Limited has vide its letter inter-alia stated, \"At the outset would like to deny the news item.\"","bflag":null,"csvName":null,"desc":"News Verification","difference":"-","dt":"15042014173100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"860385","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-04-15 17:31:00","symbol":"BIOCON"},{"an_dt":"14-Feb-2014 14:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_14022014_02142014144402_2.zip","attchmntText":"Biocon Limited has given their clarification to the Exchange in response to a media query with respect to the legal action pursued by Roche Products (India) Private Limited on the launch of Biosimilar Trastuzumab.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"14022014144400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"786606","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-02-14 14:44:00","symbol":"BIOCON"},{"an_dt":"10-Feb-2014 12:40:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_14_10022014123054.zip","attchmntText":"Biocon Limited has submitted to the Exchange vide letter dated February 06, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with Disclosure under Regulation 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.","bflag":null,"csvName":null,"desc":"Discl. under SEBI Insider Trading and Takeover Regulation","difference":"-","dt":"10022014124000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"778773","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-02-10 12:40:00","symbol":"BIOCON"},{"an_dt":"06-Feb-2014 10:32:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_dis_06022014_02062014103202_1.zip","attchmntText":"Franklin Templeton Investment Funds  has submitted to the Exchange, vide letter dated February 05, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"-","dt":"06022014103200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"775632","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-02-06 10:32:00","symbol":"BIOCON"},{"an_dt":"05-Feb-2014 13:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCOMN_pr_05022014_02052014130002_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 05, 2014 titled\"Shri Ghulam Nabi Azad Inaugurates \"Baxter Global Research Center\" at Syngene\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"05022014130000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"771256","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-02-05 13:00:00","symbol":"BIOCON"},{"an_dt":"23-Jan-2014 08:31:05","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31dec2013_01232014083102_.zip","attchmntText":"Biocon Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 31-Dec-2013.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"23012014083105","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"19735","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-01-23 08:31:05","symbol":"BIOCON"},{"an_dt":"23-Jan-2014 08:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_230120143_23012014082133.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 22, 2014, titled \"Biocon delivers 16% growth led by Research Services & Branded Formulations\". Further, the Company has submitted to the Exchange a copy of Fact Sheet December-2013.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"23012014082400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"757662","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-01-23 08:24:00","symbol":"BIOCON"},{"an_dt":"23-Jan-2014 08:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCO_pr_23012014_01232014082402_2.zip","attchmntText":"Biocon Limited has submitted to the Exchange copies of two press releases dated January 22, 2014, titled \"Biocon Collaborates with Advaxis for 'ADXS-HPV', A Novel Cancer Immunotherapy\" and \"Kiran Mazumdar- Shaw to Receive 2014 Othmer Gold Medal from Chemical Heritage Foundation\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"23012014082400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"757663","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-01-23 08:24:00","symbol":"BIOCON"},{"an_dt":"20-Jan-2014 11:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/lic_20012014_01202014114801_1.zip","attchmntText":"Life Insurance Corporation Limited has submitted to the Exchange, vide letter dated January 17, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"-","dt":"20012014114800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"753597","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-01-20 11:48:00","symbol":"BIOCON"},{"an_dt":"20-Jan-2014 10:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_disc_20012014_01202014104802_3.zip","attchmntText":"Biocon Limited has submitted to the Exchange, vide letter dated January 17, 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(3) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.","bflag":null,"csvName":null,"desc":"Discl. under SEBI Insider Trading and Takeover Regulation","difference":"-","dt":"20012014104800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"753583","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-01-20 10:48:00","symbol":"BIOCON"},{"an_dt":"20-Jan-2014 10:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_18012014_01202014102002_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 18, 2014, titled\"Biocon introduces CANMAb  - World's First Biosimilar Trastuzumab for Treating Breast Cancer in India\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"20012014102000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"752905","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-01-20 10:20:00","symbol":"BIOCON"},{"an_dt":"10-Jan-2014 13:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/NSEPRBiocon_01102014132401_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 10, 2014, titled \" Biocon Academy's Flagship Program in Collaboration with KGI takes Off to a Flying Start\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"10012014132400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"744613","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-01-10 13:24:00","symbol":"BIOCON"},{"an_dt":"02-Jan-2014 08:56:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_02012014_01022014085602_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press statement being issued by the Company held on January 01, 2014.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"02012014085600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"735503","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2014-01-02 08:56:00","symbol":"BIOCON"},{"an_dt":"18-Dec-2013 12:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_18122013_12182013120002_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 18, 2013, titled, \"Biocon and Quark Pharmaceuticals Collaborate to Develop Novel siRNA based Therapeutics\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18122013120000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"721946","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-12-18 12:00:00","symbol":"BIOCON"},{"an_dt":"26-Nov-2013 15:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_11262013151202_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 26, 2013, titled\"Biocon & Mylan Receive Indian Regulatory Approval for Biosimilar Trastuzumab for Treating Breast Cancer\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"26112013151200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"698919","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-11-26 15:12:00","symbol":"BIOCON"},{"an_dt":"11-Nov-2013 12:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_11112013_11112013122402_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 11, 2013, titled \"Biocon Unveils Biocon Academy - A Center of Excellence for Advanced Learning in Applied Biosciences\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"11112013122400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"687070","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-11-11 12:24:00","symbol":"BIOCON"},{"an_dt":"28-Oct-2013 10:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_26102013_10282013102802_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 25, 2013 titled \"Biocon Ranked at No. 6 among Top 20 Global Biotech Employers by the Science Magazine\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"28102013102800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"673559","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-10-28 10:28:00","symbol":"BIOCON"},{"an_dt":"25-Oct-2013 08:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_25102013_10252013082801_2.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a Press Release dated October 24, 2013, titled \"Sustained Momentum in Biopharma & Research Services delivers 19% growth for Biocon.\" Further, the Company has submitted to the Exchange a copy of fact sheet for September 2013.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25102013082800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"671464","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-10-25 08:28:00","symbol":"BIOCON"},{"an_dt":"24-Oct-2013 20:59:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30sep2013_B.zip","attchmntText":"Biocon Limited has submitted to the exchange the standalone & consolidated financial results for the period ended 30-sep-2013.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"24102013205902","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"18276","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-10-24 20:59:02","symbol":"BIOCON"},{"an_dt":"13-Sep-2013 12:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_press_09132013121201_1.zip","attchmntText":"Biocon Limited has submitted to the Exchange, vide letter dated September 13, 2013 a copy of press release dated \"Biocon Partners with CytoSorbents to Market CytoSorb_A'First-in-Class' Therapy for Sepsis Management\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"13092013121200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"637027","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-09-13 12:12:00","symbol":"BIOCON"},{"an_dt":"12-Aug-2013 12:20:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_08122013122003_3.zip","attchmntText":"Biocon Limited has submitted to the Exchange, vide letter dated August 10, 2013 a copy of press release dated \"Biocon Launches ALZUMAb - a 'First in Class' Novel Biologic Treatment for Psoriasis Patients in India\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"12082013122000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"613032","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-08-12 12:20:00","symbol":"BIOCON"},{"an_dt":"30-Jul-2013 11:44:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the dividend of Rs.7.50 per equity share declared by the members of the Company at the Annual General Meeting held on July 26, 2013 will be paid out on July 31, 2013.","bflag":null,"csvName":null,"desc":"Date of payment of dividend","difference":"-","dt":"30072013114400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"604168","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-07-30 11:44:00","symbol":"BIOCON"},{"an_dt":"30-Jul-2013 11:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_outcomeagm_30072013_07302013114402_1.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of the Proceedings of the Annual General Meeting of the Company held on July 26, 2013.","bflag":null,"csvName":null,"desc":"Annual General Meeting Updates","difference":"-","dt":"30072013114400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"604169","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-07-30 11:44:00","symbol":"BIOCON"},{"an_dt":"26-Jul-2013 10:16:16","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30JUN2013_B_Q1.zip","attchmntText":"Biocon Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with the Limited Review Report for the period ended June 30,2013.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"26072013101616","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"16773","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-07-26 10:16:16","symbol":"BIOCON"},{"an_dt":"26-Jul-2013 08:52:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_factsheet_26072013_07262013085202_1.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of fact sheet for June -2013.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"26072013085200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"602378","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-07-26 08:52:00","symbol":"BIOCON"},{"an_dt":"26-Jul-2013 08:28:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors of the Company have noted the proposal for merger of its subsidiary Clinigene International Limited with Syngene International Limited, at its meeting held on July 25, 2013.","bflag":null,"csvName":null,"desc":"Outcome of Board Meeting","difference":"-","dt":"26072013082800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"601964","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-07-26 08:28:00","symbol":"BIOCON"},{"an_dt":"26-Jul-2013 08:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_26072013_07262013082402_2.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 25, 2013, titled \"Biocon Delivers a Healthy Growth of 22% driven by strong traction in Biopharma\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"26072013082400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"601963","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-07-26 08:24:00","symbol":"BIOCON"},{"an_dt":"19-Jun-2013 17:04:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Company has fixed Book Closure from July 13, 2013 to July 26, 2013 for the purpose of Annual General Meeting & Declaration of Dividend. The Annual General Meeting to be held on July 26, 2013.","bflag":null,"csvName":null,"desc":"AGM/Book Closure","difference":"-","dt":"19062013170400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"577506","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-06-19 17:04:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2013 11:08:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2013 as follows: Net Sales of Rs. 242760 lacs for year ending on 31-MAR-2013 against Rs. 204903 lacs for the year ending on 31-MAR-2012. Net Profit / (Loss) of Rs. 50882 lacs for the year ending on 31-MAR-2013 against Rs. 33843 lacs for the year ending on 31-MAR-2012.","bflag":null,"csvName":null,"desc":"Results Update, Year ended, 31-MAR-2013 (Consolidated)","difference":"-","dt":"26042013110800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-04-26 11:08:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2013 11:07:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2013 as follows: Net Sales of Rs. 63012 lacs for the quarter ending on 31-MAR-2013 . Net Profit / (Loss) of Rs. 24861 lacs for the quarter ending on 31-MAR-2013.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 31-MAR-2013 (Consolidated)","difference":"-","dt":"26042013110700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-04-26 11:07:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2013 11:05:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2013 as follows: Net Sales of Rs. 45757 lacs for the quarter ending on 31-MAR-2013 . Net Profit / (Loss) of Rs. 3829 lacs for the quarter ending on 31-MAR-2013.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 31-MAR-2013 (Standalone)","difference":"-","dt":"26042013110500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-04-26 11:05:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2013 11:05:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2013 as follows: Net Sales of Rs. 183748 lacs for year ending on 31-MAR-2013 against Rs. 150480 lacs for the year ending on 31-MAR-2012. Net Profit / (Loss) of Rs. 27570 lacs for the year ending on 31-MAR-2013 against Rs. 25550 lacs for the year ending on 31-MAR-2012.","bflag":null,"csvName":null,"desc":"Results Update, Year ended, 31-MAR-2013 (Standalone)","difference":"-","dt":"26042013110500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-04-26 11:05:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2013 09:54:27","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31MAR2013_B_Q4A.zip","attchmntText":"Biocon Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2013.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"26042013095427","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"15141","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-04-26 09:54:27","symbol":"BIOCON"},{"an_dt":"26-Apr-2013 09:16:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 25, 2013 has appointed Mr Daniel M Bradbury as an Additional Director of the Company . He will hold office up to the date of ensuing Annual General Meeting, wherein his appointment as a Director will be placed before shareholders for approval.","bflag":null,"csvName":null,"desc":"Appointment of Director","difference":"-","dt":"26042013091600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"541047","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-04-26 09:16:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2013 08:52:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that he Board of Directors of the Company at its meeting held on April 25, 2013 has recommended a final dividend of Rs. 5/- per share (i.e. 100%) and a special dividend of Rs. 2.50/- per share (i.e.50%) for the financial year 2012-13.The declaration of dividend is subject to shareholders' approval at the ensuing Annual General Meeting of the Company. Subsequent to Shareholders' approval the dividend will be paid within a period of 30 days from the date of such approval.","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"26042013085200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"541041","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-04-26 08:52:00","symbol":"BIOCON"},{"an_dt":"26-Apr-2013 08:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_26042013_04262013084402_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a Press Release dated April 25, 2013, titled \"Biocon delivers a strong performance of 18% Revenue Growth in FY13 driven by an evolving Product Portfolio & Research Services; Board recommends a dividend of Rs. 5/ share (100%) and a Special Dividend of Rs. 2.50/ share (50%) following the re-licensing of insulin analogs portfolio.\" Further, the Company has submitted to the Exchange a copy of fact sheet for March 2013.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"26042013084400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"541039","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-04-26 08:44:00","symbol":"BIOCON"},{"an_dt":"20-Mar-2013 09:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_reg_20032013_03202013091602_1.zip","attchmntText":"Biocon Limited has submitted to the Exchange vide letter March 19, 2013 a copy of disclosure under Regulation 13(4) & (6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.","bflag":null,"csvName":null,"desc":"Disclosure under Insider Trading Regulation","difference":"-","dt":"20032013091600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"520485","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-03-20 09:16:00","symbol":"BIOCON"},{"an_dt":"28-Feb-2013 16:56:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Updates_28022013_02282013165602_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding \"Updation of the status regarding merger of wholly owned subsidiary\".","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"28022013165600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"510076","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-02-28 16:56:00","symbol":"BIOCON"},{"an_dt":"27-Feb-2013 18:08:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that 14,500 (Fourteen Thousand Five Hundred Only) equity shares of the Company were transferred to employees from the ESOP Trust pursuant to exercise of stock options by them. There is no change in the listed and paid-up share capital of the Company pursuant to the exercise of said stock options.","bflag":null,"csvName":null,"desc":"ESOPs/ESOS/ESPS","difference":"-","dt":"27022013180800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"509289","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-02-27 18:08:00","symbol":"BIOCON"},{"an_dt":"14-Feb-2013 08:12:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_14022013_02142013081202_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 14, 2013, titled \"Biocon Enhances Partnership with Mylan through Strategic Collaboration for Insulin Products\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"14022013081200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"501816","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-02-14 08:12:00","symbol":"BIOCON"},{"an_dt":"25-Jan-2013 10:52:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_PR1_25012013_01252013105202_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 25, 2013, titled \"Kiran Mazumdar-Shaw joins U.S. Pharmacopeial (USP) Board of Trustees\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25012013105200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"486117","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-01-25 10:52:00","symbol":"BIOCON"},{"an_dt":"25-Jan-2013 08:40:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_PR_25012013_01252013084001_1.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 24, 2013, titled \"Biocon's Nine Months Revenue Continues to Deliver steady Growth in FY13\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25012013084000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"485627","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-01-25 08:40:00","symbol":"BIOCON"},{"an_dt":"25-Jan-2013 08:14:56","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31DEC2012_B_Q3.zip","attchmntText":"Biocon Limited has submitted to the Exchange the Standalone and Consolidated Financial Results along with the Limited Review Report for the period ended December 31,2012.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"25012013081456","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"13718","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-01-25 08:14:56","symbol":"BIOCON"},{"an_dt":"08-Jan-2013 08:46:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_08012013.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 08, 2013, titled \"Biocon Receives Marketing Authorization for its Novel Biologic Itolizumab for Psoriasis\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"08012013084600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2013-01-08 08:46:00","symbol":"BIOCON"},{"an_dt":"26-Nov-2012 19:26:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_PR_26112012.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 26, 2012, titled \"Biocon Partners with Trinity College Dublin to Fund Scholarships in Genetics Research for India phD students\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"26112012192600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-11-26 19:26:00","symbol":"BIOCON"},{"an_dt":"16-Nov-2012 08:45:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_PR_16112012.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 16, 2012, titled \"Biocon announces that it has entered into an option agreement with Bristol-Myers Squibb for Biocon's IN-105, an oral insulin drug candidate\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"16112012084500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-11-16 08:45:00","symbol":"BIOCON"},{"an_dt":"31-Oct-2012 10:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon01_prest_31102012.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 30, 2012, titled \"Biocon delivers healthy growth in H1FY13 Research Services & Branded Formulations propel strong growth\". Further, the Company has submitted to the Exchange a copy of Fact Sheet September-12.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"31102012102800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-10-31 10:28:00","symbol":"BIOCON"},{"an_dt":"31-Oct-2012 09:08:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2012 as follows: Net Sales of Rs. 46140 lacs for the quarter ending on 30-SEP-2012 against Rs. 43160 lacs and Rs. 37849 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively. Net Profit / (Loss) of Rs. 8836 lacs for the quarter ending on 30-SEP-2012 against Rs. 6884 lacs and Rs. 6807 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-SEP-2012 (Standalone)","difference":"-","dt":"31102012090800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-10-31 09:08:00","symbol":"BIOCON"},{"an_dt":"31-Oct-2012 09:08:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2012 as follows: Net Sales of Rs. 59240 lacs for the quarter ending on 30-SEP-2012 against Rs. 57086 lacs and Rs. 50844 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively. Net Profit / (Loss) of Rs. 8965 lacs for the quarter ending on 30-SEP-2012 against Rs. 7880 lacs and Rs. 8570 lacs for the quarters ending on 30-JUN-2012 and 30-SEP-2011 respectively.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-SEP-2012 (Consolidated)","difference":"-","dt":"31102012090800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-10-31 09:08:00","symbol":"BIOCON"},{"an_dt":"31-Oct-2012 08:53:34","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30SEP2012_B_Q2H.zip","attchmntText":"Biocon Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2012 with Limited Review Report.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"31102012085334","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"12407","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-10-31 08:53:34","symbol":"BIOCON"},{"an_dt":"31-Oct-2012 08:48:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon02_pr_31102012.zip","attchmntText":"Biocon Limited has informed the Exchange regarding two press releases dated October 31, 2012, titled \"GE Capital to invest in Syngene, Biocon's Research Services Subsidiary\" and \"Biocon Announces Positive Results from its Global Phase 3 study with Recombinant Human Insulin\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"31102012084800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-10-31 08:48:00","symbol":"BIOCON"},{"an_dt":"28-Sep-2012 12:26:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_REG01_28092012.zip","attchmntText":"Biocon Limited has submitted to the Exchange vide letter September 27, 2012 a copy of intimation under Regulation 13(4) & (6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.","bflag":null,"csvName":null,"desc":"Disclosure under Insider Trading Regulation","difference":"-","dt":"28092012122600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-09-28 12:26:00","symbol":"BIOCON"},{"an_dt":"28-Sep-2012 10:54:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_REG_28092012.zip","attchmntText":"Biocon Limited has submitted to the Exchange vide letter September 27, 2012 a copy of intimation under Regulation 13(4) & (6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.","bflag":null,"csvName":null,"desc":"Disclosure under Insider Trading Regulation","difference":"-","dt":"28092012105400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-09-28 10:54:00","symbol":"BIOCON"},{"an_dt":"24-Sep-2012 12:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_pr_24092012_001.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 24, 2012, titled \"Biocon - the only Asian Company to Feature in the Global Top 20 BioPharma Employers\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"24092012122800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-09-24 12:28:00","symbol":"BIOCON"},{"an_dt":"14-Sep-2012 14:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_pr_14082012.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 14, 2012, titled \"Manipal Education Malaysia and Biocon Ink Industry Academia Partnership for the Graduate Program & Talent Management for Biotech Sector\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"14092012142400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-09-14 14:24:00","symbol":"BIOCON"},{"an_dt":"04-Sep-2012 09:24:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_REG_04092012.zip","attchmntText":"Biocon Limited has submitted to the Exchange vide letter September 03, 2012 a copy of intimation under Regulation 13(4) & (6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.","bflag":null,"csvName":null,"desc":"Disclosure under Insider Trading Regulation","difference":"-","dt":"04092012092400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-09-04 09:24:00","symbol":"BIOCON"},{"an_dt":"31-Jul-2012 13:36:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_pagm_31072012.ZIP","attchmntText":"Biocon Limited has submitted to the Exchange a copy of the Chairman's Speech at the Annual General Meeting of the Company held on July 26, 2012.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"31072012133600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-07-31 13:36:00","symbol":"BIOCON"},{"an_dt":"27-Jul-2012 13:16:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the final dividend of Rs. 5.00 per equity share declared by the members of the Company at the Annual General Meeting held on July 26, 2012 will be paid out on July 31, 2012.","bflag":null,"csvName":null,"desc":"Date of payment of dividend","difference":"-","dt":"27072012131600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-07-27 13:16:00","symbol":"BIOCON"},{"an_dt":"27-Jul-2012 13:11:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_pagm_27072012.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of the Proceedings of the Annual General Meeting of the Company held on July 26, 2012.","bflag":null,"csvName":null,"desc":"Proceedings of Annual General Meeting","difference":"-","dt":"27072012131100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-07-27 13:11:00","symbol":"BIOCON"},{"an_dt":"26-Jul-2012 10:56:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 57086 lacs for quarter ending on 30-JUN-2012 against Rs. 44168 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. 7880 lacs for the quarter ending on 30-JUN-2012 against Rs. 7005 lacs for the quarter ending on 30-JUN-2011.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-JUN-2012 (Consolidated)","difference":"-","dt":"26072012105600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-07-26 10:56:00","symbol":"BIOCON"},{"an_dt":"26-Jul-2012 10:55:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2012 as follows: Net Sales of Rs. 43160 lacs for quarter ending on 30-JUN-2012 against Rs. 33890 lacs for the quarter ending on 30-JUN-2011. Net Profit / (Loss) of Rs. 6884 lacs for the quarter ending on 30-JUN-2012 against Rs. 6040 lacs for the quarter ending on 30-JUN-2011.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-JUN-2012 (Standalone)","difference":"-","dt":"26072012105500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-07-26 10:55:00","symbol":"BIOCON"},{"an_dt":"26-Jul-2012 08:46:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_26072012.zip","attchmntText":"Biocon Limited has submitted to the Exchange  a copy of two press releases dated July 25, 2012, titled \"Sustained impetus across verticals drives Biocon's Q1 growth\" and \"Biocon announces positive results from its Phase 1 comparative PK-PD study with Biosimilar Insulin Glargine\". Further, the Company has submitted to the Exchange a copy of fact sheet for December 2011.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"26072012084600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-07-26 08:46:00","symbol":"BIOCON"},{"an_dt":"26-Jul-2012 08:38:14","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30JUN2012_B_Q1.zip","attchmntText":"Biocon Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2012 with Limited Review Report.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"26072012083814","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"10542","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-07-26 08:38:14","symbol":"BIOCON"},{"an_dt":"28-Jun-2012 19:22:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_Ltd_270612.zip","attchmntText":"Biocon Limited has informed the Exchange that there were certain typographical errors / classification issues in the Balance Sheet and Segment Reporting under Clause 41 of the Listing Agreement for the year ended March 31, 2012. These do not have any impact on the results of the Operations and the financial position of Biocon Limited and Biocon group (Consolidated) for the year ended on date.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"28062012192200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-06-28 19:22:00","symbol":"BIOCON"},{"an_dt":"26-Jun-2012 14:52:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Company has announced the Book Closure from July 07, 2012 to July 21, 2012 (both days inclusive) for the purpose of Annual General Meeting and Final Dividend. Further, the Annual General Meeting will be held on July 26, 2012.","bflag":null,"csvName":null,"desc":"AGM / Book Closure","difference":"-","dt":"26062012145200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-06-26 14:52:00","symbol":"BIOCON"},{"an_dt":"26-May-2012 12:06:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that \"It is with deep sadness that Biocon announces that demise of Dr. Neville Bain, Non-Executive Director and Chairman of the Audit Committee on May 22nd, 2012 at his home in London. Dr. Bain Joined the Board of Biocon Limited in 1999 and has contributed substantially to building high standards of Governance in Biocon's Financial Reporting and Risk Management Systems. Biocon Pays homage to a Director who carried out his fiduciary duties in an impeccable manner. We offer our heartfelt condolences to his wife and family. May his soul rest in peace\".","bflag":null,"csvName":null,"desc":"Demise of Director","difference":"-","dt":"26052012120600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-05-26 12:06:00","symbol":"BIOCON"},{"an_dt":"16-May-2012 17:56:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_pr_16052012.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 16, 2012, titled \"Designing the future of Cancer research Symposium on Integrative Research in Oncology\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"16052012175600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-05-16 17:56:00","symbol":"BIOCON"},{"an_dt":"03-May-2012 09:30:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_03052012.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 03, 2012, titled \"Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India.\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"03052012093000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-05-03 09:30:00","symbol":"BIOCON"},{"an_dt":"27-Apr-2012 10:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_27042012.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 27, 2012, titled \"Strong growth momentum across business verticals drives Biocon's 16% YoY increase in revenues in FY12\". Further, the Company has submitted to the Exchange a copy of fact sheet for March 2012.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"27042012102800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-04-27 10:28:00","symbol":"BIOCON"},{"an_dt":"27-Apr-2012 10:25:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 27, 2012 have recommended a final dividend of 100% (Rs 5.00 per share) on the share capital of the Company, subject to the approval of the members at the ensuing Annual General Meeting.","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"27042012102500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-04-27 10:25:00","symbol":"BIOCON"},{"an_dt":"27-Apr-2012 10:17:22","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31MAR2012_B_Q4A.zip","attchmntText":"Biocon Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2012.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"27042012101722","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"8884","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-04-27 10:17:22","symbol":"BIOCON"},{"an_dt":"09-Apr-2012 07:57:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_pr_09042012.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 05, 2012, titled \"Biocon Research Centre Inaugurated by Nobel Laureate Prof Kurt Wuthrich\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"09042012075700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-04-09 07:57:00","symbol":"BIOCON"},{"an_dt":"16-Mar-2012 18:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_LIC_Reg2916032012.zip","attchmntText":"Life Insurance Corporation of India has submitted to the Exchange, vide its letter dated March 16, 2012 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with Regulation 13 (1) and (6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.","bflag":null,"csvName":null,"desc":"Disclosure under SEBI Takeover Regulations","difference":"-","dt":"16032012181600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-03-16 18:16:00","symbol":"BIOCON"},{"an_dt":"13-Mar-2012 07:59:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_pr_13032012.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 13, 2012, titled \"Biocon and Pfizer conclude Commercialization Agreement\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"13032012075900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-03-13 07:59:00","symbol":"BIOCON"},{"an_dt":"25-Jan-2012 08:28:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_PR_25012012.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 24, 2012, titled \"Biocon's nine-month revenues driven by growth in Branded Formulations, Emerging Markets and Research Services\". Further, the Company has submitted to the Exchange a copy of fact sheet for December 2011.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"25012012082800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-01-25 08:28:00","symbol":"BIOCON"},{"an_dt":"24-Jan-2012 22:02:02","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31DEC2011_B_Q3.zip","attchmntText":"Biocon Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2011.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"24012012220202","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"7460","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-01-24 22:02:02","symbol":"BIOCON"},{"an_dt":"10-Jan-2012 08:05:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_pr_10012012.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 09, 2012 titled \"Biocon Announces Positive Efficacy Data with its Novel Monoclonal Antibody Itolizumab in a Pivotal Psoriasis Study.\"","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"10012012080500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2012-01-10 08:05:00","symbol":"BIOCON"},{"an_dt":"21-Dec-2011 13:10:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_21112011.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 21, 2011, titled \"Clinigene International Enters into Collaborative Clinical Research Services Agreement with Pacific Biomarkers\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21122011131000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-12-21 13:10:00","symbol":"BIOCON"},{"an_dt":"20-Oct-2011 11:02:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCONLtd01_PR_20102011.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 20, 2011, titled \"Biocon launches INSUPen, a convenient and affordable reusable insulin delivery device\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"20102011110200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-10-20 11:02:00","symbol":"BIOCON"},{"an_dt":"20-Oct-2011 08:00:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_20102011.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 19, 2011, titled \"Biocon Limited Announces Earnings for the Half Year ended September 30, 2011\". Further, the Company has submitted to the Exchange a copy of fact sheet for September 2011.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"20102011080000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-10-20 08:00:00","symbol":"BIOCON"},{"an_dt":"20-Oct-2011 07:58:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30SEP2011_B_Q2H.zip","attchmntText":"Biocon Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30, 2011.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"20102011075833","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"5870","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-10-20 07:58:33","symbol":"BIOCON"},{"an_dt":"20-Oct-2011 07:56:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2011 as follows: Net Sales of Rs. 50844 lacs for quarter ending on 30-SEP-2011 against Rs. 67877 lacs for the quarter ending on 30-SEP-2010. Net Profit / (Loss) of Rs. 8570 lacs for the quarter ending on 30-SEP-2011 against Rs. 8922 lacs for the quarter ending on 30-SEP-2010.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-SEP-2011 (Consolidated)","difference":"-","dt":"20102011075600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-10-20 07:56:00","symbol":"BIOCON"},{"an_dt":"20-Oct-2011 07:56:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2011 as follows: Net Sales of Rs. 37849 lacs for quarter ending on 30-SEP-2011 against Rs. 33612 lacs for the quarter ending on 30-SEP-2010. Net Profit / (Loss) of Rs. 6807 lacs for the quarter ending on 30-SEP-2011 against Rs. 8733 lacs for the quarter ending on 30-SEP-2010.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-SEP-2011 (Standalone)","difference":"-","dt":"20102011075600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-10-20 07:56:00","symbol":"BIOCON"},{"an_dt":"12-Sep-2011 08:16:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_PR_12092011.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 10, 2011, titled \"Biocon announces project commencement for first high-end biopharmaceutical manufacturing and R&D facility in Bio-XCell, Malaysia\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"12092011081600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-09-12 08:16:00","symbol":"BIOCON"},{"an_dt":"22-Aug-2011 15:03:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_22082011.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 22, 2011, titled \"Spaulding Clinical, US and Clinigene International, India Announce Strategic Partnership for Providing Comprehensive Early Clinical Solutions to Pharmaceutical and Biotech Clients\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"22082011150300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-08-22 15:03:00","symbol":"BIOCON"},{"an_dt":"28-Jul-2011 11:02:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BICON_reg_28072011.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of intimation under Regulation 13(3) & (6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.","bflag":null,"csvName":null,"desc":"Disclosure under Insider Trading Regulation","difference":"-","dt":"28072011110200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-07-28 11:02:00","symbol":"BIOCON"},{"an_dt":"22-Jul-2011 14:07:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BICON_proceedingagm_22072011.zip","attchmntText":"Biocon Limited has informed the Exchange regarding the proceeding of Annual General Meeting held on July 21, 2011.","bflag":null,"csvName":null,"desc":"Proceedings of Annual General Meeting","difference":"-","dt":"22072011140700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-07-22 14:07:00","symbol":"BIOCON"},{"an_dt":"22-Jul-2011 14:01:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the final dividend of Rs.3.00 per equity share declared by the members of the Company at the Annual General Meeting held on July 21, 2011 will be paid out on July 27, 2011.","bflag":null,"csvName":null,"desc":"Date of payment of dividend","difference":"-","dt":"22072011140100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-07-22 14:01:00","symbol":"BIOCON"},{"an_dt":"21-Jul-2011 09:49:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BICONLTD_PR_21072011.zip","attchmntText":"Biocon Limited has informed the Exchange regarding the press release dated July 21, 2011 titled \"Syngene and Endo to expand their collaboration in cancer research\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21072011094900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-07-21 09:49:00","symbol":"BIOCON"},{"an_dt":"21-Jul-2011 09:37:23","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30JUN2011_B_Q1.zip","attchmntText":"Biocon Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended June 30,2011.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"21072011093723","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"4301","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-07-21 09:37:23","symbol":"BIOCON"},{"an_dt":"21-Jul-2011 09:37:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_21072011.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 21, 2011, titled \"Biocon Limited Announces Earnings for the first quarter ended June 30, 2011\". Further, the Company has submitted to the Exchange a copy of fact sheet for June 2011.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21072011093700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-07-21 09:37:00","symbol":"BIOCON"},{"an_dt":"21-Jul-2011 09:32:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 33890 lacs for quarter ending on 30-JUN-2011 against Rs. 32240 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 6040 lacs for the quarter ending on 30-JUN-2011 against Rs. 7230 lacs for the quarter ending on 30-JUN-2010.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-JUN-2011 (Standalone)","difference":"-","dt":"21072011093200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-07-21 09:32:00","symbol":"BIOCON"},{"an_dt":"21-Jul-2011 09:31:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 44168 lacs for quarter ending on 30-JUN-2011 against Rs. 66228 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 7005 lacs for the quarter ending on 30-JUN-2011 against Rs. 7674 lacs for the quarter ending on 30-JUN-2010.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-JUN-2011 (Consolidated)","difference":"-","dt":"21072011093100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-07-21 09:31:00","symbol":"BIOCON"},{"an_dt":"27-Jun-2011 14:59:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_noticeagm_27062011.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of the notice of the Annual General Meeting of the Members of the company to be held on July 21, 2011.","bflag":null,"csvName":null,"desc":"Annual General Meeting","difference":"-","dt":"27062011145900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-06-27 14:59:00","symbol":"BIOCON"},{"an_dt":"17-Jun-2011 16:26:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Company has announced the Book Closure from July 09, 2011 to July 21, 2011 (both days inclusive) for the purpose of Annual General Meeting and Final Dividend. Further, the Annual General Meeting will be held on July 21, 2011.","bflag":null,"csvName":null,"desc":"AGM / Book Closure","difference":"-","dt":"17062011162600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-06-17 16:26:00","symbol":"BIOCON"},{"an_dt":"04-May-2011 13:54:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the payment date for the interim dividend of Rs.1.50 per equity share declared by the Board of Directors of the Company in its meeting held on April 28, 2011 will be May 12, 2011.","bflag":null,"csvName":null,"desc":"Date of payment of dividend","difference":"-","dt":"04052011135400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-05-04 13:54:00","symbol":"BIOCON"},{"an_dt":"03-May-2011 19:10:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors in its meeting held on April 28, 2011 have appointed Mr. John Russell Fotheringham Walls as an Additional Director of the Company with immediate effect. He will hold office up to the date of the Annual General Meeting, when his appointment as a director will be placed for the approval of the shareholders.","bflag":null,"csvName":null,"desc":"Appointment of Director","difference":"-","dt":"03052011191000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-05-03 19:10:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2011 10:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on April 28, 2011 have declared an interim dividend of 30% (Rs 1.50 per share). A final dividend of 60% (Rs. 3.00 per share), has also been recommended by the Board subject to the approval of the members thereby taking the total dividend for the year to 90% (Rs. 4.50 per share) on the share capital of the Company.","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"28042011100000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-04-28 10:00:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2011 09:44:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_pr_28042011.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 28, 2011, titled \"Biocon Limited announces earnings for the full year ended March 31, 2011\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"28042011094400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-04-28 09:44:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2011 09:40:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 277073 lacs for year ending on 31-MAR-2011 against Rs. 236782 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 36752 lacs for the year ending on 31-MAR-2011 against Rs. 29325 lacs for the year ending on 31-MAR-2010.","bflag":null,"csvName":null,"desc":"Results Update, Year ended, 31-MAR-2011 (Consolidated)","difference":"-","dt":"28042011094000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-04-28 09:40:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2011 09:39:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2011 as follows: Net Sales of Rs. 37136 lacs for quarter ending on 31-MAR-2011 against Rs. 32732 lacs for the quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 8803 lacs for the quarter ending on 31-MAR-2011 against Rs. 7264 lacs for the quarter ending on 31-MAR-2010.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 31-MAR-2011 (Standalone)","difference":"-","dt":"28042011093900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-04-28 09:39:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2011 09:38:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 153156 lacs for year ending on 31-MAR-2011 against Rs. 116309 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 45925 lacs for the year ending on 31-MAR-2011 against Rs. 24836 lacs for the year ending on 31-MAR-2010.","bflag":null,"csvName":null,"desc":"Results Update, Year ended, 31-MAR-2011 (Standalone)","difference":"-","dt":"28042011093800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-04-28 09:38:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2011 09:37:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2011 as follows: Net Sales of Rs. 70163 lacs for quarter ending on 31-MAR-2011 against Rs. 65684 lacs for the quarter ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 10081 lacs for the quarter ending on 31-MAR-2011 against Rs. 8062 lacs for the quarter ending on 31-MAR-2010.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 31-MAR-2011 (Consolidated)","difference":"-","dt":"28042011093700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-04-28 09:37:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2011 09:36:33","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31MAR2011_B_Q4A.zip","attchmntText":"Biocon Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended March 31,2011.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"28042011093633","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"2914","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-04-28 09:36:33","symbol":"BIOCON"},{"an_dt":"25-Apr-2011 11:01:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors at its meeting held on April 28, 2011 has fixed May 06, 2011 as the record date for payment of the Interim Dividend, if any, declared by the Board of Directors in their meeting to be held on April 28, 2011.","bflag":null,"csvName":null,"desc":"Record Date","difference":"-","dt":"25042011110100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-04-25 11:01:00","symbol":"BIOCON"},{"an_dt":"20-Jan-2011 10:07:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_pr_20012011.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 20, 2011, titled \"Biocon delivers strong Q3 performance with growth across businesses\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"20012011100700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-01-20 10:07:00","symbol":"BIOCON"},{"an_dt":"20-Jan-2011 10:05:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 50168 lacs for quarter ending on 31-DEC-2010 against Rs. 30083 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 21159 lacs for the quarter ending on 31-DEC-2010 against Rs. 6580 lacs for the quarter ending on 31-DEC-2009.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 31-DEC-2010 (Standalone)","difference":"-","dt":"20012011100500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-01-20 10:05:00","symbol":"BIOCON"},{"an_dt":"20-Jan-2011 10:04:21","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_31DEC2010_B_Q3.zip","attchmntText":"Biocon Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended December 31,2010.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"20012011100421","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"1492","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-01-20 10:04:21","symbol":"BIOCON"},{"an_dt":"11-Jan-2011 09:01:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_11012011.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 10, 2010, titled \"Biocon announces preliminary data on its novel oral insulin drug candidate\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"11012011090100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2011-01-11 09:01:00","symbol":"BIOCON"},{"an_dt":"27-Oct-2010 10:43:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_pr_27102010.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 27, 2010, titled \"BIOCON'S STRATEGIC FOREIGN DIRECT INVESTMENT IN MALAYSIA TO SPUR COUNTRY'S BIOTECH INDUSTRY\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"27102010104300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-10-27 10:43:00","symbol":"BIOCON"},{"an_dt":"22-Oct-2010 09:30:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_22102010.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 22, 2010, titled \"Biocon Continues To Deliver Strong Performance Signs Strategic Global Commercialization Agreement With PFIZER\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"22102010093000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-10-22 09:30:00","symbol":"BIOCON"},{"an_dt":"22-Oct-2010 09:29:24","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_30SEP2010_B_Q2H.zip","attchmntText":"Biocon Limited has submitted to the Exchange the Standalone and Consolidated Financial Results for the period ended September 30,2010.","bflag":null,"csvName":null,"desc":"Financial Result Updates","difference":"-","dt":"22102010092924","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":"150","smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-10-22 09:29:24","symbol":"BIOCON"},{"an_dt":"22-Oct-2010 09:26:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 33612 lacs for quarter ending on 30-SEP-2010 against Rs. 29215 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 8733 lacs for the quarter ending on 30-SEP-2010 against Rs. 6236 lacs for the quarter ending on 30-SEP-2009.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-SEP-2010 (Standalone)","difference":"-","dt":"22102010092600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-10-22 09:26:00","symbol":"BIOCON"},{"an_dt":"22-Oct-2010 09:25:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2010 as follows: Net Sales of Rs. 67877 lacs for quarter ending on 30-SEP-2010 against Rs. 57993 lacs for the quarter ending on 30-SEP-2009. Net Profit / (Loss) of Rs. 8922 lacs for the quarter ending on 30-SEP-2010 against Rs. 7419 lacs for the quarter ending on 30-SEP-2009.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-SEP-2010 (Consolidated)","difference":"-","dt":"22102010092500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-10-22 09:25:00","symbol":"BIOCON"},{"an_dt":"18-Oct-2010 17:04:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_PR_18102010.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 18, 2010, titled \"Biocon and Pfizer enter into Global Commercialization Agreement\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18102010170400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-10-18 17:04:00","symbol":"BIOCON"},{"an_dt":"27-Sep-2010 11:29:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_pr_27092010.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 27, 2010, titled \"Biocon and CIM to Collaborate in Immunology Research Program\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"27092010112900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-09-27 11:29:00","symbol":"BIOCON"},{"an_dt":"16-Sep-2010 14:49:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_pr_16092010.zip","attchmntText":"Biocon Limited has informed the Exchange vide its letter dated September 16, 2010 regarding a press release, titled \"Biocon partners with Teleradiology Solutions for Clinical Trials Radiology\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"16092010144900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-09-16 14:49:00","symbol":"BIOCON"},{"an_dt":"16-Aug-2010 18:03:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_pr_16082010.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 16, 2010, titled \"Biocon launches new healthcare division for critical illnesses & acute hospital acquired infections\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"16082010180300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-08-16 18:03:00","symbol":"BIOCON"},{"an_dt":"28-Jul-2010 19:11:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/BIOCON_proceedingofagm_28072010.zip","attchmntText":"Biocon Limited has informed the Exchange regarding the proceeding of Annual General Meeting of the Company held on July 23, 2010.","bflag":null,"csvName":null,"desc":"Proceedings of Annual General Meeting","difference":"-","dt":"28072010191100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-07-28 19:11:00","symbol":"BIOCON"},{"an_dt":"23-Jul-2010 09:27:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_pr_23072010.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated  July 23, 2010, titled \"Biocon Starts FY11 on a Strong Note\" along with Fact Sheet.","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"23072010092700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-07-23 09:27:00","symbol":"BIOCON"},{"an_dt":"23-Jul-2010 09:24:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 66228 lacs for quarter ending on 30-JUN-2010 against Rs. 49593 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 7674 lacs for the quarter ending on 30-JUN-2010 against Rs. 5755 lacs for the quarter ending on 30-JUN-2009.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-JUN-2010 (Consolidated)","difference":"-","dt":"23072010092400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-07-23 09:24:00","symbol":"BIOCON"},{"an_dt":"23-Jul-2010 09:23:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2010 as follows: Net Sales of Rs. 32240 lacs for quarter ending on 30-JUN-2010 against Rs. 24279 lacs for the quarter ending on 30-JUN-2009. Net Profit / (Loss) of Rs. 7230 lacs for the quarter ending on 30-JUN-2010 against Rs. 4755 lacs for the quarter ending on 30-JUN-2009.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-JUN-2010 (Standalone)","difference":"-","dt":"23072010092300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-07-23 09:23:00","symbol":"BIOCON"},{"an_dt":"30-Jun-2010 17:18:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/Biocon_agmnot_30062010.zip","attchmntText":"Biocon Limited has submitted to the Exchange a copy of the notice of the Annual General Meeting of the Members of the company to be held on July 23, 2010.","bflag":null,"csvName":null,"desc":"Annual General Meeting","difference":"-","dt":"30062010171800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-06-30 17:18:00","symbol":"BIOCON"},{"an_dt":"24-May-2010 18:25:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_PR_24052010.ZIP","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 24, 2010, titled \"Biocon Limited and Optimer Pharmaceuticals announce Manufacturing and Supply Agreement for Fidaxomicin\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"24052010182500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-05-24 18:25:00","symbol":"BIOCON"},{"an_dt":"21-May-2010 10:26:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Company has announced the Book Closure from July 10, 2010 to July 23, 2010 (both days inclusive) for the purpose of Annual General Meeting and Dividend. Further, the Annual General Meeting will be held on July 23, 2010.","bflag":null,"csvName":null,"desc":"AGM/Book Closure","difference":"-","dt":"21052010102600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-05-21 10:26:00","symbol":"BIOCON"},{"an_dt":"07-May-2010 13:11:00","attFileSize":null,"attchmntFile":"https://nsearchives.nseindia.com/corporate/biocon_pr_07052010.zip","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 07, 2010, titled \"Biocon takes \"Diabetes Awareness\" to the masses\".","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"07052010131100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-05-07 13:11:00","symbol":"BIOCON"},{"an_dt":"29-Apr-2010 18:40:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated  April 29, 2010, titled \"Clinigene Announces Appointment of its New COO\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR1_29042010.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"29042010184000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-04-29 18:40:00","symbol":"BIOCON"},{"an_dt":"29-Apr-2010 09:55:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has submitted to the Exchange a copy for Fact Sheet for 'FY2010 vs. FY2009; Q4 FY 2010 vs Q4 FY 2009'. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_FactSheet_29042010.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"29042010095500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-04-29 09:55:00","symbol":"BIOCON"},{"an_dt":"29-Apr-2010 09:42:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board for Directors of the Company at their meeting held on  April 29, 2010 have recommended, subject to the approval of the members dividend of 70% (Rs. 3.50) per share on the enhanced share capital of the company.","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"29042010094200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-04-29 09:42:00","symbol":"BIOCON"},{"an_dt":"29-Apr-2010 09:28:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 65684 lacs for quarter ending on 31-MAR-2010 against Rs. 46626 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 8062 lacs for the quarter ending on 31-MAR-2010 against Rs. 2488 lacs for the quarter ending on 31-MAR-2009.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 31-MAR-2010 (Consolidated)","difference":"-","dt":"29042010092800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-04-29 09:28:00","symbol":"BIOCON"},{"an_dt":"29-Apr-2010 09:27:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 236782 lacs for year ending on 31-MAR-2010 against Rs. 160867 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 29325 lacs for the year ending on 31-MAR-2010 against Rs. 9312 lacs for the year ending on 31-MAR-2009.","bflag":null,"csvName":null,"desc":"Results Update, Year ended, 31-MAR-2010 (Consolidated)","difference":"-","dt":"29042010092700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-04-29 09:27:00","symbol":"BIOCON"},{"an_dt":"29-Apr-2010 09:26:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated  April 29, 2010, titled \"Biocon revenues cross half-billion dollar mark, Revenues at Rs.2,405 crores; EBITDA at Rs. 509 crores; PAT at Rs. 293 crores; Board recommends dividend of Rs. 3.50 per Equity Shares (70%)\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_29042010.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"29042010092600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-04-29 09:26:00","symbol":"BIOCON"},{"an_dt":"29-Apr-2010 09:24:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2010 as follows: Net Sales of Rs. 116309 lacs for year ending on 31-MAR-2010 against Rs. 91234 lacs for the year ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 24836 lacs for the year ending on 31-MAR-2010 against Rs. 11181 lacs for the year ending on 31-MAR-2009.","bflag":null,"csvName":null,"desc":"Results Update, Year ended, 31-MAR-2010 (Standalone)","difference":"-","dt":"29042010092400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-04-29 09:24:00","symbol":"BIOCON"},{"an_dt":"29-Apr-2010 09:23:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2010 as follows: Net Sales of Rs. 32732 lacs for quarter ending on 31-MAR-2010 against Rs. 22160 lacs for the quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 7264 lacs for the quarter ending on 31-MAR-2010 against Rs. 2414 lacs for the quarter ending on 31-MAR-2009.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 31-MAR-2010 (Standalone)","difference":"-","dt":"29042010092300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-04-29 09:23:00","symbol":"BIOCON"},{"an_dt":"06-Apr-2010 08:09:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 05, 2010, titled \"Biocon Biopharmaceuticals Private Limited becomes wholly owned subsidiary\". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/BIOCON_pr_06042010.ZIP target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"06042010080900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-04-06 08:09:00","symbol":"BIOCON"},{"an_dt":"05-Apr-2010 10:21:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that \"Pursuant to a business restructuring between CIMAB S.A and Biocon Limited ('Company'), Biocon SA, a wholly subsidiary of the Company has entered into an agreement to acquire the 49% equity stake held by CIMAB SA in Biocon Biopharmaceuticals Private Limited ('BBPL'). Post this acquisition, BBPL will become a wholly owned subsidiary of the Company. The Company and CIMAB shall continue their partnership on research, development and commercialization of a range of novel biopharmaceutical products\".","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"05042010102100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-04-05 10:21:00","symbol":"BIOCON"},{"an_dt":"22-Mar-2010 14:48:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 22, 2010, titled \"Syngene to Collaborate with Endo Pharmaceuticals to Develop Anti-cancer Novel Therapeutic Molecules\". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_pr_22032010.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"22032010144800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-03-22 14:48:00","symbol":"BIOCON"},{"an_dt":"04-Feb-2010 17:08:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 04, 2010, titled \" Biocon and Bayer join hands to create awareness for self monitoring in diabetics\". A copy of the press release shall be available on the NSE website http://www.nseindia.com) under: Corporates > Latest announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_Pr_04022010.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"04022010170800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-02-04 17:08:00","symbol":"BIOCON"},{"an_dt":"22-Jan-2010 11:32:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 22, 2010  titled \"Biocon Explores Investment in Malaysia in partnership with Biotechcorp\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_22012010.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"22012010113200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-01-22 11:32:00","symbol":"BIOCON"},{"an_dt":"21-Jan-2010 09:34:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 21, 2010  titled \"Biocon Limited Announces Results for the Nine Months Ended December 31, 2009; Revenues at Rs 1,739 crores; EBITDA at Rs 369 crores; PAT at Rs 213 crores\". Further a copy of the press release along with Fact Sheet shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_pr_21012010.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release/Others","difference":"-","dt":"21012010093400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-01-21 09:34:00","symbol":"BIOCON"},{"an_dt":"21-Jan-2010 09:26:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 30083 lacs for quarter ending on 31-DEC-2009 against Rs. 21987 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 6580 lacs for the quarter ending on 31-DEC-2009 against Rs. 2408 lacs for the quarter ending on 31-DEC-2008.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 31-DEC-2009 (Standalone)","difference":"-","dt":"21012010092600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-01-21 09:26:00","symbol":"BIOCON"},{"an_dt":"21-Jan-2010 09:25:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2009 as follows: Net Sales of Rs. 63512 lacs for quarter ending on 31-DEC-2009 against Rs. 43619 lacs for the quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 8089 lacs for the quarter ending on 31-DEC-2009 against Rs. 2820 lacs for the quarter ending on 31-DEC-2008.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 31-DEC-2009 (Consolidated)","difference":"-","dt":"21012010092500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2010-01-21 09:25:00","symbol":"BIOCON"},{"an_dt":"10-Dec-2009 15:03:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 10, 2009, titled \"Biocon and HCG Group of Hospitals Ltd join hands to fight against Cervical Cancer\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_pr_10122009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"10122009150300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-12-10 15:03:00","symbol":"BIOCON"},{"an_dt":"01-Dec-2009 13:10:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited had informed the Exchange regarding the execution of a definitive agreement. The Company has now informed the Exchange that the Company has completed the acquisition formalities of the bulk pharmaceutical business undertaking of M/s IDL Specialty Chemicals Limited, located near Hyderabad.","bflag":null,"csvName":null,"desc":"Updates","difference":"-","dt":"01122009131000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-12-01 13:10:00","symbol":"BIOCON"},{"an_dt":"29-Oct-2009 20:36:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that Company have received an intimation on October 28, 2009 under Form C, pursuant to Regulation 13(3) of SEBI (Prohibition of Insider Trading) Regulations, 1992 (Annexure I) from HDFC Asset Management Company Limited that there is a decrease in their holdings by 2.054% and the aggregate holding of the schemes of HDFC Mutual Fund in the company is 5.139% of the paid up share capital of Biocon Limited. The details of the same shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/BIOCON_REG_29102009.ZIP target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Reg.13-SEBI(Prohibition of Insider Trading Regulations)1992","difference":"-","dt":"29102009203600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-10-29 20:36:00","symbol":"BIOCON"},{"an_dt":"22-Oct-2009 10:38:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 22, 2009  titled \"Biocon Limited Announces Results for the Half-Year Ended September 30, 2009; Revenues rise to Rs 1,098 crores; EBITDA at Rs.236 crores; PAT at Rs 132 crores\". Further a copy of the press release along with Fact Sheet shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/BIOCON_pr_22102009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release/Others","difference":"-","dt":"22102009103800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-10-22 10:38:00","symbol":"BIOCON"},{"an_dt":"22-Oct-2009 10:26:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 29215 lacs for quarter ending on 30-SEP-2009 against Rs. 24670 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 6236 lacs for the quarter ending on 30-SEP-2009 against Rs. 3353 lacs for the quarter ending on 30-SEP-2008.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-SEP-2009 (Standalone)","difference":"-","dt":"22102009102600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-10-22 10:26:00","symbol":"BIOCON"},{"an_dt":"22-Oct-2009 10:26:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 53494 lacs for half year ending on 30-SEP-2009 against Rs. 46788 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 10991 lacs for the half year ending on 30-SEP-2009 against Rs. 6352 lacs for the half year ending on 30-SEP-2008.","bflag":null,"csvName":null,"desc":"Results Update, Half Year ended, 30-SEP-2009 (Standalone)","difference":"-","dt":"22102009102600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-10-22 10:26:00","symbol":"BIOCON"},{"an_dt":"22-Oct-2009 10:25:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2009 as follows: Net Sales of Rs. 57993 lacs for quarter ending on 30-SEP-2009 against Rs. 43930 lacs for the quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 7419 lacs for the quarter ending on 30-SEP-2009 against Rs. 2502 lacs for the quarter ending on 30-SEP-2008.","bflag":null,"csvName":null,"desc":"Results Update, Quarter ended, 30-SEP-2009 (Consolidated)","difference":"-","dt":"22102009102500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-10-22 10:25:00","symbol":"BIOCON"},{"an_dt":"22-Oct-2009 10:24:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the half year ended on 30-SEP-2009 as follows: Net Sales of Rs. 107586 lacs for half year ending on 30-SEP-2009 against Rs. 70323 lacs for the half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 13174 lacs for the half year ending on 30-SEP-2009 against Rs. 4006 lacs for the half year ending on 30-SEP-2008.","bflag":null,"csvName":null,"desc":"Results Update, Half Year ended, 30-SEP-2009 (Consolidated)","difference":"-","dt":"22102009102400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-10-22 10:24:00","symbol":"BIOCON"},{"an_dt":"30-Sep-2009 19:25:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the company has entered into a definitive agreement, to acquire the bulk pharmaceutical business undertaking of IDL Specialty Chemicals Limited located near Hyderabad, subject to the closing conditions detailed in the said agreement.","bflag":null,"csvName":null,"desc":"Agreement","difference":"-","dt":"30092009192500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-09-30 19:25:00","symbol":"BIOCON"},{"an_dt":"29-Sep-2009 14:47:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 29, 2009, titled \"Kiran Mazumdar Shaw in Financial Times' 'Top 50 women in business' list\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/BIOCON_PR_29092009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"29092009144700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-09-29 14:47:00","symbol":"BIOCON"},{"an_dt":"24-Sep-2009 11:54:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange vide its letter dated September 24, 2009 regarding a press release dated September 23, 2009, titled \"Biocon among 20 Indian companies in Forbes 'Best Under A Billion' list\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_24092009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"24092009115400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-09-24 11:54:00","symbol":"BIOCON"},{"an_dt":"11-Sep-2009 09:51:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 11, 2009, titled \"Biocon Limited and Amylin Pharmaceuticals Enter a Global Development and Commercialization Agreement for a Novel Peptide Hybrid.\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/BIOCON_pr_11092009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"11092009095100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-09-11 09:51:00","symbol":"BIOCON"},{"an_dt":"20-Aug-2009 16:23:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 20, 2009, titled \"Kiran Mazumdar Shaw features on the Forbes list of The World's 100 Most Powerful Women\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_20082009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"20082009162300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-08-20 16:23:00","symbol":"BIOCON"},{"an_dt":"11-Aug-2009 20:19:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange vide its letter dated August 11, 2009, regarding a press release dated August 10, 2009  titled \"The Syngene Vivarium receives official accreditation by AAALAC\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_pr_11082009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"11082009201900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-08-11 20:19:00","symbol":"BIOCON"},{"an_dt":"24-Jul-2009 11:05:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the proceedings of the Annual General Meeting of the Company held on July 23, 2009. The details of the same shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/BIOCONLTD_PAGM_24072009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Proceedings of AGM","difference":"-","dt":"24072009110500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-07-24 11:05:00","symbol":"BIOCON"},{"an_dt":"23-Jul-2009 09:46:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 23, 2009  titled \"Biocon's Q1 FY ' 10 Results Surge Ahead Revenues Rs.505 crores. EBITDA Rs.111crores. PAT Rs.58 crores\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/BIOCON_pr_23072009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"23072009094600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-07-23 09:46:00","symbol":"BIOCON"},{"an_dt":"23-Jul-2009 09:37:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 24279 lacs for quarter ending on 30-JUN-2009 against Rs. 22118 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 4755 lacs for the quarter ending on 30-JUN-2009 against Rs. 3001 lacs for the quarter ending on 30-JUN-2008.","bflag":null,"csvName":null,"desc":"Standalone Results Update, Quarter ended, 30-JUN-2009","difference":"-","dt":"23072009093700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-07-23 09:37:00","symbol":"BIOCON"},{"an_dt":"23-Jul-2009 09:36:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2009 as follows: Net Sales of Rs. 49593 lacs for quarter ending on 30-JUN-2009 against Rs. 26393 lacs for the quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 5755 lacs for the quarter ending on 30-JUN-2009 against Rs. 1502 lacs for the quarter ending on 30-JUN-2008.","bflag":null,"csvName":null,"desc":"Consolidated Results Update, Quarter ended, 30-JUN-2009","difference":"-","dt":"23072009093600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-07-23 09:36:00","symbol":"BIOCON"},{"an_dt":"29-Jun-2009 10:04:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated June 29, 2009, titled \"Biocon Announces Strategic Collaboration with Mylan to enter the Global Generic Biologics Market\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_29062009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"29062009100400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-06-29 10:04:00","symbol":"BIOCON"},{"an_dt":"25-Jun-2009 15:31:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited had informed the Exchange that the Company has announce the Book Closure from July 15, 2009 to July 23, 2009 (both days inclusive) for the purpose of Annual General Meeting to be held on July 23, 2009 & Dividend. The Company has now informed the Exchange that the company has revised the book closure dates as follows: The company has announce the Book Closure from July 10, 2009 to July 23, 2009 (both days inclusive) for the purpose of Annual General Meeting to be held on July 23, 2009 & Dividend.","bflag":null,"csvName":null,"desc":"Revision in Book Closure","difference":"-","dt":"25062009153100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-06-25 15:31:00","symbol":"BIOCON"},{"an_dt":"22-Jun-2009 14:06:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Company has announce the Book Closure from July 15, 2009 to July 23, 2009 (both days inclusive) for the purpose of Annual General Meeting to be held on July 23, 2009 & Dividend.","bflag":null,"csvName":null,"desc":"AGM/Book Closure","difference":"-","dt":"22062009140600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-06-22 14:06:00","symbol":"BIOCON"},{"an_dt":"08-Jun-2009 16:41:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated June 08, 2009, titled \"Biocon inks partnership with ISB to launch the Biocon Cell for Innovation Management ; Initial contribution of Rs. 1 crore to set up the cell\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_PR_080620098.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"08062009164100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-06-08 16:41:00","symbol":"BIOCON"},{"an_dt":"29-May-2009 12:11:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 29, 2009, titled \"Biocon launches BASALOG(TM) - long lasting basal insulin for Type 1 & Type 2 Diabetics\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_pr_29052009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"29052009121100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-05-29 12:11:00","symbol":"BIOCON"},{"an_dt":"12-May-2009 11:29:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 11, 2009  titled \"Kiran Mazumdar Shaw awarded the prestigious 'Nikkei Asia Prize' 2009 for Regional Growth\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_12052009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"12052009112900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-05-12 11:29:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2009 10:25:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 91234 lacs for year ending on 31-MAR-2009 against Rs. 87693 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 11181 lacs for the year ending on 31-MAR-2009 against Rs. 43494 lacs for the year ending on 31-MAR-2008.","bflag":null,"csvName":null,"desc":"Standalone Results Update, Year ended, 31-MAR-2009","difference":"-","dt":"28042009102500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-04-28 10:25:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2009 10:24:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 22160 lacs for quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 2414 lacs for the quarter ending on 31-MAR-2009.","bflag":null,"csvName":null,"desc":"Standalone Results Update, Quarter ended, 31-MAR-2009","difference":"-","dt":"28042009102400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-04-28 10:24:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2009 10:22:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2009 as follows: Net Sales of Rs. 160867 lacs for year ending on 31-MAR-2009 against Rs. 105379 lacs for the year ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 9312 lacs for the year ending on 31-MAR-2009 against Rs. 46391 lacs for the year ending on 31-MAR-2008.","bflag":null,"csvName":null,"desc":"Consolidated Results Update, Year ended, 31-MAR-2009","difference":"-","dt":"28042009102200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-04-28 10:22:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2009 10:21:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 46626 lacs for quarter ending on 31-MAR-2009. Net Profit / (Loss) of Rs. 2488 lacs for the quarter ending on 31-MAR-2009.","bflag":null,"csvName":null,"desc":"Consolidated Results Update, Quarter ended, 31-MAR-2009","difference":"-","dt":"28042009102100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-04-28 10:21:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2009 10:17:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 28, 2009  titled \"Biocon Group Delivers 16% Growth in Operating Profits - PAT Impacted By MTM. Board Recommends Rs.3 per share (60%) As Dividend \". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_pr_28042009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"28042009101700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-04-28 10:17:00","symbol":"BIOCON"},{"an_dt":"28-Apr-2009 10:14:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on  April 28, 2009 have recommended, subject to the approval of the members dividend of 60% (Rs. 3) per share on the enhanced share capital of the company.","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"28042009101400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-04-28 10:14:00","symbol":"BIOCON"},{"an_dt":"23-Mar-2009 08:50:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has submitted to the Exchange a copy of press release, dated March 23, 2009, titled \"Bristol-Myers Squibb and Biocon's Syngene open new R&D Facility at Biocon Park\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_23032009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"23032009085000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-03-23 08:50:00","symbol":"BIOCON"},{"an_dt":"18-Mar-2009 15:39:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has submitted to the Exchange a copy of press release, dated March 18, 2009, titled \"Biocon wins prestigious 2009 BioSingapore Asia Pacific Biotechnology Award for Best Listed Company\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_18032009.ZIP target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18032009153900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-03-18 15:39:00","symbol":"BIOCON"},{"an_dt":"09-Mar-2009 15:15:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has submitted to the Exchange a copy of press release issued by Syngene International Limited (\"Syngene\") a subsidiary of the Company, dated March 09, 2009, titled \"Syngene and DuPont Crop Protection Forge Alliance Partnership\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_09032009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"09032009151500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-03-09 15:15:00","symbol":"BIOCON"},{"an_dt":"02-Mar-2009 13:28:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has submitted to the Exchange a copy of press release issued by Axicorp GmbH (\"Axicorp\"), a  Biocon Company, which has been released at Friedrichsdorf, Germany, dated March 02, 2009, titled \"Axicorp Press Release\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biobon_pr_02032009.ZIP target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"02032009132800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-03-02 13:28:00","symbol":"BIOCON"},{"an_dt":"21-Jan-2009 11:47:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has submitted to the Exchange a copy of press release issued by Syngene International Limited (\"Syngene\") a wholly owned subsidiary of the Company, dated January 21, 2009, titled \"Syngene partners with Sapient Discovery to expand integrated drug discovery offerings\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon01_PR01_21012009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21012009114700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-01-21 11:47:00","symbol":"BIOCON"},{"an_dt":"21-Jan-2009 10:22:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 21, 2009  titled \"Biocon's 9 months FY-09 maintains growth momentum, Revenues : Rs. 1,187 crs (including AxiCorp) : Rs. 889 crs (excluding AxiCorp) : EBITDA Rs. 277 crs : PAT Rs. 174 crs (excluding MTM)\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_Pr_21012009.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21012009102200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-01-21 10:22:00","symbol":"BIOCON"},{"an_dt":"21-Jan-2009 10:11:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 43619 lacs for quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 2820 lacs for the quarter ending on 31-DEC-2008.","bflag":null,"csvName":null,"desc":"Consolidated Results Update, Quarter ended, 31-DEC-2008","difference":"-","dt":"21012009101100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-01-21 10:11:00","symbol":"BIOCON"},{"an_dt":"21-Jan-2009 10:11:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2008 as follows: Net Sales of Rs. 21987 lacs for quarter ending on 31-DEC-2008. Net Profit / (Loss) of Rs. 2408 lacs for the quarter ending on 31-DEC-2008.","bflag":null,"csvName":null,"desc":"Standalone Results Update, Quarter ended, 31-DEC-2008","difference":"-","dt":"21012009101100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2009-01-21 10:11:00","symbol":"BIOCON"},{"an_dt":"16-Oct-2008 10:12:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the press announcement dated October 16, 2008, titled \"BIOCON's H1 FY'09 Sustains Growth In Challenging Conditions- Revenues Rs.734 crores (Including AxiCorp); Revenues Rs.593 crores (Excluding AxiCorp); EBITDA Rs.168 crores. PAT Rs.100 crores (Excluding MTM Loss of Rs.60 crores)\". A copy of the press announcement along with Fact Sheet shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PA_16102008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Announcement","difference":"-","dt":"16102008101200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-10-16 10:12:00","symbol":"BIOCON"},{"an_dt":"16-Oct-2008 09:54:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 46788 lacs for half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 6352 lacs for the half year ending on 30-SEP-2008.","bflag":null,"csvName":null,"desc":"Standalone Results Update, Half Yearly ended, 30-SEP-2008","difference":"-","dt":"16102008095400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-10-16 09:54:00","symbol":"BIOCON"},{"an_dt":"16-Oct-2008 09:53:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the half year ended on 30-SEP-2008 as follows: Net Sales of Rs. 70323 lacs for half year ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 4006 lacs for the half year ending on 30-SEP-2008.","bflag":null,"csvName":null,"desc":"Consolidated Results Update, Half Yearly ended, 30-SEP-2008","difference":"-","dt":"16102008095300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-10-16 09:53:00","symbol":"BIOCON"},{"an_dt":"16-Oct-2008 09:52:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 24670 lacs for quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 3353 lacs for the quarter ending on 30-SEP-2008.","bflag":null,"csvName":null,"desc":"Standalone Results Update, Quarter ended, 30-SEP-2008","difference":"-","dt":"16102008095200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-10-16 09:52:00","symbol":"BIOCON"},{"an_dt":"16-Oct-2008 09:51:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 43930 lacs for quarter ending on 30-SEP-2008. Net Profit / (Loss) of Rs. 2502 lacs for the quarter ending on 30-SEP-2008.","bflag":null,"csvName":null,"desc":"Consolidated Results Update, Quarter ended, 30-SEP-2008","difference":"-","dt":"16102008095100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-10-16 09:51:00","symbol":"BIOCON"},{"an_dt":"10-Oct-2008 08:42:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 09, 2008  titled \"NeoBiocon and Abraxis Bioscience Launch Abraxane in the UAE For Treatment of Breast Cancer\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_10102008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"10102008084200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-10-10 08:42:00","symbol":"BIOCON"},{"an_dt":"22-Sep-2008 16:25:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 22, 2008  titled \" Biocon is the 7th largest biotech employer in the world: Med Ad News \". A copy of the press release shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_pr_22092008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"22092008162500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-09-22 16:25:00","symbol":"BIOCON"},{"an_dt":"08-Sep-2008 16:42:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 08, 2008,  titled \"Biocon Limited presents human clinical data on IN-105 (oral insulin) at the EASD meeting in Rome\". A copy of the press release shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).  <a href=/content/corporate/BIOCON_PR_08092008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"08092008164200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-09-08 16:42:00","symbol":"BIOCON"},{"an_dt":"12-Aug-2008 12:16:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the members at the Annual General Meeting of the Company held on July 18, 2008 approved the issue of Bonus Shares in the ratio of one fully paid equity share for every equity share held in the Company. Further to the same, the Board has fixed September 12, 2008 as the record date for determining the eligibility and other conditions pursuant to the aforesaid approval by the members.","bflag":null,"csvName":null,"desc":"Record Date","difference":"-","dt":"12082008121600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-08-12 12:16:00","symbol":"BIOCON"},{"an_dt":"18-Jul-2008 16:37:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 18, 2008, titled \"Biocon and Abraxis Bioscience Launch Abraxane in India For Treatment of Breast Cancer\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/bio_pr_18072008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18072008163700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-07-18 16:37:00","symbol":"BIOCON"},{"an_dt":"18-Jul-2008 16:35:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has submitted to the Exchange a copy of the proceedings of the Annual General Meeting of the Company held on July 17, 2008. A copy of the same shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_proceedings_18072008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Proceedings of AGM","difference":"-","dt":"18072008163500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-07-18 16:35:00","symbol":"BIOCON"},{"an_dt":"17-Jul-2008 11:28:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 17, 2008, titled \"Biocon is world's top 20 biotechnology company : Med Ad News\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/BioconLtd_Pr_17072008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"17072008112800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-07-17 11:28:00","symbol":"BIOCON"},{"an_dt":"17-Jul-2008 10:09:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a  press announcement relating to the results dated July 17, 2008, titled \"Biocon's Q1 Fy'09 impacted by Exceptional factors, Revenues Rs. 277 crores. EBITDA Rs. 70 crores, PAT Rs. 15 crores (MTM provision Rs. 26 crores).\" The details of the press announcement shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_17072008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Announcement","difference":"-","dt":"17072008100900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-07-17 10:09:00","symbol":"BIOCON"},{"an_dt":"17-Jul-2008 10:02:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 26393 lacs for quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 1502 lacs for the quarter ending on 30-JUN-2008.","bflag":null,"csvName":null,"desc":"Consolidated Results Update, Quarter ended, 30-JUN-2008","difference":"-","dt":"17072008100200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-07-17 10:02:00","symbol":"BIOCON"},{"an_dt":"17-Jul-2008 10:01:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 22118 lacs for quarter ending on 30-JUN-2008. Net Profit / (Loss) of Rs. 3001 lacs for the quarter ending on 30-JUN-2008.","bflag":null,"csvName":null,"desc":"Standalone Results Update, Quarter ended, 30-JUN-2008","difference":"-","dt":"17072008100100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-07-17 10:01:00","symbol":"BIOCON"},{"an_dt":"07-Jul-2008 15:02:00","attFileSize":null,"attchmntFile":"-","attchmntText":"News Verification : The media had reports that Biocon Limited may hive off its research and development activity to a separate entity as part of its focus on innovation.. The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Biocon Limited has vide its letter inter-alia stated, \"We wish to inform that the company, with a view to achieve great focus on its research programmes is proposing to set up a new R&D entity for discovery and innovative drug development initiatives. The creation of the new entity is under way and further modalities are being worked out. Further the proposal of setting up a Greenfield formulations facility is part of the future expansion plans of the company. The company is yet to firm up its investment plans in terms of size and the time period for the said project.\"","bflag":null,"csvName":null,"desc":"News Verification","difference":"-","dt":"07072008150200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-07-07 15:02:00","symbol":"BIOCON"},{"an_dt":"05-Jun-2008 11:25:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Annual General Meeting of the Company will be held on July 17, 2008.","bflag":null,"csvName":null,"desc":"AGM","difference":"-","dt":"05062008112500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-06-05 11:25:00","symbol":"BIOCON"},{"an_dt":"04-Jun-2008 12:11:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated June 04, 2008, titled \"Biocon launches 'ERYPRO Safe(TM)'and 'NUFIL Safe (TM)' Pre-filled Syringes in collaboration with Safety Syringes Inc., USA\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_PR_04062008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"04062008121100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-06-04 12:11:00","symbol":"BIOCON"},{"an_dt":"22-Apr-2008 10:20:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Register of Members and Share Transfer register shall remain closed for a period of 7 days from July 05, 2008 to July 12, 2008 (both days inclusive) for the payment of Dividend.","bflag":null,"csvName":null,"desc":"Book Closure","difference":"-","dt":"22042008102000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-04-22 10:20:00","symbol":"BIOCON"},{"an_dt":"22-Apr-2008 10:12:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors of the Company at its Meeting held on April 22, 2008 has recommended a dividend for the year (subject to the approval of the members at the ensuing Annual General Meeting) of Rs. 3/- per equity share (60%) and a special dividend of Rs. 2/- per share (40%).","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"22042008101200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-04-22 10:12:00","symbol":"BIOCON"},{"an_dt":"22-Apr-2008 10:11:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 21975 lacs for quarter ending on 31-MAR-2008 against Rs. 23359 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 6203 lacs for the quarter ending on 31-MAR-2008 against Rs. 4729 lacs for the quarter ending on 31-MAR-2007.","bflag":null,"csvName":null,"desc":"Standalone Results Update, Quarter ended, 31-MAR-2008","difference":"-","dt":"22042008101100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-04-22 10:11:00","symbol":"BIOCON"},{"an_dt":"22-Apr-2008 10:10:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 87693 lacs for year ending on 31-MAR-2008 against Rs. 85098 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 43494 lacs for the year ending on 31-MAR-2008 against Rs. 15835 lacs for the year ending on 31-MAR-2007.","bflag":null,"csvName":null,"desc":"Standalone Results Update, Year ended, 31-MAR-2008","difference":"-","dt":"22042008101000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-04-22 10:10:00","symbol":"BIOCON"},{"an_dt":"22-Apr-2008 10:10:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press announcement relating to results dated April 22, 2008, titled \"Biocon Group Delivers Healthy Performance for FY 2007-08; Board Recommends 1:1 Bonus Shares & 100% Dividend.\". A copy of the press announcement shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_22042008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Announcement","difference":"-","dt":"22042008101000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-04-22 10:10:00","symbol":"BIOCON"},{"an_dt":"22-Apr-2008 10:08:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the year ended on 31-MAR-2008 as follows: Net Sales of Rs. 105378 lacs for year ending on 31-MAR-2008 against Rs. 98573 lacs for the year ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 46391 lacs for the year ending on 31-MAR-2008 against Rs. 20026 lacs for the year ending on 31-MAR-2007.","bflag":null,"csvName":null,"desc":"Consolidated Results Update, Year ended, 31-MAR-2008","difference":"-","dt":"22042008100800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-04-22 10:08:00","symbol":"BIOCON"},{"an_dt":"22-Apr-2008 10:06:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board of Directors of the Company at its Meeting held on April 22, 2008 has recommended, subject to the approval of Members, issue of Bonus Shares in the ratio of 1:1.","bflag":null,"csvName":null,"desc":"Bonus","difference":"-","dt":"22042008100600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-04-22 10:06:00","symbol":"BIOCON"},{"an_dt":"22-Apr-2008 10:06:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-MAR-2008 as follows: Net Sales of Rs. 26663 lacs for quarter ending on 31-MAR-2008 against Rs. 27824 lacs for the quarter ending on 31-MAR-2007. Net Profit / (Loss) of Rs. 6530 lacs for the quarter ending on 31-MAR-2008 against Rs. 6070 lacs for the quarter ending on 31-MAR-2007.","bflag":null,"csvName":null,"desc":"Consolidated Results Update, Quarter ended, 31-MAR-2008","difference":"-","dt":"22042008100600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-04-22 10:06:00","symbol":"BIOCON"},{"an_dt":"15-Apr-2008 09:07:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding clarification to the article that has appeared on the Cover Page of 'Mint' on April 14, 2008 with the headline 'Biocon to buy US firm for $400 mn', that: \"Biocon Limited would like to clarify that this article is speculative and deny the Headline and the related information contained in the article. While it is true that the company had earlier indicated an intent to acquire marketing companies abroad, no acquisition target has been identified and the information contained in the article is unsubstantiated. There has been no comment form any Biocon spokesperson, as is clearly mentioned in the article: 'A Biocon spokesperson declined to comment as the firm is in the silent period ahead of the announcement of its quarterly results in keeping with the guidelines of stock market regulator Securities and Exchange Board of India (SEBI)'. All announcements by the company will be made as per SEBI guidelines, with prior intimation to the Stock Exchanges\".","bflag":null,"csvName":null,"desc":"News Clarification","difference":"-","dt":"15042008090700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-04-15 09:07:00","symbol":"BIOCON"},{"an_dt":"11-Feb-2008 10:23:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 11, 2008, titled \"Biocon acquires 70% stake in German Pharmaceutical company, AxiCorp : Biosimilars will be main focus.\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_11022008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"11022008102300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-02-11 10:23:00","symbol":"BIOCON"},{"an_dt":"17-Jan-2008 11:53:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has submitted to the Exchange the auditor's report in respect of the audited financial results for the quarter ended December 31, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_AuditorReport_17012008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Auditor's report","difference":"-","dt":"17012008115300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-01-17 11:53:00","symbol":"BIOCON"},{"an_dt":"17-Jan-2008 10:58:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 17, 2008, titled \"Biocon and IATRICa Partner to develop Novel Immunoconjugate Therapeutics against Cancer and Infectious Diseases.\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Bioconltd_PR_17012008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"17012008105800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-01-17 10:58:00","symbol":"BIOCON"},{"an_dt":"17-Jan-2008 10:07:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 17, 2008, titled \"Biocon's 9 Months FY 08 Registers Growth in Revenues & Profits Post Enzymes Divestment; Revenues Rs. 811 crs: EBITDA Rs. 240 crs: PAT Rs. 160 crs\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_17012008.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"17012008100700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-01-17 10:07:00","symbol":"BIOCON"},{"an_dt":"17-Jan-2008 09:57:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 19419 lacs for quarter ending on 31-DEC-2007 against Rs. 21408 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 28404 lacs for the quarter ending on 31-DEC-2007 against Rs. 4751 lacs for the quarter ending on 31-DEC-2006.","bflag":null,"csvName":null,"desc":"Standalone Results Update, Quarter ended, 31-DEC-2007","difference":"-","dt":"17012008095700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-01-17 09:57:00","symbol":"BIOCON"},{"an_dt":"17-Jan-2008 09:56:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 31-DEC-2007 as follows: Net Sales of Rs. 23734 lacs for quarter ending on 31-DEC-2007 against Rs. 24648 lacs for the quarter ending on 31-DEC-2006. Net Profit / (Loss) of Rs. 29183 lacs for the quarter ending on 31-DEC-2007 against Rs. 5531 lacs for the quarter ending on 31-DEC-2006.","bflag":null,"csvName":null,"desc":"Consolidated Results Update, Quarter ended, 31-DEC-2007","difference":"-","dt":"17012008095600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2008-01-17 09:56:00","symbol":"BIOCON"},{"an_dt":"18-Oct-2007 12:40:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has submitted to the Exchange the auditor's report in respect of the audited financial results for the quarter ended September 30, 2007. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_AR_18102007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Auditor's report","difference":"-","dt":"18102007124000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-10-18 12:40:00","symbol":"BIOCON"},{"an_dt":"18-Oct-2007 12:09:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 18, 2007, titled \"Biocon Limited and Abraxis Bioscience announce the Approval of \"Abraxine\" in India for the treatment of Breast Cancer\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_PR1_181007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18102007120900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-10-18 12:09:00","symbol":"BIOCON"},{"an_dt":"18-Oct-2007 11:27:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 18 2007, titled \"Biocon's H-1 FY'08 Delivers 27% Profit Growth\". A copy of the press release shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_PR_181007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18102007112700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-10-18 11:27:00","symbol":"BIOCON"},{"an_dt":"18-Oct-2007 11:23:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the half year ended on 30-SEP-2007 as follows: Net Sales of Rs. 54982 lacs for half year ending on 30-SEP-2007 against Rs. 46101 lacs for the half year ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 10679 lacs for the half year ending on 30-SEP-2007 against Rs. 8425 lacs for the half year ending on 30-SEP-2006.","bflag":null,"csvName":null,"desc":"Consolidated Results Update, Half Yearly ended, 30-SEP-2007","difference":"-","dt":"18102007112300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-10-18 11:23:00","symbol":"BIOCON"},{"an_dt":"18-Oct-2007 11:23:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 23559 lacs for quarter ending on 30-SEP-2007 against Rs. 21911 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 4401 lacs for the quarter ending on 30-SEP-2007 against Rs. 3597 lacs for the quarter ending on 30-SEP-2006.","bflag":null,"csvName":null,"desc":"Standalone Results Update, Quarter ended, 30-SEP-2007","difference":"-","dt":"18102007112300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-10-18 11:23:00","symbol":"BIOCON"},{"an_dt":"18-Oct-2007 11:22:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-SEP-2007 as follows: Net Sales of Rs. 27899 lacs for quarter ending on 30-SEP-2007 against Rs. 24900 lacs for the quarter ending on 30-SEP-2006. Net Profit / (Loss) of Rs. 5395 lacs for the quarter ending on 30-SEP-2007 against Rs. 4534 lacs for the quarter ending on 30-SEP-2006.","bflag":null,"csvName":null,"desc":"Consolidated Results Update, Quarter ended, 30-SEP-2007","difference":"-","dt":"18102007112200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-10-18 11:22:00","symbol":"BIOCON"},{"an_dt":"01-Oct-2007 10:32:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that: \"Pursuant to the approval received through postal ballot from the Members of the Company, the results of which were declared on September 3, 2007 for the divestment of Enzymes Business to M/s Novozymes South Asia Private Limited, Bangalore ('Novozymes'), the Company has on October 1, 2007 completed all activities relating to the aforesaid divestment and transferred the Enzymes business to Novozymes\".","bflag":null,"csvName":null,"desc":"Divestment","difference":"-","dt":"01102007103200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-10-01 10:32:00","symbol":"BIOCON"},{"an_dt":"21-Sep-2007 15:52:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated September 21, 2007, titled \"Biocon Limited presents human clinical data on IN-105 (oral insulin) at the EASD meeting in Amsterdam\". The details of the press release shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_21092007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21092007155200","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-09-21 15:52:00","symbol":"BIOCON"},{"an_dt":"06-Sep-2007 15:13:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the Declaration of the Results of voting conducted by Postal Ballot in terms of the Notice dated July 18, 2007. Pursuant to Section 192A of the Companies Act, 1956 read with the Companies (passing of the resolution by postal ballot) Rules, 2001, approval of the Members of the Company was sought by means of Postal Ballot vide Notice dated July 18, 2007, for the purpose of divestment of the Enzymes business of the Company (other than the business in the field of Human Healthcare related Enzymes). The details of the same shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PBResults.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Results of Postal Ballot","difference":"-","dt":"06092007151300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-09-06 15:13:00","symbol":"BIOCON"},{"an_dt":"09-Aug-2007 14:59:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 09, 2007, titled \"Biocon Limited and Abraxis Bioscience announces Licensing Agreement for the commercialization of Abraxane in India\". The details of the press release shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_09082007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"09082007145900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-08-09 14:59:00","symbol":"BIOCON"},{"an_dt":"03-Aug-2007 15:59:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that: \"Kiran Kumar G has been appointed as the Company Secretary and Compliance Officer of Biocon Limited with effect from August 1, 2007\".","bflag":null,"csvName":null,"desc":"Appointment of Company Secretary and Compliance Officer","difference":"-","dt":"03082007155900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-08-03 15:59:00","symbol":"BIOCON"},{"an_dt":"30-Jul-2007 10:34:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that as per Section 192A of the Companies Act, 1956 read with the Companies (Passing of the Resolution by Postal Ballot) Rules, 2001, the consent of the Shareholders is required to be obtained by means of Postal Ballot for the following resolution: Ordinary Resolution under Section 293(1)(a) of the Companies Act, 1956, for sale of Enzymes business. The Board of Directors has appointed Mr. K. Srinivasan, a Consulting Company Secretary, Bangalore, as Scrutinizer for conducting the Postal Ballot voting process in a fair and transparent manner. The duly completed postal ballot form should reach the Scrutinizer before the close of working hours on August 31, 2007. The results will be announced by the Chairman or any Director of the Company on September 03, 2007. A copy of the Notice of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PB_30072007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Postal Ballot","difference":"-","dt":"30072007103400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-07-30 10:34:00","symbol":"BIOCON"},{"an_dt":"30-Jul-2007 10:28:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 30, 2007, titled \"Pharma - Biotech Alliance Neobiocon established in Dubiotech\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_30072007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"30072007102800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-07-30 10:28:00","symbol":"BIOCON"},{"an_dt":"19-Jul-2007 15:56:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 19, 2007, titled \"Abraxis Bioscience and Biocon Limited Announce Licensing Agreement for G-CSF in North America and the European Union\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_PR_190707.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"19072007155600","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-07-19 15:56:00","symbol":"BIOCON"},{"an_dt":"18-Jul-2007 11:31:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 18, 2007, titled \"Biocon to Focus on Biopharmaceuticals, Divesting Enzymes for USD 115 Million to Novozymes\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_18072007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18072007113100","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-07-18 11:31:00","symbol":"BIOCON"},{"an_dt":"18-Jul-2007 10:05:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated July 18, 2007, titled \"Biocon's Q1 FY'08 Delivers 36% Profit Growth\". The details of the press release shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR1_18072007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18072007100500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-07-18 10:05:00","symbol":"BIOCON"},{"an_dt":"18-Jul-2007 09:58:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the consolidated Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 27083 lacs for quarter ending on 30-JUN-2007 against Rs. 21151 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 5283 lacs for the quarter ending on 30-JUN-2007 against Rs. 3891 lacs for the quarter ending on 30-JUN-2006.","bflag":null,"csvName":null,"desc":"Consolidated Results Update, Quarter ended, 30-JUN-2007","difference":"-","dt":"18072007095800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-07-18 09:58:00","symbol":"BIOCON"},{"an_dt":"18-Jul-2007 09:58:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the standalone Results for the quarter ended on 30-JUN-2007 as follows: Net Sales of Rs. 22740 lacs for quarter ending on 30-JUN-2007 against Rs. 18370 lacs for the quarter ending on 30-JUN-2006. Net Profit / (Loss) of Rs. 4486 lacs for the quarter ending on 30-JUN-2007 against Rs. 2757 lacs for the quarter ending on 30-JUN-2006.","bflag":null,"csvName":null,"desc":"Standalone Results Update, Quarter ended, 30-JUN-2007","difference":"-","dt":"18072007095800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-07-18 09:58:00","symbol":"BIOCON"},{"an_dt":"07-Jun-2007 17:54:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated June 07, 2007, titled \"Biocon signs Memorandum of Understanding with Deakin University , Australia - To establish Deakin Research Institute in Bangalore\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_07062007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"07062007175400","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-06-07 17:54:00","symbol":"BIOCON"},{"an_dt":"31-May-2007 10:48:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated May 31, 2007, titled \"Biocon Limited and Students Working Against Tobacco (SWAT) conduct unique campaign on World Anti-Tobacco Day\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_PR_310507.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"31052007104800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-05-31 10:48:00","symbol":"BIOCON"},{"an_dt":"30-May-2007 13:08:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Annual General Meeting of the Company will be held on July 18, 2007.","bflag":null,"csvName":null,"desc":"AGM","difference":"-","dt":"30052007130800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-05-30 13:08:00","symbol":"BIOCON"},{"an_dt":"19-Apr-2007 10:17:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board, at its meeting held on April 19, 2007, has recommended a dividend for the year (subject to the approval of shareholders at the ensuing Annual General Meeting) of Rs. 3 per Equity Share of Rs. 5 each (60%). Further, the register of members and share transfer books will remain closed from July 02, 2007 to July 19, 2007 both days inclusive, for the purpose of payment of dividend.","bflag":null,"csvName":null,"desc":"Dividend/Book Closure","difference":"-","dt":"19042007101700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-04-19 10:17:00","symbol":"BIOCON"},{"an_dt":"19-Apr-2007 10:09:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated April 19, 2007, titled \"Biocon's FY 2006-07 performance shows healthy growth - Revenues Rs. 990 crs; EBITDA Rs. 287 crs; PAT Rs. 200 crs\". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_PR_190407.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"19042007100900","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-04-19 10:09:00","symbol":"BIOCON"},{"an_dt":"21-Mar-2007 14:17:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 21, 2007, titled \"Biocon conducts ground breaking ceremony of new research facility at Biocon Park\". The copy of the press release shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/biocon_PR.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"21032007141700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-03-21 14:17:00","symbol":"BIOCON"},{"an_dt":"14-Mar-2007 10:10:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release, dated March 14, 2007, titled \"Biocon's Syngene enters into Research Partnership with Bristol-Myers Squibb.\" The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_14032007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"14032007101000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-03-14 10:10:00","symbol":"BIOCON"},{"an_dt":"08-Mar-2007 14:33:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated March 08, 2007, titled \"Biocon Limited Unveils A Comprehensive Portfolio of Renal Therapy Products\". The details of the press release shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_08032007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"08032007143300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-03-08 14:33:00","symbol":"BIOCON"},{"an_dt":"20-Feb-2007 11:43:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated February 20, 2007, titled \"Biocon and Bentley Announce Approval and Expansion of Bentley's Nasulin(TM) Phase II Studies in India\". The details of the press release shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_20022007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"20022007114300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-02-20 11:43:00","symbol":"BIOCON"},{"an_dt":"19-Feb-2007 11:30:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that \"Biocon Limited is contemplating to acquire about 50 acres of land in Jawaharlal Nehru Pharma City in Vishakapatna for its future manufacturing expansion needs. The proposed investment is in the order of Rs. 500 crores over five years\".","bflag":null,"csvName":null,"desc":"Miscellaneous","difference":"-","dt":"19022007113000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-02-19 11:30:00","symbol":"BIOCON"},{"an_dt":"18-Jan-2007 10:15:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding two press releases dated January 18, 2007, titled \"Bicon's 9 Months FY 07 Delivers Robust Profits, Revenues Rs. 710 crs : EBITDA Rs. 200 crs : PAT Rs. 140 crs\" and \"Biocon Grants Exclusive Marketing License for BIOMAb EGFR for Pakistan\". The details of the press releases shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_18012007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18012007101500","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-01-18 10:15:00","symbol":"BIOCON"},{"an_dt":"05-Jan-2007 09:43:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated January 05, 2007, titled \"Biocon Limited and Neopharma sign MOU for a JV\". The details of the press release shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocob_PR_05012007.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"05012007094300","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2007-01-05 09:43:00","symbol":"BIOCON"},{"an_dt":"26-Dec-2006 13:27:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated December 26,2006, titled \"Clinigene Pride Study reaffirms Insugen� Safety & Efficiency - Completes India's largest documented safety study on insulin vials\". The details of the press release shall be available on the NSE website   (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_PR_26122006.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"26122006132700","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-12-26 13:27:00","symbol":"BIOCON"},{"an_dt":"18-Oct-2006 10:28:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated October 18,2006, titled \"Biocon's HIFY07 delivers Robust Performance & Growing Profits\". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).<a href=/content/corporate/Biocon_181006.zip target=NEW> For more details click here.</a>","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18102006102800","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-10-18 10:28:00","symbol":"BIOCON"},{"an_dt":"18-Sep-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release, dated September 17 2006, titled \"Biocon launches innovative cancer drug - World's first humanized anti-EGFR monoclonal anitbody launched by Shah Rukh Khan\". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18092006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-09-18 00:00:00","symbol":"BIOCON"},{"an_dt":"04-Sep-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release, dated September 04 2006, titled \"Syngene international and Innate Pharmaceuticals collaborate to develop virulence blockers\". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"04092006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-09-04 00:00:00","symbol":"BIOCON"},{"an_dt":"03-Aug-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has submitted to the Exchange a copy of the minutes of the AGM of the Company held on July 19, 2006. A copy of the minutes of the AGM shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).","bflag":null,"csvName":null,"desc":"Minutes of AGM","difference":"-","dt":"03082006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-08-03 00:00:00","symbol":"BIOCON"},{"an_dt":"25-Jul-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the following business were transacted at the AGM of the Company held on July 19,2006: 1) A dividend at the rate of 50% (i.e Rs.2.50 per share of the face value of Rs.5 each) for the year 2005-06, as recommended by the Board, was declared to be paid to the shareholders 2) Mr. John Shaw, Director, who retires by rotation, was re-appointed as Director of the Company. 3) Prof. Ravi Mazumdar, Director, who retires by rotation, was re-appointed as Director of the Company. 4) M/s. S.R. Batliboi & Associates, Chartered Accountants, who retired at the conclusion of AGM, were re-appointed as Auditors of the Company till the conclusion of the next AGM at remuneration to be fixed by the Board of Directors on the recommendation of Audit Committee of the Company. 5) The shareholders approved to pay the compensation to Non Executive and Independent Directors for their professional services to the Company and authorized the Board of Directors to pay the Non-Executive and Independent Directors such compensation including, Sitting fees for Advisory Boards, professional consultancy fees, etc such amounts and in any such form/manner as the Board may from time to time determine.","bflag":null,"csvName":null,"desc":"Proceedings of AGM","difference":"-","dt":"25072006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-07-25 00:00:00","symbol":"BIOCON"},{"an_dt":"19-Jul-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the press release dated July 19, 2006, titled \"Biocon registers 21% increase in revenues to Rs.213 crores in Q1-FY07\". The details of the Press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"19072006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-07-19 00:00:00","symbol":"BIOCON"},{"an_dt":"19-Jul-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the press release dated July 19, 2006, titled \"Biocon Bayer Healthcare sign exclusive marketing agreement for insugen� for the Chinese Market\". The details of the Press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"19072006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-07-19 00:00:00","symbol":"BIOCON"},{"an_dt":"16-Jun-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that Chinappa M B has sold 30,000 shares on June 15, 2006 and June 16, 2006 of Biocon Ltd. The shareholding of Chinappa M B after the said sale is 30,999 shares of Biocon Ltd.","bflag":null,"csvName":null,"desc":"Disc under Regulation 13(6)of SEBI Insider Trading Reg.,1992","difference":"-","dt":"16062006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-06-16 00:00:00","symbol":"BIOCON"},{"an_dt":"07-Jun-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release, dated, June 06, 2006, titled, \"Dr. APJ Abdul Kalam Dedicates India�s First Cancer Drug Biomab(TM) EGFR to the Nation and Inaugurates India�s largest Biotech-hub �Biocon Park�. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"07062006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-06-07 00:00:00","symbol":"BIOCON"},{"an_dt":"06-Jun-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Annual General Meeting of the Company will be held on July 19, 2006. The Register of Members and Share Transfer Books of the Company will remain closed from July 01, 2006 to July 19, 2006 (both days inclusive) for the purpose of payment of dividend (if approved by Members at AGM).","bflag":null,"csvName":null,"desc":"AGM/Book Closure","difference":"-","dt":"06062006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-06-06 00:00:00","symbol":"BIOCON"},{"an_dt":"18-May-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that Dr. Neville Bain has sold 50,000 shares on May 11, 2006; 31,000 shares on May 12, 2006; 27,464 shares on May 15, 2006; 37,789 shares on May 16, 2006 of the share capital of Biocon Ltd. The total shareholding of the Dr. Neville Bain after the said sale is 750,000 aggregating to 0.75% of the total share capital of the Biocon Ltd.(2) Goutam Das has sold 25,000 shares on May 10, 2006 and 5,000 shares on May 11, 2006 of the share capital of Biocon Ltd. The total shareholding of the Goutam Das after the said sale is 631,535 of the total share capital of the Biocon Ltd.","bflag":null,"csvName":null,"desc":"Reg.13-SEBI(Prohibition of Insider Trading Regulations)1992","difference":"-","dt":"18052006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-05-18 00:00:00","symbol":"BIOCON"},{"an_dt":"17-May-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the company has received intimation from the \"Biocon India Limited Employee Welfare Trust\", that they have transferred 825,307 numbers of shares on April 26,2006 and May 03,2006, to the Directors and employees of the Company on exercise of their options under Employee Stock Option Plan, 2000. Further, the company has also received intimation from Officers and non executive Directors regarding the details of the change in the shareholding. The entire shares are being transferred and there is no change in the share capital of the company. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).","bflag":null,"csvName":null,"desc":"Disclosure under the SEBI(Prohibition of Insider Trading)","difference":"-","dt":"17052006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-05-17 00:00:00","symbol":"BIOCON"},{"an_dt":"15-May-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that Dr. Shri Kumar Suryanarayan has sold 65,000 shares of Biocon Limited on May 03, 2006 - May 08, 2006. The shareholding of Dr. Shri Kumar Suryanarayan after the said sale is 11,34,310 shares of the total paid up capital of Biocon Limited.","bflag":null,"csvName":null,"desc":"Reg.13-SEBI(Prohibition of Insider Trading Regulations)1992","difference":"-","dt":"15052006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-05-15 00:00:00","symbol":"BIOCON"},{"an_dt":"10-May-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that Mr. Rakesh Bamzai, Officer has sold 20,000 shares of Biocon Limited on April 28, 2006. The shareholding of Mr. Rakesh Bamzai after the said sale is 235,535 shares of the total share capital of Biocon Limited.","bflag":null,"csvName":null,"desc":"Disc under Regulation 13(6)of SEBI Insider Trading Reg.,1992","difference":"-","dt":"10052006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-05-10 00:00:00","symbol":"BIOCON"},{"an_dt":"20-Apr-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board of the Directors in its meeting held on April 20, 2006 has recommended a dividend of @ 50% (Rs.2.50/- per equity share of Rs.5/- each).","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"20042006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-04-20 00:00:00","symbol":"BIOCON"},{"an_dt":"20-Apr-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release, dated, April 20, 2006, titled, \"Biocon's FY 2005-06 Performance in line with expectations in a very competitive year - Revenues Rs. 793 crs : EBITDA Rs. 234 crs : PAT Rs. 174 crs\" The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).  ","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"20042006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-04-20 00:00:00","symbol":"BIOCON"},{"an_dt":"17-Apr-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release, dated, April 17, 2006, titled, \"Hon'ble Finance Minister P. Chidambaram inaugurates Biocon's new Biologics facility\". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"17042006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-04-17 00:00:00","symbol":"BIOCON"},{"an_dt":"28-Mar-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release, dated, March 28, 2006, titled, \"Biocon wins bid for acquiring Nobex's assets\". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"28032006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-03-28 00:00:00","symbol":"BIOCON"},{"an_dt":"08-Mar-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that  :- (1) Mr. Rakesh Bamzai, Officer has sold 25,000 shares of Biocon Limited on March 01, 2006. The shareholding of Mr. Rakesh Bamzai after the said sale is 255,535 shares of the total share capital of Biocon Limited. (2) Ajay Bhardwaj has sold 150,000 shares of Biocon Limited on February 27, 2006. The shareholding of Mr. Ajay Bhardwaj after the said sale is 1,023,536 shares of the total share capital of Biocon Limited.","bflag":null,"csvName":null,"desc":"Reg.13-SEBI(Prohibition of Insider Trading Regulations)1992","difference":"-","dt":"08032006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-03-08 00:00:00","symbol":"BIOCON"},{"an_dt":"08-Mar-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries has acquired 1,664,234 shares aggregating to 1.66% of the share capital of Biocon Limited on January 27, 2006. The mode of acquisition is Open Market and the shareholding of Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries after the said acquisition is 5,135,238 shares aggregating to 5.13% of the share capital of Biocon Limited.  The details of the acquisition shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements). ","bflag":null,"csvName":null,"desc":"Reg7(3)&Reg13(6)of SEBI Subs. Acq &Takeovers&Insider Trading","difference":"-","dt":"08032006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-03-08 00:00:00","symbol":"BIOCON"},{"an_dt":"22-Feb-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that Mr. Rakesh Bamzai, Officer has sold 7,392 shares of Biocon Limited on February 13, 2006. The shareholding of Mr. Rakesh Bamzai after the said sale is 280,535 shares of the total share capital of Biocon Limited.","bflag":null,"csvName":null,"desc":"Reg.13-SEBI(Prohibition of Insider Trading Regulations)1992","difference":"-","dt":"22022006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-02-22 00:00:00","symbol":"BIOCON"},{"an_dt":"31-Jan-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Fidelity International has informed the Exchange that Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries has acquired 1,664,234 shares aggregating to 1.66% of the share capital of Biocon Limited on January 27, 2006. The mode of acquisition is Market purchase and the shareholding of Funds under the management of FMR Corp and its direct and indirect subsidiaries and Fidelity International Limited and its direct and indirect subsidiaries after the said acquisition is 5,135,238 shares aggregating to 5.13% of the share capital of Biocon Limited.  The details of the acquisition shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Disc under Reg Subs Acq &Takeover & SEBI Insider Trading Reg","difference":"-","dt":"31012006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-01-31 00:00:00","symbol":"BIOCON"},{"an_dt":"30-Jan-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Glentec International has informed the Exchange that they have sold 3,000,000 shares aggregating to 3.00% of the total paid up capital of Biocon Limited on January 25, 2006 (200,000 shares) and on January 27, 2006 (2,800,000 shares). The mode of sale is Open market-Bulk Deals and the shareholding of Glentec International after the said sale is 1,97,67,597 shares aggregating to 19.77% of the total paid up capital of Biocon Limited.","bflag":null,"csvName":null,"desc":"Reg.7(1A) -SEBI (Substantial Acq of shares & Takeovers),1997","difference":"-","dt":"30012006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-01-30 00:00:00","symbol":"BIOCON"},{"an_dt":"30-Jan-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that Glentec International has sold 3,000,000 shares aggregating to 3.00% of the total paid up capital of Biocon Limited on January 25, 2006 and January 27, 2006. The mode of sale is Open market-Bulk Deals and the shareholding of Glentec International after the said sale is 19,767,597 shares aggregating to 19.77% of the total paid up capital of Biocon Limited.","bflag":null,"csvName":null,"desc":"Disc under Reg Subs Acq &Takeover & SEBI Insider Trading Reg","difference":"-","dt":"30012006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-01-30 00:00:00","symbol":"BIOCON"},{"an_dt":"18-Jan-2006 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the press release dated January 18,2006 titled \"Biocon's 9 months (FY06) performance continues in line with expectations- Revenues Rs.578 Crs : EBITDA Rs.173 Crs : PAT Rs. 126 Crs\". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18012006000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2006-01-18 00:00:00","symbol":"BIOCON"},{"an_dt":"29-Dec-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Glentec International has informed the Exchange that they have sold 1,432,403 shares aggregating to 1.43% of the total paid up capital of Biocon Limited on December 28, 2005. The mode of sale is Open market-Block Deal and the shareholding of Glentec International after the said sale is 22,767,597 shares aggregating to 22.77% of the total paid up capital of Biocon Limited.","bflag":null,"csvName":null,"desc":"Reg 7 of SEBI (Susbs Acq of shares & Takeovers)","difference":"-","dt":"29122005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-12-29 00:00:00","symbol":"BIOCON"},{"an_dt":"29-Dec-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that Glentec International has sold 1,432,403 shares aggregating to 1.43% of the total paid up capital of Biocon Limited on December 28, 2005. The mode of sale is through Open Market-Block deal and the shareholding of Glentec International after the said sale is 22,767,597 shares aggregating to 22.77% of the total paid up capital of Biocon Limited.","bflag":null,"csvName":null,"desc":"Disc under Reg Subs Acq &Takeover & SEBI Insider Trading Reg","difference":"-","dt":"29122005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-12-29 00:00:00","symbol":"BIOCON"},{"an_dt":"23-Dec-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that (1) Mr. MB Chinappa, Officer has sold 18,000 shares of Biocon Limited as on December 09, 2005. The shareholding of Mr. MB Chinappa, after the said sale is 31,390 shares of the total share capital of Biocon Limited. (2) Mr. Rakesh Bamzai, Officer has sold 20,000 shares of Biocon Limited as on December 19, 2005. The shareholding of Mr. Rakesh Bamzai , after the said sale is 287,927 shares of the total share capital of Biocon Limited.","bflag":null,"csvName":null,"desc":"Reg.13-SEBI(Prohibition of Insider Trading Regulations)1992","difference":"-","dt":"23122005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-12-23 00:00:00","symbol":"BIOCON"},{"an_dt":"05-Dec-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that, \"Nobex Corporation, Biocon's research development partner, has informed Biocon that they have taken shelter under Chapter 11 of US Bankruptcy laws. Based on progress made till date, Biocon does not anticipate any disruption to its ongoing oral insulin research program, licensed from Nobex. Biocon is also seeking to acquire the intellectual property assets of Nobex. Biocon's investment in Nobex till date is USD 1 Million in Common Stock and USD 4.8 Million in convertible loans.\"","bflag":null,"csvName":null,"desc":"Miscellaneous","difference":"-","dt":"05122005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-12-05 00:00:00","symbol":"BIOCON"},{"an_dt":"16-Nov-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 16, 2005 titled \"Biocon Limited signs a licensing agreement with Bently Pharmaceuticals, Inc. to Develop and market Bentley's intransal insulin spray in 85 Countries; Announces the signing of a Commercial supply agreement for insulin API\". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"16112005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-11-16 00:00:00","symbol":"BIOCON"},{"an_dt":"14-Nov-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated November 13, 2005 titled \"Biocon organizes 'Winning Colours' for Juvenile Diabetics to commemorate World Diabetes Day - Yusuf Arakkal and Waheeda Rehman pledge their support.\" The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"14112005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-11-14 00:00:00","symbol":"BIOCON"},{"an_dt":"19-Oct-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Company has issued a press release dated October 19, 2005 in respect of its financial performance for the half year ended September 30, 2005. The details of the press release titled 'BIOCON'S H1 - FY '06 PERFORMANCE IN LINE WITH EXPECTATIONS; Revenues Rs.377 crs : EBITDA Rs.112 crs : PAT Rs.82 crs', shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"19102005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-10-19 00:00:00","symbol":"BIOCON"},{"an_dt":"05-Oct-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has submitted to the Exchange the  copy of the Minutes of the AGM of the Company held on July 20, 2005.The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements).","bflag":null,"csvName":null,"desc":"Minutes of AGM","difference":"-","dt":"05102005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-10-05 00:00:00","symbol":"BIOCON"},{"an_dt":"23-Aug-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release dated August 23, 2005, titled \"Biocon & Nobex have partnered to develop an Oral B-Type Natriuretic peptide product for treating cardiovascular disease\". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"23082005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-08-23 00:00:00","symbol":"BIOCON"},{"an_dt":"20-Jul-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the company has issued a press release dated July 20, 2005, titled \"Biocon's First Quarter Performance in line with Expectations- Revenues at Rs: 176 crores. EBITDA at Rs: 52 crores. PAT at Rs: 39 crores\" . The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"20072005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-07-20 00:00:00","symbol":"BIOCON"},{"an_dt":"08-Jul-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Company have received intimation from the Biocon India Limited Employee Welfare Trust', on July 02, 2005, that they have transferred 926,397 numbers of shares on June 28, 2005, to the Directors and employees of the Company on exercise of their options under Employee Stock Option Plan, 2000. The Company has also received intimation from employees and non executive Directors on July 02, 2005 regarding the change in their shareholding. The Company has further informed that the entire shares are being transferred from the Trust and there is no change in the Share Capital of the Company.  The details of the change in shareholding of Biocon India Limited Employee Welfare Trust as well as the employees and non executive Directors shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Disc under Regulation 13(6)of SEBI Insider Trading Reg.,1992","difference":"-","dt":"08072005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-07-08 00:00:00","symbol":"BIOCON"},{"an_dt":"05-Jul-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Board has appointed Ms. Usha T N  as the Whole Time Company Secretary of the Company. Further she has also been appointed as Compliance Officer. Her appointment is effective with effect from June 20, 2005 and Murali Krishnan K.N. ceases to be the Compliance Officer with effect from June 20, 2005.","bflag":null,"csvName":null,"desc":"Appointment of Company Secretary","difference":"-","dt":"05072005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-07-05 00:00:00","symbol":"BIOCON"},{"an_dt":"30-Jun-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the \"Biocon India Limited Employee Welfare Trust \" has on June 28, 2005 transferred 926,397 number of shares of Rs.5 each to the Directors and employees of the Company on exercise of their options under Employee Stock Option Plan, 2000.","bflag":null,"csvName":null,"desc":"ESOP","difference":"-","dt":"30062005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-06-30 00:00:00","symbol":"BIOCON"},{"an_dt":"28-Jun-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding a press release being issued by the Company announcing the signing of a Letter of Intent by Clinigene International, subsidiary of Biocon Limited, with SCIREX Corporation, USA to collaborate on global clinical trials. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"28062005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-06-28 00:00:00","symbol":"BIOCON"},{"an_dt":"27-Jun-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has submitted to the Exchange a copy of the Notice of AGM of the company scheduled to be held on July 20,2005. The details of the AGM Notice shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server /Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Notice of AGM","difference":"-","dt":"27062005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-06-27 00:00:00","symbol":"BIOCON"},{"an_dt":"14-Jun-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that:- (1) The Register of Members and the Share Transfer Books of the Company will remain closed from July 01 to July 20, 2005, both days inclusive. (2) The shareholders whose name appears in the Register of members as on July 01, 2005 (opening) are entitled for the dividend, if approved at the AGM. (3). The Annual General Meeting of the company will be held on July 20, 2005. (4) Company has appointed a Share Transfer Agent, details are as below: Karvy Computershare Private Limited Karvy House, 46, Avenue 4, Street No. 1, Banjara Hills, Hyderabad - 500034 Telephone: 040-23312454/23320751/752/251","bflag":null,"csvName":null,"desc":"Book Closure/Others","difference":"-","dt":"14062005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-06-14 00:00:00","symbol":"BIOCON"},{"an_dt":"13-Jun-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the AGM of the Company will be held on July 20, 2005.","bflag":null,"csvName":null,"desc":"Date of AGM","difference":"-","dt":"13062005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-06-13 00:00:00","symbol":"BIOCON"},{"an_dt":"01-Jun-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Company intend to issue a Press Release announcing the signing of a Memorandum of Understanding to collaborate in Research and Research Education Initiatives with Karolinska Institute, Sweden. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"01062005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-06-01 00:00:00","symbol":"BIOCON"},{"an_dt":"20-Apr-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that for the year 2004-05 the board has recommended a dividend @ 40% (Rs.2/- per equity share of Rs.5/- each, as against a dividend of Rs.1/- per equity share for the last year).","bflag":null,"csvName":null,"desc":"Dividend","difference":"-","dt":"20042005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-04-20 00:00:00","symbol":"BIOCON"},{"an_dt":"20-Apr-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the register of members and share transfer books will remain closed from July 01, 2005 to July 20, 2005 both days inclusive, for the purpose of payment of dividend.","bflag":null,"csvName":null,"desc":"Book Closure","difference":"-","dt":"20042005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-04-20 00:00:00","symbol":"BIOCON"},{"an_dt":"20-Apr-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the company has issued a press release dated April 20,2005 titled \"Biocon Group's FY 2005 revenue crosses Rs. 700 crores - PAT increases 42% to Rs. 198 crores\" . The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"20042005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-04-20 00:00:00","symbol":"BIOCON"},{"an_dt":"30-Mar-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Clarification of News : The press had reports that Biocon Limited might announce a bonus issue.The Exchange, in order to verify the accuracy or otherwise of the information reported in the press and to inform the market place so that the interest of the investors is safeguarded, had written to the officials of the company. Biocon Limited has vide its letter inter-alia stated, \"The company certainly has not made/issued any such statement to the media\".","bflag":null,"csvName":null,"desc":"Clarification of News","difference":"-","dt":"30032005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-03-30 00:00:00","symbol":"BIOCON"},{"an_dt":"20-Jan-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the company has on January 20,2005 issued  a press release titled \"Biocon's 9 months profits grow 63% to Rs.155 crores\". The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"20012005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-01-20 00:00:00","symbol":"BIOCON"},{"an_dt":"20-Jan-2005 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that:1)Mr.Ashok Bhandarkar,Company Secretary,has resigned from the services of the company with effect from the close of business hours on January 31,2005.Consequently, he ceases to be the compliance officer of the company effective from that date. 2)The board has appointed Mr.K N Muarali Krishnan, President-Group Finance as the Compliance Officer,w.e.f February 01,2005, for an interim period until a whole time Company Secretary is appointed. He shall be responsible for all the compliances under SEBI regulations and the listing agreements with the Stock Exchanges.  ","bflag":null,"csvName":null,"desc":"Change in Company Secretary/Compliance Officer","difference":"-","dt":"20012005000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2005-01-20 00:00:00","symbol":"BIOCON"},{"an_dt":"18-Nov-2004 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange regarding the press release to be issued  announcing the proposed strategic partnership between Biocon Limited and Vaccinex.Inc USA,to discover and co-develop therapeutic antibody products.The details of the press release issued by the Company shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"18112004000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2004-11-18 00:00:00","symbol":"BIOCON"},{"an_dt":"10-Nov-2004 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Company has on November 10,2004 issued a press release titled \"BIOCON LAUNCHES INSUGEN(TM)-THE NEW GENERATION BIO-INSULIN, World's first recombinant human insulin using Pichia Expression.\"  The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"10112004000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2004-11-10 00:00:00","symbol":"BIOCON"},{"an_dt":"21-Oct-2004 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that Dr. Bala Manian has, upon his appointment as a director on the Board of the Company, disclosed his holding in the share capital of the company. The details are as follows: Dr. Bala Manian holds 1,250 shares as on October 20, 2004. The mode of acquisition is through private purchase.","bflag":null,"csvName":null,"desc":"Reg.13-SEBI(Prohibition of Insider Trading Regulations)1992","difference":"-","dt":"21102004000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2004-10-21 00:00:00","symbol":"BIOCON"},{"an_dt":"20-Oct-2004 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that at its meeting held on October 20, 2004 the BOD have inducted Dr. Bala Manian as an independent director of the company.","bflag":null,"csvName":null,"desc":"Appointment","difference":"-","dt":"20102004000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2004-10-20 00:00:00","symbol":"BIOCON"},{"an_dt":"20-Oct-2004 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the folowing press releases are proposed to be released in the press : 1) Biocon, Nobex partner to develop Oral Insulin Products; 2) Syngne's (a subsidiary of Biocon) new research centre to be inaugurated by Mr. Kapil Sibal on October 21, 2004. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"20102004000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2004-10-20 00:00:00","symbol":"BIOCON"},{"an_dt":"28-Sep-2004 00:00:00","attFileSize":null,"attchmntFile":"-","attchmntText":"Biocon Limited has informed the Exchange that the Company has commenced Phase II clinical trials of its drug TheraCIM (h-R3), a humanized monoclonal antibody, for the treatment of head and neck cancers, after obtaining all the necessary approvals from the concerned authorities. The details of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/CorporateAnnouncements).","bflag":null,"csvName":null,"desc":"Press Release","difference":"-","dt":"28092004000000","exchdisstime":"-","fileSize":"-","hasXbrl":false,"old_new":null,"orgid":null,"seq_id":null,"smIndustry":"Pharmaceuticals","sm_isin":"INE376G01013","sm_name":"Biocon Limited","sort_date":"2004-09-28 00:00:00","symbol":"BIOCON"}]